>  <CLASS>
Chemical

>  <TARGET>
Toxicological findings in a fatal ingestion of methamphetamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This paper presents the case history of a fatality caused by the complications brought about by the presence of methamphetamine and ethanol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Drug concentrations are reported from samples obtained approximately 15 min after the subject was last observed to be chewing what was then believed to be gum, 3 h after the initial toxic symptoms were displayed, 6, 11, and 22 h later.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The subjects conditions deteriorated over the course of this time, and he was declared dead 33 h after the initial display of toxic symptoms.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The toxicological findings and concentration levels of the reported biological specimens concurred with the expected findings in a case of methamphetamine toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methodological issues in biomonitoring of low level exposure to benzene.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Data from a pilot study on unmetabolized benzene and trans,trans muconic acid (t,t-MA) excretion in filling station attendants and unexposed controls were used to afford methodological issues in the biomonitoring of low benzene exposures (around 0.1 ppm).

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Urinary concentrations of benzene and t,t-MA were measured by dynamic head-space capillary GC/FID and HPLC, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The accuracy of the HPLC determination of t,t-MA was assessed in terms of inter- and intra-method reliability.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
The adequacy of urinary t,t-MA and benzene as biological markers of low benzene exposure was evaluated by analysing the relationship between personal exposure to benzene and biomarker excretion.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Filling station attendants excreted significantly higher amounts of benzene, but not of t,t-MA, than controls.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Adjusting for occupational benzene exposure, smokers excreted significantly higher amounts of t,t-MA, but not of unmetabolized benzene, than nonsmokers.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
A comparative analysis of the present and previously published biomonitoring surveys showed a good inter-study agreement regarding the amount of t,t-MA and unmetabolized benzene excreted (about 0.1-0.2 mg/l and 1-2 micrograms/l, respectively) per unit of exposure (0.1 ppm).

$$$$
>  <CLASS>
NONE

>  <TARGET>
For each biomarker, based on the distribution of parameters observed in the pilot study, we calculated the minimum sample size required to estimate the population mean with given confidence and precision.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EMLA cream as a topical anesthetic for the repeated mechanical debridement of venous leg ulcers: a double-blind, placebo-controlled study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A granulating surface is important for skin grafting and healing of leg ulcers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Mechanical debridement to remove necrotic tissue often must be stopped before completion because of pain.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Our purpose was to assess the effect of EMLA cream on the number of debridements required to obtain a clean ulcer and on pain during debridement and to determine its safety after repeated doses.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In this randomized double-blind, placebo-controlled study, 69 patients with venous leg ulcers received cream before debridement until a clean ulcer was obtained (or a maximum of 15 debridements).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EMLA decreased the median number of debridements required for a clean ulcer (EMLA 11.5, placebo >15; P = .019) and decreased pain by 50% (P = .003).

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Plasma levels of lidocaine, prilocaine, and their main metabolites were low without any apparent accumulation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EMLA produces effective pain relief for the debridement of leg ulcers and shortens the time to a clean ulcer.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A highly sensitive method for the determination of coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human cytochrome P450 (P450 or CYP) enzymes was developed using high-performance liquid chromatography (HPLC).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The newly developed HPLC method was found to be about 100-fold more sensitive than the previous spectrofluorimetric method in detecting the metabolite 7-hydroxycoumarin (umbelliferone).

$$$$
>  <CLASS>
Parent

>  <TARGET>
With this high sensitivity, the kinetics of coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation catalyzed by human liver microsomal and recombinant P450 enzymes were determined more precisely.

$$$$
>  <CLASS>
Parent

>  <TARGET>
With 36 different substrate concentrations in these two reactions, coumarin 7-hydroxylation was found to be catalyzed mainly by a single enzyme CYP2A6 and 7-ethoxycoumarin was oxidized by at least two enzymes CYP2E1 and CYP1A2 in human liver microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Direct assay of nonopioid analgesics and their metabolites in human urine by capillary electrophoresis and capillary electrophoresis-mass spectrometry.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Capillary electrophoresis (CE) was used for the analysis of nonopioid analgesics and their metabolites directly in urine samples.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A simple, reliable screening method was developed that allows identification of the drug and/or its metabolites in urine after oral application of paracetamol, acetylsalicylic acid, antipyrine, ibuprofen, naproxen, ketoprofen and propyphenazone by their migration in CE and by their UV spectra recorded with a diode-array detector in a common CE-UV system with 50 mM borax pH 9.4 as separation buffer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the CE-electrospray (ESI)-MS coupling a volatile 50 mM ammonium acetate buffer at pH 9.8 was used.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In order to analyze the metabolic pattern in more detail different methods were developed for each drug.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The separation of the metabolites of acetylsalicylic acid could be improved by injection of the urine sample at the cathodic side of the capillary.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In order to identify antipyrine as neutral compound as well as its neutral metabolites-a micellar electrokinetic chromatography (MEKC) method was developed.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
To investigate the effect of co-administration of the non-steroidal anti-inflammatory drug (NSAID) lornoxicam on the pharmacokinetics of (R)- and (S)-phenprocoumon and their effect on factor II and VII activities.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Six healthy male volunteers completed an open crossover study.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Plasma concentrations of (R)- and (S)-phenprocoumon and activities of coagulation factors II and VII were measured after a single oral dose of 9 mg phenprocoumon racemate.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
In the second session, lornoxicam administration was started 3 days before phenprocoumon administration and continued twice daily until the last blood sample was drawn.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Lornoxicam co-administration resulted in a statistically significant increase of the area under the concentration-time curve (AUC) of the more potent (S)-isomer of phenprocoumon from a median value of 100 (range 68-146) mg x h x 1(-1) to 124 (92-239) mg x h x 1(-1).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the (R)-isomer, the AUC increase from 96 (70-142) mg x h x 1(-1) in the absence to 108 (75-155) mg x h x 1(-1) in the presence of lornoxicam was not statistically significant.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
In a model-based analysis, an increase of (S)-phenprocoumon and (R)-phenprocoumon bioavailability of 14% [95% CI (9%, 19%)] and 6% (2%, 10%) and a decrease of their clearances by 15% (8%, 21%) and 6% (0%, 13%) was obtained.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Lornoxicam co-administration did not influence the free fractions of (R)- or (S)-phenprocoumon.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Contrary to what was expected from the changes in pharmacokinetics, a statistically significant decrease in the effect of phenprocoumon on factor II and VII activity was observed for the sessions with lornoxicam co-administration.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
For factor VII, lornoxicam was found to increase the concentration causing half-maximal effect (C50) of phenprocoumon by 70% [95% CI (38%, 111%)].

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Co-administration of lornoxicam at the upper limit of recommended doses mainly altered the pharmacokinetics of the more potent (S)-isomer and to a lesser degree those of (R)-phenprocoumon.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Despite these changes in pharmacokinetics, a decrease of the effect on factor II and VII activity was observed.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
These results suggest that in the case of lornoxicam co-administration in a patient treated with phenprocoumon the prothrombin time should be monitored closely.

$$$$
>  <CLASS>
Parent

>  <TARGET>
LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood.

$$$$
>  <CLASS>
Parent

>  <TARGET>
An analytic technique using liquid chromatography (LC) coupled with electrospray-mass spectrometry (ESI-MS) has been developed for the simultaneous determination of the new immunosuppressant SDZ RAD (40-O-[2-hydroxy)ethylrapamycin) and cyclosporine (Cs), including their metabolites in blood.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With the time-sparing, automated on-line extraction technique, the recovery of SDZ RAD averaged 95% and that of Cs, 94%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The calibration lines were linear from 0.5 to 100 microg/L (r2 = 0.99) for SDZ RAD and from 10 to 1,000 microg/L (r2 = 0.99) for Cs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The method has been tested on blood samples from renal transplant recipients taken between 1 and 5 hours after oral SDZ RAD and Cs administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In blood, we found the following metabolites: Hydroxy-SDZ RAD, dihydroxy-SDZ RAD, demethyl-SDZ RAD, and the ring-opened form of SDZ RAD.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The main metabolite of SDZ RAD in blood was hydroxy-SDZ RAD.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This novel LC/ESI-MS technique provided an excellent method for simultaneous quantitative monitoring of SDZ RAD and Cs, including their relevant groups of metabolites in patients treated simultaneously with these immunosuppressants.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In the urine of normal subjects who were given an oral dose of 500 mg spironolactone (3-(3-oxo-7alpha-acetylthio-17beta-hydroxy-4-androsten-17alpha-yl)-propionic acid gamma-lactone; Aldactone) together with 100uCi H-20, 21 spironolactone, a so far unknown major metabolite has been detected by thin layer chromatography.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The metabolite then could be isolated by means of counter-current-distribution.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
According to masspectral and magnetic resonance data, the metabolite has been assigned the structure of 3-(3-oxo-7alpha-methyl sulfonyl-6beta, 17beta-dihydroxy-4-androsten-17alpha-yl)-propionic acid gamma-lactone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
By oxidation of the corresponding methylsulfinyl compound - another already known metabolite of spironolactone - with m-chloroperbenzoic acid, a compound has been isolated which proved to be identical with the new metabolite according to TLC, MS and NMR.

$$$$
>  <CLASS>
Parent

>  <TARGET>
By oxidation of the corresponding methylsulfinyl compound - another already known metabolite of spironolactone - with m-chloroperbenzoic acid, a compound has been isolated which proved to be identical with the new metabolite according to TLC, MS and NMR.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The effects of inhibition and induction of the metabolism of buspirone on the plasma concentrations of 1-(2-pyrimidinyl)-piperazine (a piperazine metabolite), the principal active metabolite of buspirone, were investigated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Two separate randomized, placebo-controlled cross-over studies with two phases were carried out in healthy volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In Study I, six subjects took itraconazole 200 mg daily or matched placebo orally for 4 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On day 4, 10 mg buspirone was administered orally.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In study II, six subjects took rifampicin 600 mg daily or matched placebo orally for 5 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On day 6, 30 mg buspirone was administered orally.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
Buspirone and piperazine metabolite concentrations in plasma were determined by gas chromatography.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
Itraconazole decreased the mean AUC of the piperazine metabolite by 50% (P<0.05) and the Cmax by 57% (P<0.05) compared with placebo, whereas the mean AUC and Cmax of unchanged buspirone were increased 14.5-fold (P<0.05) and 10.5-fold (P<0.05), respectively, by itraconazole.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Itraconazole decreased the mean AUC of the piperazine metabolite by 50% (P<0.05) and the Cmax by 57% (P<0.05) compared with placebo, whereas the mean AUC and Cmax of unchanged buspirone were increased 14.5-fold (P<0.05) and 10.5-fold (P<0.05), respectively, by itraconazole.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
Rifampicin had no significant effect on the AUC of the piperazine metabolite, but it increased the mean Cmax of the piperazine metabolite by 35% (P=0.08).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rifampicin had no significant effect on the AUC of the piperazine metabolite, but it increased the mean Cmax of the piperazine metabolite by 35% (P=0.08).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean AUC and Cmax of parent buspirone were reduced by 91% (P<0.05) and 85% (P<0.05), respectively, by rifampicin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mean AUC and Cmax of parent buspirone were reduced by 91% (P<0.05) and 85% (P<0.05), respectively, by rifampicin.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
The mean ratio of the AUC of the piperazine metabolite to that of buspirone was decreased 34-fold (P<0.05) by itraconazole and increased 7.6-fold (P<0.05) by rifampicin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean ratio of the AUC of the piperazine metabolite to that of buspirone was decreased 34-fold (P<0.05) by itraconazole and increased 7.6-fold (P<0.05) by rifampicin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In conclusion, itraconazole and rifampicin caused only relatively minor changes in the plasma concentrations of the active piperazine metabolite of buspirone, although they had drastic effects on the concentrations of parent buspirone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In conclusion, itraconazole and rifampicin caused only relatively minor changes in the plasma concentrations of the active piperazine metabolite of buspirone, although they had drastic effects on the concentrations of parent buspirone.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Ethyl glucuronide--a marker of alcohol consumption and a relapse marker with clinical and forensic implications.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Ethyl glucuronide (EtG) is a non-volatile, water-soluble, direct metabolite of ethanol that can be detected in body fluids and hair.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We investigated urine and serum samples from three patient groups: (1) 33 in-patients in acute alcohol withdrawal; (2) 30 detoxified in-patients (treated for at least 4 weeks) from a 'motivation station'; and (3) 43 neuro-rehabilitation patients (non-alcoholics; most of them suffering from stroke, traumatic brain injury, Parkinson's disease etc.)

$$$$
>  <CLASS>
Chemical

>  <TARGET>
using gas chromatography/mass spectrometry (GC/MS) with deuterium-labelled EtG as the internal standard and additionally in the second group of patients using liquid chromatography (LC/MS-MS).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We found no correlation between the concentration of EtG in urine at hospitalization and the blood-ethanol concentration (r = 0.17), the time frame of detection (r = 0.5) or the total amount of clomethiazole required for the treatment of withdrawal symptoms (r = 0.28).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In four out of 30 in-patients from the 'motivation station'--where neither clinical impression nor routine laboratory findings gave indications of relapse--concentrations of EtG in urine ranged between 4.2 and 196.6 mg/l.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EtG concentrations in urine of between 2.89 and 23.49 mg/l were found in seven out of 43 neuro-rehabilitation patients using GC/MS.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The GC/MS and the LC/MS-MS results showed a correlation of 0.98 with Pearson's correlation test and 1.0 with Spearman's correlation test.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We suggest that EtG is a marker of alcohol consumption that can be detected for an extended time period after the complete elimination of alcohol from the body.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When used as a relapse marker with a specific time frame of detection intermediate between short- and long-term markers, EtG fills a clinically as well as forensically important gap.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Its specificity and sensitivity exceed those of all other known ethanol markers.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Prodrug for bioreductive activation-independent delivery of menahydroquinone-4: human liver enzymatic activation and its action in warfarin-poisoned human liver.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The N,N-dimethylglycine esters of menahydroquinone-4 (1-mono, 1; 4-mono, 2; 1,4-bis, 3) were established in previous reports as prodrugs that could achieve the systemic bioreductive activation-independent delivery of menahydroquinone-4 (MKH), the active form of menaquinone-4 (MK-4), in rat.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The present study was undertaken to investigate if the prodrugs could undergo cleavage to parent drug (MKH) by a human tissues enzyme catalyzed hydrolytic pathway, the mechanism of the prodrugs for vitamin K-dependent carboxylation in human liver and their action in the warfarin poisoned human liver.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The present study was undertaken to investigate if the prodrugs could undergo cleavage to parent drug (MKH) by a human tissues enzyme catalyzed hydrolytic pathway, the mechanism of the prodrugs for vitamin K-dependent carboxylation in human liver and their action in the warfarin poisoned human liver.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The hydrolysis of the esters was shown to be catalyzed by esterases located in human liver but not in human plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The susceptibility of the esters to undergo human liver esterase hydrolysis was affected by the esterified position: 1>2>3.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
By using a human liver microsomal test system, the stimulation of vitamin K-dependent carboxylation with the prodrugs was determined.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The prodrug could stimulate the carboxylation activity in the absence of dithiothreitol, an artificial activator of the reductive activation pathway of MK-4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The carboxylation activity of the prodrug was strongly inhibited in the presence of eserine, an esterase inhibitor.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The prodrug could also stimulate the carboxylase under warfarin-poisoned conditions, where the vitamin K cycle was strongly inhibited.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The results confirmed that the prodrug could generate MKH in human liver (active site), and that the resultant MKH could act as a cofactor for the carboxylase without reductive activation processes of MK-4 to MKH.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Such bioreductive activation-independent vitamin K-dependent carboxylation characteristic of the prodrug leads to enhanced pharmacological efficacy in the treatment of hypoprothrombinaemia induced in patients with coumarin and cephalosporin therapies.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Species differences in the hepatic and intestinal metabolism of cyclosporine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cyclosporin A (cyclosporine, CSA) is an immunosuppressive drug with a narrow therapeutic index.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In the present study the metabolism of CSA was investigated in the liver and small intestinal microsomes obtained from rat, hamster, rabbit, dog, baboon and man by measuring the disappearance of CSA and the formation of the principal metabolites of CSA, namely hydroxylated and N-demethylated CSA.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
In the present study the metabolism of CSA was investigated in the liver and small intestinal microsomes obtained from rat, hamster, rabbit, dog, baboon and man by measuring the disappearance of CSA and the formation of the principal metabolites of CSA, namely hydroxylated and N-demethylated CSA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CSA was metabolized at a very slow rate (2-8% metabolism in 30 min) in rat liver microsomes whereas microsomes from dog livers were very efficient (70-100% metabolism in 30 min) in metabolizing CSA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Hydroxylation and N-demethylation accounted for most of the CSA metabolized in all the species tested.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Microsomes from the small intestine produced qualitatively a similar metabolic profile as compared with the microsomes from the liver, but at a slower rate in all the species tested.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The relative importance of the different metabolic pathways, however, differed between species.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study points to the importance of recognizing the similarities and the differences in the metabolism of CSA in different species when data from animal studies are extrapolated to man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A comparison of 1H8- and 2H8-toluene toxicokinetics in men.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To examine the bioequivalence of an isotope-labelled tracer to study toxicant disposition, we conducted 33 controlled human exposures to a mixture of 50 ppm 1H8-toluene and 50 ppm 2H8-toluene for 2 h, and measured concentrations in blood and breath, and metabolite levels in urine for 100 h post-exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A physiologically based kinetic (PBK) model found that compared with 1H8-toluene, 2H8-toluene had a 6.4+/-13% (mean+/-SD) lower AUC, a 6.5+/-13% higher systemic clearance (1.46+/-0.27 versus 1.38+/-0.25 l/h-kg), a 17+/-22% larger terminal volume of distribution (66.4+/-14 versus 57.2+/-10 l/kg) and a 9.7+/-26% longer terminal half-life (38+/-12 versus 34+/-10 h) (p < 0.05 for all comparisons).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The higher 2H8-toluene clearance may have been due to an increased rate of ring oxidation, consistent with the 17% higher observed fraction of 2H5- versus 1H5-cresol metabolites in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The larger terminal volume and half-lives for 2H8-toluene suggested a higher adipose tissue/blood partition coefficient.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Observed isotope differences were small compared with interindividual differences in 1H8-toluene kinetics from previous studies.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The PBK model allowed us to ascribe observed isotope differences in solvent toxicokinetics to underlying physiologic mechanisms.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vivo evaluation in mice and metabolism in blood of human volunteers of [123I]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We report the in vivo evaluation (biodistribution, displacement and metabolization in blood, brain and heart) in mice and the metabolism in blood of human volunteers of iodine-123 labelled 1-(2-iodophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline carboxamide ([123I]iodo-PK11195), a potential radioligand for visualization of inflammation in humans by single-photon emission tomography.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In three series of 18 white mice (NMRI, 20-25 g), the concentration of radioactivity was measured during 48 h. Blood samples were taken, organs and intestines were excised, excretion was collected and all tissues were weighed and counted for radioactivity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The tissue uptake of radioactivity was measured as % of the injected activity/g of tissue.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The excretion was expressed as % of the injected activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Selective tissue uptake was investigated by pretreatment of another three series of 18 mice with cold PK11195 (1 mg/kg body weight).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was an inflow of [123I]iodo-PK11195 in the brain and among peripheral organs, heart (42.3%), lungs (133.5%) and kidneys (18.4%) had the highest uptake.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After pretreatment with cold PK11195, there was a decrease in accumulation in the latter three organs, especially in heart (ca.55%) and lungs (ca.80%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolite analysis was performed using high-performance liquid chromatography (HPLC).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
First, the extraction yield of [123I]iodo-PK11195 from blood and tissue was assessed, and found to be >90%.

$$$$
>  <CLASS>
Parent

>  <TARGET>
From blank blood samples and organs spiked with [123I]iodo-PK11195 it was concluded that no metabolization took place during the extraction procedure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Analysis of plasma, brain and heart of mice showed that 10 min p.i.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
[123I]iodo-PK11195 was the only significant (ca.95%) radioactive compound in brain and heart where-as in plasma other radioactive products (>60%) appeared.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Analysis of plasma samples of the three human volunteers at 7, 20, 37 and 50 min p.i. showed that [123I]iodo-PK11195 rapidly decomposes into two polar metabolites, which at these time points accounted for, respectively 31%, 62%, 75% and 77% of the total activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Analytical methodology for enantiomers of salbutamol in human urine for application in doping control.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Liquid chromatographic procedure with fluorimetric detection for chiral separation and quantification of salbutamol enantiomers in urine samples has been developed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The extraction of free salbutamol from urine has been considered using liquid-liquid and solid-phase procedures.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The effect of pH, salting-out effect and organic solvent has been studied in liquid-liquid extraction from aqueous and urine samples.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For solid-phase extraction, different mechanisms (polar, non-polar, cation-exchange and interactions with a polymeric phase) have been tested and the effect of the urine matrix on the extraction recoveries has been considered.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Bond-Elut Certify extraction cartridges provided the best specificity and good recoveries for salbutamol in urine.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
The sample is acidified, applied to the preconditioned cartridges and, after a washing step, salbutamol enantiomers are eluted with a mixture of chloroform and 2-propanol (80:20, v/v) containing 2% ammonia.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Atenolol is used as external standard.

$$$$
>  <CLASS>
Neither parent compound nor metabolites

>  <TARGET>
Enantioselective separation is accomplished with a Chirex 3022 stationary phase (urea type silica-bonded chiral phase) using a mobile phase containing hexane-dichloromethane-methanol-trifluoroacetic acid (250:218:31:1, v/v) and fluorimetric detection with excitation and emission wavelengths set at 230 and 309 nm, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method proposed is rapid, selective and sensitive, and seems to be useful to differentiate between an authorized and a prohibited use of the drug in doping control.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
7-Ethyl-10-hydroxycamptothecine (SN-38) is the active metabolite of the topoisomerase I inhibitor and antineoplastic agent, irinotecan (CPT-11).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Here, we present a new and sensitive reversed-phase high-performance liquid chromatographic method for the determination of SN-38 in human plasma samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sample pretreatment involves a protein precipitation of 1-mL samples with 2 mL of acetonitrile, followed by a one-step solvent extraction with 5 mL of chloroform, with camptothecine used as internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Chromatographic separation was achieved on an analytical column packed with Hypersil ODS material (100 x 4.6 mm i.d., 5 microm P.S.), and isocratic elution with a mixture of acetonitrile:0.1 M ammonium acetate containing 10 mM tetrabutylammonium sulfate (23:77, v/v), pH 5.3 (hydrochloric acid).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The column effluent was monitored at excitation and emission wavelengths of 380 and 556 nm, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The limit of quantitation of the method presented was at the low femtomole level ( approximately 8.4 fmol; equivalent to 5 pg/mL), with the standard curves being linear over nearly three orders of magnitude.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Intraassay precision was <9%, while interassay variations were between 2 and 5%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The extraction efficiency was concentration independent and averaged 88.0 +/- 14.3% (mean +/- standard deviation; n = 59).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The described method will be used in future studies to assess the extent of enterohepatic recirculation of SN-38 in cancer patients following intravenous CPT-11 treatment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The CYP2D6*10 (*10) allele that causes decreased CYP2D6 activity is present in Asians with a high frequency of about 50%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this study we studied the effects of the *10 allele on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The subjects were 67 Japanese inpatients with schizophrenia who had only the wild-type or *10 alleles.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Thirty-four patients were homozygous for the wild-type allele, and 26 were heterozygous and 7 were homozygous for the *10 allele.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All patients had been receiving 12 mg/day haloperidol for at least 2 weeks.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma concentrations of haloperidol and reduced haloperidol were measured by HPLC.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean +/- SD values of haloperidol Css in the patients with 0, 1, and 2 *10 alleles were 22.8+/-11.0, 30.1+/-10.6, and 31.2+/-21.2 nmol/L, respectively, and those values for reduced haloperidol were 6.1+/-2.9, 9.5+/-3.7, and 9.9+/-6.2 nmol/L, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean haloperidol Css was significantly (P < .05) higher in the patients with 1 *10 allele than in those with no *10 alleles.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean Css of reduced haloperidol was significantly (P < .05) higher in the patients with 1 and 2 *10 alleles than in those with no *10 alleles.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study suggests that the *10 allele plays an important role in controlling the Css of both haloperidol and reduced haloperidol, especially in Asian subjects.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Saturable metabolic pathways for ethotoin in man.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The urinary excretion pattern of ethotoin and five metabolites were examined in three patients receiving continuous treatment with ethotoin at two dose levels, in order to investigate the mechanism behind the dose-dependent kinetics of this anticonvulsant drug.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The results suggest a partial saturation in the dealkylation process at high dose levels in three patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A rough approximation of the Michaelis-Menten constants for different enzymatic processes was attempted.

$$$$
>  <CLASS>
NONE

>  <TARGET>
On the basis of the results obtained, the p-hydroxylation may be a saturable process.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The dose-dependent kinetics of ethotoin in man seem to be explicable by the existence of partly saturable enzymatic pathways.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics of spironolactone in man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Five healthy male volunteers received 500 mg Aldactone orally together 100 muCi 3H-20-21-spironolactone; one elderly patient received 1 mCi 3H-spironolactone without additional 'cold' drug.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For 6 days the disposition kinetics of the drug were studied in plasma, urine and feces.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The tritium concentrations in plasma reached a peak between 25-40 min after administration amounting to 2-3% of the dose/1.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Up to the 12th h, they fell rapidly and showed a monoexponential decline (t 1/2: 2.57 +/- 0.27 days) between the 36th and 96th h. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
Later, a striking increase in the speed of elimination of radioactivity from plasma (t 1/2: 1.66 +/- 0.21 days) was observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The biological half-life of labeled material in plasma was longer than that of fluorigenic compounds.

$$$$
>  <CLASS>
NONE

>  <TARGET>
47-57% of the dose were excreted in urine and the remaining amount could be detected in feces (total recovery 90%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The half-life of the urinary excretion rate was distinctly shorter (t 1/2: 0.9 +/- 0.11 days) than that of total radioactivity in plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This, together with an observed increase of the polar fraction in urine from 35 up to 85%, which was accompanied by a decrease in plasma from 55 to 35%, suggests either tubular reabsorption or enterohepatic recirculation of lipophilic compounds.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
TLC-separation of the lipophilic fraction in urine revealed two previously unknown compounds of which the main congener was identified as 3-(3-oxo-7 alpha-methylsulfonyl-6 beta, 17 beta-dihydroxy-4-androsten-17 alpha-yl) propionic acid gamma-lactone, as well as canrenone and the metabolites which have already been described (Karim and Brown, 1972; Karim et al., 1975).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
This metabolite represents the main lipophilic degradation product in urine within the first hours, whereas the 6 beta-OH-7 alpha-methylsulfinyl-spirolactone leveled off and seemed to be and endexcretion product.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For further characterisation, the polar fraction was subjected to acidic hydrolysis.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The known metabolic pathways of spironolactone degradation are discussed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Accuracy of five on-site immunoassay drugs-of-abuse testing devices.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Many current "on-site" urine drug-testing products claim performance equivalent to laboratory testing.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Five commercially available products (PharmScreen, Roche TestCup, Accusign DOA 2, Status DS, and American Bio Medica-Rapid Drug Screen) were challenged with quality-control specimens of known drug metabolite concentrations, 25% above and 25% below the SAMHSA cutoffs, and with known positive and negative donor specimens previously analyzed by immunoassay and gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results indicate discrepancies between claims and performance for all products, particularly with amphetamines.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The implications for employer-based drug testing are discussed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To investigate the in vitro potential of selective serotonin reuptake inhibitors (SSRIs) to inhibit two CYP2C9-catalysed reactions, tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To investigate the in vitro potential of selective serotonin reuptake inhibitors (SSRIs) to inhibit two CYP2C9-catalysed reactions, tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The formation of 4-hydroxytolbutamide from tolbutamide and that of 7-hydroxywarfarin from (S)-warfarin as a function of different concentrations of SSRIs and some of their metabolites was studied in microsomes from three human livers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Both tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation followed one enzyme Michaelis-Menten kinetics.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Kinetic analysis of 4-hydroxytolbutamide formation yielded a mean apparent Michaelis-Menten constant (Km) of 133 microM and a mean apparent maximal velocity (Vmax) of 248 pmol x min(-1) x mg(-1); formation of 7-hydroxywarfarin yielded a mean Km of 3.7 microM and a mean Vmax of 10.5 pmol x min(-1) x mg(-1).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amongst the SSRIs and some of their metabolites tested, only fluvoxamine markedly inhibited both reactions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The average computed inhibition constant (Ki) values and ranges of fluvoxamine when tolbutamide and (S)-warfarin were used as substrate, were 13.3 (6.4-17.3) microM and 13.0 (8.4-18.7) microM, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The average Ki value of fluoxetine for (S)-warfarin 7-hydroxylation was 87.0 (57.0-125) microM.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The average Ki value of fluoxetine for (S)-warfarin 7-hydroxylation was 87.0 (57.0-125) microM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amongst the SSRIs tested, fluvoxamine was shown to be the most potent inhibitor of both tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Amongst the SSRIs tested, fluvoxamine was shown to be the most potent inhibitor of both tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fluoxetine, norfluoxetine, paroxetine, sertraline, desmethylsertraline, citalopram, desmethylcitalopram had little or no effect on CYP2C9 activity in vitro.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This is consistent with in vivo data indicating that amongst the SSRIs, fluvoxamine has the greatest potential for inhibiting CYP2C9-mediated drug metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We have studied the possible effect of two inhibitors of CYP3A4, erythromycin and itraconazole, on the pharmacokinetics of oral lignocaine in nine volunteers using a cross-over study design.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The subjects were given erythromycin orally (500 mg three times a day), itraconazole (200 mg once a day) or placebo for four days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On day 4, each subject ingested a single dose of 1 mg/kg of oral lignocaine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Plasma samples were collected until 10 hr and concentrations of lignocaine and its major metabolite, monoethylglycinexylidide were measured by gas chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both erythromycin and itraconazole increased the area under the lignocaine plasma concentration-time curve [AUC(0-infinity)] and lignocaine peak concentrations by 40-70% (P<0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Compared to placebo and itraconazole, erythromycin increased monoethylglycinexylidide peak concentrations by approximately 40% (P<0.01) and AUC(0-infinity) by 60% (P<0.01).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The clinical implication of this study is that erythromycin and itraconazole may significantly increase the plasma concentrations and toxicity of oral lignocaine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The extent of the interaction of lignocaine with these CYP3A4 inhibitors was, however, less than that of, e.g. midazolam or buspirone, and it did not correlate with the CYP3A4 inhibiting potency of erythromycin and itraconazole.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Identification of urinary metabolites of clemastine after oral administration to man.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The metabolism of clemastine, 2-[2-[1-(4-chlorophenyl)-1-phenylethoxylethyl])-1-methylpyrrolidin e, has been studied in three adult male volunteers after a single oral dose of 20 mg as the fumarate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After enzymatic hydrolysis solvent extracts of urine were derivatized with N-methyl-N-trimethylsilyltrifluoroacetamide-ammonium iodide and analysed by gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The structures of metabolites were determined on the basis of electron impact and chemical ionization mass spectra and the identities of some (e.g. carbinol, 4-chlorobenzophenone and 4-chlorophenylstyrene) were confirmed by use of authentic standards.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The principal route of metabolism of clemastine in man involves direct oxidation, O-dealkylation (fission of the ether bond), aromatic hydroxylation, aliphatic oxidation, alcoholic dehydration, and then enzymatic hydrolysis.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The principal route of metabolism of clemastine in man involves direct oxidation, O-dealkylation (fission of the ether bond), aromatic hydroxylation, aliphatic oxidation, alcoholic dehydration, and then enzymatic hydrolysis.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Of the total amount of metabolites excreted in the urine 35% was carbinol (metabolite M3, major metabolite), 15% was M1, 17% was M2, 11% was M4, 9% was M5, 8% was M6 and 5% was M7.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Possible preferential metabolism of xylene isomers following occupational exposure to mixed xylenes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Solvent exposures commonly involve mixtures of substances or mixtures of isomers of a single solvent.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These may be metabolised through common pathways, resulting in the potential for metabolic interactions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These may then lead to accumulation of solvent or metabolic intermediates, some of which may be toxic.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This paper describes a pilot study conducted to determine the correlation between airborne xylene isomers and the appearance of methylhippuric acid (MHA) isomers in urine of workers exposed mainly to xylene.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The project also aimed to determine whether there is preferential metabolism of any isomer by comparison of the ratios of airborne isomers with the ratios of metabolite isomers appearing in urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A total of 12 workers (11 male, 1 female) were recruited into this study, with 2 of the participants providing samples on more than one occasion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Workers included flooring contractors (5), printers (2), chemical manufacturers (2), histology technicians (2) and one householder using a xylene-based varnish.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Subjects were aged between 24 and 48 years (37.6+/-2.0 years; mean +/- SEM).

$$$$
>  <CLASS>
NONE

>  <TARGET>
After giving informed consent, workers provided a prework and postwork urine sample on a midweek work day.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Samples were stored frozen prior to analysis.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Breathing-zone air samples were collected using personal air samplers at 50 ml/min.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Solvents were trapped on activated-charcoal sampling tubes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Subjects wore pumps for 18-304 (178+/-24) min on the same day on which urine samples were collected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Xylene exposures ranged from 1.6 to over 7000 ppm.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In all, 7 of 16 measurements exceeded the Australian TWA standard of 80 ppm.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Two of the flooring contractors wore respiratory protective equipment (RPE) and the two histopathology technicians used workplace ventilation systems.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Total urinary MHA output ranged from 10 to 8000 mmol/mol creatinine, with 6 of 16 samples exceeding the modified biological exposure index of 702 mmol/mol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Correlations between airborne concentrations of individual xylene isomers and their corresponding MHA isomers were poor but improved when workers using RPE were excluded from the analysis.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Correlations between airborne concentrations of individual xylene isomers and their corresponding MHA isomers were poor but improved when workers using RPE were excluded from the analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Gradients of the regression lines (millimoles of MHA per mole of creatinine per parts per million of xylene) were 3.2 for o-isomers, 7.0 for p-isomers, and 14.4 for m-isomers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Comparisons of isomer ratios of xylene in air were made with the corresponding ratio of MHA isomers in urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Comparisons of isomer ratios of xylene in air were made with the corresponding ratio of MHA isomers in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These revealed higher ratios of m-MHA to other MHA isomers than those of m-xylene to the other xylene isomers.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
These revealed higher ratios of m-MHA to other MHA isomers than those of m-xylene to the other xylene isomers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The MHA isomer ratios were expected to be the same as the airborne xylene isomer ratios if there were no preferential elimination of any isomer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
m-MHA appeared in urine in a greater proportion than would be predicted from the proportion of m-xylene detected in air.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The time course of the appearance of MHA isomers in urine also suggests that interactions were taking place, with m-MHA appearing in high proportion in urine following several days of repeated heavy xylene exposure.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The time course of the appearance of MHA isomers in urine also suggests that interactions were taking place, with m-MHA appearing in high proportion in urine following several days of repeated heavy xylene exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On a single moderate exposure, m-MHA appeared initially in high proportion in the first few hours but was undetectable in urine after 18 h. p-MHA was detectable for up to 6 h after exposure, and o-MHA remained detectable after 18 h. This study suggests that excretion of m-MHA in urine is favoured over that of the other isomers following exposure to mixed xylenes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This is independent of airborne xylene isomer composition and suggests that the metabolism of m-xylene occurs preferentially to that of the other isomers.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
It is not clear at which step in the metabolism of xylene this preference occurs, although other work indicates that the initial oxidation of xylene to methylbenzyl alcohol by cytochrome P450 2E1 occurs at the same rate for each isomer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These findings suggest that there is potential for metabolic interactions between xylene isomers and that these may be the basis for xylene toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Synthesis of glucuronides of multidrug resistance reversing drug MS-209.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We synthesized the glucuronides of MS-209 to identify the two main unknown metabolites in human urine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We synthesized the glucuronides of MS-209 to identify the two main unknown metabolites in human urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Reaction of MS-209 and glucuronyl trichloroacetimidate gave two beta-isomers, which were each glucuronate of (R)- and (S)-MS-209.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Reaction of MS-209 and glucuronyl trichloroacetimidate gave two beta-isomers, which were each glucuronate of (R)- and (S)-MS-209.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These spectrum data were identical with the metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Application to pharmacokinetics.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A high-performance liquid chromatographic method coupled with fluorimetric detection has been developed for the determination of atracurium and its major metabolite, laudanosine, in human plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection is performed at 240 nm for excitation and 320 nm for emission.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Verapamil was used as the internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The proposed technique, involving the direct precipitation of plasma proteins is reproducible, selective and sensitive.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Linear detector responses were observed for the calibration curve standards in the range of 40 to 2000 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Precision, expressed as C.V., was in the range 1 to 14%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limit of quantification for both atracurium and laudanosine was 40 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method has been validated and stability tests under various conditions have been performed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This method has been used to determine the pharmacokinetic profile of atracurium and laudanosine in patients with acute respiratory distress syndrome.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This method has been used to determine the pharmacokinetic profile of atracurium and laudanosine in patients with acute respiratory distress syndrome.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In human liver microsomes the oxidations of benzene, chlorzoxazone, aniline, dimethylformamide, and 4-nitrophenol were significantly correlated with each other and with the level of cytochrome P450 (CYP) 2E1 estimated by immunoblotting.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Moreover, benzene oxidation to water-soluble metabolites was suppressed by 0.1 mM diethyldithiocarbamate, supposedly a specific inhibitor of CYP2E1 at this level.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Moreover, benzene oxidation to water-soluble metabolites was suppressed by 0.1 mM diethyldithiocarbamate, supposedly a specific inhibitor of CYP2E1 at this level.

$$$$
>  <CLASS>
Parent

>  <TARGET>
None of these metabolic rates correlated with immunochemically determined levels of CYP1A2, 2C9, and 3A4 nor oxidation of 7-ethoxyresorufin, tolbutamide, and nifedipine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Benzene oxidation to water-soluble metabolites was characterized by typical Michaelis-Menten kinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The different benzene K(m) values seen in individual human microsomal samples were not correlated with the level or activity of CYP1A2, 2C9, 2E1, and 3A4 but could be due to CYP2E1 microheterogeneity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The lowest K(m) for benzene oxidation could be related to C/D and/or c1/c2 polymorphism of CYP2E1 gene.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Covalent binding of benzene reactive metabolites to microsomal proteins was also correlated with the CYP2E1 metabolic rates and immunochemical levels.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
At high concentrations of benzene covalent binding was inversely related to benzene concentrations (as well as to formation of water-soluble metabolites) in agreement with the view that secondary metabolites, mainly benzoquinone, are responsible for the covalent binding.

$$$$
>  <CLASS>
Parent

>  <TARGET>
6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The aim of the present study was to identify the enzymes in human liver catalyzing hydroxylations of bile acids.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Fourteen recombinant expressed cytochrome P450 (CYP) enzymes, human liver microsomes from different donors, and selective cytochrome P450 inhibitors were used to study the hydroxylation of taurochenodeoxycholic acid and lithocholic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Recombinant expressed CYP3A4 was the only enzyme that was active towards these bile acids and the enzyme catalyzed an efficient 6alpha-hydroxylation of both taurochenodeoxycholic acid and lithocholic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The Vmax for 6alpha-hydroxylation of taurochenodeoxycholic acid by CYP3A4 was 18.2 nmol/nmol P450/min and the apparent Km was 90 microM.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cytochrome b5 was required for maximal activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human liver microsomes from 10 different donors, in which different P450 marker activities had been determined, were separately incubated with taurochenodeoxycholic acid and lithocholic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A strong correlation was found between 6alpha-hydroxylation of taurochenodeoxycholic acid, CYP3A levels (r2=0.97) and testosterone 6beta-hydroxylation (r2=0.9).

$$$$
>  <CLASS>
Parent

>  <TARGET>
There was also a strong correlation between 6alpha-hydroxylation of lithocholic acid, CYP3A levels and testosterone 6beta-hydroxylation (r2=0.7).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Troleandomycin, a selective inhibitor of CYP3A enzymes, inhibited 6alpha-hydroxylation of taurochenodeoxycholic acid almost completely at a 10 microM concentration.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Troleandomycin, a selective inhibitor of CYP3A enzymes, inhibited 6alpha-hydroxylation of taurochenodeoxycholic acid almost completely at a 10 microM concentration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Other inhibitors, such as alpha-naphthoflavone, sulfaphenazole and tranylcypromine had very little or no effect on the activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The apparent Km for 6alpha-hydroxylation of taurochenodeoxycholic by human liver microsomes was high (716 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
This might give an explanation for the limited formation of 6alpha-hydroxylated bile acids in healthy humans.

$$$$
>  <CLASS>
Parent

>  <TARGET>
From the present results, it can be concluded that CYP3A4 is active in the 6alpha-hydroxylation of both taurochenodeoxycholic acid and lithocholic acid in human liver.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aim of this retrospective study was to investigate the influence of oxcarbazepine (OCBZ) and methsuximide (MSM) on lamotrigine (LTG) serum concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of OCBZ compared to carbamazepine (CBZ) and the effect of MSM on LTG serum concentrations were examined in patients with and without valproic acid (VPA) comedication.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Altogether, 376 samples from 222 patients were analyzed in routine drug monitoring.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Two or more serum samples from the same patient were considered only if the comedication had been changed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For statistical evaluation, regression analytical methods and an analysis of variance were performed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the analysis of variance, the LTG serum concentration in relation to LTG dose/ body weight--level-to-dose ratio (LDR), in (microg/mL)/(mg/kg)--was calculated and compared for different drug combinations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The nonlinear regression analysis including the LTG dose per body weight, age, gender, and the different kinds of comedication revealed that these variables have a significant influence on LTG serum concentration (r2 = 0.724).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The relationship between LTG dose/body weight and serum concentration deviates only slightly from linearity, the LTG concentration was about 18% lower in women than in men, and age had a significant influence.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The data indicate that children have significantly lower LTG concentrations than adults on a comparable LTG dose per body weight and that children may be more prone to enzyme induction by comedicated drugs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methsuximide has a strong inducing effect on the LTG metabolism and decreases the LTG concentrations markedly (about 70% compared to LTG monotherapy).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Methsuximide has a strong inducing effect on the LTG metabolism and decreases the LTG concentrations markedly (about 70% compared to LTG monotherapy).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Carbamazepine also reduces the LTG concentrations considerably (by 54%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The inducing effect of OCBZ (29%) was less pronounced but also significant.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The inducing effect of MSM, CBZ, and OCBZ was also seen in combination with VPA: VPA alone increases the LTG concentration approximately 211%, whereas in addition to MSM (8%), CBZ (21%), or OCBZ (111%), the increase of LTG was significantly smaller.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The analysis of variance confirmed the results of the regression analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of MSM on the LTG concentration should be considered if MSM is added or withdrawn in patients treated with LTG.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Oxcarbazepine had a less pronounced inducing effect on LTG metabolism compared to CBZ.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Oxcarbazepine had a less pronounced inducing effect on LTG metabolism compared to CBZ.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
If CBZ is replaced by OCBZ as comedication, an increase in LTG serum concentrations should be expected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by 12 recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes have been investigated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Arachidonic acid (50 microM) significantly inhibited CYP1A1- and 1A2-dependent 7-ethoxycoumarin O-deethylations, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent R-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Arachidonic acid (50 microM) significantly inhibited CYP1A1- and 1A2-dependent 7-ethoxycoumarin O-deethylations, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent R-warfarin 7-hydroxylation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This chemical also inhibited slightly the xenobiotic oxidations catalysed by CYP1B1, 2B6, 2C9, 2D6, 2E1 and 3A4 in recombinant enzyme systems.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Retinol, retinoic acid and cholecalciferol were strong inhibitors for xenobiotic oxidations catalysed by recombinant CYP1A1, 2C8 and 2C19.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In human liver microsomes, arachidonic acid inhibited CYP1A2-dependent theophylline hydroxylation, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent omeprazole 5-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In human liver microsomes, arachidonic acid inhibited CYP1A2-dependent theophylline hydroxylation, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent omeprazole 5-hydroxylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Taxol 6alpha-hydroxylation was also inhibited by retinol and retinoic acid, and omeprazole 5-hydroxylation was inhibited by retinol in human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Taxol 6alpha-hydroxylation was also inhibited by retinol and retinoic acid, and omeprazole 5-hydroxylation was inhibited by retinol in human liver microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These results suggest that xenobiotic oxidations by P450 enzymes are affected by endobiotic chemicals and that the endobiotic-xenobiotic interactions as well as drug-drug interactions may be of great importance when understanding the basis for pharmacological and toxicological actions of a number of xenobiotic chemicals.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Disposition of ropinirole in animals and man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The disposition and metabolic fate of ropinirole, a novel compound indicated for the symptomatic treatment of Parkinson's disease, was studied in the mouse, rat, cynomolgus monkey and man, following oral and intravenous administration of ropinirole hydrochloride.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The disposition and metabolic fate of ropinirole, a novel compound indicated for the symptomatic treatment of Parkinson's disease, was studied in the mouse, rat, cynomolgus monkey and man, following oral and intravenous administration of ropinirole hydrochloride.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In all species, nearly all of the p.o. administered dose (94%) was rapidly absorbed from the gastrointestinal tract following administration of 14C-ropinirole hydrochloride.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In rat and monkey, the compound distributed rapidly beyond total body water and was shown to cross the blood-brain barrier.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood clearance of the compound was high, approximately equal to one-half the hepatic blood flow in the monkey and similar to the hepatic blood flow in rat.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Terminal phase elimination half-lives for the compound were relatively short (0.5 and 1.3 h in rat and monkey respectively), although there was evidence of a second elimination phase in the monkey with an elimination half-life of approximately 5-11 h. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma concentrations of ropinirole after the intravenous dose were not determined in the mouse and were below the lower limit of quantification in man (0.08 ng/ml) at the doses used in the studies described in this paper.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In both animals and man, ropinirole was extensively metabolized.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In the rat, the major metabolic pathway was via hydroxylation of the aromatic ring to form 7-hydroxy ropinirole.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In mouse, monkey and man, the major pathway was via N-depropylation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The N-despropyl metabolite was metabolized further to form 7-hydroxy and carboxylic acid derivatives.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolites formed in all species were generally metabolized further by glucuronidation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
7-Hydroxy ropinirole is the only metabolite of ropinirole previously shown to possess significant dopamine agonist activity in vivo.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In all species, the major route of excretion of ropinirole-related material after oral or intravenous administration of the compound was renal (60-90% of dose).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Determination of the urinary benzene metabolites S-phenylmercapturic acid and trans,trans-muconic acid by liquid chromatography-tandem mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
To investigate how various levels of exposure affect the metabolic activation pathways of benzene in humans and to examine the relationship between urinary metabolites and other biological markers, we have developed a sensitive and specific liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of urinary S-phenylmercapturic acid (S-PMA) and trans,trans-muconic acid (t,t-MA).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The assay involves spiking urine samples with [13C6]S-PMA and [13C6]t,t-MA as internal standards and clean up of samples by solid-phase extraction with subsequent analysis by liquid chromatography coupled with electrospray-tandem mass spectrometry-selected reaction monitoring (LC-ES-MS/MS-SRM) in the negative ionization mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The efficacy of this assay was evaluated in human urine specimens from smokers and non-smokers as the benzene-exposed and non-exposed groups.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The coefficient of variation of runs on different days (n = 8) for S-PMA was 7% for the sample containing 9.4 microg S-PMA/l urine, that for t,t-MA was 10% for samples containing 0.07 mg t,t-MA/l urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean levels of urinary S-PMA and t,t-MA in smokers were 1.9-fold (P = 0.02) and 2.1-fold (P = 0.03) higher than those in non-smokers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean urinary concentration (+/-SE) was 9.1 +/- 1.7 microg S-PMA/g creatinine [median 5.8 microg/g, ranging from not detectable (1 out of 28) to 33.4 microg/g] among smokers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In non-smokers' urine the mean concentration was 4.8 +/- 1.1 microg S-PMA/g creatinine (median 3.6 microg/g, ranging from 1.0 to 19.6 microg/g).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For t,t-MA in smokers' urine the mean (+/-SE) was 0.15 +/- 0.03 mg/g creatinine (median 0.11 mg/ g, ranging from 0.005 to 0.34 mg/g); the corresponding mean value for t,t-MA concentration in non-smokers' urine was 0.07 +/- 0.02 mg/g creatinine [median 0.03 mg/g, ranging from undetectable (1 out of 18) to 0.48 mg/g].

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was a correlation between S-PMA and t,t-MA after logarithmic transformation (r = 0.41, P = 0.005, n = 46).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The lineage-specific human tyrosinase promoter has been used to successfully target gene expression at the transcriptional level to melanoma cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The tyrosinase promoter, alone and in combination with a single, or a dual, tandem melanocyte-specific enhancer, was used to regulate expression of the firefly luciferase reporter gene.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Transient transfections of these tissue-specific luciferase constructs in human and murine melanoma (Pmel, B16mel) and colon carcinoma (WiDr, MC38) cell lines resulted in melanoma-specific luciferase expression that was amplified 5- and 500-fold with the addition of a single or double enhancer, respectively, to the tyrosinase promoter.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When the double enhancer-promoter construct expressed the highly toxic Escherichia coli purine nucleoside phosphorylase (PNP) gene, transfection of the same cell lines followed by administration of the prodrug 6-methyl purine deoxyriboside (6-MPDR) at a concentration of 50 microM caused melanoma-specific in vitro cell killing.

$$$$
>  <CLASS>
Parent

>  <TARGET>
When the double enhancer-promoter construct expressed the highly toxic Escherichia coli purine nucleoside phosphorylase (PNP) gene, transfection of the same cell lines followed by administration of the prodrug 6-methyl purine deoxyriboside (6-MPDR) at a concentration of 50 microM caused melanoma-specific in vitro cell killing.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Within 5 days after prodrug administration methylthiazol-tetrazolium (MTT) cytotoxicity assays showed that only 15 and 9% of Pmel and B16mel cells, respectively, remained viable compared with controls.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This effect was highly specific, as 90 and 96% of WiDr and MC38 colon carcinoma cells remained viable 5 days after identical treatment.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
This effect was a direct result of increased tissue-specific conversion of 6-MPDR to the toxic metabolite 6-methylpurine (6-MP), as documented by HPLC analysis of culture supernatants.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These results show that the dual tandem melanocyte-specific enhancer provides powerful amplification of the transcriptional targeting of gene expression afforded by use of the tyrosinase promoter.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This amplification translates into increased, highly specific cytotoxicity to melanoma by the PNP/6-MPDR enzyme/prodrug system and, therefore, has potential efficacy in the use of gene therapy for the treatment of metastatic melanoma.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The timing of hemodialysis after high-dose CY was extrapolated from available data on the pharmacokinetics of high-dose CY and hemodialysis clearance of conventional dose CY and its metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacokinetic analyses indicated that the elimination of high-dose CY and its alkylating metabolites is impaired in ESRD but is cleared with hemodialysis.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The patient's early post-transplant course was uncomplicated, and WBC and platelet engraftment occurred by day +22.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Bone marrow examination on day +25 showed trilineage engraftment with no AML; cytogenetics showed 100% donor karyotype.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The patient remains in remission with 100% donor karyotype at 3 years post transplant.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clinical results indicate that the administration of high-dose CY is feasible with hemodialysis support for patients with ESRD.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nitroxide metabolism in the human keratinocyte cell line HaCaT.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Metabolism of different nitroxides with piperidine structure used as spin labels in electron spin resonance (ESR) studies in vitro and in vivo was investigated in human keratinocytes of the cell line HaCaT by GC and GC-MS technique combined with S-band ESR.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of different nitroxides with piperidine structure used as spin labels in electron spin resonance (ESR) studies in vitro and in vivo was investigated in human keratinocytes of the cell line HaCaT by GC and GC-MS technique combined with S-band ESR.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Besides the well known reduction of the nitroxyl radicals to the ESR silent hydroxylamines as primary products our results indicate the formation of the corresponding secondary amines.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These reductions are inhibited by the thiol blocking agent N-ethylmaleimide and by the strong inhibitors of the thioredoxin reductase (TR) 2-chloro-2,4-nitrobenzene and 2,6-dichloroindophenol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The competitive inhibitor TR inhibitor azelaic acid and the cytochrome P-450 inhibitor metyrapone lack any effects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The rates of reduction to the hydroxylamines and secondary amines were dependent on the lipid solubility of the nitroxides.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therefore, it can be assumed that the nitroxides must enter the cells for their bioreduction.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The mostly discussed intracellular nitroxide reducing substances ascorbic acid and glutathione were unable to form the secondary amines.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mostly discussed intracellular nitroxide reducing substances ascorbic acid and glutathione were unable to form the secondary amines.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In conclusion, our results suggest that the secondary amine represents one of the major metabolites of nitroxides besides the hydroxylamine inside keratinocytes formed via the flavoenzyme thioredoxin reductase most probably.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Further metabolic conversions were detected with 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl and the benzoate of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl as substrates.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The disposition and metabolism of flurbiprofen in several species including man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flurbiprofen was rapidly absorbed in all species studied.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Half-lives of elimination measured 0 to 12 h after a single dose were: mouse 3.4 h, rat 2.5 h, dog 10.1 h, baboon 3.1 h and man 3.9 h. A second phase of elimination was seen in the dog.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flurbiprofen accumulated in the circulation of the dog on repeated dosing.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After dosing with [14C]flurbiprofen, tissue levels of radioactivity in dog and baboon were similar to that in plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In the rat, levels were slightly elevated in liver, kidney, large intestine and thyroid after repeated dosing.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The dog excreted equal amounts of radioactivity in urine and faeces.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In other species renal excretion was the more important route.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Six metabolites have been detected, the most important being: 2-(2-fluoro-4'-hydroxy-4-biphenylyl)propionic acid (metabolite 1), 2-(i-fluoro-3',4'-dihydroxy-4-biphenylyl)propionic acid (metabolite 2) and 2-(2-fluoro-3'-hydroxy-4'-methoxy-4-biphenylyl)propionic acid (metabolite 3).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The proportions of the metabolites and the extents of their conjugation varied among the species.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolites were detected in the circulation of rat, mouse and baboon but not in dog and man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flurbiprofen did not affect the hepatic drug-metabolizing enzyme system of rat.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flurbiprofen was extensively bound to serum protein of rat, dog, baboon and man.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Assessment of the exposure of children to environmental tobacco smoke (ETS) by different methods.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In order to elucidate the role of exposure to environmental tobacco smoke (ETS) in various acute and chronic illnesses in children, it is important to assess the degree of exposure by suitable methods.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For this purpose, we determined the exposure to ETS in 39 children (4-15 years) and 43 adults (16+ years) by questionnaires, personal diffusion samplers for nicotine, and cotinine measurements in saliva and urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition, the influence of the smoking status and the location of the home (urban or suburban) on the benzene exposure of the children was investigated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On average, the 24 children living in homes with at least one smoker were exposed to ETS for 3.1 h/d.

$$$$
>  <CLASS>
Parent

>  <TARGET>
On average, the 24 children living in homes with at least one smoker were exposed to ETS for 3.1 h/d.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
On average, the 24 children living in homes with at least one smoker were exposed to ETS for 3.1 h/d.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is significantly longer (P<0.001) than the daily exposure time of the 15 children from nonsmoking homes (0.3 h/d).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The nicotine concentrations on the personal samplers worn over 7 days were 0.615 and 0.046 microg/m3 for children from smoking and nonsmoking homes, respectively (P<0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Average salivary cotinine levels were 1.95 ng/ml in children from smoking homes and 0.11 ng/ml in children from nonsmoking homes (P< 0.01).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The corresponding urinary cotinine levels were 29.4 and 4.5 ng/mg creatinine (P< 0.001).

$$$$
>  <CLASS>
NONE

>  <TARGET>
There was no difference in the extent of ETS exposure between children and adults from smoking households.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Adults from nonsmoking homes tended to have higher ETS exposure than children from nonsmoking homes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Exposure to benzene, which was determined by means of personal samplers, measurements of benzene in exhaled air and of the urinary benzene metabolite trans, trans-muconic acid, was not significantly related to the smoking status of the home but primarily dependent on the location of the home.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pineal and extra-pineal origins of 5-sulphatoxy N-acetyl-serotonin in humans.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In humans 6-sulphatoxy melatonin (SaMT) is the principal metabolite of endogenous and exogenous melatonin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
5-sulphatoxy N-acetyl-serotonin (SNAS) is a minor metabolite of exogenous melatonin, but it has not been established whether the levels of endogenous SNAS in plasma derives principally from endogenous melatonin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We have developed the first radioimmunoassay (RIA) for SNAS and used it (together with RIAs for melatonin and SaMT) to determine whether endogenous SNAS derives from endogenous melatonin or from platelet serotonin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Our results show a) the values of endogenous SNAS, unlike endogenous SaMT, increased with blood collection procedures that increased the values of serotonin, b) the values of endogenous SNAS in urine or in platelet-poor plasma were approximately the same as those of endogenous SaMT, but, unlike SaMT, did not show a diurnal rhythm, and c) we confirmed that SNAS was a minor metabolite of orally ingested melatonin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Our results show a) the values of endogenous SNAS, unlike endogenous SaMT, increased with blood collection procedures that increased the values of serotonin, b) the values of endogenous SNAS in urine or in platelet-poor plasma were approximately the same as those of endogenous SaMT, but, unlike SaMT, did not show a diurnal rhythm, and c) we confirmed that SNAS was a minor metabolite of orally ingested melatonin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Thus, our conclusion is that SNAS is a minor metabolite of exogenous melatonin, but is not a significant metabolite of endogenous melatonin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In all probability, endogenous SNAS is principally the metabolite of platelet serotonin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Oral and dermal absorption of chlorpyrifos: a human volunteer study.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
To determine the kinetics of elimination of urinary dialkylphosphate metabolites after oral and dermally applied doses of the organophosphate pesticide chlorpyrifos to human volunteers and to determine whether these doses affected plasma and erythrocyte cholinesterase activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Five volunteers ingested 1 mg (2852 nmol) of chlorpyrifos.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood samples were taken over 24 hours and total void volumes of urine were collected over 100 hours.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Four weeks later 28.59 mg (81567 nmol) of chlorpyrifos was administered dermally to each volunteer for 8 hours.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Unabsorbed chlorpyrifos was washed from the skin and retained for subsequent measurement.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The same blood and urine sampling regime was followed as for the oral administration.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Plasma and erythrocyte cholinesterase concentrations were determined for each blood sample.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The concentration of two urinary metabolites of chlorpyrifos--diethylphosphate and diethyl-thiophosphate--was determined for each urine sample.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The apparent elimination half life of urinary dialkylphosphates after the oral dose was 15.5 hours and after the dermal dose it was 30 hours.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Most of the oral dose (mean (range) 93% (55-115%)) and 1% of the applied dermal dose was recovered as urinary metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
About half (53%) of the dermal dose was recovered from the skin surface.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The absorption rate through the skin, as measured by urinary metabolites was 456 ng/cm2/h.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood plasma and erythrocyte cholinesterase activity did not fall significantly during either dosing regime.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
An oral dose of chlorpyrifos was readily absorbed through the skin and almost all of the dose was recovered as urinary dialkylphosphate metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Excretion was delayed compared with the oral dose.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Only a small proportion of the applied dose was recovered during the course of the experiment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The best time to collect urine samples for biological monitoring after dermal exposure is before the shift the next day.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The amounts of chlorpyrifos used did not depress acetyl cholinesterase activity but could be readily detected as urinary dialkylphosphate metabolites indicating that the urinary assay is a more sensitive indicator of exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Although cell cultures are increasingly being used as models for studying the biological actions of flavonoids, no information on the fate, such as uptake and metabolism, exists for these natural products in these models.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study examined the elimination of quercetin, one of the most abundant flavonoids, from the cultured human hepatocarcinoma cell line Hep G2 using [14C]-labelled compound with HPLC and LC/MS for structure characterization.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study examined the elimination of quercetin, one of the most abundant flavonoids, from the cultured human hepatocarcinoma cell line Hep G2 using [14C]-labelled compound with HPLC and LC/MS for structure characterization.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
These cells showed a 9.6-fold accumulation of quercetin and the formation of an O-methylated metabolite, isorhamnetin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
However, a rapid elimination of quercetin, with no unchanged compound present beyond 8 h, was mainly due to oxidative degradation.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The initial intermediate reaction appears to involve peroxidation, leading to a dioxetan, as evidenced by a 32-amu increase in the molecular ion by LC/MS.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Subsequently, opening of the C-ring leads to the formation of carboxylic acids, the major one identified in this study as protocatechuic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A separate reaction results in a polymeric quercetin product which is highly retained on a reversed-phase C18 HPLC column.

$$$$
>  <CLASS>
Parent

>  <TARGET>
It is postulated that these degradative and metabolic changes contribute to the multiple biological actions reported for quercetin, using cell culture models.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interestingly, part of the degradative pathway could be inhibited by including nontoxic concentrations of EDTA in the cell culture medium.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Determination of ethyl glucuronide, a minor metabolite of ethanol, in human serum by liquid chromatography-electrospray ionization mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A rapid and sensitive determination procedure using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) has been developed for the determination of ethyl glucuronide (EtG) in human serum.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Samples were precipitated with methanol, centrifuged and the supernatant was evaporated to dryness followed by reconstitution with distilled water.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As mobile phase 30 mM ammonium acetate-acetonitrile (30:70, v/v) was utilized.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The base peak observed at m/z 221 was the [M-H]- ion of EtG, which was detectable in satisfactory sense.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection limit was 0.03 microg/ml in the selected ion monitoring mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A calibration graph constructed for EtG in serum gave good linearity over the range from 0.1 to 25 microg/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This paper also presents the application of this LC-ESI-MS procedure to the analysis of authentic serum samples.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Excretion study of the beta2-agonist reproterol in human urine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
An excretion study of the beta2-agonist 7-[3-[(beta-3,5-trihydroxyphenethyl)amino]-propyl]theophylline (reproterol) in human urine, which is reportedly misused by athletes and horses as a doping agent, is presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The study was performed after an oral administration of 20 mg of reproterol hydrochloride.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The collected urine samples were prepared using the standard anabolic steroid extraction procedure and analyzed by gas chromatography coupled with quadrupole mass spectrometry and, also, with high-resolution mass spectrometry (HRMS).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The main reproterol metabolite was found, whereas unchanged reproterol was not detected.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The structure of the main metabolite was confirmed by an accurate HRMS measurement of diagnostic ions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Finally, an excretion urine profile of the main metabolite is presented.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mass spectrum of another possible unidentified reproterol metabolite is also reported.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Simultaneous determination of local anesthetics including ester-type anesthetics in human plasma and urine by gas chromatography-mass spectrometry with solid-phase extraction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The present study describes the simultaneous determination of seven different kinds of local anesthetics and one metabolite by GC-MS with solid-state extraction: Mepivacaine, propitocaine, lidocaine, procaine (an ester-type local anesthetics), cocaine, tetracaine (an ester-type local anesthetics), dibucaine (Dib) and monoethylglycinexylidide (a metabolite of lidocaine) were clearly separated from each other and simultaneously determined by GC-MS using a DB-1 open tubular column.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The present study describes the simultaneous determination of seven different kinds of local anesthetics and one metabolite by GC-MS with solid-state extraction: Mepivacaine, propitocaine, lidocaine, procaine (an ester-type local anesthetics), cocaine, tetracaine (an ester-type local anesthetics), dibucaine (Dib) and monoethylglycinexylidide (a metabolite of lidocaine) were clearly separated from each other and simultaneously determined by GC-MS using a DB-1 open tubular column.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Their recoveries ranged from 73-95% at the target concentrations of 1.00, 10.0 and 100 microg/ml in plasma, urine and water.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Coefficients of variation of the recoveries ranged from 2.3-13.1% at these concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The quantitation limits of the method were approximately 100 ng/ml for monoethylglycinexylidide, propitocaine, procaine, cocaine, tetracaine and dibucaine, and 50 ng/ml for lidocaine and mepivacaine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This method was applied to specimens of patients who had been treated with drip infusion of lidocaine, and revealed that simultaneous determination of lidocaine and monoethylglycinexylidide in the blood and urine was possible.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The human cytochrome P450 (CYP) isoforms mediating nortriptyline 10-hydroxylation have been identified using kinetic studies on heterologously expressed human CYPs and chemical inhibition studies on human liver microsomes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Nortriptyline was metabolized to E-10-hydroxynortriptyline by human lymphoblast-expressed CYPs 2D6 (Km 2.1 microM) and 3A4 (Km 37.4 microM) with high and low affinity, respectively, whereas CYPs 1A2, 2A6, 2B6, 2C9, 2C19, and 2E1 had no detectable activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Human liver microsomal nortriptyline E-10-hydroxylation displayed biphasic kinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The high-affinity component (Km 1.3 +/- 0.4 microM, n = 11 livers) was selectively inhibited by the CYP 2D6 inhibitor quinidine, whereas the CYP3A4 inhibitor ketoconazole selectively inhibited the low-affinity component (K(m) 24.4 +/- 7 microM, n = 11 livers).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition by ketoconazole increased with increasing substrate concentration, whereas the reverse was true for quinidine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The Vmax of the low-affinity component in human liver microsomes was significantly correlated (r2 = 0.84) with the relative activity factor for CYP3A4, a measure of the amount of catalytically active enzyme.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A simulation of the relative contribution of CYPs 2D6 and 3A4 to net nortriptyline hydroxylation rate suggested that the relative contribution of CYP3A4 is only 20% even at the higher end of the therapeutic range.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Induction of CYP3A4 will increase its importance and increase the net metabolic rate, whereas inhibition of CYP3A4 will be of little importance due to its minimal relative contribution under uninduced conditions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The identification of CYP3A4 as a low-affinity nortriptyline E-10-hydroxylase explains the ability of poor metabolizers of debrisoquin to hydroxylate nortriptyline, as well as the increased in vivo clearance via this pathway caused by CYP3A4-inducing drugs such as pentobarbital, carbamazepine, and rifampin.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The role of drug metabolism in drug discovery (lead compound selection) and the traditional role of identifying the enzymes involved in biotransformation pathways (reaction phenotyping) have both relied heavily on the availability and use of a human liver bank.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The assessment of drug metabolizing enzyme activity and variability in a series of individual human livers is essential when characterizing the enzymes involved in metabolic pathways (i.e. correlation analysis).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In this regard, a human liver bank of 21 samples (14 males, six females, and one unknown) was characterized with respect to the activity of several important drug metabolizing enzymes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The total CYP450 content of the livers ranged from 0.06 to 0.46 nmol/mg microsomal protein.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The fold variations found in specific enzyme contents were as follows: CYP1A2 (3x), CYP2A6 (21x), CYP2C9 (8x), CYP2C19 (175x), CYP2D6 (18x), CYP2E1 (5x), CYP3A4 (18x), FMO (2.5x), UDPGT (4x), NAT (7x), COMT (5x), ST (5x), TPMT (3x), and GST (2.5x).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In general, the fold variation of the Phase II enzymes was lower compared with the Phase I enzymes, with the exceptions of CYP1A2, CYP2E1, and FMO.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similar data were reviewed from other established liver banks and compared with regard to the relative variability observed in drug metabolizing capacities found in this study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetic and pharmacodynamic interactions between the gastrokinetic drug cisapride and the antipsychotic drugs bromperidol and haloperidol were studied in 29 schizophrenic inpatients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fourteen patients were taking bromperidol (12-24 mg/d), and 15 were taking haloperidol (12-36 mg/d).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cisapride 10 mg/d was coadministered for 1 week, and blood sampling was performed before cisapride treatment, 1 week after starting cisapride treatment, and I week after stopping cisapride treatment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
On the same days as the blood sampling, psychotic symptoms and side effects were evaluated using the Brief Psychiatric Rating Scale (BPRS) and the Udvalg for Kliniske Undersgelser (UKU) side effect rating scale (UKU), respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Plasma concentrations of bromperidol, haloperidol, and their reduced metabolites were measured by high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean BPRS scores after adding cisapride were significantly higher than those before cisapride (p<0.01) and after stopping cisapride (p<0.001) in the haloperidol group in this uncontrolled study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A similar tendency was observed in the bromperidol group, although it did not reach statistical significance (p = 0.08).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cisapride coadministration caused no significant changes in the mean plasma concentrations of bromperidol, haloperidol, and their reduced metabolites or in the mean UKU score.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cisapride coadministration caused no significant changes in the mean plasma concentrations of bromperidol, haloperidol, and their reduced metabolites or in the mean UKU score.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The present study suggests that there is no significant pharmacokinetic interaction between cisapride and bromperidol or haloperidol, but cisapride appears to deteriorate psychotic symptoms by a pharmacodynamic interaction in schizophrenic patients treated with haloperidol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Two separate gas chromatographic methods for the determination of buspirone and its active metabolite, 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma are described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both procedures involve solid-phase extraction (the packing material of the cartridges used was C8 for buspirone and a mixed-mode sorbent for 1-PP), injection of the sample into a gas chromatograph equipped with a fused-silica capillary column and a nitrogen-phosphorus detector, and analysis with temperature programming (from 220 degrees C to 285 degrees C for buspirone and from 138 degrees C to 285 degrees C for 1-PP).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The coating material of the analytical column was 5% diphenyl dimethyl silicone for buspirone and 50% diphenyl dimethyl silicone for 1-PP.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zolpidem was used as an internal standard in the buspirone assay and 1-phenylpiperazine in the 1-PP assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The between-run coefficients of variation ranged from 3.2% to 9.4% and from 2.9% to 8.6% for samples spiked with three different concentrations of buspirone and 1-PP, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The suitability of these assays for pharmacokinetic studies was shown by analyzing timed plasma samples from volunteers after ingestion of a single therapeutic dose of buspirone (10 mg).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nail analysis for drugs of abuse: extraction and determination of cannabis in fingernails by RIA and GC-MS. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fingernail clippings were evaluated as analytical specimens for the detection and quantitation of cannabinoids.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Specimens were obtained from consenting adults attending a drug clinic, along with information concerning the drugs which they had used over the previous six months.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Methods for the surface decontamination and extraction of the specimens were evaluated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Detergent, water, and methanol washes followed by alkaline hydrolysis and liquid-liquid extraction were selected for use in the study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Extracts were analyzed by radioimmunoassay (RIA) and gas chromatography-mass spectrometry (GC-MS) to detect and quantitate cannabinoids present in fingernail clippings.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Positive RIA results were obtained from specimens from six known cannabis users.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mean cannabinoid concentration in fingernail clippings determined by RIA was 1.03 ng/mg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using GC-MS, the mean delta9-tetrahydrocannabinol concentration in fingernail clippings from a further 14 known cannabis users was 1.44 ng/mg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using GC-MS, the average 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid concentration in fingernail clippings from three known cannabis users extracted in acidic pH was 19.85 ng/mg.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Based on these results, fingernails are potentially useful biological specimens for the detection of past cannabis use in cases of medicolegal interest.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
GC-MS confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A procedure for the simultaneous confirmation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in urine specimens by gas chromatography-mass spectrometry (GC-MS) is described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After the addition of nalorphine and naltrexone as the two internal standards, the urine is hydrolyzed overnight with beta-glucuronidase from E. coli.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The urine is adjusted to pH 9 and extracted with 8% trifluoroethanol in methylene dichloride.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After evaporating the organic, the residue is sequentially derivatized with 2% methoxyamine in pyridine, then with propionic anhydride.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The ketone groups on hydrocodone, hydromorphone, oxycodone, oxymorphone, and naltrexone are converted to their respective methoximes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Available hydroxyl groups on the O3 and O6 positions are converted to propionic esters.

$$$$
>  <CLASS>
NONE

>  <TARGET>
After a brief purification step, the extracts are analyzed by GC-MS using full scan electron impact ionization.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nalorphine is used as the internal standard for codeine, morphine, and 6-acetylmorphine; naltrexone is used as the internal standard for the 6-keto-opioids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The method is linear to 2000 ng/mL for the 6-keto-opioids and to 5000 ng/mL for the others.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The limit of quantitation is 25 ng/mL in hydrolyzed urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Day-to-day precision at 300 and 1500 ng/mL ranged between 6 and 10.9%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The coefficients of variation for 6-acetylmorphine were 12% at both 30 and 150 ng/mL.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A list of 38 other basic drugs or metabolites detected by this method is tabulated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amphetamine and fenproporex levels following multidose administration of fenproporex.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Drugs that are metabolized to amphetamine or methamphetamine are potentially of significant concern in the interpretation of positive drug-testing results for amphetamines.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A number of different drugs have been reported to produce amphetamine in the urine of users.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A number of different drugs have been reported to produce amphetamine in the urine of users.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
A number of different drugs have been reported to produce amphetamine in the urine of users.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
One of these compounds, fenproporex, has been shown to be metabolized to amphetamine, and previous reports indicated the parent compound could be detected at low levels for up to 48 h. 

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Administration of fenproporex for seven days (one 10-mg dose per day) to five healthy volunteers resulted in amphetamine being detected in the urine of all subjects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Peak concentrations of amphetamine ranged from approximately 2850 to 4150 ng/mL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amphetamine could be detected (> or = 5 ng/mL) in the urine for up to nearly 170 h after the last dose.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Analysis of the metabolically produced amphetamine showed the presence of both enantiomers, which can be helpful in the differentiation of some illicit amphetamine use from the use of this precursor drug.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In addition, evaluation of the enantiomeric composition of the metabolite (amphetamine) can be a valuable tool in the interpretation of time since last dose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
More significantly, all samples that contained amphetamine at a concentration of > or = 500 ng/mL were shown to also contain detectable amounts of the parent compound.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
D0870, an azole antifungal agent, produced dose-related increases in total cytochrome P450 and aldrin epoxidase when administered as 14 daily oral doses (0, 0.5, 2.5 and 12.5 mg/kg/day) to the male rat.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Administered as single doses, D0870 increased pentobarbitone-sleeping time in a dose-related manner.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In human hepatic microsomal incubations, D0870 produced pronounced inhibition of CYP2C9 (tolbutamide hydroxylase) and, to a lesser degree, CYP3A4 (testosterone 6beta-hydroxylase), but had more limited effects on CYP1A2, 2C19 and 2D6 activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In human hepatic microsomal incubations, D0870 produced pronounced inhibition of CYP2C9 (tolbutamide hydroxylase) and, to a lesser degree, CYP3A4 (testosterone 6beta-hydroxylase), but had more limited effects on CYP1A2, 2C19 and 2D6 activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In comparison with ketoconazole, itraconazole and fluconazole, D0870 was the most potent inhibitor of CYP2C9 activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is predicted that D0870 may inhibit the in vivo clearance of CYP2C9 substrates by approximately 58%, thereby increasing their steady-state concentrations by 2.4 times, which would be of clinical significance for some compounds.

$$$$
>  <CLASS>
Parent

>  <TARGET>
During incubation of [14C]-D0870 with cultured human hepatocytes for up to 72 h, two discrete metabolites (A and B) were formed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Formation of metabolite A was abolished by both quinidine and ketoconazole and is probably CYP3A4-mediated, whereas generation of metabolite B did not appear to be dependent on cytochrome P450.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
D0870 has potential to produce both induction and inhibition of cytochrome P450 enzymes in man.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Renal handling of drugs in the healthy elderly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It is commonly assumed that renal function, and in parallel the excretion of drugs, is considerably reduced in the elderly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Endogenous creatinine clearance or indirect estimates of this parameter are generally recommended for adapting drug dosage.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The present study evaluates the validity of both assumptions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We compared pharmacokinetics (and pharmacodynamics) of 50 mg atenolol, 800 mg piracetam and 25 mg hydrochlorothiazide plus 50 mg triamterene in ten healthy young [25 (2) years] and 11 healthy elderly subjects [68 (5) years].

$$$$
>  <CLASS>
Parent

>  <TARGET>
Inulin (Cin) and para-aminohippurate [PAH (CPAH)] clearance (infusion clearance technique), endogenous (C(Cr)) and calculated (Cockroft-Gault) creatinine clearance, analysis of drugs and their metabolites (HPLC), were performed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Renal haemodynamics and the pharmacokinetics of beta-adrenergic blocking agent, diuretics and the nootropic agent piracetam, respectively, were measured on separate days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Similar results were obtained for hydrochlorothiazide, whereas no marked differences between the groups were found for triamterene and its metabolite.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Similar results were obtained for hydrochlorothiazide, whereas no marked differences between the groups were found for triamterene and its metabolite.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Furthermore, the pharmacodynamic action of diuretics was not significantly altered in the elderly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The true GFR of the healthy elderly remains within the normal range and is underestimated by creatinine clearance and more so by its surrogate (Cockroft-Gault clearance).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In parallel, pharmacokinetics of renally excreted drugs are not affected in the healthy elderly to a clinically significant extent.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For drugs with a narrow therapeutic window, indirect estimates of GFR appear to be an unreliable means for calculating correct dosage in the elderly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Studies of a series of 1-(benzofuran-2-ylmethyl)imidazoles, 1-5, previously proposed as potential agents for prostatic cancer by their inhibition of 17beta-hydroxylase:17,20-lyase (P450 17), have been extended to their selectivity against placental microsomal aromatase (P450(Arom)) in man.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The compounds were 3-7-fold more potent than aminoglutethimide and had some selectivity for P450 17 as expressed by the ratio (IC50 P450(Arom))/(IC50 P450) 17)/17.0 (2), 10.3 (3), 34.6 (4) and 42.0 (5), where IC50 is the concentration resulting in 50% inhibition.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The lower potency of 1-5 towards P450(Arom) compared with the racemic alpha-phenyl-substituted compounds (6, 80-1000 x aminoglutethimide) and some racemic alpha-methyl (8.5 and 12.2 x aminoglutethimide) and alpha-ethyl (12.1 and 32.9 x aminoglutethimide) analogues has been rationalized.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
The lower potency of 1-5 towards P450(Arom) compared with the racemic alpha-phenyl-substituted compounds (6, 80-1000 x aminoglutethimide) and some racemic alpha-methyl (8.5 and 12.2 x aminoglutethimide) and alpha-ethyl (12.1 and 32.9 x aminoglutethimide) analogues has been rationalized.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This work selectively extends studies of the P450 17 inhibitor 5, a potential prostatic cancer agent, towards other cytochrome P450 enzymes in the steroidogenic pathway and provides a general method for determining the relative influence of chemical manipulation of a parent inhibitor towards two enzymes in the pathway using additional literature data.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro evaluation of aromatase enzyme in granulosa cells using a [11C]vorozole binding assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An in vitro method for measuring aromatase cytochrome P450 enzyme (P450AROM) in human granulosa cells (GC) has been developed, based on binding of the 11C-labeled aromatase inhibitor vorozole.

$$$$
>  <CLASS>
NONE

>  <TARGET>
GC were obtained following superstimulation during in vitro fertilisation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method revealed a binding affinity (Kd) of 0.4 nM and a maximum binding (Bmax) at 11 fmol/4000 cells which is equal to 1.6 million binding sites per cell.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Linear Scatchard plots indicated a single type of binding site.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
P450AROM concentrations measured by [11C]vorozole binding correlated positively with aromatisation of [1beta-3H]androst-4-ene-3,17-dione measured as [3H]water release, and a positive association was also found with the ovarian in vivo response to follicle-stimulating hormone (FSH) stimulation expressed as 1000 times the ratio of the number of oocytes recovered from a patient and the total dose of recombinant FSH administered.

$$$$
>  <CLASS>
Parent

>  <TARGET>
P450AROM concentrations measured by [11C]vorozole binding correlated positively with aromatisation of [1beta-3H]androst-4-ene-3,17-dione measured as [3H]water release, and a positive association was also found with the ovarian in vivo response to follicle-stimulating hormone (FSH) stimulation expressed as 1000 times the ratio of the number of oocytes recovered from a patient and the total dose of recombinant FSH administered.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Frozen cells could be used for P450AROM quantitation, provided the correct freezing procedure was used.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quantitation of P450AROM, based on binding of [11C]vorozole is an accurate and sensitive in vitro method, which might be extended to the measurement of aromatase expression by a noninvasive technique in the intact ovary in vivo using positron emission tomography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Synthesis and structure-activity relationships of 6-phenylaliphatic-substituted C19 steroids having a 1,4-diene, 4,6-diene, or 1,4,6-triene structure as aromatase inhibitors.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A series of 6alpha- and 6beta-phenylaliphatic-substituted androsta-1,4-diene-3,17-diones [9b-f and 10b-f; (CH2)nPh, n = 1-5] and their 4,6-diene and 1,4,6-triene analogs (11b-f and 12b-f) along with their respective phenyl analogs 9a-12a were synthesized and tested as aromatase inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All of the steroids examined were very powerful competitive inhibitors of aromatase in human placental microsomes with apparent Ki values ranging from 8.5 to 80 nM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The inhibitory activities of the benzyl- and phenethyl-4,6-dienes 11b and 11c (Ki, 9.0 and 10 nM) as well as the 6-phenethyl-1,4,6-triene 12c (Ki, 8.5 nM) were extremely high among them.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
All of the phenylaliphatic steroids, except for the 6beta-phenethyl compound 10c, and the 6-phenyl-4,6-diene 11a had higher affinity for aromatase than the corresponding parent 1,4-diene, 4,6-diene, and 1,4,6-triene steroids 9g, 11g, and 12g.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All of the 6alpha-substituted 1,4-dienes (9a-9g) and the 6-substituted 1,4,6-trienes (12a-12g) caused a time-dependent inactivation of aromatase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the other hand, only the 6beta-substituted 1,4-dienes (10a-10d) having no or less than four carbon atoms between the steroid nucleus and the phenyl group also caused a time-dependent inactivation of aromatase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Their inactivation rates (k(inact) 0.076-0.156 min(-1)) were higher than the respective parent steroids, 9g and 12g.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, in the 4,6-diene series, only the 6-phenpropyl steroids 11d inactivated aromatase in a time-dependent manner with 0.155 min(-1) of k(inact) value.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The inactivation was prevented by the substrate androstenedione, and no significant effect of L-cysteine on the inactivation was observed in each case.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results indicate that length and/or stereochemistry of the C-6 substituent of steroids 9-12 as well as a terminal phenyl group incorporated in the C-6 substituent play a critical role not only in tight binding to the active site of aromatase but also in the cause of a time-dependent inactivation of the enzyme.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Doxazosin is an antihypertensive drug that gives rise to 6- and 7-hydroxydoxazosin during hepatic metabolism.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The structures of the hydroxymetabolites suggest that they may possess antioxidative properties.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aim of the present study was to examine whether doxazosin and 6- and 7-hydroxydoxazosin were able to scavenge free radicals and whether these compounds might protect low-density lipoprotein (LDL) against in vitro and ex vivo oxidation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both 6- and 7-hydroxydoxazosin showed radical scavenging capacity as assessed by measuring scavenging of 1,1-diphenyl-2-picrylhydrazyl radicals.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro incubation with 10 microM 6- and 7-hydroxydoxazosin significantly reduced human mononuclear cell-mediated oxidation of LDL, measured as the formation of lipid peroxides and the relative electrophoretic mobility of LDL (to 10 and 6% of the control, respectively).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, formation of conjugated dienes in LDL during Cu2+-induced oxidation was significantly reduced in the presence of 5 microM 6- and 7-hydroxydoxazosin (to 28% of tmax [time to maximum] of control).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, treatment of hypertensive patients with increasing doses of doxazosin (from 1 to 8 mg/day) for 8 weeks altered neither Cu2+-catalyzed, 2,2'azobis-(2-amidinopropane hydrochloride)-initiated, nor cell-mediated oxidation of patient LDL ex vivo.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Furthermore, the total antioxidative capacity of plasma was unaffected by treatment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In conclusion, the present study shows that 6- and 7-hydroxydoxazosin have radical scavenging properties and protect LDL against in vitro oxidation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, treatment of hypertensive male subjects with increasing doses of doxazosin for 8 weeks did not affect ex vivo oxidation of LDL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Testing for anabolic steroids in hair from two bodybuilders.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Two male bodybuilders were recently arrested by the French customs in Strasbourg (France) in possession of 2050 tablets and 251 ampoules of various anabolic steroids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It was claimed that the steroids were for personal use and not for trafficing as suggested by the police.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Urine and hair specimens were collected from both suspects to clarify the claims.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nandrolone, stanozolol, testosterone and their corresponding metabolites were identified in the urine of both subjects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After decontamination, the hair was hydrolyzed by sodium hydroxide in presence of deuterated internal standards.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After extraction with ethyl acetate and silylation, the drugs were identified by GC-MS in the electron impact mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Hair from both males were positive for nandrolone (196 and 260 pg/mg), testosterone (46 and 71 pg/mg) and stanozolol (135 and 156 pg/mg), clearly indicating steroids abuse.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Although not yet recognized by the International Olympic Committee, hair analysis may be a useful adjunct to conventional drug testing in urine from athletes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A high-performance liquid chromatographic (HPLC) method for the simultaneous determination of cilostazol, a quinolinone derivative, and its known metabolites OPC-13015, OPC-13213, OPC-13217, OPC-13366, OPC-13269, OPC-13326 and OPC-13388 in human plasma was developed and validated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol, its metabolites and two internal standards, OPC-3930 and OPC-13112, were extracted from human plasma by a combination of liquid-liquid and liquid-solid phase extractions, with combined organic solvents of n-butanol, methanol, chloroform, methyl-tert.-butyl ether, and a Sep-Pak silica column.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cilostazol, its metabolites and two internal standards, OPC-3930 and OPC-13112, were extracted from human plasma by a combination of liquid-liquid and liquid-solid phase extractions, with combined organic solvents of n-butanol, methanol, chloroform, methyl-tert.-butyl ether, and a Sep-Pak silica column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The combined extract was then evaporated and the residue was reconstituted in ammonium acetate buffer (pH 6.5).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The reconstituted solution was injected onto a HPLC system and was subjected to reversed-phase HPLC on a 5 microm ODS-80TM column to obtain quality chromatograph and good peak resolution.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A gradient mobile phase with different percentages of acetonitrile in acetate buffer (pH 6.5) was used for the resolution of analytes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cilostazol, its metabolites and the two internal standards were well separated at baseline from each other with resolution factor being 74 and 138.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This HPLC method was demonstrated to be specific for all analytes of interest with no significant interference from the endogenous substances of human plasma.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The lower limit of quantitation was 20 ng/ml for cilostazol and all metabolites.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The method was validated initially for an extended linear range of 20-600 ng/ml for all metabolites and cilostazol, and has been revised later for a linear range of 20-1200 ng/ml for cilostazol and two major and active metabolites OPC-13015 and OPC-13213.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The overall accuracy (relative recovery) of this method was established to be 98.5% to 104.9% for analytes with overall precision (CV) being 1.5% to 9.0%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The long-term stability of clinical plasma samples was established for at least one year at -20 degrees C. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Two internal standards of OPC-3930 and OPC-13112 were evaluated and validated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, the data indicated that there was no significant difference for all accuracy and precision obtained by using either OPC-3930 or OPC-13112.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
OPC-3930 was chosen as the internal standard for the analysis of plasma samples from clinical studies due to its shorter retention time.

$$$$
>  <CLASS>
Parent

>  <TARGET>
During the validation standard curves had correlation coefficients greater than or equal to 0.998 for cilostazol and the seven metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These data clearly demonstrate the reliability and reproducibility of the method.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
CPT-11 is a prodrug activated by carboxylesterases to the active metabolite SN-38 which is a potent inhibitor of topoisomerase I. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
CPT-11 is of clinical interest in the treatment of colorectal cancer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We evaluated the activities of CPT-11 converting carboxylesterase (CPT-CE) and topoisomerase I (topo I) in 53 colorectal tumours, in eight liver metastases and in normal tissue adjacent to the tumours.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Both CPT-CE and topo I activities were widely variable in the malignant and the normal tissue of patients with colorectal carcinomas.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CPT-CE was only two to threefold lower in primary tumours compared to normal liver, suggesting that a local conversion to SN-38 might occur in tumour cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
CPT-CE was similar in liver and in normal colon tissues.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Levels of topo I in tumour ranged from 580 to 84 900 U mg protein(-1) and was above 40 000 U mg protein(-1) in 11 of 53 patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similarly, a very high ratio (> 5) between tumour and normal tissues were observed in 12 of 53 patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
An inverse correlation was observed between the topo I activity and the clinical stage of disease.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clinical studies are in progress in our institution to explore a possible relationship between CPT-CE and topo I activities in tumour cells and the response to CPT-11-based chemotherapy in patients with colorectal cancer.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Direct determination of methamphetamine enantiomers in urine by liquid chromatography with a strong cation-exchange precolumn and phenyl-beta-cyclodextrin-bonded semi-microcolumn.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Methamphetamine enantiomers in drug abusers' urine were clearly separated by semi-microcolumn liquid chromatography using a column-switching system.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The system consists of two separation processes: firstly, a strong cation-exchange precolumn removes neutral and anionic substances in urine, and then methamphetamine enantiomers trapped in the column are transferred to and separated in a phenyl-beta-cyclodextrin-bonded semi-microcolumn (Chiral Drug, 150 mm x 1.5 mm I.D.).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
(S)-(+)-Methamphetamine was baseline separated from (R)-(-)-methamphetamine within 25 min, directly from urine samples.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection limit for both enantiomers was 0.1 microg/ml.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A sensitive HPLC-MS method was developed for the simultaneous determination of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide (aldocyclophosphamide), 4-ketocyclophosphamide, caboxyphosphamide and 3-dechloroethylifosfamide in human plasma.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
4-Hydroxycyclophosphamide was converted with methylhydroxylamine to the stable methyloxime form.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
4-Hydroxycyclophosphamide was converted with methylhydroxylamine to the stable methyloxime form.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We used a solid-phase extraction with C18 cartridges followed by HPLC-MS with the single mass spectrometer SSQ 7000 of Finnigan.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limits of detection were 15 ng/ml for cyclophosphamide, 3-dechloroethylifosfamide and ketocyclophosphamide in each case and 30 ng/ml for carboxyphosphamide and 4-hydroxycyclophosphamide, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
First results of pharmacokinetics are shown.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The role of metabolism in determining susceptibility to parathion toxicity in man.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Human liver microsomes (n = 16) activated parathion (O, O, diethyl O-p-nitrophenyl phosphorothioate, 20 and 200 microM) to paraoxon at a rate of 23.3-199.3 and 18.7-310.3 pmol/min per mg protein, respectively.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
p-Nitrophenol, was also formed, at 321.1-769.2 and 406.2-778.3 pmol/min per mg protein.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This represented a 16-fold and 2-fold range in capacity to activate and detoxify parathion, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Parathion was activated with an apparent Km of 9-16 microM (n = 3).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The activation of parathion (200 microM) was positively correlated with nifedipine oxidation, indicating the involvement of CYP3A.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The activation of parathion (200 microM) was positively correlated with nifedipine oxidation, indicating the involvement of CYP3A.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Correlations were not significant with ethoxyresorufin-O-dealkylation (CYP1A1/2), pentoxyresorufin-O-dealkylation (CYP2B6), p-nitrophenol hydroxylation (CYP2E1), paraoxon hydrolysis (A-esterase) or phenylvalerate hydrolysis (B-esterase).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Paraoxon formation from parathion was markedly reduced by CYP3A inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Experiments with EDTA indicated that A-esterase was not functionally important at low levels of paraoxon.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Human P450s 3A4 and 3A5 expressed microsomes were the most efficient at biotransforming parathion to paraoxon, although P450s 1A1, 2B6 and 2C8 also catalysed the reaction.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study has determined wide interindividual variations in capacity to metabolise parathion, mainly by CYP3A, which may influence its manifest toxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Maintenance of steroid metabolism and hormone responsiveness in cryopreserved dog, monkey and human hepatocytes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The efficient and effective use of hepatocytes from larger species and rare human material requires a reliable storage method for cells not needed on the day of preparation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cryopreservation would seem to be the only viable alternative.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In this study the suitability of a published cryopreservation technique on dog, monkey and human hepatocytes has been examined and the cells were tested for functionality directly after thawing and subsequent to culture using steroid metabolism and hormone responsiveness of glycogen phosphorylase a. 

$$$$
>  <CLASS>
Parent

>  <TARGET>
Monkey and human hepatocytes appear to survive the freezing and thawing process better than dog cells-the latter losing the ability to respond to adrenergic stimuli and their ability to maintain steroid metabolism in culture.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Although monkey and human cells do preserve their steroid metabolising capacity after freeze/thawing, there is not the significant increase in enzyme activity seen during culturing freshly isolated cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It would appear, therefore, that some damage has occurred to the cells during the freeze/thaw process.

$$$$
>  <CLASS>
NONE

>  <TARGET>
As previously noted, Williams' medium E is superior to Ham's F-10 in maintaining enzyme activities in culture.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It is suggested that cryopreservation is the way forward for the development of stockpiles of viable hepatocytes for biomedical and toxicological research and development but that further modifications to the process are still necessary to optimise the maintenance of liver-specific functions in the thawed cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Intratumoral levels of estrogens in breast cancer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Breast cancer tissue is an endocrine organ and particularly the estrogen biosynthetic properties of this tissue have been well studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The concentration of estradiol in breast cancer tissue from postmenopausal patients is considerably higher than that in the circulation and appears to depend largely on local production.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Androgenic precursor steroids are abundantly present, but estrogen storage pools like fatty acid derivatives appear to be less important than initially thought.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Androgenic precursor steroids are abundantly present, but estrogen storage pools like fatty acid derivatives appear to be less important than initially thought.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
New, potent and highly specific aromatase inhibitors effectively inhibit peripheral conversion of androgens to estrogens (Cancer Res. 53: 4563, 1993) as well as intratumour aromatase, median aromatase activity being 89% lower in the tissue from patients pretreated with aromatase inhibitor 7 days prior to surgery (P < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Also the intratissue concentrations of estrogens were decreased (64% and 80% reduction, respectively for estrone and estradiol; P = 0.001 and <0.05; Cancer Res. 57: 2109, 1997).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results illustrate that intratissue estrogen biosynthesis is effectively inhibited by the new generation of aromatase inhibitors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The pathophysiological consequences of this finding are currently under study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of thiopurine S-methyltransferase activity by impurities in commercially available substrates: a factor for differing results of TPMT measurements.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thiopurine S-methyltransferase (TPMT) activity, when measured in red blood cells (RBC) with a recently published TPMT activity assay using 6-thioguanine (6-TG) as substrate, could not be reproduced in another laboratory.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We investigated factors which could influence the results of the TPMT activity measurement.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We tested twelve 6-TG and four 6-mercaptopurine (6-MP) compounds from different suppliers as substrates and determined the enzyme kinetic parameters Km and Vmax.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, we studied the influence of different 6-TG compounds on the affinity of the methyl donor S-adenosyl-L-methionine (SAM) to the TPMT enzyme.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All 6-TG products were of equal purity (declared >98% by the supplier): this was ascertained by HPLC.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, the rate of methylation obtained following incubation with 6-TG from different suppliers ranged from 10% to 100% when incubated with the same RBC lysate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The lowest apparent Km value for a 6-TG was 22.3 micromol x l(-1), while the product with the highest methylation rate showed a Km of 156 micromol x l(-1).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
From these results we assume that there is a contaminant in some 6-TG products, which acts as a strong inhibitor of TPMT activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Compounds possibly used for the synthesis of 6-TG (guanine, pyridine, 6-chloroguanine) did not affect the methylation rate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thioxanthine, which is known to be a strong inhibitor of TPMT when added to the assay system to give a 2% contamination, reduced TPMT activity from 100% to 72%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using 6-MP from different suppliers as substrate resulted in Km values ranging from 110 to 162 micromol x l(-1) and Vmox values ranging from 54 to 68 nmol 6-MMP x g(-1)Hb x h(-1).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The Km value for the methyl donor SAM was similar to and independent from the thiopurine substrates tested (range 4.9-11 micromol-l(-1) SAM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast to other investigators, we found non-enzymatic S-methylation, which was negligible under our assay conditions (3% with 128 micromol x l(-1) SAM), but could become relevant in experiments using higher SAM concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
TPMT enzyme activity determined with 6-TG as substrate may be strongly inhibited by a contaminant in some of the 6-TG lots distributed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The low potential for drug interactions with zanamivir.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The objective of this study was to assess the potential of zanamivir, a specific inhibitor of influenza A and B virus neuraminidase, to interact with other coadministered therapies in the clinical setting.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Potential interactions with zanamivir were examined in a series of in vitro and in vivo model systems.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The expression of microsomal cytochrome P450 (CYP) isoenzymes was examined after daily treatment of rats with intravenous zanamivir.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The ability of zanamivir to inhibit the metabolism of CYP probe substrates was studied in human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The binding of zanamivir to human and animal red blood cell fractions and plasma proteins was measured.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Finally, the effect of commonly coadministered drugs on the ability of zanamivir to inhibit viral replication in vitro was tested.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zanamivir had no effect on the expression of microsomal CYP isoenzymes after daily intravenous treatment of rats with zanamivir 1, 9 or 90 mg/kg for 5 weeks.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zanamivir at concentrations up to 500 mumol/L (150 mg/L) had no effect on the metabolism of the CYP probe substrates bufuralol, chlorzoxazone, coumarin, ethoxyresorufin, mephenytoin, midazolam, phenacetin and tolbutamide by human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The binding of zanamivir 0.05 to 10 mg/L to human, dog and rat red blood cells and plasma proteins was low.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The in vitro potency of zanamivir against influenza virus in Madin Darby canine kidney cells was not adversely affected by aspirin (acetylsalicylic acid) 1.2 mmol/L, paracetamol (acetaminophen) 6.6 mmol/L, ibuprofen 243 mumol/L, phenylephrine 6 mmol/L, oxymetazoline 380 mumol/L, promethazine 35 mumol/L and co-amoxiclav (amoxicillin-clavulanic acid) 1.66 mmol/L.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These data suggest the following: (i) there is no theoretical basis for expecting metabolic interactions between zanamivir and other coadministered compounds; (ii) zanamivir is unlikely to interact with coadministered compounds that are protein bound; and (iii) commonly coadministered drugs will not interfere with the antiviral activity of zanamivir in vivo.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Although none of these in vitro or in vivo studies were exhaustive, and although none were performed in humans, all the data are consistent with zanamivir having a very low potential for interactions with coadministered drugs in the clinical setting.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Simultaneous determination of the urinary metabolites of toluene, xylene and styrene using high-performance capillary electrophoresis.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Comparison with high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A simple and rapid method using high-performance capillary electrophoresis (HPCE) for the simultaneous determination of the urinary metabolites of toluene, xylene and styrene, plus creatinine and uric acid in human urine specimens and standard solutions is described.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A simple and rapid method using high-performance capillary electrophoresis (HPCE) for the simultaneous determination of the urinary metabolites of toluene, xylene and styrene, plus creatinine and uric acid in human urine specimens and standard solutions is described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The compounds were well separated from each other on a fused-silica capillary utilizing a 20 mM sodium tetraborate buffer (pH 9.65) with 15 mM beta-cyclodextrin and UV detection at 200 and 225 nm.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The total analysis time was less than 6 min per sample.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The capillary zone electrophoresis (CZE) method shows a good correlation with the high-performance liquid chromatography (HPLC) method with respect to urinary hippuric acid concentrations in the urine specimens of subjects exposed to the vapors of a solvent mixture of toluene and xylene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In comparing these two techniques, HPCE was found to be superior to HPLC because the analysis time is shorter, and the separation of m-MHA and p-MHA takes a long time with HPLC.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methylphenidate is the most commonly prescribed psychostimulant in clinical use today.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Known methylphenidate metabolites include ritalinic acid, corresponding lactams, and p-hydroxymethylphenidate.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Recent in vitro work using rat liver preparations has indicated that the methylphenidate ethyl ester, ethylphenidate, is formed upon incubation with ethanol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Recent in vitro work using rat liver preparations has indicated that the methylphenidate ethyl ester, ethylphenidate, is formed upon incubation with ethanol.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
This report describes the first detection of ethylphenidate in human blood and liver samples obtained from two suicide victims who had overdosed on methylphenidate and coingested ethanol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This report describes the first detection of ethylphenidate in human blood and liver samples obtained from two suicide victims who had overdosed on methylphenidate and coingested ethanol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amounts of ethylphenidate detected in whole blood specimens in these two cases (8 ng/mL and 1 ng/mL, respectively) were small relative to methylphenidate and ritalinic acid concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nonetheless, given the high likelihood that methylphenidate and ethanol coingestion frequently occurs, the detection of ethylphenidate in humans warrants further investigation into the extent of its formation as well as into any associated toxicity in nonoverdose situations.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Direct semiquantitative screening of drugs of abuse in serum and whole blood by means of CEDIA DAU urine immunoassays.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The purpose of this study was to test the direct applicability of CEDIA DAU urine immunoassays to serum or whole blood.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The performance of the urine assays for sensitive screening of amphetamines (AMP), benzoylecgonine (BZE), benzodiazepines (BENZ), methadone (MET), opiates (OPI), and tetrahydrocannabinol carboxylic acid (THCCOOH) was evaluated on the BM/Hitachi 911 analyzer with unpretreated serum and whole blood.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The limit of detection was 0 ng/mL for all tests.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cutoff values were set from 10 to 40 ng/mL for the different assays.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The assays were found to be linear between the following concentrations: AMP 0-2500 ng/mL, BZE 0-1200 ng/mL, BENZ 0-1600 ng/mL, MET 0-600 ng/mL, OPI 0-720 ng/mL, and THCCOOH 24-60 ng/mL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Precision results (within run) for different concentrations were as follows: AMP 3.1-5.7%, BZE 2.4-6.6%, BENZ 4.3-8.0%, MET 2.0-5.5%, OPI 2.8-7.6%, and THCCOOH 1.4-2.4%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Between-run results were as follows: AMP 8.7-15.5%, BZE 6.4-7.5%, BENZ 8.2-15.8%, MET 2.7-5.1%, OPI 4.3-11.2%, and THCCOOH 2.6-7.4%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Sensitivity, specificity, and comparison of CEDIA semiquantitation with GC-MS quantitative results were performed on 500 original serum and whole blood samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The data provided sufficient documentation to use the CEDIA urine-screening technique without any adaptation as a sensitive serum/whole blood screening for BZE, BENZ, MET, OPI, and THCCOOH.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serum screening for amphetamines is not sensitive enough in the unchanged urine mode.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It will require some adaptation to a serum mode (probably a higher sample volume [BM/Hitachi 911] combined with protein precipitation of the sample).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Buprenorphine, which is used in France as a substitution drug for opioid addiction, is widely abused, and several fatal cases have been reported.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In order to confirm a recent intoxication or to establish retrospectively chronic abuse, a simple and reliable gas chromatographic-mass spectrometric method was developed and validated for quantitation of buprenorphine and its active metabolite norbuprenorphine in urine and hair.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Two milliliters of urine or 50 mg of pulverized hair was submitted to a pretreatment (enzymatic hydrolysis for urine and decontamination with dichloromethane followed by incubation in 0.1 M HCI for hair).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Buprenorphine-d4 was chosen as the internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Selective solid-phase extraction with Bond Elut Certify columns provided recoveries higher than 85% for urine and 43% for hair.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
By using a mixture of MSTFA/TMSIM/TMCS (100:2:5), buprenorphine and norbuprenorphine produced stable silylated derivatives.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection was carried out with a quadrupole mass detector working in El selected ion monitoring mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ions at m/z 450 and 468 were chosen for the quantitation of buprenorphine and norbuprenorphine, respectively (m/z 454 was used for the internal standard).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Limits of quantitation were 0.25 and 0.20 ng/mL, respectively, for buprenorphine and norbuprenorphine in urine and 0.005 ng/mg for the two compounds in hair.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Calibration curves were linear from 0 to 50 ng/mL in urine and from 0 to 0.4 ng/mg in hair.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Between-day and within-day precisions were less than 8.4% in hair and 6.1% in urine for both molecules in all cases.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This method was applied to urine and hair samples collected from patients in a withdrawal treatment program and demonstrated its good applicability in routine analysis and its benefit for clinicians.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This technique, which requires instruments already available to many toxicology laboratories, offers an attractive alternative to more sophisticated techniques.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Assessment of occupational exposures in a general population: comparison of different methods.

$$$$
>  <CLASS>
NONE

>  <TARGET>
To evaluate the relative merits of job specific questionnaires and various alternative assessment methods of occupational exposures often used in general population studies.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Subjects were participants in a hospital based case-control study of risk factors for male infertility.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Estimates of exposure to organic solvents and chromium, based on job specific questionnaires, generic questionnaires, self reports of exposure, an external job exposure matrix (JEM), and a population specific JEM were compared with passive diffuse dosimeter results and measurements in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine samples from the end of the shift were analysed for metabolites of toluene, xylene, several glycol ethers, trichloroethylene, and chromium.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Urine samples from the end of the shift were analysed for metabolites of toluene, xylene, several glycol ethers, trichloroethylene, and chromium.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Passive dosimeter date, metabolites of specific solvents, and urinary chromium concentrations were available for 89, 267, and 156 subjects, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The alternative methods and measurements in urine were compared by means of the Cohen's kappa statistic and by computing the positive predictive value, sensitivity, and specificity of the alternative methods against measurements in urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Passive dosimeter results indicated that exposure classifications with job specific questionnaire information could discriminate between high and low exposures.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The kappa coefficients were < 0.4, so agreement between the various methods and measurements in urine was poor.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Sensitivity of the methods ranged from 0.21 to 0.85, whereas specificity ranged from 0.34 to 0.94.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Positive predictive values ranged from 0.19 to 0.58, with the highest values for job specific questionnaires.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The results indicate that the implementation of job specific questionnaires in a general population study might be worth the extra expense it entails, bearing in mind the paramount importance of avoiding false positive exposure estimates when exposure prevalence is low.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cyclophosphamide metabolism in children with Fanconi's anaemia.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Although patients with Fanconi's anaemia (FA) exhibit a heightened sensitivity to DNA cross-linking agents, modified doses of CY continue to be used in their conditioning prior to BMT.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We measured the pharmacokinetics and metabolism of CY in six children with FA using an established high performance thin layer chromatography technique.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CY doses ranged between 5 and 20 mg/kg (median 10 mg/kg).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The median CY clearance was 0.6 l/h/m2 (range 0.4-1.1 l/h/m2), t1/2 was 8.1 h (range 6.7-9.5 h) and volume of distribution was 0.19 l/kg (range 0.16-0.34 l/kg), respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results contrast with those previously reported from a comparable group of non-FA children in whom the median CY clearance was 3.2 l/h/m2 (range 2-5 l/h/m2) (P = 0.035), t1/2 was 2.4 h (range 2-3.8 h) (P = 0.035) and volume of distribution 0.5 l/kg (range 0.26-0.95 l/kg) (NS).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Unlike the control group in whom the presence of inactive metabolites of CY was common, metabolites could not be found in any FA patient.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The enhanced sensitivity of children with FA to CY may in part result from altered drug metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Grapefruit juice has no effect on quinine pharmacokinetics.

$$$$
>  <CLASS>
Parent

>  <TARGET>
As quinine is mainly metabolised by human liver CYP3A4 and grapefruit juice inhibits CYP3A4, the effect of grapefruit juice on the pharmacokinetics of quinine following a single oral dose of 600 mg quinine sulphate was investigated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The study was carried out in ten healthy volunteers using a randomised cross-over design.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Subjects were studied on three occasions, with a washout period of 2 weeks.

$$$$
>  <CLASS>
NONE

>  <TARGET>
During each period, subjects received a pretreatment of 200 ml orange juice (control), full-strength grapefruit juice or half-strength grapefruit juice twice daily for 5 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On day 6, the subjects were given a single oral dose of 600 mg quinine sulphate with 200 ml of one of the juices.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Plasma and urine samples for measurement of quinine and its major metabolite, 3-hydroxyquinine, were collected over a 48-h period and analysed by means of a high-performance liquid chromatography method.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The intake of grapefruit juice did not significantly alter the oral pharmacokinetics of quinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There were no significant differences among the three treatment periods with regard to pharmacokinetic parameters of quinine, including the peak plasma drug concentration (Cmax), the time to reach Cmax (tmax), the terminal elimination half-life (t1/2), the area under the concentration-time curve and the apparent oral clearance.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The pharmacokinetics of the 3-hydroxyquinine metabolite were slightly changed when volunteers received grapefruit juice.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).

$$$$
>  <CLASS>
Parent

>  <TARGET>
These results suggest that there is no significant interaction between the parent compound quinine and grapefruit juice, so it is not necessary to advise patients against ingesting grapefruit juice at the same time that they take quinine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Since quinine is a low clearance drug with a relatively high oral bioavailability, and is primarily metabolised by human liver CYP3A4, the lack of effect of grapefruit juice on quinine pharmacokinetics supports the view that the site of CYP inhibition by grapefruit juice is mainly in the gut.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Amphetamine (AM) and five amphetamine derivatives, N-ethylamphetamine (NEA), N-butylamphetamine (NBA), 4-methoxyamphetamine (M-AM), 4-methoxy-N-ethylamphetamine (M-NEA) and 4-methoxy-N-butylamphetamine (M-NBA) were incubated with microsomal preparations from cells expressing human CYP2D6 to determine whether the enzyme was capable of catalyzing the direct ring oxidation of all substrates; the N-dealkylation of NEA, NBA, M-NEA and M-NBA; and the O-demethylation of M-AM, M-NEA and M-NBA.

$$$$
>  <CLASS>
NONE

>  <TARGET>
None of the six compounds examined was N-dealkylated to any extent.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The only metabolites produced from AM, NEA and NBA were the corresponding ring 4-hydroxylated compounds, and the rates of formation were low.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
All ring 4-methoxylated substrates were efficiently O-demethylated by CYP2D6 to their corresponding phenols.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The size of the N-alkyl group influenced the rates of formation of these phenolamines.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The size of the N-alkyl group influenced the rates of formation of these phenolamines.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In contrast to reported findings with 2- and 3-methoxyamphetamines, none of the 4-methoxyamphetamines was ring-oxidized in the CYP2D6 enzyme system to 2- or 3-hydroxy-4-methoxyamphetamines or to dihydroxyamphetamines.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In contrast to reported findings with 2- and 3-methoxyamphetamines, none of the 4-methoxyamphetamines was ring-oxidized in the CYP2D6 enzyme system to 2- or 3-hydroxy-4-methoxyamphetamines or to dihydroxyamphetamines.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Danish University Antidepressant Group (DUAG).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To examine the problems of establishing dose-effect and concentration-effect relationships of antidepressant therapy with clomipramine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This randomized double-blind study compared five fixed doses of clomipramine hydrochloride: 25, 50, 75, 125, and 200 mg/day in hospitalized or day patients at nine clinical centers in Denmark.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A 1-week washout period was followed by 6 weeks of active treatment and weekly depression ratings.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In total, 151 patients (100 women and 51 men) with major depression scoring > or =18 on the Hamilton Depression Scale (HDS) or > or =9 on the Hamilton Depression subscale (HDSS) before and after the washout period were randomized.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The treatment groups (n = 29 to 32) were well balanced with respect to sex, age, and depression rating.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Serum concentrations of clomipramine plus metabolites were measured at weekly intervals.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A sparteine test was performed before and during drug treatment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
There was pronounced interpatient variability in response and kinetics at each dose.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Drop-outs attributable to adverse events increased with rising doses, whereas drop-outs caused by worsening or lack of effect or nonresponse declined with increasing dose.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Completer analyses showed a moderate and statistically significant relationship between depression rating and dose at all ratings after 1 to 6 weeks of treatment (trend analysis).

$$$$
>  <CLASS>
NONE

>  <TARGET>
HDS items representing core symptoms of depression showed a particularly consistent dose-effect relationship.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Early sustained response occurred more frequently with the two highest doses.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serum levels of clomipramine and desmethylclomipramine showed weak correlation with depression ratings (Rs = -0.18 to -0.27; P < .05 to P < .01).

$$$$
>  <CLASS>
NONE

>  <TARGET>
A few blood pressure measurements and a few typical side-effect ratings showed a statistically significant dose-effect and concentration-effect relationship.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serum concentration of clomipramine and desmethylclomipramine showed a pronounced disproportionate increase with increasing dose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clomipramine inhibited in a dose-dependent fashion CYP2D6 (sparteine oxidation).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The dose-effect curves, indicating the probability of a certain outcome at a given dose, were flat and overlapping suggesting a narrow therapeutic range.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This pattern is similar to that observed with newer antidepressants.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Peripheral markers of oxidative stress in Parkinson's disease.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The role of L-DOPA.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Oxidative stress plays a central role in the pathogenesis of Parkinson's disease (PD).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
L-DOPA, the gold standard in PD therapy, may paradoxically contribute to the progression of the disease because of its pro-oxidant properties.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The issue, however, is controversial.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this study, we evaluated peripheral markers of oxidative stress in normal subjects, untreated PD patients and PD patients treated only with L-DOPA.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We also measured platelet and plasma levels of L-DOPA, 3-O-methyldopa (the long-lasting metabolite of the drug), and dopamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We also measured platelet and plasma levels of L-DOPA, 3-O-methyldopa (the long-lasting metabolite of the drug), and dopamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We found that isolated platelets of treated PD patients form higher amounts of 2,3-dihydroxybenzoate, an index of hydroxyl radical generation, than platelets of controls or untreated patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In treated patients, platelet levels of 2,3-dihydroxybenzoate were positively correlated with platelet levels of L-DOPA, 3-O-methyldopa, and with the score of disease severity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Disease severity was correlated with platelet and plasma levels of L-DOPA, as well as with the daily intake of the drug.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No significant differences in platelet levels of cytosolic and mitochondrial isoforms of the antioxidant enzyme superoxide dismutase were found between PD patients, either treated or untreated, and controls.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Our findings lend further support to the hypothesis that L-DOPA might promote free radical formation in PD patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Role of individual susceptibility in risk assessment of pesticides.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This study presents criteria for assessing the individual pesticide burden of workers in the chemical industry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A group of 1003 workers exposed to methylparathion or ethylparathion (alkyl phosphates), propoxur (carbamate), or cyfluthrin (pyrethroid) was investigated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After exposure to methylparathion or ethylparathion the methylparathion or ethylparathion and methylparaoxon or ethylparaoxon concentrations in plasma, the p-nitrophenol concentration in urine, and the activities of cholinesterase and acetylcholinesterase were measured.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For exposure to propoxur the propoxur concentration in plasma, the 2-isopropoxyphenol concentration in urine, and the cholinesterase and acetylcholinesterase activities were measured.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For exposure to cyfluthrin the cyfluthrin concentration in plasma was measured.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
At the same propoxur concentration only workers with a low individual acetylcholinesterase activity reported symptoms.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Workers who metabolised cyfluthrin rapidly reported less symptoms than workers with a lower rate of metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This tendency was also evident in cases of mixed exposure (cyfluthrin and methylparathion).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In the assessment of exposure to pesticides susceptibility of the individual person has to be considered.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Distribution of PCB congeners, DDE, hexachlorobenzene, and methylsulfonyl metabolites of PCB and DDE among various fractions of human blood plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Distribution of PCB congeners, DDE, hexachlorobenzene, and methylsulfonyl metabolites of PCB and DDE among various fractions of human blood plasma.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The concentrations of chlorinated biphenyls (CBs), 1, 1-bis(4-chlorophenyl)-2,2-dichloroethene (DDE), hexachlorobenzene (HCB), and the methylsulfonyl metabolites of CBs (MeSO(2)-CBs) and DDE (MeSO(2)-DDE) were determined in human plasma samples and in the fractions obtained by ultracentrifugation of plasma into very-low-density (VLDL), low-density (LDL), high-density (HDL) lipoprotein and lipoprotein depleted (LPDP) fractions (containing primarily albumin).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The concentrations of chlorinated biphenyls (CBs), 1, 1-bis(4-chlorophenyl)-2,2-dichloroethene (DDE), hexachlorobenzene (HCB), and the methylsulfonyl metabolites of CBs (MeSO(2)-CBs) and DDE (MeSO(2)-DDE) were determined in human plasma samples and in the fractions obtained by ultracentrifugation of plasma into very-low-density (VLDL), low-density (LDL), high-density (HDL) lipoprotein and lipoprotein depleted (LPDP) fractions (containing primarily albumin).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The concentrations of triacylglycerols, cholesterol, phospholipids, and apolipoprotein B (apoB) were determined.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The organochlorine compounds were associated with all fractions, but predominantly with the LPDP fraction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On an average 44% of CBs, 61% of MeSO(2)-CBs, 73% of DDE, 77% of MeSO(2)-DDE, and 45% of HCB were distributed in the LPDP fraction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A tendency to greater association of 3-methylsulfonyl substituted than of corresponding 4-methylsulfonyl substituted chlorobiphenyls to the LPDP fraction was noticed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among the lipoprotein fractions, LDL was the main carrier of HCB, DDE and CBs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
MeSO(2)-DDE was predominantly found in HDL and MeSO(2)-CBs were distributed equally among the LDL and HDL fractions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Calculating the concentrations of organochlorine compounds in relation to the content of apoB, the levels were about 10 times higher in VLDL than in LDL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Acute symptoms during non-inhalation exposure to combinations of toluene, trichloroethylene, and n-hexane.

$$$$
>  <CLASS>
NONE

>  <TARGET>
To study the acute effect of exposure to a mixture of three commonly used solvents in humans using a route of exposure not involving the nose and lungs, in this case a gastrointestinal application.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In a 2(3)-factorial experiment eight healthy male volunteers were exposed to the eight combinations of toluene (1.5 and 4 mg. min(-1)) trichloroethylene (1.5 and 4 mg. min(-1)), and n-hexane (0.3 and 1.0 mg. min(-1)) for 60 min given into the stomach via a feeding tube.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The body burden was measured by the exhaled solvent concentrations and the urinary excretion of metabolites during and after exposure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The subjective ratings of tiredness, sleepiness, headache, nausea, feeling of intoxication, and dizziness were estimated by continuous linear analogue rating scales before and 30, 90, and 240 min after the start of exposure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Concentrations of the three solvents in the end exhaled air varied between 0 and 46 mg. min(-3).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The ratings of symptoms were generally low and there was no difference between the high and low doses.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Neither was there any correlation between the concentration of solvents in the exhaled air and the ratings.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The study show no effects at levels in end exhaled air of mixtures of solvents which in inhalation studies have given signs of a possible neurotoxic effect.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The lack of symptoms using this alternative route supports the hypothesis that "neurotoxic" symptoms in relation to exposure to very low air concentrations of solvents are mainly indirect, mediated by irritation or smell.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol (THCCOOH) and cannabinoids was monitored in prison inmates.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Urinary specimens were collected up to five times per day.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EMIT (cutoff 20 ng/mL; EMIT20) and gas chromatography (GC) (cutoff 10.3 ng/mL, LOD 1.4 ng/mL) were used for cannabinoid screening and THCCOOH confirmation, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary creatinine concentrations were recorded.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Of the samples with positive EMIT screens, 78% were confirmed by GC analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The plotting of THCCOOH/creatinine ratios (THCCOOH/C) versus time gave smoother excretion curves than THCCOOH concentrations alone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on THCCOOH/C the first 5 days after the last reported intake, the mean urinary excretion half-life was 1.3 days in infrequent users, and a median of 1.4 days was found in frequent users.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Based on THCCOOH/C the first 5 days after the last reported intake, the mean urinary excretion half-life was 1.3 days in infrequent users, and a median of 1.4 days was found in frequent users.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Based on THCCOOH/C the first 5 days after the last reported intake, the mean urinary excretion half-life was 1.3 days in infrequent users, and a median of 1.4 days was found in frequent users.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In the latter group, apparent terminal urinary excretion half-lives up to 10.3 days were observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The last positive specimens were found after 4 days for THCCOOH with cutoff 15.0 ng/mL (NIDA/SAMSHA), 5 days for THCCOOH with cutoff 10.3 ng/mL, and 12 days for cannabinoids (EMIT20) in infrequent users and after 17, 22, and 27 days, respectively, in frequent users.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Increases in urinary cannabinoids were sometimes found without concomitant increase in THCCOOH or THCCOOH/C.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
One subject admitted new cannabis intake, after which marked increases in THCCOOH and THCCOOH/C were observed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In others, new intake was suspected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Considerable variations between consecutive specimens were also observed in THCCOOH concentration and THCCOOH/C ratio without suspicion of a new intake.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Over-the-counter anabolic steroids 4-androsten-3,17-dione; 4-androsten-3beta,17beta-diol; and 19-nor-4-androsten-3,17-dione: excretion studies in men.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Since the appearance of 4-androsten-3,17-dione (I) as a nutritional supplement in early 1997, we have frequently observed a characteristic deterioration of endogenous steroid profiles in athletes' urine in routine anabolic steroid testing in which concentrations of major endogenous urinary steroids and testosterone exceed normal.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human excretion studies are performed with I and newer, over-the-counter "supplements" 4-androsten-3beta,17beta-diol (II) and 19-nor-4-androsten-3,17-dione (III).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Endogenous urinary steroids affected by I and II are androsterone, etiocholanolone, their hydroxylated derivatives 5alpha- and 5beta-androstan-3alpha,17beta-diols, testosterone, and epitestosterone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Endogenous urinary steroids affected by I and II are androsterone, etiocholanolone, their hydroxylated derivatives 5alpha- and 5beta-androstan-3alpha,17beta-diols, testosterone, and epitestosterone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Their concentrations briefly increase by one to two orders of magnitude and return to normal 24 h after oral administration of I and II.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The average male may test positive for testosterone because testosterone concentration rises faster than that of epitestosterone, causing the testosterone/epitestosterone (T/E) ratio to rise above the positive cutoff of 6:1.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A remarkable distinction in excretion patterns was observed in eastern Asian men, for whom I and II did not affect urinary concentrations of testosterone and did not increase the T/E ratio.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
First-pass metabolism deactivates most of the orally administered drugs I and II, rapidly converting them into inactive androsterone and etiocholanolone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Drug II is a more effective testosterone booster because of its different metabolic pathway.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After the use of III, a precursor of the potent anabolic nandrolone, high concentrations of norandrosterone and noretiocholanolone appear in urine, similar to nandrolone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These are detectable in urine for 7-10 days after a single oral dose of III (50 mg).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of fluvoxamine on the pharmacokinetics of quinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To investigate the possible involvement of cytochromes CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This was an open study of six healthy young male volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of a 200-mg single oral dose of quinidine were studied before and during daily treatment with 100 mg fluvoxamine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Biomarkers of other isozyme activities in the form of caffeine, sparteine, mephenytoin, tolbutamide and cortisol metabolism were applied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results showed a statistically significant median reduction of 2944% in the quinidine total apparent oral clearance, partial clearances by 3-hydroxylation and N-oxidation and residual clearance during fluvoxamine treatment.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The results showed a statistically significant median reduction of 2944% in the quinidine total apparent oral clearance, partial clearances by 3-hydroxylation and N-oxidation and residual clearance during fluvoxamine treatment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Renal clearance was unaffected by fluvoxamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of fluvoxamine on the formation clearances of 3-hydroxyquinidine and quinidine-N-oxide most likely reflects inhibition of cytochrome P4503A4 by fluvoxamine at clinically relevant doses.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The effect of fluvoxamine on the formation clearances of 3-hydroxyquinidine and quinidine-N-oxide most likely reflects inhibition of cytochrome P4503A4 by fluvoxamine at clinically relevant doses.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results of this study do not rule out a possible involvement of CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The results of this study do not rule out a possible involvement of CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The results of this study do not rule out a possible involvement of CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cytotoxicity and aromatase (CYP19) activity modulation by organochlorines in human placental JEG-3 and JAR choriocarcinoma cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The human placental JEG-3 and JAR choriocarcinoma cell lines have been used as placental models for the study of aromatase (CYP19) activity and endocrine functions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the present study, 21 organochlorines (OCs) mediated decreases in aromatase activity and protein and DNA content and increases in the percent lactate dehydrogenase (LDH) leakage in JEG-3 cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These effects were highly variable among the types of OC and their treatment concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Lowest observed effective concentrations reached 0.001 microM for several OCs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Aromatase activity decreases and OC-mediated cytotoxicity were related.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, it was not possible to clearly assess the capacity of the OCs to modulate aromatase activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Similar to 1,4-naphthoquinone, the most cytotoxic OCs contained a hydroxyl (4'-OH-2,4,6-trichlorobiphenyl and tris(4-chlorophenyl)methanol) or methylsulfonyl- (3- and 4-MeSO(2)-2, 2',5,5'-tetrachlorobiphenyl and -2,3',4',5-tetrachlorobiphenyl, and 3'- and 4'-MeSO(2)-2,2',3,4,5'-pentachlorobiphenyl and -2,2',4,5, 5'-pentachlorobiphenyl) functional group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Modulation of aromatase activity and LDH leakage were less for 3,3',4,4', 5-pentachlorobiphenyl and benzo[a]pyrene and insignificant for five alkyl-substituted trichloro-dibenzofurans and 2,3,7, 8-tetrachloro-dibenzo-p-dioxin (up to 10 microM).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cytotoxicity-related effects were influenced by the cell density and the presence of 10% fetal calf serum in the medium during compound incubation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similar cytotoxic effects were observed for the JAR cell line.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The involvement of an apoptotic mechanism of cytotoxicity in OC-treated JEG-3 cells was suggested by the binding of APO2.7 (an antibody specific to apoptotic cells), DNA fragmentation, and trypan blue staining.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
JEG-3 and JAR cells appear too sensitive toward OC-mediated cytotoxicity for use as in vitro bioassays to evaluate the potential modulation of aromatase activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
However, these cell lines may prove useful for examining the capacity of xenobiotics to modulate placental toxicity.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Detoxification of carcinogenic aromatic and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The metabolic activation pathways associated with carcinogenic aromatic and heterocyclic amines have long been known to involve N-oxidation, catalyzed primarily by cytochrome P4501A2, and subsequent O-esterification, often catalyzed by acetyltransferases (NATs) and sulfotransferases (SULTs).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We have found a new enzymatic mechanism of carcinogen detoxification: a microsomal NADH-dependent reductase that rapidly converts the N-hydroxy arylamine back to the parent amine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The following N-OH-arylamines and N-OH-heterocyclic amines were rapidly reduced by both human and rat liver microsomes: NOH-4-aminoazobenzene, N-OH-4-aminobiphenyl (N-OH-ABP), N-OH-aniline, N-OH-2-naphthylamine, N-OH-2-aminofluorene, N-OH-4,4'-methylenebis(2-chloroaniline) (N-OH-MOCA), N-OH-1-naphthyamine, N-OH-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP), N-OH-2-amino-alpha-carboline (N-OH-AalphaC), N-OH-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (N-OH-MeIQx), and N-OH-2-amino-3-methylimidazo[4,5-f]quinoline (N-OH-IQ).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In addition, primary rat hepatocytes and human HepG2 cells efficiently reduced N-OH-PhIP to PhIP.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This previously unrecognized detoxification pathway may limit the bioavailability of carcinogenic N-OH heterocyclic and aromatic amines for further activation, DNA adduct formation, and carcinogenesis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aim of this study was to compare the disposition of the tricyclic antidepressant clomipramine (C) in Japanese and Swedish patients receiving continuous treatment.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving monotherapy (N = 12) and in those receiving C plus benzodiazepines (BZDs) (N = 96) as well as in Swedes receiving C monotherapy (N = 131) and in those receiving C plus BZDs (N = 43) were used.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving monotherapy (N = 12) and in those receiving C plus benzodiazepines (BZDs) (N = 96) as well as in Swedes receiving C monotherapy (N = 131) and in those receiving C plus BZDs (N = 43) were used.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A population kinetic approach with Bayesian feedback was used to estimate the individual clearance values for C. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
The relationships between kinetic variables and covariates were evaluated by linear multiple regression.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When combining all populations in a linear multiple regression, clearance was correlated with ethnic group (p < 0.00001) and age (p < 0.0005), but it was uncorrelated with gender, body weight, and administration of BZDs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, the lower oral clearance of C in Japanese patients compared with that in Swedish patients is not accounted for by the lower body weight in Japanese patients or by concomitant treatment with BZDs and is therefore likely to be a true ethnic difference.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The higher C/DC ratio implicates a more pronounced serotonergic than noradrenergic effect in Japanese patients than in Swedish patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

$$$$
>  <CLASS>
NONE

>  <TARGET>
CYP2D6 and CYP2C19 are polymorphically expressed enzymes that show marked interindividual and interethnic variation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aim of this study was to determine the frequency of the defective alleles in CYP2D6 and CYP2C19 in Africans and to test whether the genotype for CYP2C19 is better correlated with the proguanil/cylcoguanil ratio than the mephenytoin S/R ratio.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Two hundred and sixteen black Tanzanians were phenotyped for CYP2D6 with the use of sparteine, and for CYP2C19 with the use of mephenytoin and proguanil.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Of these 196 subjects were also genotyped for CYP2D6 (including the CYP2D6*1, CYP2D6*3 and CYP2D6*4 alleles) and 195 were genotyped for CYP2C19 (including the CYP2C19*1, CYP2C19*2 and the CYP2C19*3 alleles).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Furthermore 100 subjects were examined for the allele duplication in CYP2D6, leading to ultrarapid metabolism, with long PCR.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The sparteine metabolic ratio (MR) was statistically significantly higher in the Tanzanian group of homozygous, extensive metabolizers compared to a historical control group of white Danish extensive metabolizers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Only one poor metabolizer for CYP2D6 (MR=124 and genotype CYP2D6*1/CYP2D6*4 ) was found.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The gene frequencies were 0.96 for the CYP2D6*1 allele and 0.04 for the CYP2D6*4 allele.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No CYP2D6*3 alleles were found.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Nine subjects had an allele duplication in CYP2D6 (9%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
For CYP2C19 there were seven subjects (3.6%) who were phenotyped as poor metabolizers, but only three subjects (1.5%) had a genotype (CYP2C19*2/CYP2C19*2 ) indicative of poor metabolism.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The gene frequencies were 0.90 for the CYP2C19*1 allele and 0.10 for the CYP2C19*2 allele.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No CYP2C19*3 alleles were found.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mephenytoin S/R ratios were not bimodally distributed.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mephenytoin S/R ratios were not bimodally distributed.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The mephenytoin S/R ratios were not bimodally distributed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Both the genotyping and phenotyping results show that there is a substantial difference between an African black population and a Caucasian population in the capacity to metabolize drugs via CYP2D6 and CYP2C19.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To identify the human cytochrome P450 enzyme(s) involved in the in vitro metabolism of rosiglitazone, a potential oral antidiabetic agent for the treatment of type 2 diabetes-mellitus.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Method The specific P450 enzymes involved in the metabolism of rosiglitazone were determined by a combination of three approaches; multiple regression analysis of the rates of metabolism of rosiglitazone in human liver microsomes against selective P450 substrates, the effect of selective chemical inhibitors on rosiglitazone metabolism and the capability of expressed P450 enzymes to mediate the major metabolic routes of rosiglitazone metabolism.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Result The major products of metabolism following incubation of rosiglitazone with human liver microsomes were para-hydroxy and N-desmethyl rosiglitazone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The rate of formation varied over 38-fold in the 47 human livers investigated and correlated with paclitaxel 6alpha-hydroxylation (P<0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Formation of these metabolites was inhibited significantly (>50%) by 13-cis retinoic acid, a CYP2C8 inhibitor, but not by furafylline, quinidine or ketoconazole.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In addition, both metabolites were produced by microsomes derived from a cell line transfected with human CYP2C8 cDNA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
There was some evidence for CYP2C9 playing a minor role in the metabolism of rosiglitazone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Sulphaphenazole caused limited inhibition (<30%) of both pathways in human liver microsomes and microsomes from cells transfected with CYP2C9 cDNA were able to mediate the metabolism of rosiglitazone, in particular the N-demethylation pathway, albeit at a much slower rate than CYP2C8.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sulphaphenazole caused limited inhibition (<30%) of both pathways in human liver microsomes and microsomes from cells transfected with CYP2C9 cDNA were able to mediate the metabolism of rosiglitazone, in particular the N-demethylation pathway, albeit at a much slower rate than CYP2C8.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rosiglitazone caused moderate inhibition of paclitaxel 6alpha-hydroxylase activity (CYP2C8; IC50=18 microm ), weak inhibition of tolbutamide hydroxylase activity (CYP2C9; IC50=50 microm ), but caused no marked inhibition of the other cytochrome P450 activities investigated (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A and 4A).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Conclusion CYP2C8 is primarily responsible for the hydroxylation and N-demethylation of rosiglitazone in human liver; with minor contributions from CYP2C9.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Characterization of lidocaine metabolism by rat nasal microsomes: implications for nasal drug delivery.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Lidocaine has been recently approved for use as an intranasal spray in the treatment of migraine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In this study, we investigated the metabolism of lidocaine to its primary metabolite monoethylglycine xylidide (MEGX), by rat nasal olfactory and respiratory microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The metabolic parameters were compared with metabolism employing rat and human hepatic microsomes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The olfactory and respiratory microsomes both exhibited considerable activity for conversion of lidocaine to MEGX in comparison with the activity in the hepatic tissues.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The rat olfactory microsomes had a markedly higher affinity than the rat hepatic or respiratory microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
However, the turnover rate was only about one-half that of rat liver.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Employing Western immunoblotting we investigated the presence of cytochrome P450s (CYPs) 1A2, 3A2, 2B1 and 2C11 in rat nasal tissues; these isozymes are known to partcipated in the metabolism of lidocaine in rat liver.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These isozymes were found to be present in significant amounts in both the nasal olfactory and respiratory tissue; this is the first known report of the presence of CYP2C11 in nasal mucosae.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Our studies underscore the importance of CYP-mediated drug metabolism in nasal tissues.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The effect of this 'nasal first-pass' should be weighed carefully while considering the fate and the bioavailability of drugs delivered via the intranasal route.

$$$$
>  <CLASS>
NONE

>  <TARGET>
On-line coupling of automated solid-phase extraction with high-performance liquid chromatography and electrochemical detection.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Quantitation of oxidizable drugs of abuse and their metabolites in plasma and urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The concentration effect of automated on-line solid-phase extraction (SPE) in combination with HPLC and very sensitive electrochemical detection was employed for the determination of N-ethyl-4-hydroxy-3-methoxy-amphetamine (HMEA, the main metabolite of the ecstasy analogue MDE), delta 9-tetrahydrocannabinol (THC) and 11-nor-delta 9-tetrahydrocannabinol-carboxylic acid (THC-COOH) in plasma and urine in comparison to a previously published psilocin assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The concentration effect of automated on-line solid-phase extraction (SPE) in combination with HPLC and very sensitive electrochemical detection was employed for the determination of N-ethyl-4-hydroxy-3-methoxy-amphetamine (HMEA, the main metabolite of the ecstasy analogue MDE), delta 9-tetrahydrocannabinol (THC) and 11-nor-delta 9-tetrahydrocannabinol-carboxylic acid (THC-COOH) in plasma and urine in comparison to a previously published psilocin assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the SPE either CBA (functional group: carboxypropyl)- or CH (functional group: cyclohexyl)-sorbent was used.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The following separation was carried out on a reversed-phase column (LiChroCart, Superspher 60 RP select B from Merck).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Depending on the hydrodynamic voltammogram of the analyzed substance the oxidation potential varied from 920 mV up to 1.2 V. In spite of using high potentials, precision and accuracy were always within the accepted statistical requirements.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limits of quantitation were between 5 ng/ml (THC, THC-COOH in plasma) and 20 ng/ml (HMEA in plasma).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Advantages of on-line SPE in comparison with off-line methods were less manual effort, evidently smaller volumes (< or = 400 microliters) of plasma or urine and almost always higher recovery rates (> 93%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The assays have been successfully proven with real biological samples and found suitable for use in routine analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Biomarkers of dose and susceptibility in cyclists exposed to monoaromatic hydrocarbons.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A quasi-experimental field study was carried out in 24 volunteers with the aim of: (i) assessing personal exposure to aromatic hydrocarbons polluting urban areas; and (ii) exploring the role of polymorphic enzymes relevant to the biotransformation of benzene in the inter-individual variability of biomarkers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A quasi-experimental field study was carried out in 24 volunteers with the aim of: (i) assessing personal exposure to aromatic hydrocarbons polluting urban areas; and (ii) exploring the role of polymorphic enzymes relevant to the biotransformation of benzene in the inter-individual variability of biomarkers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Each subject covered by bicycle: (i) inner city routes with often jammed traffic; and (ii) open rural routes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Time-weighted average airborne concentrations of benzene, toluene, ethylbenzene and xylenes (BTEX) were determined during 2-h runs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
BTEX were determined by solid-phase micro-extraction (SPME) followed by gas chromatography coupled with mass spectrometry (GC-MS) in blood and spot urine samples collected just before and immediately after the runs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary t,t-muconic acid was measured by high performance liquid chromatography (HPLC)-UV.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Genotypes of epoxide hydrolase (EH) and glutathione-S-transferase class mu-1 (GSTM1) were also characterised.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As compared to pre-run values, benzene and toluene in blood, and toluene and xylenes in urine significantly increased after urban runs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary t,t-muconic acid was significantly higher in post-run samples after both urban (P < 0.001) and rural runs (P < 0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Despite a narrow range of exposure levels, a significant relationship was observed between airborne benzene and post-run t,t-muconic acid (r2 = 0.349, P < 0.00).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When subgroups were distinguished according to EH and GSTM, subjects bearing both the EH wild type and GSTM 'null' genotype showed significant exposure-related changes in t,t-muconic acid excretion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Even at very low exposure levels, a 2-h bike run in a polluted urban environment may give rise to measurable changes in biomarkers of internal dose of selected aromatic hydrocarbons.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Genetically-based metabolic differences may account for part of the inter-individual variability of biomarkers of exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of S-phenylmercapturic acid in urine as an indicator of exposure to benzene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
S-phenylmercapturic acid (S-PMA) was measured in urine from 145 subjects exposed to low benzene concentrations in the air (C(I), benzene).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The 8-h, time-weighted exposure intensity of individual workers was monitored by means of charcoal tubes and subsequent gas-chromatographic analysis after desorption with CS2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
S-PMA excretion level in urine was determined by high-performance liquid chromatography with fluorescence detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The following linear correlation was found between S-PMA concentrations in urine and benzene concentrations in the breathing zone: log(S-PMA, microg/g creatinine) = 0.712 log (C(I)-benzene, ppm) + 1.644 (n = 145, r = 0.74, P < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The geometric mean (GSD) of S-PMA concentrations in urine from 45 subjects occupationally not exposed to benzene but smoking more than 20 cigarettes/day was 7.8 microg/g creatinine (2.11), the corresponding value among non-smokers being 1.0 microg/g creatinine (2.18).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is concluded that the urinary level of S-PMA can be regarded as a useful indicator of exposure to benzene.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
An assay for the quantitative determination of the mercapturic acid conjugate of N,N',N"-triethylenethiophosphoramide (thioTEPA-mercapturate) in human urine has been developed.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
ThioTEPA-mercapturate, a recently identified metabolite of the alkylating anticancer agent thioTEPA, was analyzed using LC-MS and with direct sample injection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sulphadiazine was used as internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Linearity was accomplished in the therapeutic relevant range of 1-25 microg/ml; recovery was 84% and both accuracy and precision were less than 20% for the lower limit of quantification (1.0 microg/ml) and less than 10% for the other concentration levels.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The stability of thioTEPA-mercapturate proved to be satisfactory over a period of 2 months, when kept at -80 degrees C. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
ThioTEPA-mercapturate urine concentrations of two patients treated with thioTEPA are presented demonstrating the applicability of the assay for clinical samples.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Rapid determination of the anti-cancer drug chlorambucil (Leukeran) and its phenyl acetic acid mustard metabolite in human serum and plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A bioanalytical method for the determination of the anticancer drug chlorambucil (Leukeran) and its phenyl acetic acid mustard metabolite in human serum and plasma is described.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Automated solid-phase extraction of the analytes is carried out with C18 sorbent packed in a 96 well format microtitre plate using a robotic sample processor.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The extracts are analysed by isocratic reversed-phase liquid chromatography using pneumatically and thermally assisted electrospray ionisation (TurboIonspray) with selected reaction monitoring.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method is specific and sensitive, with a range of 4-800 ng/ml in human serum and plasma for both parent drug and metabolite (sample volume 200 microl).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method is accurate and precise with intra-assay and inter-assay precision (C.V.) of <15% and bias <15% for both analytes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The automated extraction procedure is significantly faster than manual sample pre-treatment methods, a batch of 96 samples is extracted in 50 min allowing for faster sample turnaround.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The method has been used to provide pharmacokinetic support to biocomparability studies of Leukeran following single doses of oral tablet formulations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection.

$$$$
>  <CLASS>
Parent

>  <TARGET>
An assay method for the quantification of cyclophosphamide (CY) and five metabolites from human plasma is presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The procedure is adapted to the chemical properties of the compounds of interest: non-polar compounds are extracted into methylene chloride, concentrated and analyzed by GC-NPD after derivatization, and the remaining aqueous fraction is deproteinated with acetonitrile-methanol prior to separation via reversed-phase HPLC and detection using atmospheric pressure ionization (API)-MS. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
Standard curves are linear over the required range and reproducible over five months.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Plasma concentration-time profiles of CY and metabolites from a patient receiving CY by intravenous infusion (60 mg/kg, once a day for two days) are presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A retrospective study of buprenorphine and norbuprenorphine in human hair after multiple doses.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The analysis of hair has been proposed as a tool for monitoring drug-treatment compliance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study was performed to determine if buprenorphine (BPR) and norbuprenorphine (NBPR) could be detected in human hair after controlled administration of drug and to determine if segmental analysis of hair was an accurate record of the dosing history.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Subjects with dark hair (six males, six females) received 8 mg sublingual BPR for a maximum of 180 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Single hair collections were made once after BPR treatment and stored at -20 degrees C until analysis.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Hair was aligned scalp-end to tip and then segmented in 3-cm sections.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For this study, it was assumed that the mean hair growth rate was 1.0 cm/month.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Deuterated internal standard was added to hair segments (2-20 mg of hair) and digested overnight at room temperature with 1 N NaOH.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Specimens were extracted with a liquid-liquid procedure and analyzed by liquid chromatography-tandem mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limits of quantitation for BPR and NBPR were 3 pg/mg and 5 pg/mg, respectively, for 20 mg of hair.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
BPR and NBPR concentrations were highest for all subjects in hair segments estimated to correspond to the subject's period of drug treatment.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
With one exception, NBPR was present in higher concentrations in hair than was the parent compound.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
BPR concentrations in hair segments ranged from 3.1 pg/mg to 123.8 pg/mg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
NBPR concentrations ranged from 4.8 pg/mg to 1517.8 pg/mg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In one subject, BPR and NBPR were not detected in any hair segment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In some subjects, BPR and NBPR were detected in hair segments that did not correspond to the period of drug treatment, suggesting that drug movement may have occurred by diffusion in sweat and other mechanisms.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The data from this study also indicate that there is a high degree of intersubject variability in measured concentration of BPR and NBPR in hair segments, even when subjects receive the same dose for an equivalent number of treatment days.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Future prospective studies involving controlled drug administration will be necessary to evaluate whether hair can serve as an accurate historical record of variations in the pattern of drug use.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Monitoring the major cannabinoid metabolite (delta9-THCCOOH) to creatinine ratio (M/C) has been used to predict new drug use.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Monitoring the major cannabinoid metabolite (delta9-THCCOOH) to creatinine ratio (M/C) has been used to predict new drug use.

$$$$
>  <CLASS>
NONE

>  <TARGET>
According to Huestis and Cone, the best accuracy (85.4%) for predicting new marijuana use was a ratio > or = 0.5 from two urine specimens collected at least 24 h apart.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Manno et al. recommended an M/C ratio of > or = 1.5.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Subjects with a history of chronic marijuana use were screened for cannabinoid use by immunoassay (50-ng/mL cutoff), and presumptive positives were confirmed by gas chromatography-mass spectrometry for delta9-THCCOOH (15-ng/mL cutoff).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Creatinine was analyzed with a cutoff concentration of 25 mg/dL.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The study objective was to apply the criteria from both groups of workers to determine if consecutive urine specimens (collected at least 24 h apart) positive for cannabinoids could be used to differentiate new marijuana use from the excretion of residual cannabinoid metabolite (delta9-THCCOOH) in an uncontrolled setting.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Serial urine specimens (826) were collected from 26 individuals.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Huestis and Cone and Manno et al. ratios indicated new drug use in 83% and 33% of serial urine specimens collected at least 24 h apart, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Clinically, the Huestis and Cone ratio is recommended because of a lower false-negative rate (7.4%) than the Manno et al. false-negative rate (24%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In legal situations, we recommend using the Manno et al. ratio because of its lower false-positive rate (0.1%) as stated by Huestis and Cone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effects of smoking, CYP2D6 genotype, and concomitant use of enzyme inducers or inhibitors on the steady state plasma concentrations of haloperidol (HAL) and reduced haloperidol (RHAL) were evaluated in 92 schizophrenic inpatients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All but three of these patients received concomitant medication, in many cases with drugs potentially interacting with HAL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Of the 92 patients, 63 were treated orally with HAL in a daily dose of 0.4 to 50 mg; 29 patients were treated intramuscularly with a daily equivalent dose of HAL decanoate (expressed as HAL) of 1.8 to 17.9 mg. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A wide interindividual variation in HAL dose and in steady state plasma concentrations of HAL and RHAL was observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the patients treated orally, the daily oral dose was about 4 times higher and the dose-normalized HAL (but not RHAL) plasma concentrations were significantly lower in smokers (n = 40) than in nonsmokers (n = 23) (p < 0.01).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The dose-normalized RHAL (but not HAL) plasma concentrations and the RHAL/HAL ratio were significantly higher in poor metabolizers (PMs) than in extensive metabolizers (EMs).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was a trend toward an effect of potentially interacting drugs (inducers or inhibitors) on dose, dose-normalized HAL and RHAL plasma concentrations, and the RHAL/HAL ratio.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the patients treated intramuscularly, the dose-normalized HAL (but not RHAL) plasma concentrations were significantly lower in smokers than in nonsmokers, but no differences in doses were observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This naturalistic study of modest sample size in a polymedicated population shows an effect of smoking and CYP2D6 genotype (and to a lesser extent, of interacting drugs) on the kinetics of HAL.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In this study, we describe the synthesis of a new family of indolizinone derivatives designed to fit an extrahydrophobic pocket within the active site of aromatase and to strongly inhibit human aromatase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This could help improve the specificity of the inhibitors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Equine aromatase, very well characterized biochemically, is used as a comparative model.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Indeed, in a previous comparison between both human and equine aromatases, we described the importance of the interaction between the inhibitor and this pocket for the indane derivative MR 20814.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
MR 20492 and MR 20494 are more potent inhibitors of human aromatase (Ki/Km: 1.0+/-0.3 and 0.5+/-0.3, respectively).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The Ki/Km for MR 20494 is slightly higher than that obtained for fadrozole (0.1+/-0.0) and Ki/Km for both indolizinone derivatives are lower than those obtained for 4-hydroxyandrostenedione (1.9+/-0.8) and MR 20814 (8.1+/-.7).

$$$$
>  <CLASS>
NONE

>  <TARGET>
These new compounds are not enzyme inactivators.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Moreover, as indicated by the higher Ki/Km values obtained with equine enzyme (9.0+/-0.6 and 6.1+/-1.6 for MR 20492 and MR 20494, respectively), both human and equine aromatase active sites appear to be structurally different.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Difference absorption spectra study (350-500 nm) revealed that MR20492 and MR20494 were characterized by a combination of type-I and -II spectra with both enzymes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This result could be due to the isomerization of the molecule in polar solvent (Z and E forms).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The evaluation of these new molecules, as well as 4-hydroxyandrostenedione and fadrozole, on aromatase activity in transfected 293 cell cultures evidenced a strong inhibition (IC50: 0.20+/-0.03 microM, 0.20+/-0.02 microM and 0.50+/-0.40 microM for MR 20494, fadrozole and 4-OHA, respectively) except for MR 20492 (3.9+/-0.9 microM) and MR 20814 (10.5+/-0.6 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results proved that these molecules formed part of a promising family of potent inhibitors and that they penetrate 293 cells, without evidencing any cytotoxicity in Hela cells with MTT assay.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is thus encouraging for the development of new drugs for the treatment of estrogen-dependent cancers, these molecules also constitute new tools for understanding the aromatase active site.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this work, UDP-glucuronosyltransferases (UGTs), UGT1A3, 2B7(H268) and 2B7(Y268), stably expressed in human embryonic kidney cells (HK293) were used to assess glucuronidation activities with a variety of steroid hormone and bile acid substrates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The rate of synthesis of carboxyl- and hydroxyl-linked glucuronides was determined under optimal reaction conditions.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Expressed UGT1A3 catalyzed bile acid glucuronidation at high rates exclusively at the carboxyl moiety for all compounds tested.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Expressed UGT1A3 catalyzed bile acid glucuronidation at high rates exclusively at the carboxyl moiety for all compounds tested.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, UGT1A4 catalyzed bile acid glucuronidation at very low rates exclusively at the 3alpha-hydroxyl function.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In contrast, UGT1A4 catalyzed bile acid glucuronidation at very low rates exclusively at the 3alpha-hydroxyl function.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Both UGT2B7 allelic variants glucuronidated the bile acid substrates at both carboxyl and hydroxyl moieties, however, the 3alpha-hydroxyl position was preferentially conjugated compared to the carboxyl function.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Similarly, androsterone, a 3alpha-hydroxylated androgenic steroid, was glucuronidated at very high rates by expressed UGT2B7.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Of the estrogenic compounds tested, UGT2B7 catalyzed the glucuronidation of estriol at rates comparable to those determined for androsterone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Of the estrogenic compounds tested, UGT2B7 catalyzed the glucuronidation of estriol at rates comparable to those determined for androsterone.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Other structural discrimination was found with UGT2B7 which had activity toward estriol and estradiol exclusively at the 17beta-OH position, yielding the cholestatic steroid D-ring glucuronides.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
For the investigation of intracerebral dopamine metabolism, 6-[(18)F]fluoro-l-m-tyrosine (FmT) has been proposed as an alternative tracer that, unlike 6-[(18)F]fluoro-l-dopa, is not subjected to O-methylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We have studied the time course of FmT and its labelled metabolites in plasma after intravenous injection into humans, employing a method that we have developed and validated to analyze labelled metabolites of FmT in plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The study population comprised 38 subjects, 14 of whom were taking an aromatic amino acid decarboxylase inhibitor (carbidopa), and obtained arterialized venous blood samples at various times after an intravenous injection of between 185 and 370 MBq of FmT.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The major metabolite of FmT present in plasma was 6-[(18)F]fluoro-3-hydroxyphenylacetic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The time course of the fraction of radioactivity in plasma attributable to FmT was fitted well by the decay of two exponential functions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The fast component of the decay accounted for 40%-50% of the radioactivity and had a half-life of about 5 min.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When the total available FmT was calculated for each individual subject and expressed as a proportion of total radioactivity, this quantity did not differ significantly from that determined from the corresponding population mean.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was significantly more (15% on average) FmT available over the course of the 2-h experiment in the group pretreated with carbidopa.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Our results demonstrate that the major metabolite in plasma after an intravenous injection of FmT is 6-[(18)F]fluoro-3-hydroxyphenylacetic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The clearance of FmT from plasma compares well with the clearance of intravenously administered levodopa.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Carbidopa increases significantly the availability of FmT in plasma.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These results verify, in a large number of human subjects, earlier analyses of FmT metabolism in other species.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We validate a population-derived approach that can adequately describe the time course of FmT in plasma, alleviating the need for metabolite analysis.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Possible reasons for the observed differences in metabolic behavior and drug interaction liability between the structurally similar oral anticoagulants warfarin and phenprocoumon were explored.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Incubating (S)-phenprocoumon with human liver microsomes and cDNA-expressed CYP2C9 and determining its metabolism both in the absence and presence of the CYP2C9 inhibitor, sulfaphenazole, confirmed that phenprocoumon is a substrate for CYP2C9.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Incubating (S)-phenprocoumon with human liver microsomes and cDNA-expressed CYP2C9 and determining its metabolism both in the absence and presence of the CYP2C9 inhibitor, sulfaphenazole, confirmed that phenprocoumon is a substrate for CYP2C9.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Comparing the metabolic behavior of (S)- and (R)-warfarin, (S)- and (R)-phenprocoumon, and fixed structural mimics of the various tautomeric forms [(S)- and (R)-4-methoxyphenprocoumon, (S)- and (R)-2-methoxyphenprocoumon, (S)- and (R)-4-methoxywarfarin, (S)- and (R)-2-methoxywarfarin, and 9(S)- and 9(R)-cyclocoumarol] available to these two drugs with expressed CYP2C9 provides compelling evidence indicating that the ring closed form of (S)-warfarin and the ring opened anionic form of (S)-phenprocoumon are the major and specific structural forms of the two drugs that interact with the active site of CYP2C9.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The conclusion that (S)-warfarin and (S)-phenprocoumon interact with CYP2C9 in very different structural states provides a clear basis for the significant differences observed in their metabolic profiles.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Moreover, in accord with a previously established CoMFA model these results are consistent with the hypothesis that the active site of CYP2C9 possesses at least two major substrate binding sites, a pi-stacking site for aromatic rings and an ionic binding site for organic anions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An additional electrostatic binding site also appears to contribute to the orientation of coumarin analogs in the CYP2C9 active site by interacting with the C2-carbonyl group of the coumarin nucleus.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Practical immunochemical method for determination of 3,5, 6-trichloro-2-pyridinol in human urine: applications and considerations for exposure assessment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An analytical method is described for the quantitative determination of 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) in human urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This is the primary analyte found in urine as a result of exposure to chlorpyrifos, chlorpyrifos-methyl, triclopyr, or 3,5,6-TCP.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Conjugates of 3,5,6-TCP are released from urine by acid hydrolysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The free 3,5,6-TCP is purified using C(18) solid-phase extraction, eluting the analyte with 1-chlorobutane.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An aliquot of 1-chlorobutane is placed in a vial containing Trichloropyridinol Sample Diluent and evaporated, leaving the 3,5,6-TCP in the aqueous sample diluent.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The samples are assayed using the Trichloropyridinol RaPID Assay immunoassay test kit.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Final results are calculated using a standard curve constructed by linear regression after a ln/Logit data transformation is performed of the concentration and the absorbance readings, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The calculated lower limit of quantitation for 3,5,6-TCP in fortified control urine samples is 2.96 ng/mL (2.96 ppb).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Residues of 3,5,6-TCP determined using both immunochemical and gas chromatography with mass spectrometric detection correlate well.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To investigate the roles of CYP3A4 and CYP1A2 in the 3-hydroxylation of quinine in vivo.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In a randomized, three-way crossover study, nine healthy Swedish volunteers received single oral doses of quinine hydrochloride (500 mg), quinine hydrochloride (500 mg) plus ketoconazole (100 mg twice daily for 3 days), and quinine hydrochloride (500 mg) plus fluvoxamine (25 mg twice daily for 2 days) on three different occasions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Blood and urine samples were collected before quinine intake and up to 96 hours thereafter.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Plasma and urine samples were analyzed for both quinine and its main metabolite 3-hydroxyquinine with HPLC methods.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cytochrome P450 3A4 is important for the 3-hydroxylation of quinine in vivo.

$$$$
>  <CLASS>
NONE

>  <TARGET>
On the other hand, CYP1A2 had no significant effect on this metabolic pathway.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Interspecies variations in fatty acid hydroxylations involving cytochromes P450 2E1 and 4A.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The liver microsomal fractions of seven mammalian species including rat, dog, monkey, hamster, mouse, gerbil and humans, catalyzed the hydroxylation of saturated (lauric, myristic and palmitic) and unsaturated (oleic and linoleic) fatty acids to the corresponding omega and (omega-1)-hydroxylated derivatives, while stearic acid was not metabolized.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The liver microsomal fractions of seven mammalian species including rat, dog, monkey, hamster, mouse, gerbil and humans, catalyzed the hydroxylation of saturated (lauric, myristic and palmitic) and unsaturated (oleic and linoleic) fatty acids to the corresponding omega and (omega-1)-hydroxylated derivatives, while stearic acid was not metabolized.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Lauric acid was the most efficiently hydroxylated, and the rank of catalytic activity was lauric > myristic > oleic > palmitic > linoleic.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Lauric acid was the most efficiently hydroxylated, and the rank of catalytic activity was lauric > myristic > oleic > palmitic > linoleic.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Among the mammalian species studied, mouse and hamster presented the highest level of fatty acid omega and (omega-1)-hydroxylases, while the lowest activity was observed in dog and monkey.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In all the animal species, the (omega-1)-hydroxylation of fatty acids correlated significantly with the immunodetectable content of CYP2E1 and the 4-nitrophenol hydroxylation activity, known to be mediated by cytochrome P450 2E1.

$$$$
>  <CLASS>
Parent

>  <TARGET>
On the contrary, only the omega-hydroxylation of lauric acid slighly correlated with the level of cytochrome P450 4A, while no significant correlation was found with the omega-hydroxylation of the other fatty acids.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Furthermore, chemical and immuno-inhibitions of the hydroxylations of fatty acids led to the conclusion that fatty acid (omega-1)-hydroxylase activity is catalyzed by P450 2E1 in all the mammalian species, while the fatty acid omega-hydroxylase activity may be catalyzed by cytochromes P450 from the 4A family.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Therefore, lauric acid (omega-1)-hydroxylation along with 4-nitrophenol hydroxylation can be used as a specific and sensitive method to measure the level of CYP2E1 induction in humans and various animals.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
This study investigated the pharmacokinetics of cyclophosphamide (CP) and its main metabolite 4-hydroxycyclophosphamide (4-OH-CP) in patients with breast cancer undergoing high dose chemotherapy prior to autologous stem cell transplantation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An enzyme turn-over model was also developed to study the time course of cyclophosphamide induction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fourteen patients received a combination of CP (6 g m-2 ), thiotepum (500 mg m-2 ) and carboplatin (800 mg m-2 ) as a 96 h infusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma concentrations of CP and 4-OH-CP were determined with h.p.l.c.

$$$$
>  <CLASS>
NONE

>  <TARGET>
and a pharmacokinetic and enzyme turn-over model applied to data using NONMEM.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
CP plasma concentrations were described by a two-compartment model with a noninducible and an inducible pathway, the latter forming 4-OH-CP.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In the final enzyme model, CP affects the amount of enzymes by increasing the enzyme production rate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CP concentrations decreased during the infusion with no subsequent change in 4-OH-CP concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CP inducible and noninducible clearance were estimated to 1.76 l h-1 (90% C.I. 0.92-2.58) and 1.14 l h-1 (0.31-1.85), respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The induction resulted in an approximately doubled CP clearance through the inducible pathway at the end of treatment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The model predicted the enzyme turn-over half-life to be 24 h. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The presented mechanism-based enzyme induction model where the pharmacokinetics of the inducer and the enzyme pool counterbalance each other successfully described CP autoinduction.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It is reasonable to believe that CP affects its own elimination by increasing the enzyme production rate and thereby increasing the amount of enzyme by which CP is eliminated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Many substrates of cytochrome P450 (CYP) 3A4 are used for in vitro investigations of drug metabolism and potential drug-drug interactions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The aim of the present study was to determine the relationship between 10 commonly used CYP3A4 probes using modifiers with a range of inhibitory potency.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The effects of 34 compounds on CYP3A4-mediated metabolism were investigated in a recombinant CYP3A4 expression system.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Inhibition of erythromycin, dextromethorphan and diazepam N-demethylation, testosterone 6beta-hydroxylation, midazolam 1-hydroxylation, triazolam 4-hydroxylation, nifedipine oxidation, cyclosporin oxidation, terfenadine C-hydroxylation and N-dealkylation and benzyloxyresorufin O-dealkylation was evaluated at the apparent Km or S50 (for substrates showing sigmoidicity) value for each substrate and at an inhibitor concentration of 30 microM.

$$$$
>  <CLASS>
NONE

>  <TARGET>
While all CYP3A4 probe substrates demonstrate some degree of similarity, examination of the coefficients of determination, together with difference and cluster analysis highlighted that seven substrates can be categorized into two distinct substrate groups.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Erythromycin, cyclosporin and testosterone form the most closely related group and dextromethorphan, diazepam, midazolam and triazolam form a second group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Terfenadine can be equally well placed in either group, while nifedipine shows a distinctly different relationship.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Benzyloxyresorufin shows the weakest correlation with all the other CYP3A4 probes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Modifiers that caused negligible inhibition or potent inhibition are generally comparable in all assays, however, the greatest variability is apparent with compounds causing, on average, intermediate inhibition.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Modifiers of this type may cause substantial inhibition, no effect or even activation depending on the substrate employed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
It is recommended that multiple CYP3A4 probes, representing each substrate group, are used for the in vitro assessment of CYP3A4-mediated drug interactions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In vitro studies suggest that the oxidation of quinidine to 3-hydroxyquinidine is a specific marker reaction for CYP3A4 activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To assess the possible use of this reaction as an in vivo marker of CYP3A4 activity, we studied the involvement of cytochromes CYP2C9, CYP2E1 and CYP3A4 in the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
An open study of 30 healthy young male volunteers was performed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of a 200 mg single oral dose of quinidine was studied before and during daily administration of 100 mg diclofenac, a CYP2C9 substrate (n=6); 200 mg disulfiram, an inhibitor of CYP2E1 (n=6); 100 mg itraconazole, an inhibitor of CYP3A4 (n=6); 250 ml single strength grapefruit juice twice daily, an inhibitor of CYP3A4 (n=6); 250 mg of erythromycin 4 times daily, an inhibitor of CYP3A4 (n=6).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The pharmacokinetics of a 200 mg single oral dose of quinidine was studied before and during daily administration of 100 mg diclofenac, a CYP2C9 substrate (n=6); 200 mg disulfiram, an inhibitor of CYP2E1 (n=6); 100 mg itraconazole, an inhibitor of CYP3A4 (n=6); 250 ml single strength grapefruit juice twice daily, an inhibitor of CYP3A4 (n=6); 250 mg of erythromycin 4 times daily, an inhibitor of CYP3A4 (n=6).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Probes of other enzyme activities, caffeine (CYP1A2), sparteine (CYP2D6), mephenytoin (CYP2C19), tolbutamide (CYP2C9) and cortisol (CYP3A4) were also studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Concomitant administration of diclofenac reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Concomitant administration of diclofenac reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Concomitant administration of disulfiram did not alter any of the pharmacokinetic parameters of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Concomitant administration of itraconazole reduced quinidine total clearance, partial clearance by 3-hydroxylation and partial clearance by N-oxidation by 61, 84 and 73%, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Concomitant administration of itraconazole reduced quinidine total clearance, partial clearance by 3-hydroxylation and partial clearance by N-oxidation by 61, 84 and 73%, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The renal clearance was reduced by 60% and the elimination half-life increased by 35%.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Concomitant administration of grapefruit juice reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 15, 19 and 27%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The elimination half-life of quinidine was increased by 19%.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The caffeine metabolic index was reduced by 25%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Concomitant administration of erythromycin reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 34, 50 and 33%, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Concomitant administration of erythromycin reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 34, 50 and 33%, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cmax was increased by 39%.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The results confirm an important role for CYP3A4 in the oxidation of quinidine in vivo, and this applies particularly to the formation of 3-hydroxyquinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
While a minor contribution of CYP2C9 to the N-oxidation of quinidine is possible, a major involvement of the CYP2C9 or CYP2E1 enzymes in the oxidation of quinidine in vivo is unlikely.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We investigated the effect of cytochrome P450 (CYP2D6) genotypes on plasma levels of haloperidol (HAL) and reduced haloperidol (RHAL) in 47 Japanese male schizophrenic inpatients being treated with HAL.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Mutation-specific polymerase chain reaction (PCR) analysis was used to detect CYP2D6*10 as the C188C1T mutation in exon 1.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A long-PCR analysis method was used to detect CYP2D6*5.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Allele frequencies of CYP2D6*5 and CYP2D6*10 were 4.3% and 34.0%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma concentrations of HAL and RHAL were measured using high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The ranges of the plasma concentration of HAL and RHAL corrected to the dose were 0.28-1.60 (mean +/- SD, 0.66+/-0.25, n = 47) ng/mL/mg and 0.03-3.00 (mean+/-SD, 0.36+/-0.46, n = 47) ng/mL, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma RHAL/HAL ratios (R/H ratios) ranged from 0.06 to 1.88 (mean +/- SD, 0.48+/-0.32, n = 47).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The analysis was performed among the four genotype groups: CYP2D6*1/CYP2D6*1 (n = 11), CYP2D6*1/CYP2D6*10 (n = 11), CYP2D6*10/CYP2D6*10 (n = 6) and those who have CYP2D6*5 allele (CYP2D6*1/ CYP2D6*5 or CYP2D6*5/CYP2D6*10 (n = 4).

$$$$
>  <CLASS>
Parent

>  <TARGET>
We observed significant tendency in effects of CYP2D6 genotypes on plasma concentration of HAL and significant effects on plasma concentration of RHAL, and R/H ratio.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results we obtained suggested that the plasma concentration of HAL and RHAL were determined partly by CYP2D6 polymorphic activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The authors report preliminary findings on the effect of the new generation antiepileptic drug (AED) felbamate (FBM) on steady state plasma concentrations of clobazam (CLB), a benzodiazepine (frequently used as add-on therapy in patients with refractory epilepsy) and its active metabolite n-desmethyl-clobazam (N-CLB).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors report preliminary findings on the effect of the new generation antiepileptic drug (AED) felbamate (FBM) on steady state plasma concentrations of clobazam (CLB), a benzodiazepine (frequently used as add-on therapy in patients with refractory epilepsy) and its active metabolite n-desmethyl-clobazam (N-CLB).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors prospectively collected plasma samples from 66 children and adults with epilepsy receiving chronic CLB therapy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the basis of concomitant AEDs, patients were divided into three subgroups otherwise comparable for age and weight-adjusted daily dose of CLB: group A (n = 22), receiving CLB monotherapy or CLB plus AEDs without inducing properties of cytochrome P450 (CYP) metabolism, namely valproic acid (VPA) or lamotrigine (LTG); group B (n = 28), receiving CLB plus AED inducer polytherapy (carbamazepine, phenobarbital, phenytoin), even associated with VPA (n = 9) or LTG (n = 12); group C (n = 16), receiving CLB plus FBM, associated with AED inducers, VPA or LTG.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Level to weight-adjusted dose ratio (L/D) of CLB in groups B and C was twofold lower compared to group A (p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
L/D of N-CLB was twofold higher in group B and fivefold in group C compared to group A (p < 0.00 1).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These data confirm previous reports of a significant increase in CLB clearance in patients receiving AED inducers, leading to an accumulation of its main metabolite.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
They also provide novel evidence of a further marked increase in N-CLB plasma concentrations in patients receiving FBM cotherapy.

$$$$
>  <CLASS>
NONE

>  <TARGET>
From a clinical point of view, this finding should be kept in mind in explaining possible toxicity in patients on complex AED polytherapy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Quantitative aspects of drugs of abuse in urine samples: intercollaborative studies conducted in the European Union.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A description of a quantification performance by laboratories taking part in two intercollaborative studies (surveys 1 and 2) carried out in 1993 (n = 195) and 1994 (n = 228), respectively, on urine drug testing in the European Union is presented.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The performance of laboratories that quantified at least one substance (33.8% and 34.6% out of the total laboratories in surveys 1 and 2, respectively) is reported as a function of the analytic technique applied for quantification, the number of parameters investigated, the precision and accuracy of results obtained, and the influence of availability of reference material, including deuterated drug-standard analogue solutions provided in survey 2.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Quantification of different drugs of abuse was mainly carried out by gas chromatography coupled to mass spectrometry (63.1% of analyses in survey 1 vs. 68.6% in survey 2).

$$$$
>  <CLASS>
NONE

>  <TARGET>
It should be noted about the data obtained that the results for quantification were not particularly satisfactory in terms of precision and accuracy (CV mean = 62.8 in survey 1 and 50.4 in survey 2 and error % mean = 12.7 in survey 1 and 18.6 in survey 2).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The provision of reference materials increased the number of substances quantified (45.3% in survey 1 vs. 51.8% in survey 2) and improved the performance (CV mean of matching laboratories when quantifying matching substances: 50.1% in survey 1 vs. 35.5% in survey 2).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The impact of a "learning factor" (the opportunity to be challenged a second time and to correct past errors) and the influence of the provision of deuterated analogues in survey 2 was investigated in a population of repeater laboratories that quantified both in surveys 1 and 2 (55 vs. 63 laboratories, respectively).

$$$$
>  <CLASS>
NONE

>  <TARGET>
According to the European experience reported, it may be observed that laboratories able to afford quantitative analyses provided better overall analytic performance.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is probably because quantification implies some validation of the analytic procedure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Participation in interlaboratory comparison programs also aimed at assessing the performance of quantitative analyses should be considered a quality asset for laboratories involved in drug testing.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Aims To establish whether enantioselective metabolism of racemic (rac )-salbutamol occurs in the lungs by determining its enantiomeric disposition following inhalation, in the absence and presence of oral charcoal, compared with that following the oral and intravenous routes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Methods Fifteen healthy subjects (eight male) were randomized into an open design, crossover study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma and urine salbutamol enantiomer concentrations were measured for 24 h following oral (2 mg) with or without oral charcoal (to block oral absorption), inhaled (MDI; 1200 microg) with or without oral charcoal and intravenous (500 microg) rac-salbutamol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Systemic exposure (plasma AUC(0,infinity) and urinary excretion (Au24h ) of both enantiomers were calculated, and relative exposure to (R)-salbutamol both in plasma (AUC(R)-/AUC(S)- ) and urine (Au(R)-/Au(S)- ) was derived for each route.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Relative exposure after the inhaled with charcoal and oral routes were compared with the intravenous route.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Results AUC(R)-/AUC(S)- [geometric mean (95% CI)] was similar following the intravenous [0.32 (0.28, 0.36)] and inhaled with charcoal rates [0.29 (0.24, 0.36); P=0.046], but was far lower following oral dosing [0.05 (0.03, 0.07); P<0.001].

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similar results were found when relative exposure was analysed using Au24h.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Conclusions These results show no evidence of significant enantioselective presystemic metabolism in the lungs, whilst confirming it in the gut and systemic circulation, indicating that the (R)- and (S)-enantiomers are present in similar quantities in the airways following inhaled rac-salbutamol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP3A4 is generally believed to be the major CYP enzyme involved in the biotransformation of lidocaine in man; however, recent in vivo studies suggest that this may not be the case.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We have examined the effects of the CYP3A4 inhibitors erythromycin and ketoconazole and the CYP1A2 inhibitor fluvoxamine on the N-deethylation, i.e. formation of monoethylglycinexylidide (MEGX), and 3-hydroxylation of lidocaine by human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We have examined the effects of the CYP3A4 inhibitors erythromycin and ketoconazole and the CYP1A2 inhibitor fluvoxamine on the N-deethylation, i.e. formation of monoethylglycinexylidide (MEGX), and 3-hydroxylation of lidocaine by human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The experiments were carried out at lidocaine concentrations of 5 microM (clinically relevant concentration) and 800 microM.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The formation of both MEGX and 3-hydroxylidocaine was best described by a two-enzyme model.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
At 5 microM of lidocaine, fluvoxamine was a potent inhibitor of the formation of MEGX (IC50 1.2 microM).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
At 5 microM of lidocaine, fluvoxamine was a potent inhibitor of the formation of MEGX (IC50 1.2 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ketoconazole and erythromycin also showed an inhibitory effect on MEGX formation, but ketoconazole (IC50 8.5 microM) was a much more potent inhibitor than erythromycin (IC50 200 microM).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Ketoconazole and erythromycin also showed an inhibitory effect on MEGX formation, but ketoconazole (IC50 8.5 microM) was a much more potent inhibitor than erythromycin (IC50 200 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
At 800 microM of lidocaine, fluvoxamine (IC50 20.7 microM) and ketoconazole (IC50 20.4 microM) displayed a modest inhibitory effect on MEGX formation, whereas erythromycin was a weak inhibitor (IC50 >250 microM).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
At 800 microM of lidocaine, fluvoxamine (IC50 20.7 microM) and ketoconazole (IC50 20.4 microM) displayed a modest inhibitory effect on MEGX formation, whereas erythromycin was a weak inhibitor (IC50 >250 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The 3-hydroxylation of lidocaine was potently inhibited by fluvoxamine at both lidocaine concentrations (IC50 0.16 microM at 5 microM and 1.8 microM at 800 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The 3-hydroxylation of lidocaine was potently inhibited by fluvoxamine at both lidocaine concentrations (IC50 0.16 microM at 5 microM and 1.8 microM at 800 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Erythromycin and ketoconazole showed a clear inhibitory effect on the 3-hydroxylation of lidocaine at 5 microM of lidocaine (IC50 9.9 microM and 13.9 microM, respectively), but did not show a consistent effect at 800 microM of lidocaine (IC50 >250 microM and 75.0 microM, respectively).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Erythromycin and ketoconazole showed a clear inhibitory effect on the 3-hydroxylation of lidocaine at 5 microM of lidocaine (IC50 9.9 microM and 13.9 microM, respectively), but did not show a consistent effect at 800 microM of lidocaine (IC50 >250 microM and 75.0 microM, respectively).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Although further studies are needed to elucidate the role of distinct CYP enzymes in the biotransformation of lidocaine in humans, the findings of this study suggest that while both CYP1A2 and CYP3A4 are involved in the metabolism of lidocaine by human liver microsomes, CYP1A2 is the more important isoform at clinically relevant lidocaine concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To clarify the mechanism(s) for the interaction between warfarin and benzbromarone, a uricosuric agent, and to predict changes in the in vivo pharmacokinetics of (S)-warfarin from in vitro data.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To clarify the mechanism(s) for the interaction between warfarin and benzbromarone, a uricosuric agent, and to predict changes in the in vivo pharmacokinetics of (S)-warfarin from in vitro data.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Warfarin enantiomers and benzbromarone in serum, 7-hydroxywarfarin in urine, and serum unbound fractions of warfarin enantiomers were measured in patients with heart disease given warfarin with (n = 13) or without (n = 18) oral benzbromarone (50 mg/d).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro inhibition constants (K(i)) of benzbromarone for (S)-warfarin 7-hydroxylation were determined with use of human CYP2C9 and liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro inhibition constants (K(i)) of benzbromarone for (S)-warfarin 7-hydroxylation were determined with use of human CYP2C9 and liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The magnitude of changes in the formation clearance for 7-hydroxylation (CLf), the unbound oral clearance (CL(oral,u)), and the oral clearance (CL(oral)) for (S)-warfarin were predicted by equations incorporating the in vitro Ki, the theoretical maximum unbound hepatic benzbromarone concentration, and the fractions of warfarin eliminated through metabolism and of CYP2C9-mediated metabolic reaction susceptible to inhibition by benzbromarone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The magnitude of changes in the formation clearance for 7-hydroxylation (CLf), the unbound oral clearance (CL(oral,u)), and the oral clearance (CL(oral)) for (S)-warfarin were predicted by equations incorporating the in vitro Ki, the theoretical maximum unbound hepatic benzbromarone concentration, and the fractions of warfarin eliminated through metabolism and of CYP2C9-mediated metabolic reaction susceptible to inhibition by benzbromarone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The patients given warfarin with benzbromarone required a 36% less (P < .01) warfarin dose than those given warfarin alone (2.5 versus 3.9 mg/d) to attain similar international normalized ratios (2.1 and 2.2, respectively), and the former had 65%, 53%, and 54% lower (P < .05 or P < .01) CLf, CL(oral),u, and CL(oral) for (S)-warfarin than the latter, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, no significant differences were observed for (R)-warfarin kinetics between the groups.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Benzbromarone was found to be a potent competitive inhibitor (Ki < 0.01 micromol/L) for (S)-warfarin 7-hydroxylation mediated by CYP2C9.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Benzbromarone was found to be a potent competitive inhibitor (Ki < 0.01 micromol/L) for (S)-warfarin 7-hydroxylation mediated by CYP2C9.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The average changes in the in vivo CLf, CL(oral),u, and CL(oral)values for (S)-warfarin induced by benzbromarone were largely predictable by the proposed equations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Benzbromarone would intensify anticoagulant response of warfarin through an enantioselective inhibition of CYP2C9-mediated metabolism of pharmacologically more potent (S)-warfarin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Benzbromarone would intensify anticoagulant response of warfarin through an enantioselective inhibition of CYP2C9-mediated metabolism of pharmacologically more potent (S)-warfarin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The magnitude of changes in the in vivo warfarin kinetics may be predicted by in vitro data.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of N-nitrosobenzylmethylamine by human cytochrome P-450 enzymes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
N-Nitrosobenzylmethylamine (NBzMA) is a potent esophageal carcinogen in rodents, and has been found as a dietary contaminant in certain areas of China where esophageal cancer is endemic.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To determine which cytochrome P-450 enzymes in humans are primarily responsible for NBzMA metabolism, microsomes from lymphoblastoid cell lines expressing a panel of human cytochrome P-450s (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, CYP2C9, CYP2C19, and CYP3A4) and a panel of 10 different human liver microsomal preparations were examined for their abilities to metabolize [3H]NBzMA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In addition, the ability of human liver microsomes to form various NBzMA metabolites was correlated with the abilities of these preparations to metabolize coumarin, ethoxyresorufin, chlorzoxazone, 7-ethoxy-4-trifluoromethylcoumarin, S-mephenytoin, and nifedipine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
NBzMA metabolites were quantitated by reversed-phase high-performance liquid chromatography (HPLC) coupled with flow-through radioactivity detection.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Major metabolites included benzaldehyde, benzyl alcohol, benzoic acid, and several uncharacterized radioactive peaks.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Of the representative P-450 activities, only CYP2E1 and CYP2A6 catalyzed substantial metabolism of NBzMA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Compared to CYP2E1, CYP2A6 metabolized NBzMA more readily.

$$$$
>  <CLASS>
Parent

>  <TARGET>
NBzMA acted as a potent inhibitor of coumarin 7-hydroxylation in CYP2A6 microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Human liver microsomes metabolized NBzMA readily.

$$$$
>  <CLASS>
Parent

>  <TARGET>
NBzMA metabolite formation was most highly correlated with coumarin 7-hydroxylase activity, a marker of CYP2A6 activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
8-Methoxypsoralen substantially inhibited NBzMA metabolism in human hepatic microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
8-Methoxypsoralen substantially inhibited NBzMA metabolism in human hepatic microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When the effects of the potent isothiocyanates PEITC and PHITC were analyzed on microsomes from cell lines expressing CYP2E1 and CYP2A6, it was found that PEITC inhibited both enzymes, PHITC was the more effective inhibitor of CYP2E1, and PHITC was an ineffective inhibitor of CYP2A6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Collectively, these data indicate that CYP2A6 and, to a lesser degree, CYP2E1 are important P-450 enzymes in the activation of NBzMA in human systems.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Effects of matrix components on aromatase activity in breast stromal cells in culture.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Local estradiol production within breast tissue is maintained by the aromatase cytochrome P450arom complex, which has been localized primarily to the stromal component of tumors but also has been detected in the breast epithelial cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Paracrine interactions between stromal and epithelial components of the breast are critical to the sustained growth and progression of breast tumors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Maintenance of the differentiated state, including hormone and growth factor responsiveness, requires extracellular matrix proteins as substrata for cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This research has focused on developing a cell culture system that more closely mimics in vivo interactions in order to dissect actual paracrine signaling between these two cell types.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Human fibroblasts were isolated from breast tissue and were maintained in a cell culture system grown on plastic support or on a collagen I support matrix.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The collagen I matrix model supports cell maintenance and subsequent differentiation on collagen rather than maximal proliferation, therefore allowing for a more accurate environment for the study of hormonal control and cellular communication.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Initial experiments compared aromatase activity of patient fibroblasts grown on plastic versus collagen I using the tritiated water release method.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Constitutive aromatase activity was found to be lower when cells were grown on a collagen gel for 4-7 days (7.7 fold lower) using DMEM/F12 containing 10% dextran coated charcoal stripped serum.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, fibroblasts grown on collagen I appeared to be significantly more responsive to stimulation by 100 nM dexamethasone (plastic: 6.0 fold induction, collagen: 33.2 fold induction) when pretreated for 12 h prior to measurement of aromatase activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In an effort to examine paracrine interactions between the stromal and epithelial cells in breast tissue, experiments using conditioned media from fibroblast cultures were performed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Testosterone administration to fibroblasts results in the production of estradiol into the media in sufficient concentrations to elicit an increase in pS2 expression when the conditioned media is administered to MCF-7 cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The addition of a potent aromatase inhibitor resulted in a complete suppression of fibroblast-derived estrogens and showed only a modest increase in pS2 expression.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Culturing breast fibroblasts and epithelial cells on extracellular matrix allows for a more meaningful examination of the paracrine interactions between these cell types within the context of an appropriate extracellular environment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This study highlights the need for evaluation of gene expression in cell culture systems that accurately reflect the tissue microenvironment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rifampicin treatment greatly increases the apparent oral clearance of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We investigated the effect of cytochrome P450 induction by rifampicin on the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We investigated the effect of cytochrome P450 induction by rifampicin on the in vivo oxidative metabolism of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of a 200 mg oral single dose quinidine were studied before and after one week of daily treatment with 600 mg rifampicin in six healthy young male volunteers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Biomarker reactions of cytochrome P450 isozyme activities in the form of caffeine, sparteine, mephenytoin, tolbutamide and cortisol metabolism were applied.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The median total apparent oral clearance and partial clearance by 3-hydroxylation of quinidine increased 9 times.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The partial clearance by N-oxidation increased 6 times.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The Cmax and the elimination half life were reduced 3 times.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No statistically significant changes were found for quinidine tmax and renal clearance.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The cortisol metabolic ratio increased 5 times, while no statistically significant effects were seen for other CYP marker reactions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results indicate that the inductive effect of rifampicin is likely to be of clinical relevance particularly when used concomitantly with drugs metabolized by CYP3A4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Trospium chloride, an atropine derivative used for the treatment of urge incontinence, was tested for inhibitory effects on human cytochrome P450 enzymes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Metabolic activities were determined in liver microsomes from two donors using the following selective substrates: dextromethorphan (CYP2D6), denitronifedipine (CYP3A4), caffeine (CYP1A2), chlorzoxazone (CYP2E1), S-(+)-mephenytoin (CYP2C19), S-(-)-warfarin (CYP2C9) and coumarin (CYP2A6).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Incubations with each substrate were carried out without a possible inhibitor and in the presence of trospium chloride at varying concentrations (37-3000 microM) at 37 degrees in 0.1 M KH2PO4 buffer containing up to 3% DMSO.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolite concentrations were determined by high-performance liquid chromatography (HPLC) in all cases except CYP2A6 where direct fluorescence spectroscopy was used.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
First, trospium chloride IC50 values were determined for each substrate at respective K(M) concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Trospium chloride did not show relevant inhibitory effects on the metabolism of most substrates (IC50 values considerably higher than 1 mM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The only clear inhibition was seen for the CYP2D6-dependent high-affinity O-demethylation of dextromethorphan, where IC50 values of 27 microM and 44 microM were observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therefore, additional dextromethorphan concentrations (0.4-2000 microM) were tested.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Trospium chloride was a competitive inhibitor of the reaction with Ki values of 20 and 51 microM, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, trospium chloride has negligible inhibitory effects on CYP3A4, CYP1A2, CYP2E1, CYP2C19, CYP2C9 and CYP2A6 activity but is a reasonably potent inhibitor of CYP2D6 in vitro.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Compared to therapeutic trospium chloride peak plasma concentrations below 50 nM, the 1000-times higher competitive inhibition constant Ki however suggests that inhibition of CYP2D6 by trospium chloride is without any clinical relevance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A new HPLC method has been developed for the quantitative determination of methotrexate (MTX) and its 7-hydroxyl metabolite in human plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Samples were purified by protein precipitation with acetone and methanol, and a sample clean-up with a mixture of n-butanol and diethyl ether.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The analytes were separated on an RP Inertsil ODS-80A column and eluted in a solvent system containing 5% (v/v) tetrahydrofuran in water (pH 2.0).

$$$$
>  <CLASS>
NONE

>  <TARGET>
UV absorption measurement was performed at 313 nm, and the detector response was linear in a concentration range of 10-10,000 ng/ml.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The lower limit of quantitation of MTX was 10 ng/ml using 1 ml sample aliquots.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Values for accuracy and (within-run and between-run) precision were between 95.5-111% and 3.69-11.0%, respectively, at four concentrations analyzed in quintuplicate on four separate occasions.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The assay was applied to study the effects of docetaxel co-administration on the pharmacokinetics and metabolism of MTX in cancer patients.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The assay was applied to study the effects of docetaxel co-administration on the pharmacokinetics and metabolism of MTX in cancer patients.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To investigate the clinical relevance of 4-piperidinopiperidine (4PP) in the activity of irinotecan (CPT-11), a high-performance liquid chromatography-turboionspray-tandem mass spectrometry assay for plasma 4PP was developed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Plasma samples were prepared for analysis following C18 solid-phase extraction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Chromatography was performed on a Waters Nova-Pak Phenyl column.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Chromatography was performed on a Waters Nova-Pak Phenyl column.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Chromatography was performed on a Waters Nova-Pak Phenyl column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Selected reaction monitoring with the mass transitions m/z 169.2 --> 84.2 and 139.2 --> 98.1 was used for the detection of 4PP and the internal standard (IS), 1-piperidineproprionitrile, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The assay was linear from 14.8 to 591.0 nM with absolute recoveries of 4PP (59.1 nM) and IS (143.7 nM) of 85.7% (n = 10) and 86.7% (n = 10), respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The accuracy and imprecision of the method (total) was > or = 96.8% and < or = 8.5% over the concentration range studied, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
4PP was detectable in plasma following the administration of 125, 350, 500 mg/m2 and 600 mg/m2 CPT-11 to patients, with AUC(4PP) correlated with the dose (r2 = 0.66).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma concentrations of 4PP declined slowly with a long terminal half-life (33.4 +/- 17.1 h).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Overall, the concentrations of 4PP in plasma were in the sub-micromolar range (< 206.9 nM) and substantially lower than those capable of inducing apoptosis of cancer cells.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Species comparison of hepatic and pulmonary metabolism of benzene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Benzene is an occupational hazard and environmental toxicant found in cigarette smoke, gasoline, and the chemical industry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The major health concern associated with benzene exposure is leukemia.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Studies using microsomal preparations from human, mouse, rabbit, and rat to determine species differences in the metabolism of benzene to phenol, hydroquinone and catechol, indicate that the rat is most similar, both quantitatively and qualitatively, to the human in pulmonary microsomal metabolism of benzene.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
With hepatic microsomes, rat is most similar to human in metabolite formation at the two lower concentrations examined (24 and 200 microM), while at the two higher concentrations (700 and 1000 microM) mouse is most similar in phenol formation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In all species, the enzyme system responsible for benzene metabolism approached saturation in hepatic microsomes but not in pulmonary microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In all species, the enzyme system responsible for benzene metabolism approached saturation in hepatic microsomes but not in pulmonary microsomes.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In all species, the enzyme system responsible for benzene metabolism approached saturation in hepatic microsomes but not in pulmonary microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In pulmonary microsomes from mouse, rat, and human, phenol appeared to competitively inhibit benzene metabolism resulting in a greater proportion of phenol being converted to hydroquinone when the benzene concentration increased.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The opposite effect was seen in hepatic microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These findings support the hypothesis that the lung plays an important role in benzene metabolism, and therefore, toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Tetrachloroethylene and trichloroethylene fatality: case report and simple headspace SPME-capillary gas chromatographic determination in tissues.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We describe a simple, precise, and sensitive assay of tetrachloroethylene and trichloroethylene in tissues, suitable both for emergency cases and forensic medicine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method employs headspace solid phase microextraction-capillary gas chromatography and electron capture detection.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The case is relative to a 45-year-old woman discovered unconscious in a laundry area.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The concentrations of the solvents in tissues were determined and compared to other previously published fatalities.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The structural requirements for a compound to be a potent inhibitor for mouse CYP2A5 and human CYP2A6 enzymes catalysing coumarin 7-hydroxylase activity have been studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The IC50 of 28 compounds for the pyrazole-treated male DBA/2 mouse and human liver microsomal coumarin 7-hydroxylation were determined at 10 microm coumarin concentration 15 times over Km of coumarin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The IC50 of 28 compounds for the pyrazole-treated male DBA/2 mouse and human liver microsomal coumarin 7-hydroxylation were determined at 10 microm coumarin concentration 15 times over Km of coumarin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The three most potent inhibitors for CYP2A5 were gamma-nonanoic lactone, gamma-decanolactone and gamma-phenyl-gamma-butyrolactone with an IC50 = 1.9+/-0.4, 2.1+/-0.2 and 2.4+/-0.3 microM and for CYP2A67-methylcoumarin, butylcyclohexane and indan with an IC50. = 30+/-3.2, 43+/-9 and 50+/-11 microM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among the 28 compounds studied, only 2-benzoxazolinone, 2-indanone and gamma-valerolactone showed similar inhibitory activity in both species.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Indan had a lower IC50 for human than for mouse coumarin 7-hydroxylation, whereas the IC50 of 24 other compounds was higher for human than for mouse coumarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Indan had a lower IC50 for human than for mouse coumarin 7-hydroxylation, whereas the IC50 of 24 other compounds was higher for human than for mouse coumarin 7-hydroxylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The largest difference in IC50 between mouse and human activity was observed with 5-substituted phenyl, pentyl, hexyl, heptyl or octyl gamma-lactones or 6-substituted delta-lactones.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
IC50 of gamma-undecanolactone and gamma-decanolactone was 500 times lower for mouse than human coumarin 7-hydroxylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
IC50 of gamma-undecanolactone and gamma-decanolactone was 500 times lower for mouse than human coumarin 7-hydroxylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The difference in the IC50 between human and mouse coumarin 7-hydroxylation decreased substantially with the corresponding compounds without the lactone ring.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The difference in the IC50 between human and mouse coumarin 7-hydroxylation decreased substantially with the corresponding compounds without the lactone ring.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is concluded that certain 5- or 6-position substituted gamma- and delta-lactones are potent inhibitors for mouse CYP2A5 but not for the orthologous human CYP2A6 and that the active site of CYP2A6 could be smaller than the active site of CYP2A5.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We have investigated cytochrome P450 (P450) and associated monooxygenase activities in human brain mitochondria isolated from eight regions of four human brain samples obtained at autopsy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
P450-associated monooxygenase activities including aminopyrine N-demethylase (APD), 7-ethoxycoumarin O-deethylase (ECD), p-nitrophenol hydroxylase (PNPH), and N-nitrosodimethylamine N-demethylase (ND-MAD) were detectable in the mitochondria from human brain regions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Immunoblot experiments using antisera to purified rat liver microsomal P450, namely P4502B1/2, P4501A1/2, and P4502E1, revealed immunoreactive bands in isolated mitochondria from different regions of the human brain.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The antibody to P4502B1/2 and P4501A1/2 inhibited the human brain mitochondrial APD and ECD activities, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The addition of antiserum to microsomal NADPH cytochrome P450 reductase did not affect the mitochondrial P450-associated monooxygenase activities, although it completely inhibited the corresponding activities in brain microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Overall, the present study demonstrates, in human brain mitochondria, the presence of multiple forms of P450 belonging to the 1A, 2B, and 2E subfamilies that are involved in xenobiotic metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
To investigate the pharmacokinetics of levamisole and a metabolite, p-hydroxylevamisole in patients with colorectal cancer treated with 5-fluorouracil (5-FU).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To investigate the pharmacokinetics of levamisole and a metabolite, p-hydroxylevamisole in patients with colorectal cancer treated with 5-fluorouracil (5-FU).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Following an intravenous bolus dose of 5-FU, 20 patients with colorectal cancer received oral doses of 50 mg levamisole every 8 h for 3 days.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Immediately after the last dose, blood and urine samples were collected over at least an 8-h period.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Samples were assayed for levamisole and p-hydroxylevamisole by GC/MS.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The levamisole plasma and urine data were subjected to pharmacokinetic analysis using NONMEM software.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Substantial interpatient variability was observed in the levamisole plasma concentration-time curves.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Patients with cardiovascular or gastrointestinal complications demonstrated altered absorption of levamisole.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetic parameter values for levamisole were similar to those obtained previously in healthy subjects and other cancer patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There is no evidence that the pharmacokinetics of levamisole are altered by 5-FU administered immediately prior to levamisole administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The relationship between the substantial intersubject variability in levamisole plasma concentration-time curves and clinical outcome following 5-FU/levamisole adjuvant chemotherapy should be examined.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fatal flecainide intoxication.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A fatal case attributed to flecainide acetate (Tambocor), a class Ic antiarrythmic drug, is presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flecainide was detected by GC/MS in gastric contents, blood and liver as well.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The urine analysis revealed the presence of its dealkylated metabolite.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Body fluids and tissue concentrations determined by GC/ECD were 7.7 mg/kg in femoral blood, 0.26 mg/kg in bile, 18 mg/kg in liver, 0.17 mg/kg in cerebrospinal fluid, 0.22 mg/kg in brain cortex and 28.9 mg/kg in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The total amount of flecainide in gastric contents was about 43 mg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Even taking into account the postmortem redistribution of flecainide, its blood level still remains in the toxic range.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A couple of sensitive and accurate liquid chromatography-electrospray mass spectrometry (LC- S-MS) methods for the determination of the total forms of irinotecan and its active metabolite SN-38 in human serum, using the same chromatographic and detection conditions, is presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both used camptothecin as internal standard (I.S.).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The sample pretreatment for irinotecan involved a simple protein precipitation with acetonitrile, whereas a liquid-liquid extraction was necessary for SN-38.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A Symmetry C18, 3.5 microm (150 x 1 mm I.D.) reversed-phase column was used for the chromatographic separation, together with a gradient elution of acetonitrile in 5 mM ammonium formate buffer (pH 3) as mobile phase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
After ionisation in the pneumatically-assisted electrospray source and in-source collision induced dissociation, acquisition was performed in the selected ion monitoring mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Recoveries were 69 and 47% on average, detection limits 2.5 and 0.25 ng/ml and quantitation limits 10 and 0.5 ng/ml for irinotecan and SN-38, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Reproducibility was good and the method was linear from limits of quantitation up to 10,000 ng/ml for irinotecan, and up to 100 ng/ml for SN-38.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This sensitive and highly specific method is suitable both for pharmacokinetic studies and routine therapeutic drug monitoring.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Patients with Parkinson's disease (PD) in long-term levodopa therapy often complain of worsening of motor symptoms in the afternoon and evening.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The pathophysiology of this phenomenon is not known.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We evaluated the motor response to repeated doses of levodopa during a 12-hour period in 52 parkinsonian patients (19 de novo, 20 stable, and 13 wearing-off).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the day of the study, all patients received standard doses of levodopa/carbidopa at 8:00 a.m., 12:00 noon, and 4:00 p.m. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Motor measurements such as tapping test, walking time, and tremor score, and blood samples for levodopa and 3-O-methyldopa (3OMD) plasma analysis, were performed hourly.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Mean motor scores and pharmacokinetic data, evaluated for a period of 3 hours after each levodopa dose, were compared.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In de novo patients, we did not observe diurnal changes in motor score, whereas a progressive daytime worsening was visible in stable and wearing-off patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No significant difference in levodopa pharmacokinetics after each levodopa dose was observed within each patient group, whereas 3OMD plasma levels significant increased with repeated levodopa administrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, no significant correlation between motor scores and 3OMD plasma levels was observed, suggesting that the diminishing motor response to afternoon and evening doses of levodopa in patients in long-term levodopa therapy does not relate to the pharmacokinetics of the drug.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is possible that this phenomenon may be an expression of the occurrence of tolerance to repeated doses of levodopa.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Developmental changes of vitamin K epoxidase and reductase activities involved in the vitamin K cycle in human liver.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We examined the developmental changes in activities of vitamin K epoxidase, and vitamin K-2,3-epoxide reductase and vitamin K reductase in the human autopsied liver.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The activity of epoxidase, which converts vitamin K hydroquinone to its epoxide, showed a high value in the early prenatal period of 10-30 gestational weeks but decreased rather rapidly in contrast with the reductase activities.

$$$$
>  <CLASS>
NONE

>  <TARGET>
After birth, a significant decrease of the epoxidase activity was observed but no such change was seen during the postnatal period.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
On the other hand, the activities of vitamin K-2,3-epoxide reductase and vitamin K reductase, which convert vitamin K-2,3-epoxide to its hydroquinone, showed a significantly low value in the early prenatal period.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The highest activity of vitamin K epoxidase in the early prenatal period may be essential to the production of vitamin K dependent ligands for growth factors expressed in the embryo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The anticancer alkylating agents cyclophosphamide (CPA) and ifosfamide (IFA) are prodrugs that undergo extensive P450-catalyzed metabolism to yield both active (4-hydroxylated) and therapeutically inactive but neurotoxic (N-dechloroethylated) metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Whereas the human liver microsomal P450 catalysts of CPA and IFA 4-hydroxylation are well characterized, the P450 enzyme catalysts of the alternative N-dechloroethylation pathway are poorly defined.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Analysis of a panel of fifteen human P450 cDNAs in the baculovirus expression system ('Supersomes') demonstrated that CYP3A4 exhibited the highest N-dechloroethylation activity toward both CPA and IFA, whereas CYP2B6 displayed high N-dechloroethylation activity toward IFA, but not CPA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The contributions of each human P450 to overall liver microsomal N-dechloroethylation were calculated using a recently described relative substrate-activity factor method, and were found to be in excellent agreement with the results of inhibition studies using the CYP3A inhibitor troleandomycin and an inhibitory monoclonal antibody to CYP2B6.

$$$$
>  <CLASS>
Parent

>  <TARGET>
With CPA as substrate, CYP3A4 was shown to catalyze >/=95% of liver microsomal N-dechloroethylation, whereas with IFA as substrate, CYP3A4 catalyzed an average of approximately 70% of liver microsomal N-dechloroethylation (range = 40-90%), with the balance of this activity catalyzed by CYP2B6 (range = 10-70%, dependent on the CYP2B6 content of the liver).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Because CYP2B6 can make a significant contribution to human liver microsomal IFA N-dechloroethylation, but only a minor contribution to IFA 4-hydroxylation, the selective inhibition of hepatic CYP2B6 activity in individuals with a high hepatic CYP2B6 content may provide a useful approach to minimize the formation of therapeutically inactive but toxic N-dechloroethylated IFA metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism and toxicity of trichloroethylene and S-(1,2-dichlorovinyl)-L-cysteine in freshly isolated human proximal tubular cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Trichloroethylene (Tri) caused modest cytotoxicity in freshly isolated human proximal tubular (hPT) cells, as assessed by significant decreases in lactate dehydrogenase (LDH) activity after 1 h of exposure to 500 microM Tri.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Oxidative metabolism of Tri by cytochrome P-450 to form chloral hydrate (CH) was only detectable in kidney microsomes from one patient out of four tested and was not detected in hPT cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, GSH conjugation of Tri was detected in cells from every patient tested.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In contrast, GSH conjugation of Tri was detected in cells from every patient tested.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The kinetics of Tri metabolism to its GSH conjugate S-(1,2-dichlorovinyl)glutathione (DCVG) followed biphasic kinetics, with apparent Km and Vmax values of 0.51 and 24.9 mM and 0.10 and 1.0 nmol/min per mg protein, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The kinetics of Tri metabolism to its GSH conjugate S-(1,2-dichlorovinyl)glutathione (DCVG) followed biphasic kinetics, with apparent Km and Vmax values of 0.51 and 24.9 mM and 0.10 and 1.0 nmol/min per mg protein, respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
S-(1,2-dichlorovinyl)-L-cysteine (DCVC), the cysteine conjugate metabolite of Tri that is considered the penultimate nephrotoxic species, caused both time- and concentration-dependent increases in LDH release in freshly isolated hPT cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Preincubation of hPT cells with 0.1 mM aminooxyacetic acid did not protect hPT cells from DCVC-induced cellular injury, suggesting that another enzyme besides the cysteine conjugate beta-lyase may be important in DCVC bioactivation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study is the first to measure the cytotoxicity and metabolism of Tri and DCVC in freshly isolated cells from the human kidney.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These data indicate that the pathway involved in the cytotoxicity and metabolism of Tri in hPT cells is the GSH conjugation pathway and that the cytochrome P-450-dependent pathway has little direct role in renal Tri metabolism in humans.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These data indicate that the pathway involved in the cytotoxicity and metabolism of Tri in hPT cells is the GSH conjugation pathway and that the cytochrome P-450-dependent pathway has little direct role in renal Tri metabolism in humans.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro covalent binding of nafenopin-CoA to human liver proteins.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Endogenous fatty acyl-CoAs play an important role in the acylation of proteins.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A number of xenobiotic carboxylic acids are able to mimic fatty acids, forming CoA conjugates and acting as substrates in pathways of lipid metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A number of xenobiotic carboxylic acids are able to mimic fatty acids, forming CoA conjugates and acting as substrates in pathways of lipid metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this study nafenopin, a substrate for human hepatic fatty acid-CoA ligases, was chosen as a model compound to study xenobiotic acylation of human liver proteins.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In this study nafenopin, a substrate for human hepatic fatty acid-CoA ligases, was chosen as a model compound to study xenobiotic acylation of human liver proteins.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
(3)H-nafenopin (+/- unlabeled palmitate) or (14)C-palmitate (+/- unlabeled nafenopin) were incubated for up to 120 min at 37 degrees C with ATP, CoA, and homogenate protein (1 mg/ml) from four individual human livers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nafenopin covalently bound to proteins was detectable in all human livers and increased with time.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nafenopin adduct formation was directly proportional to nafenopin-CoA formation (r = 0.985, p < 0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Attachment of nafenopin to proteins involved both thioester and amide linkages with 76 and 24% of adducts formed with proteins > 100 and 50-100 kDa, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Attachment of nafenopin to proteins involved both thioester and amide linkages with 76 and 24% of adducts formed with proteins > 100 and 50-100 kDa, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Protein acylation by palmitate was also demonstrated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Palmitate significantly inhibited nafenopin-CoA formation by 29% but had no effect on nafenopin-CoA-mediated protein acylation.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Palmitate significantly inhibited nafenopin-CoA formation by 29% but had no effect on nafenopin-CoA-mediated protein acylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, nafenopin significantly inhibited protein palmitoylation by palmitoyl-CoA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This is the first study to demonstrate a direct relationship between xenobiotic-CoA formation, acylation of human liver proteins, and inhibition of endogenous palmitoylation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The ability of xenobiotics to acylate tissue proteins may have important biological consequences including perturbation of endogenous regulation of protein localization and function.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7.

$$$$
>  <CLASS>
Parent

>  <TARGET>
It is suggested that formation of more polar metabolites of all-trans-retinoic acid (atRA) via oxidative pathways limits its biological activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In this report, we investigated the biotransformation of oxidized products of atRA via glucuronidation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
For this purpose, we synthesized 4-hydroxy-RA (4-OH-RA) in radioactive and nonradioactive form, 4-hydroxy-retinyl acetate (4-OH-RAc), and 5,6-epoxy-RA, all of which are major products of atRA oxidation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Glucuronidation of these retinoids by human liver microsomes and human recombinant UDP-glucuronosyltransferases (UGTs) was characterized and compared with the glucuronidation of atRA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The human liver microsomes glucuronidated 4-OH-RA and 4-OH-RAc with 6- and 3-fold higher activity than atRA, respectively.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Analysis of the glucuronidation products showed that the hydroxyl-linked glucuronides of 4-OH-RA and 4-OH-RAc were the major products, as opposed to the formation of the carboxyl-linked glucuronide with atRA, 4-oxo-RA, and 5,6-epoxy-RA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We have also determined that human recombinant UGT2B7 can glucuronidate atRA, 4-OH-RA, and 4-OH-RAc with activities similar to those found in human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We therefore postulate that this human isoenzyme, which is expressed in human liver, kidney, and intestine, plays a key role in the biological fate of atRA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We also propose that atRA induces its own oxidative metabolism via a cytochrome P450 (CYP26) and is further biotransformed into glucuronides via UGT-mediated pathways.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We also propose that atRA induces its own oxidative metabolism via a cytochrome P450 (CYP26) and is further biotransformed into glucuronides via UGT-mediated pathways.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To study the pharmacokinetics of cilostazol following single oral administration of 50 to 200 mg in healthy young males, and after repeated oral administration of 100 mg every 12 hours to patients with peripheral arterial disease (PAD).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The healthy male single dose study was a single-centre, randomised sequence, open-label, incomplete block, 3-period, 4-treatment, crossover design.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The patient study was a single-centre, multiple dose, open-label study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
20 healthy nonsmoking male volunteers were enrolled and successfully completed the single dose study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
26 patients (21 males, 5 females) with intermittent claudication resulting from PAD were enrolled and completed the single/multiple dose study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Noncompartmental pharmacokinetic parameters, the area under the plasma concentration-time curve from zero to the time of last measurable plasma concentration, and maximum plasma concentration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Peak plasma concentrations of cilostazol occurred about 3 hours after drug administration and then declined biexponentially with concentrations detectable (> 20 micrograms/L) in the plasma for at least 36 hours postdose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The apparent elimination half-life of cilostazol (approximately 11 hours) was similar after a single dose or after multiple doses, with steady state being reached within 4 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol accumulated 1.7-fold following multiple dose administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The apparent volume of distribution (Vz/F; 2.76 L/kg) suggested extensive distribution of cilostazol in the tissues.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The oral clearance of cilostazol (CL/F; 0.18 L/h/kg) was much lower than liver blood flow, indicating a low extraction ratio drug, and hence low probability of a significant first-pass effect.

$$$$
>  <CLASS>
Parent

>  <TARGET>
None of the administered doses were recovered in the urine as unchanged cilostazol, suggesting that metabolism, rather than urinary excretion, is the major elimination route.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Following single oral doses of 50 to 200 mg, the plasma concentrations of cilostazol and its metabolites increased less than proportionally to the dose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of cilostazol in normal healthy volunteers are predictive of those in patients with PAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Single oral doses of 50 to 200 mg cilostazol as well as 100 mg cilostazol every 12 hours were well tolerated.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The plasma concentration of cilostazol and its metabolites increased less than proportionally with increasing doses.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The relatively low plasma clearance and high volume of distribution of cilostazol suggest a low first-pass effect and extensive distribution.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of cilostazol in normal volunteers is predictive of that in patients with PAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol was well tolerated in healthy volunteers and patients with intermittent claudication resulting from PAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The objectives of this research were to (1) assess the relative bioavailability following administration of a 100 mg cilostazol suspension versus 100 mg tablet; (2) assess dosage form equivalency (2 x 50 mg compared with 1 x 100 mg); (3) compare the relative bioavailability following a single 50 mg dose of cilostazol administered as an ethanolic solution versus a 50 mg tablet; and (4) determine the effects of high fat diet on the pharmacokinetics of cilostazol following a single dose of 100 mg cilostazol in the fed or fasted state.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Results were compiled from 3 separate studies to address these objectives.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All studies involved healthy adult males receiving single oral doses of cilostazol in the fed or fasted state.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The fed state consisted of administering cilostazol after ingestion of a high fat meal.

$$$$
>  <CLASS>
NONE

>  <TARGET>
One study compared the relative bioavailability of 100 mg suspension and 2 x 50 mg tablet versus 100 mg tablet in a randomised crossover design.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The study involving administration of a 50 mg cilostazol ethanolic solution was a single treatment study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effects of food on the pharmacokinetics of cilostazol after administration of 100 mg cilostazol in the fed or fasted state as well as the pharmacokinetic profile following administration of a single 50 mg oral dose of cilostazol were assessed in a randomised crossover design.

$$$$
>  <CLASS>
NONE

>  <TARGET>
All participants were healthy nonsmoking males aged between 19 and 48 years whose bodyweight was within 15% of ideal bodyweight.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Noncompartmental pharmacokinetic parameters were determined for each study participant.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The area under the plasma concentration-time curve (AUC) parameters were within the 80 to 125% criterion for bioequivalence for the cilostazol and its primary metabolite, OPC-13015.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The maximum observed plasma concentrations (Cmax) for these formulations were not equivalent and indicated that the absorption of cilostazol from a suspension is more rapid than from a tablet.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The maximum observed plasma concentrations (Cmax) for these formulations were not equivalent and indicated that the absorption of cilostazol from a suspension is more rapid than from a tablet.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The maximum observed plasma concentrations (Cmax) for these formulations were not equivalent and indicated that the absorption of cilostazol from a suspension is more rapid than from a tablet.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The apparent terminal half-lives (t1/2z) of cilostazol and OPC-13015 were shorter after administration of the suspension compared with the tablet.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cmax and AUC following administration of a single 50 mg cilostazol tablet were approximately 80% of that from the same dose administered as an ethanolic solution.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The t1/2z of cilostazol decreased from 15.5 hours after a tablet to 2.5 hours after an ethanolic solution.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Upon coadministration with a high fat meal, the Cmax of cilostazol increased 90% and AUC infinity increased 25% (p < 0.05).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The t1/2z decreased from 15.1 +/- 14.5 hours (mean +/- SD) in the fasted state to 5.4 +/- 2.0 hours in the fed state.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Single oral doses of 50 and 100 mg cilostazol were well tolerated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The relative bioavailability of the 100 mg cilostazol tablet versus an oral 100 mg cilostazol suspension is 100%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The 2 x 50 mg and 1 x 100 mg tablets are considered to be bioequivalent.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The absorption following administration of 50 mg cilostazol ethanolic solution is faster and appears to be greater than that after administration of the 50 mg tablet.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration of food increases the rate and extent of cilostazol absorption.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The oral pharmacokinetics of cilostazol and metabolites are absorption-rate limited.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The significant differences in the t1/2z observed when comparing cilostazol tablet, suspension, and solution as well as the effects of food suggest 'flip-flop' pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The pharmacokinetic profiles of cilostazol and its metabolites following a single oral dose of cilostazol 100 mg were compared between individuals with impaired and normal liver function.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The study was conducted as a single-centre, open-label, single dose pharmacokinetic and tolerability trial.

$$$$
>  <CLASS>
NONE

>  <TARGET>
12 patients with impaired and compensated liver function were compared with 12 volunteers with normal liver function.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Participants in each group were matched for gender, age and weight.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Of the 12 patients with hepatic impairment examined in this study, 10 had mild impairment (Child-Pugh class A) and 2 had moderate impairment (Child-Pugh class B).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood and urine were collected up to 144 hours after drug administration.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Pharmacokinetics were determined by noncompartmental methods.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Protein binding did not differ between the groups (95.2% healthy volunteers, 94.6% hepatically impaired patients).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Mean +/- SD unbound oral clearance of cilostazol decreased by 8.6% because of hepatic impairment (3380 +/- 1400 ml/min in healthy volunteers, 3260 +/- 2030 ml/min in hepatically impaired patients).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Total urinary excretion of metabolites was significantly higher in healthy volunteers (26 vs 17% of dose).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Overall, the pharmacokinetics of cilostazol and its metabolites, OPC-13213 and OPC-13015, were not substantially different in those with mild and moderate hepatic disease compared with values in healthy volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Except for terminal-phase disposition half-life and apparent terminal-phase volume of distribution for cilostazol, the ratios of geometric means of pharmacokinetic parameters for plasma cilostazol, OPC-13213 and OPC-13015 in those with hepatic impairment versus healthy volunteers were close to 100%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Based on the results of the pharmacokinetic analysis, dose adjustment in patients with mild hepatic impairment is not necessary.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, caution should be exercised when cilostazol is administered to patients with moderate or severe hepatic impairment.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of cilostazol were studied in patients with mild, moderate and severe renal impairment and in healthy volunteers after administration of 50 mg single and multiple doses of cilostazol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This was an open-label, single and multiple dose study administering 50 mg cilostazol every 12 hours to healthy volunteers and patients with varying degrees of renal impairment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
6 normal volunteers [creatinine clearance (CLCR) > or = 90 ml/min]; 6 patients with mild (CLCR 50 to 89 ml/min), 5 with moderate (CLCR 26 to 49 ml/min) and 6 with severe (CLCR 5 to 25 ml/min) renal impairment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Noncompartmental pharmacokinetic parameters were determined for each study participant.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
At steady state, in the severe renal disease group, cilostazol and OPC-13015 peak concentrations (Cmax) were 29 and 41% lower and the areas under the concentration-time curve over the dosage interval (AUC tau) 39 and 47% lower than in the healthy volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cmax and AUC tau of OPC-13213 were significantly higher, 173 and 209%, respectively, than those in the healthy volunteers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The accumulation ratios were not significantly different between the various renal function groups for cilostazol and its metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The estimated pharmacological activity of cilostazol and its metabolites was similar between the normal volunteers and those with severe renal impairment.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A dosage reduction in renally impaired patients is not supported by the pharmacokinetics of cilostazol and its metabolites in this patient group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro results are inconclusive as to whether cilostazol is metabolised by cytochrome P450 isoenzyme 2D6 (CYP2D6).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The goals of this study were (1) to assure the dose of quinidine and timing relative to cilostazol used in this study were adequate to cause inhibition of CYP2D6, (2) to evaluate carryover effects of quinidine administration, and (3) to evaluate the effect of CYP2D6 deficiency and administration of quinidine (a CYP2D6 inhibitor) on the pharmacokinetics of a single 100 mg oral dose of cilostazol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This study was conducted as a single-centre, open-label, randomised sequence, 2-period, crossover pharmacokinetic trial.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Water alone (treatment without quinidine) or two 200 mg oral doses of quinidine sulfate with water were administered 25 hours and 1 hour prior to a single 100 mg dose of cilostazol in period 1.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Study participants were crossed over to opposite treatment in period 2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Metoprolol 25 mg, used as a positive control, was administered 1 hour after quinidine sulfate with water or using water alone to assess the magnitude of CYP2D6 inhibition by quinidine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
22 healthy nonsmoking Caucasian (14 male and 8 female) volunteers participated in the study.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Serial blood and urine samples were collected at predose and after cilostazol administration to characterise cilostazol and its metabolite pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Additional plasma samples were taken to assess the pharmacokinetics of quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine samples were collected to measure metoprolol and hydroxymetoprolol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Administration of metoprolol with quinidine caused a significant (p < 0.001) decrease in the urinary 4-hydroxymetoprolol/metoprolol ratio compared with administration of metoprolol alone (42-fold decrease, 0.065 vs 2.707).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Hence, quinidine effectively converted extensive metabolisers of CYP2D6 to poor metabolisers of CYP2D6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The 21-day washout period was adequate to have complete recovery from quinidine inhibition of CYP2D6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The analysis of variance demonstrated that the mean maximum plasma concentration (Cmax) for cilostazol, both adjusted and unadjusted for the free fraction, was higher in the control group than in the quinidine group (p = 0.023).

$$$$
>  <CLASS>
NONE

>  <TARGET>
However, the time to Cmax (p = 0.669), the area under the plasma concentration-time curve from time zero to infinity (AUC infinity; p = 0.133), and the apparent oral clearance (p = 0.135) were unchanged.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The geometric mean ratios (90% confidence interval) comparing with quinidine (test) and without quinidine (reference) coadministration for Cmax and AUC infinity are 0.86 (0.77, 0.95) and 0.92 (0.84, 1.00), respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Similar patterns were observed for OPC-13015 and OPC-13213 with regard to Cmax, area under the plasma concentration-time curve from time zero to the last measurable concentration at time t, and AUC infinity (where determinable).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The slight decrease in the systemic availability of cilostazol and its metabolites was thought to be a result of the increased gastrointestinal motility secondary to quinidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The slight decrease in the systemic availability of cilostazol and its metabolites was thought to be a result of the increased gastrointestinal motility secondary to quinidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Administration of quinidine sulfate 200 mg profoundly inhibited CYP2D6-mediated metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effects of quinidine inhibition of CYP2D6 metabolism were completely reversible during the 21-day washout period.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Coadministration of quinidine with cilostazol had no substantial effect on cilostazol or its metabolites (OPC-13015 and OPC-13213).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration of quinidine with cilostazol had no substantial effect on cilostazol or its metabolites (OPC-13015 and OPC-13213).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Hence, CYP2D6 does not have a significant contribution in the metabolic elimination of cilostazol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of omeprazole on the metabolism of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effect of omeprazole on the metabolism of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro results suggest that cilostazol is metabolised by cytochrome P450 (CYP) isoforms 1A2, 2D6, 3A4 and 2C19.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study was designed to evaluate the effect of concomitant administration of omeprazole (a CYP2C19 inhibitor) on the pharmacokinetics of a single 100 mg oral dose of cilostazol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This study was conducted as a single-centre, open-label, nonrandomised, 2-period, crossover pharmacokinetic trial.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A single 100 mg dose of cilostazol was administered orally on days 0 and 14.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Oral omeprazole (40 mg every day) was administered on days 7 to 18.

$$$$
>  <CLASS>
NONE

>  <TARGET>
20 healthy nonsmoking male and female volunteers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Serial blood samples were collected before and after cilostazol administration to characterise the pharmacokinetics of cilostazol and its metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Following omeprazole coadministration, the increases in cilostazol maximum plasma concentration (Cmax) and area under the plasma concentration-time curve at time t (AUCt) were 18% (p = 0.062) and 26% (p < 0.001), respectively.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
For the 2 major circulating metabolites, OPC-13015 and OPC-13213, the OPC-13015 Cmax and AUCt increased by 29 and 69%, respectively (p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, for OPC-13213, the Cmax and AUCt decreased by 22 and 31%, respectively (p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The plasma protein binding of cilostazol was unaffected by coadministration of omeprazole.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Coadministration of cilostazol with omeprazole resulted in an increase in the systemic exposure of cilostazol and its active metabolite, OPC-13015, by 26 and 69%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration of cilostazol with omeprazole resulted in an increase in the systemic exposure of cilostazol and its active metabolite, OPC-13015, by 26 and 69%, respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
For the other active metabolite, OPC-13213, systemic exposure decreased by 31% because of inhibition of cilostazol metabolism to this metabolite.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These changes in systemic exposure were well tolerated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A dose of 50 mg cilostazol twice a day should be considered during coadministration of inhibitors of CYP2C19, such as omeprazole.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effects of CYP3A inhibition on the metabolism of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro results suggest that cilostazol is metabolised by cytochrome P450 (CYP) isoforms 1A2, 2D6, 3A and 2C19.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study investigated the role of CYP3A inhibition on the metabolism of cilostazol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The study was conducted as a single-centre, open-label, nonrandomised, 2-period, crossover pharmacokinetic trial.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A single dose of cilostazol 100 mg was administered orally on days 1 and 15.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Erythromycin (150 mg orally 3 times daily) was administered on days 8 to 20.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
14C-erythromycin (3 microns Ci) was administered intravenously on days 1 and 15 one hour before cilostazol administration to determine baseline and the inhibitory effect of erythromycin treatment on CYP3A activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
16 healthy nonsmoking male volunteers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Serial blood and pooled urine samples were collected before and after cilostazol administration to quantitate cilostazol and its metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serial exhalation samples were collected after intravenous 14C-erythromycin administration and radioactivity was quantitated by scintillation counting.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics were determined by noncompartmental methods and compared before and after erythromycin administration.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Tolerability assessments included adverse events, laboratory tests, vital signs and electrocardiographs.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Following erythromycin coadministration, cilostazol maximum plasma concentration (Cmax), area under the plasma concentration-time curve at time t (AUCt), and area under the curve from zero to infinity (AUC infinity) increased significantly by 47, 87, and 73%, respectively, and an approximately 50% reduction in unbound clearance was observed for the major circulating metabolite of cilostazol, OPC-13015.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Following erythromycin coadministration, cilostazol maximum plasma concentration (Cmax), area under the plasma concentration-time curve at time t (AUCt), and area under the curve from zero to infinity (AUC infinity) increased significantly by 47, 87, and 73%, respectively, and an approximately 50% reduction in unbound clearance was observed for the major circulating metabolite of cilostazol, OPC-13015.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cmax decreased significantly (p < 0.001) by 24%, while AUCt increased by 8%; this increase was not significant.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
For the second major metabolite, OPC-13213, the Cmax and AUCt increased by 29 and 141%, respectively (p < 0.001).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In vivo results are in agreement with previous in vitro human microsome studies, indicating that cilostazol is metabolised to OPC-13015 via CYP3A.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In addition, OPC-13213 concentrations increased after inhibition of CYP3A because of inhibition of sequential metabolism of OPC-13213 via CYP3A.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A starting dose for cilostazol of 50 mg twice daily should be considered during coadministration of inhibitors of CYP3A.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To assess the effects of cilostazol on lovastatin pharmacokinetics.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This was a single-centre, open-label, multiple dose, sequential treatment study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Participants received single oral doses of lovastatin 80 mg on days 1, 7 and 9, as well as oral cilostazol 100 mg twice daily on days 2 to 8, followed by a single oral 150 mg cilostazol dose on day 9.

$$$$
>  <CLASS>
NONE

>  <TARGET>
15 healthy, nonsmoking male or female volunteers (aged 18 to 60 years) were enrolled, and 12 completed the study.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Pharmacokinetic parameters were calculated using plasma concentrations of lovastatin and its beta-hydroxy metabolite and of cilostazol and its metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacokinetic parameters were calculated using plasma concentrations of lovastatin and its beta-hydroxy metabolite and of cilostazol and its metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Differences in the pharmacokinetics of each drug when given alone or in combination were assessed by analysis of variance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The maximum observed plasma concentration (Cmax) of lovastatin or its metabolite did not differ significantly when lovastatin was given alone and when it was given with 100 mg of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The maximum observed plasma concentration (Cmax) of lovastatin or its metabolite did not differ significantly when lovastatin was given alone and when it was given with 100 mg of cilostazol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean ratios of the area under the plasma concentration-time curve from zero to the time of the last measurable concentration (AUCt) for lovastatin coadministered with 100 mg of cilostazol to that with lovastatin given alone were 1.6 for lovastatin and 1.7 for its metabolite.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mean ratios of the area under the plasma concentration-time curve from zero to the time of the last measurable concentration (AUCt) for lovastatin coadministered with 100 mg of cilostazol to that with lovastatin given alone were 1.6 for lovastatin and 1.7 for its metabolite.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With 150 mg of cilostazol, lovastatin Cmax did not change, whereas Cmax of the metabolite increased 2.2-fold.

$$$$
>  <CLASS>
Parent

>  <TARGET>
With 150 mg of cilostazol, lovastatin Cmax did not change, whereas Cmax of the metabolite increased 2.2-fold.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All increases in lovastatin and metabolite AUC were statistically significant, except for the 1.6-fold increase in lovastatin AUC with 150 mg of cilostazol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
All increases in lovastatin and metabolite AUC were statistically significant, except for the 1.6-fold increase in lovastatin AUC with 150 mg of cilostazol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Maximum steady-state plasma drug concentration (Cssmax) and AUC during a dosage interval (AUC tau) for cilostazol 100 mg twice daily decreased 14 and 15%, respectively, upon lovastatin coadministration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Lovastatin and metabolite exposure is increased only by up to 2-fold when cilostazol is coadministered, which is considerably less than that observed for potent CYP3A inhibitors such as itraconazole and grapefruit juice.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Lovastatin and metabolite exposure is increased only by up to 2-fold when cilostazol is coadministered, which is considerably less than that observed for potent CYP3A inhibitors such as itraconazole and grapefruit juice.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Absorption of cilostazol decreased approximately 15% when it was given with lovastatin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No dosage adjustments are necessary for cilostazol when coadministered with lovastatin, whereas lovastatin dose reductions may be needed when the 2 drugs are given together.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To evaluate the effect of cilostazol administration on warfarin pharmacokinetics and pharmacodynamics following a single 25 mg dose of warfarin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A randomised double-blind 2-period crossover with healthy volunteers receiving either 100 mg cilostazol twice daily for 13 days or matching placebo twice daily for 13 days, and the other treatment 21 days later.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A single 25 mg dose of warfarin was given 14 days prior to the start of the study, and 7 days after the cilostazol and placebo treatments.

$$$$
>  <CLASS>
NONE

>  <TARGET>
15 normal healthy male volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Noncompartmental pharmacokinetic parameters for (R)- and (S)-warfarin, the area under the curve of the prothrombin time (AUCPT), activated partial thromboplastin time (AUCaPTT), Ivy bleeding times, unbound fraction (fu) of cilostazol, and warfarin were determined for each individual.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For (R)- and (S)-warfarin, the 90% confidence intervals for the ratios of the geometric means (90% CI) of the maximum plasma concentration and area under the plasma concentration-time curve were between 0.88 to 1.03.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The 90% CI for the AUCPT and AUCaPTT was between 0.95 and 1.06.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For Ivy bleeding time, the 90% CI for the ratios of the geometric means ranged between 0.71 and 1.22.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The fu of cilostazol did not differ significantly between the 2 treatments.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was a 17% increase in the fu of warfarin (p < 0.05), which was not clinically significant.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coadministration of warfarin with twice daily administration of cilostazol 100 mg did not alter (R)- and (S)-warfarin pharmacokinetics, prothrombin time, partial thromboplastin time, Ivy bleeding times, or cilostazol protein binding.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interaction potential and tolerability of the coadministration of cilostazol and aspirin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study evaluated the effects of repeated oral drug administration with cilostazol alone and with aspirin (acetylsalicylic acid) on platelet aggregation, coagulation and bleeding time as well as the cilostazol-aspirin pharmacokinetic interaction in healthy males.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This was a randomised, double-blind, placebo-controlled, crossover study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Participants received either cilostazol 100 mg or placebo twice a day for 10 days; aspirin 325 mg/day was coadministered for the last 5 days.

$$$$
>  <CLASS>
NONE

>  <TARGET>
After a 14-day washout period, participants received the alternative treatment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
12 healthy male volunteers were enrolled.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Differences in bleeding times, platelet aggregation, prothrombin time (PT) and activated partial thromboplastin time (aPTT) between cilostazol with aspirin and cilostazol alone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Noncompartmental pharmacokinetic parameters were determined for each study participant.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol, with or without aspirin, caused no changes in PT, aPTT or bleeding time.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was a 23 to 35% increase in inhibition of ADP-induced ex vivo platelet aggregation by cilostazol plus aspirin when compared with aspirin alone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was no additive or synergistic effect on arachidonic acid-induced platelet aggregation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Statistically significant but clinically insignificant increases in the area under the plasma concentration-time curve to the last measurable plasma concentration and trough concentrations of cilostazol and its metabolites (OPC-13015 and OPC-13213) occurred after aspirin coadministration, with no differences observed in the maximum plasma concentration Drug-related adverse events were generally mild, the most frequent being headache.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Statistically significant but clinically insignificant increases in the area under the plasma concentration-time curve to the last measurable plasma concentration and trough concentrations of cilostazol and its metabolites (OPC-13015 and OPC-13213) occurred after aspirin coadministration, with no differences observed in the maximum plasma concentration Drug-related adverse events were generally mild, the most frequent being headache.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol and aspirin coadministration did not cause clinically significant changes in PT, aPTT, bleeding time, platelet aggregation or plasma concentrations of cilostazol and its 2 active metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cilostazol and aspirin coadministration did not cause clinically significant changes in PT, aPTT, bleeding time, platelet aggregation or plasma concentrations of cilostazol and its 2 active metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cilostazol was generally well tolerated with or without aspirin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
19-oxygenations of 3-deoxy androgens, potent competitive inhibitors of estrogen biosynthesis, with human placental aromatase.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Aromatase is a cytochrome P450 enzyme complex that catalyzes the conversion of androst-4-ene-3,17-dione (AD) to estrone through three sequential oxygenations of the 19-methyl group.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
To gain insight into the ability of 3-deoxy derivative of AD, compound 1, and its 5-ene isomer 4, which are potent competitive inhibitors of aromatase, to serve as a substrate, we studied their 19-oxygenation by human placental aromatase and the metabolites isolated were analyzed by gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Inhibitors 1 and 4 were found to be oxygenated with aromatase to produce the corresponding 19-hydroxy derivatives 2 and 5 and 19-oxo derivatives 3 and 6 as well as the 17beta-reduced 19-hydroxy compounds 7 and 8.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Kinetic studies indicated that the 5-ene steroid 4 was surprisingly a good substrate for the aromatase-catalyzing 19-oxygenation with the V(max) value of 45 pmol/min per mg prot which was approx. four times higher than that of the other.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The relative K(m) value for steroids 1 and 4 obtained in this study is opposite from the relative K(i) value obtained previously in the inhibition study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results reveal that there is a difference between a binding suitable for serving as an inhibitor of aromatase and a binding suitable for serving as a substrate of the enzyme in the 3-deoxy steroid series and the C-3 carbonyl group of AD is essential for a proper binding as a substrate to the active site of aromatase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Estrogen synthesis in human colon cancer epithelial cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Epidemiological and experimental data suggest an involvement of estrogen in the development and progression of colorectal cancer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In order to determine whether local synthesis of estrogen occurred in human colonic cancer cells, two colorectal cancer cell lines, HCT8 and HCT116, were evaluated for gene expression and enzyme activity of cytochrome P450 aromatase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition, the effect on aromatase expression of charcoal-stripped fetal calf serum, of quercetin and genistein and of tamoxifen and raloxifene was investigated in both cell lines.

$$$$
>  <CLASS>
NONE

>  <TARGET>
RT-PCR analysis revealed that colorectal adenocarcinoma cell lines contain aromatase as a major component.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The conversion of [(3)H]-androstenedione to estrone and labeled water was dose-dependently inhibited by 4-hydroxyandrostenedione and obeyed Michaelis-Menten kinetic with apparent Km values of approximately 20 nM and V(max) values of approx. 200 and 500 fmol/mg protein/h for HCT8 and HCT116 cells, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The conversion of [(3)H]-androstenedione to estrone and labeled water was dose-dependently inhibited by 4-hydroxyandrostenedione and obeyed Michaelis-Menten kinetic with apparent Km values of approximately 20 nM and V(max) values of approx. 200 and 500 fmol/mg protein/h for HCT8 and HCT116 cells, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After 24 h incubation, genistein (1 microM) significantly increased aromatase activity in HCT8 cells, with no effect on HCT116 cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In accord with previous observation in reproductive tissues, quercetin (1 microM) significantly inhibited the enzyme activity in both cell lines.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Also tamoxifen (100 nM) acted as inhibitor, while raloxifene (10 nM) decreased the enzyme activity only in HCT116 cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The aromatase gene expression modulation by these effective agents was consistent with their effects on enzyme activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These findings demonstrate for the first time that colorectal adenocarcinoma cell lines express aromatase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interestingly, the enzyme activity was inhibited by quercetin, one major dietary flavonoid, by tamoxifen, a hormonal therapeutic agent for breast cancer, and by raloxifene, used in the prevention of postmenopausal osteoporosis.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolites of orally administered Perilla frutescens extract in rats and humans.

$$$$
>  <CLASS>
NONE

>  <TARGET>
As a part of our search for bioactive substances from the leaves of Perilla frutescens BRITTON var. acuta KUDO (Perillae Herba, Labiatae), the aqueous extract was orally administered to rats and humans, and metabolites in the urine, plasma, and/or bile were analyzed by a high-performance liquid chromatograph (HPLC) equipped with a photodiode array detector.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
When the extract was administered to rats, 10 metabolites, trans-caffeic acid-4-O-sulfate (1), trans-p-coumaric acid-4-O-sulfate (2), trans-ferulic acid-4-O-sulfate (3), trans-m-coumaric acid-3-O-sulfate (4), trans-caffeic acid (5), m-hydroxyphenylpropionic acid (6), trans-p-coumaric acid (7), trans-m-coumaric acid (8), luteolin (9), and apigenin (10) were detected in the urine, whereas four metabolites, scutellarein-6, 7-di-O-beta-glucuronide (11), apigenin-4'-O-sulfate-7-O-beta-glucuronide (12), apigenin-7-O-beta-glucuronide (13), and diosmetin-7-O-beta-glucuronide (14) were found in the bile.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Compounds 1-8 and 11-14 were also found in the plasma.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
When the extract was given to humans, however, two metabolites, 1-O-(2,4,5-trimethoxycinnamoyl)-beta-glucuronic acid (15) and apigenin-4'-O-beta-glucuronide (16), were found in the urine and plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Thus, a species difference in the metabolism of the extract constituents was observed between rats and humans.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Structures 1-16 were identified based on their chemical and spectral data.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Our previous study showed that several drugs inhibited quinine 3-hydroxylation, a cytochrome P450 (CYP) 3A4-mediated reaction, in vitro.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In this extended study, 13 drugs were selected and tested by human liver microsomes in order to further determine their respective inhibition constant (Ki) and type of inhibition.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
According to the apparent Ki values, the inhibitory rank order of these tested drugs was as follows: ketoconazole > doxycycline > omeprazole > tetracycline > troleandomycin (with pre-incubation) > primaquine > troleandomycin (without pre-incubation) > nifedipine > erythromycin > verapamil > oleandomycin > diltiazem > cimetidine > hydralazine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among these drugs, doxycycline, tetracycline, ketoconazole, nifedipine and hydralazine were judged as mixed inhibitors; whereas, the remaining other drugs tested were judged as competitive inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When the plasma/serum concentrations possibly attained after their usual therapeutic doses were taken into account, tetracycline, doxycycline, omeprazole, ketoconazole, nifedipine, troleandomycin and erythromycin are likely to be inhibitors of quinine metabolism in patients when these drugs are co-administrated with quinine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
When the plasma/serum concentrations possibly attained after their usual therapeutic doses were taken into account, tetracycline, doxycycline, omeprazole, ketoconazole, nifedipine, troleandomycin and erythromycin are likely to be inhibitors of quinine metabolism in patients when these drugs are co-administrated with quinine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A high throughput screening (HTS) method for the evaluation of the seven major human hepatic CYP isoform activities was developed on a 96-well format, with automation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The method utilized pooled human liver microsomes and seven probe substrates, generic conditions for incubation, reaction termination and metabolite extraction with solid phase extraction (SPE) plates.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolites from the seven reactions were pooled and quantified using a generic liquid chromatography and tandem mass spectrometry (LCMS/MS) method.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The HTS method was validated based on Km values obtained, which were in agreement with literature data.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The isoform inhibition profiles of ketoconazole, quinidine, sulfaphenazole, tranylcypromine, alpha-naphthoflavone, and 4-methylpyrazole against CYPs 3A4, 2D6, 2C9, 2A6 land 2C19), 1A2 and 2E1, respectively, were obtained by this HTS method.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Graphically obtained IC50 values are in agreement with literature reported values.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The HTS method represents a significant efficiency and selectivity improvement over traditional methods, and can be used for CYP inhibition assay and can be extended for liver activity profiling.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Bioanalytical methods for the determination of estramustine phosphate by liquid chromatography and its four main metabolites estromustine, estramustine, estrone and estradiol by gas chromatography are described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the estramustine phosphate assay the plasma was purified by protein precipitation followed by a C18 solid-phase extraction.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For the metabolite assay the plasma samples were purified by a C18 solid-phase and liquid-liquid extraction procedure and derivatised by silanization.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thereafter, estramustine and estromustine were quantified by gas chromatography with nitrogen-phosphorus detection and estradiol and estrone were quantified by gas chromatography with selected ion monitoring.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The methods were validated with respect to linearity, selectivity, precision, accuracy, limit of quantitation, limit of detection, recovery and stability.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limit of quantitation was 2.3 micromol/l for estramustine phosphate, 30 nmol/l for estromustine and estramustine, 12 nmol/l for estrone and 8 nmol/l for estradiol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The results showed good precision and accuracy for estramustine phosphate and the four metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The intermediate precision was 6.2-13.5% (C.V.) and the accuracy was 91.8-103.9%.

$$$$
>  <CLASS>
Parent and its metabolite;

>  <TARGET>
Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
An enantioselective HPLC method for the simultaneous determination of the concentration of the enantiomers of the oxcarbazepine metabolites 10-hydroxycarbazepine (MHD) and carbamazepine-10,11-trans-dihydrodiol (DHD) in human urine is described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The method is based on extraction with tert.-butylmethyl ether-dichloromethane (2:1, v/v) under alkaline conditions, separation and evaporation of the organic phase and dissolution of the residue in the mobile phase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Enantiomers are resolved on a Diacel Chiralcel OD column (250 mm x 4.6 mm I.D.) under isocratic conditions using as mobile phase n-hexane-ethanol-2-propanol (18:2:1, v/v/v) with addition of glacial acetic acid (0.1%).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The enantiomers are detected by UV at 215 nm.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The method allows reliable determination of the MHD and DHD enantiomers in human urine with limits of quantification of 0.2 mg/l and 0.4 mg/l, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ethyl glucuronide: a marker of recent alcohol consumption with clinical and forensic implications.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A marker with a specific time spectrum of detection and both high sensitivity and specificity is required to diminish the clinically as well as forensically important gap on the time axis between short- and long-term markers of alcohol consumption like ethanol and CDT, GGT or MCV, respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Ethyl glucuronide (EtG) is a non-volatile, water-soluble, stable upon storage, direct metabolite of ethanol with a molecular weight of 222 g/mol that can be detected in body fluids for an extended time period after the complete elimination of alcohol from the body.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ethyl glucuronide (EtG) is a non-volatile, water-soluble, stable upon storage, direct metabolite of ethanol with a molecular weight of 222 g/mol that can be detected in body fluids for an extended time period after the complete elimination of alcohol from the body.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We investigated 107 urine and 78 serum samples of a total of 107 inpatients in 4 groups: (1) 33 inpatients in acute alcohol withdrawal and long term treatment; (2/3) 29 and 15 addicted forensic psychiatric inpatients (#64 StGB, penal code); (4) 30 recently detoxified inpatients of a station for long term treatment by LC/MS-MS with the internal standard d5-EtG and additionally in the fourth group of patients also by gas chromatography/mass spectrometry (GC/MS).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In 2 out of 33 inpatients of the first group, EtG could be determined 3 days after hospitalization; in an other subject, a relapse could be detected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In 2 out of 29 and in 1 out of 15 forensic inpatients of group 2 and 3, respectively--where neither clinical impression nor routine laboratory findings gave an indication for relapse--concentrations of EtG ranged between 0.1 and 18 mg/l in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the serum samples of the 30 inpatients of group 4, we could demonstrate a total agreement for the results of the GC/MS and the LC/MS-MS method as to whether a sample was found to be positive or negative for EtG.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We suggest that these results strengthen our earlier findings that ethyl glucuronide is a marker of alcohol consumption in general that can be detected for an extended time period after the complete elimination of alcohol from the body and a marker for relapse control with a specific time frame of detection intermediate between short- and long-term markers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Argatroban is a peptidomimetic inhibitor of thrombin that is currently undergoing extensive clinical trials as a heparin substitute for thrombotic complications.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Argatroban is readily metabolized into a major derivative, M1, that has pharmacological characteristics distinct from its parent compound.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The currently available clot-based assays measure the cumulative anticoagulant effect of argatroban and its metabolite(s).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Available HPLC methods do not differentiate between argatroban and M1-metabolite.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A modified method was developed to simultaneouly quantitate M1-metabolite and argatroban in biological fluids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Initial validation studies for the method included clinical trials of argatroban in patients with heparin-induced thrombocytopenia, (ARG 911 Study) and coronary interventional procedures (ARG 310 Study).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma samples were extracted with acetonitrile and reconstituted in a mobile phase.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Calibration curves were prepared by running known standards of argatroban and M1-metabolite in normal human plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Ultraviolet detection was made at 320 nm.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The retention times for argatroban and M1-metabolite peaks were found to be 10.5 +/- 0.3 minutes and 3.9 +/- 0.1 minutes, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The extraction efficiency was > 95% (r2 = 0.99).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In heparin-induced thrombocytopenia patients with major bleeding complications (n = 30), the relative increase in M1-metabolite compared to argatroban varied widely (two- to eight-fold).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In heparin-induced thrombocytopenia patients with major bleeding complications (n = 30), the relative increase in M1-metabolite compared to argatroban varied widely (two- to eight-fold).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The mean concentration of argatroban during the steady infusion period was found to be 0.7 +/- 0.35 microgram/mL, and for M1-metabolite, it was 5.5 +/- 2.8 micrograms/mL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Proportionate results were not seen when higher dosages of argatroban were administered (coronary angioplasty studies).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Argatroban and M1-metabolite levels also compared well with the results in global clotting assays.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Owing to the simultaneous quantitation of argatroban and M1-metabolite, this method provides a rapid assessment of the pharmacokinetics and pharmacodynamics of argatroban.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The differential quantitation may be useful in the assessment of relative metabolic turnover of argatroban that can be related to the hepatic and renal functions in a given patient.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In the present study, the concentrations of estrone (E(1)), estradiol (E(2)) and their sulfates (E(1)S and E(2)S), as well as the sulfatase and aromatase activities, were evaluated in post-menopausal patients with breast cancer.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Comparative studies of the evaluation of these parameters were carried out in (a) tumor tissue, (b) areas surrounding the tumor, and (c) areas distant from the tumor (glandular tissue) which were considered as normal tissue.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The levels (in pm/g; mean +/- SEM) were: for E(1) in the (a) area: 320+/-95; in (b): 232+/-86; and in (c): 203+/-71; for E(2) in the (a) area: 388+/-106; in (b): 224+/-48; and in (c): 172+/-80; for E(1)S in the (a) area: 454+/-110; in (b): 259+/-90; and in (c): 237+/-65; for E(2)S in the (a) area:318+/-67; in (b): 261+/-72; and in (c): 232+/-75, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The values of E(1)S and E(2) were significantly higher in the tumor tissue than in the area considered as normal.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In all the tissues studied, the sulfatase activity was much higher than aromatase (130-200).

$$$$
>  <CLASS>
NONE

>  <TARGET>
In addition, the sulfatase levels were significantly higher in the peripheral and in the tumor tissue than in the area considered as normal.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The levels of aromatase were significantly higher in tumoral than in normal tissue.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The present data extend the "intracrine concept" for breast cancer tumors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The physiopathology and clinical significance as promoter parameters in breast cancer is to be explored.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interpretation and enantiomer analysis of methamphetamine abusers' urine and illegally brewed methamphetamine crystals.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study deals with the high-performance liquid chromatographic identification of methamphetamine (MAMP) and amphetamine (AMP) enantiomers (d- and l-forms) in five illicit MAMP crystals and in urine specimens from 30 Japanese MAMP abusers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The analysis revealed that two of the types of crystals have a different optical purity ratio (l/d) and the other three have a single crystal of either the d- or l-enantiomer.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The l/d ratios of two types of crystals were 0.04 and 49.4, and no racemic form (l/d = 1.00) was found.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The urinary analysis showed that nonmetabolized MAMP and its demethylated metabolite, AMP, were present in urine specimens of all addicts.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The stereoisomeric profiles in urine can be classified roughly into five groups according to the detected amount and the l/d ratio of MAMP and AMP enantiomers collected at one time point.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the first group, only d-MAMP and d-AMP were detected (in 16 cases).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the second group, only l-MAMP and l-AMP were detected (in one case).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the third group, the amount of the l-enantiomer detected, for both MAMP and AMP, was less than that of the d-enantiomer, and the l/d ratio was between 0.004 and 0.54 for MAMP and between 0.01 and 0.07 for AMP (in five cases).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the fourth group, the l-enantiomer of MAMP and AMP was found to be more abundant than the d-enantiomer, and the l/d ratio was between 2.63 and 30.11 for MAMP and between 1.23 and 31.30 for AMP (in four cases).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the fifth group, the amount of l-MAMP detected was greater than that of d-MAMP, and less l-AMP than d-AMP was detected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The l/d ratios were between 1.13 and 8.82 for MAMP and between 0.17 and 0.82 for AMP (in four cases).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results might be suitable for identification and the forensic toxicological investigation of AMP analogues.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Biological monitoring of standardized exposure to ethylbenzene: evaluation of a biological tolerance (BAT) value.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results of standardized 8 h lasting exposures of n = 18 volunteers to ethylbenzene (EthBz) at levels of 25 and 100% of the maximum allowable concentrations at the workplace (MAK) value of 100 ppm as well as the results of field studies are considered to evaluate a biological tolerance (BAT) value for EthBz.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the basis of the relationship between the external and internal exposure a BAT value of 1.5 mg/l has been set for the EthBz concentration in blood as the most sensitive and specific parameter of exposure to this aromatic hydrocarbon.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The interpretation of EthBz blood values has to take into account the short half-life of t1/2 = 0.5 +/- 0.08 h in the first hour after the end of exposure in which this aromatic hydrocarbon is eliminated from the blood.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The additional determination of the EthBz metabolites mandelic acid (MA) and phenylglyoxylic acid (PGA), respectively, excreted in post shift urine as well as in urine samples at the beginning of the next shift shows good correlations with the external exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The biological half-life of MA was calculated to t1/2 = 5.3 +/- 1.1 h. 

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Because the time of sampling can vary the relationship between the levels of MA to PGA the total concentration of the excreted metabolites depends less on this influence and is therefore better suited for monitoring exposed persons.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the basis of the standardized experiments a BAT value has been proposed of 2 g MA plus PGA corrected per gram creatinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both BAT values are adjusted to data which result from earlier standardized exposures during 30 min to EthBz under physical activity of 50 watt on a bicycle ergometer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sulphonation of N-hydroxy-2-acetylaminofluorene by human dehydroepiandrosterone sulphotransferase.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Sulphonation of N-hydroxy-2-acetylaminofluorene by human dehydroepiandrosterone sulphotransferase.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The aim was to determine which human recombinant sulphotransferase (ST) isoform(s) were responsible for the sulphonation and, thus, potential further bioactivation of the classical hepatic procarcinogen N-hydroxy-2-acetylaminofluorene (N-OH-2AAF).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
N-OH-2AAF was incubated together with the cosubstrate 3'-phosphoadenosine-5'-phosphosulphate (PAPS) and either human liver cytosol or recombinant P-form phenolsulphotransferase (P-PST), M-form PST, dehydroepiandrosterone-ST (DHEA-ST) or oestrogen ST (EST).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Formation of 3'-phosphoadenosine-5'-phosphate (PAP) from PAPS, measured by HPLC, was used as the assay for determination of sulphoconjugation rates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The liver cytosol produced a 100% increase in PAP formation in the presence of 200 microM N-OH-2AAF as compared with baseline levels (p < 0.01), corresponding to a rate of 19 pmol/min/mg protein.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The liver cytosol produced a 100% increase in PAP formation in the presence of 200 microM N-OH-2AAF as compared with baseline levels (p < 0.01), corresponding to a rate of 19 pmol/min/mg protein.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Recombinant P-PST, however, was without effect.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is in contrast to previous suggestions using crude enzyme preparations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Like P-PST, recombinant M-PST and EST did not sulphonate N-OH-2AAF.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On the other hand, recombinant DHEA-ST produced a 161% increase in PAP formation in the presence of 200 microM N-OH-2AAF as compared with baseline values (p < 0.001).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
On the other hand, recombinant DHEA-ST produced a 161% increase in PAP formation in the presence of 200 microM N-OH-2AAF as compared with baseline values (p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Kinetic studies of N-OH-2AAF sulphonation by DHEA-ST and human liver cytosol gave similar apparent Kms.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Kinetic studies of N-OH-2AAF sulphonation by DHEA-ST and human liver cytosol gave similar apparent Kms.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interestingly, the Vmax for N-OH-2AAF sulphonation by DHEA-ST was very similar to that of DHEA, the natural substrate for DHEA-ST.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Interestingly, the Vmax for N-OH-2AAF sulphonation by DHEA-ST was very similar to that of DHEA, the natural substrate for DHEA-ST.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This is the first paper to demonstrate the involvement of the human DHEA-ST in the sulphonation of an N-hydroxylated aromatic amide carcinogen.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This is the first paper to demonstrate the involvement of the human DHEA-ST in the sulphonation of an N-hydroxylated aromatic amide carcinogen.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A procedure is presented for determination of the catechol-O-methyltransferase (COMT) activity in liver cytosolic preparations using 3,4-dihydroxyphenethylamine as substrate and by quantifying the product 3-methoxy-4-hydroxyphenethylamine (3-MHP).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A procedure is presented for determination of the catechol-O-methyltransferase (COMT) activity in liver cytosolic preparations using 3,4-dihydroxyphenethylamine as substrate and by quantifying the product 3-methoxy-4-hydroxyphenethylamine (3-MHP).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For quantification of 3-MHP in liver cytosolic preparations a gas chromatographic-mass spectrometric procedure after liquid-liquid extraction and acetylation was established and validated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The intra- and inter-day accuracy and precision were better than 15% and 20%, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Extraction efficiency and selectivity were also sufficient.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For in statu nascendi derivatization of unstable catecholic metabolites in liver microsome preparations, cytosolic preparations with COMT activities of at least 1 nmol product/min/mg protein were used after addition of S-adenosylmethionine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Such catecholic metabolites, which are claimed to be responsible for toxic effects in vivo, e.g., neurotoxicity or carcinogenesis, must not be overlooked in in vitro metabolism studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using this trick, gas chromatography-mass spectrometry (GC-MS) was suitable for the determination of catecholic metabolites in human and rat liver preparations after the same sample preparation as for 3-MHP quantification.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The applicability was exemplified for the antidepressant paroxetine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D2 receptors using single-photon emission tomography (SPET).

$$$$
>  <CLASS>
Parent

>  <TARGET>
A lipophilic labelled metabolite of [123I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D2 receptors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Albendazole (ABZ; methyl 5-propylthio-1H-benzimidazol-2-yl carbamate) is a broad spectrum anthelmintic whose activity resides both in the parent compound and its sulphoxide metabolite (ABS).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Albendazole (ABZ; methyl 5-propylthio-1H-benzimidazol-2-yl carbamate) is a broad spectrum anthelmintic whose activity resides both in the parent compound and its sulphoxide metabolite (ABS).

$$$$
>  <CLASS>
Parent

>  <TARGET>
There are numerous reports of ABZ metabolism in animals but relatively few in humans.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We have investigated the sulphoxidation of ABZ in human liver microsomes and recombinant systems.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The specific enzymes involved in the sulphoxidation of ABZ were determined by a combination of approaches; inhibition with an antiserum directed against cytochrome P450 reductase, the effect of selective chemical inhibitors on ABZ sulphoxidation in human liver microsomes, the capability of expressed CYP and FMO to mediate the formation of ABS, regression analysis of the rate of metabolism of ABZ to ABS in human liver microsomes against selective P450 substrates and regression analysis of the rate of ABS sulphoxidation against CYP expression measured by Western blotting.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Comparison of Vmax values obtained following heat inactivation (3min at 45 degrees C) of flavin monoxygenases (FMO), chemical inhibition of FMO with methimazole and addition of an antiserum directed against cytochrome P450 reductase indicate that FMO and CYP contribute approximately 30% and 70%, respectively, to ABS production in vitro.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Comparison of Vmax values obtained following heat inactivation (3min at 45 degrees C) of flavin monoxygenases (FMO), chemical inhibition of FMO with methimazole and addition of an antiserum directed against cytochrome P450 reductase indicate that FMO and CYP contribute approximately 30% and 70%, respectively, to ABS production in vitro.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Comparison of CLint values suggests CYP is a major contributor in vivo.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A significant reduction in ABZ sulphoxidation (n = 3) was seen with ketoconazole (CYP3 A4; 32-37%), ritonavir (CYP3 A4: 34-42%), methimazole (FMO: 28-49%) and thioacetamide (FMO; 32-35%).

$$$$
>  <CLASS>
Parent

>  <TARGET>
A significant reduction in ABZ sulphoxidation (n = 3) was seen with ketoconazole (CYP3 A4; 32-37%), ritonavir (CYP3 A4: 34-42%), methimazole (FMO: 28-49%) and thioacetamide (FMO; 32-35%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Additive inhibition with ketoconazole and methimazole was 69 +/- 8% (n = 3).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
ABS production in heat - treated microsomes (3 min at 45 degrees C) correlated significantly with testosterone 6beta-hydroxylation (CYP3A4; P < 0.05) and band intensities on Western blots probed with an antibody selective for 3A4 (P < 0.05).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
ABS production in heat - treated microsomes (3 min at 45 degrees C) correlated significantly with testosterone 6beta-hydroxylation (CYP3A4; P < 0.05) and band intensities on Western blots probed with an antibody selective for 3A4 (P < 0.05).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Recombinant human CYP3 A4, CYP1A2 and FMO3 produced ABS in greater quantities than control microsomes, with those expressing CYP3A4 producing threefold more ABS than those expressing CYP1A2.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Kinetic studies showed the Km values obtained with both CYP3A4 and FMO3 were similar.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We conclude that the production of ABS in human liver is mediated via both FMO and CYP, principally CYP3A4, with the CYP component being the major contributor.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To examine the potency of ticlopidine (TCL) as an inhibitor of cytochrome P450s (CYP450s) in vitro using human liver microsomes (HLMs) and recombinant human CYP450s.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Isoform-specific substrate probes of CYP1A2, 2C19, 2C9, 2D6, 2E1 and 3A4 were incubated in HLMs or recombinant CYPs with or without TCL.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Preliminary data were generated to simulate an appropriate range of substrate and inhibitor concentrations to construct Dixon plots.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In order to estimate accurately inhibition constants (Ki values) of TCL and determine the type of inhibition, data from experiments with three different HLMs for each isoform were fitted to relevant nonlinear regression enzyme inhibition models by WinNonlin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
TCL was a potent, competitive inhibitor of CYP2C19 (Ki = 1.2 +/- 0.5 microM) and of CYP2D6 (Ki = 3.4 +/- 0.3 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These Ki values fell within the therapeutic steady-state plasma concentrations of TCL (1-3 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
TCL appears to be a broad-spectrum inhibitor of the CYP isoforms, but clinically significant adverse drug interactions are most likely with drugs that are substrates of CYP2C19 or CYP2D6.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Flavonoids are important polyphenolic substances with widespread occurrence in plants and therefore in the human diet.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Although considerable work has been done on the pharmacology of flavonoids, the understanding of their metabolism is still incomplete.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In this work, the in vitro glucuronidation of the common dietary flavonoids quercetin and kaempferol by human UDP-glucuronosyltransferase microsomes (UGT-1A9) was investigated using HPLC and LC-MS.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The two flavonoids were extensively metabolised by this enzyme with four monoglucuronides of quercetin and two of kaempferol being detected after incubation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The two flavonoids were extensively metabolised by this enzyme with four monoglucuronides of quercetin and two of kaempferol being detected after incubation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The presence of a quercetin monoglucuronide in the urine of a volunteer after consumption of Ginkgo biloba tablets was demonstrated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
OROS (methylphenidate HCl) is an osmotic controlled-release delivery system designed for once-daily oral dosing.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of OROS (methylphenidate HCl) 18 mg qd, sustained-release (SR) methylphenidate 20 mg qd, and the immediate-release (IR) formulation given as three 5 mg doses every 4 hours (tid) were compared in adults.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition, the single- and multiple-dose pharmacokinetics of the OROS formulation were studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Following OROS (methylphenidate HCl), there was a gradual increase in the mean methylphenidate plasma concentrations with peak concentrations noted at 6 to 8 hours.

$$$$
>  <CLASS>
NONE

>  <TARGET>
With the SR formulation, peak plasma concentrations were noted at approximately 4 hours.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Following the IR regimen, methylphenidate plasma concentrations fluctuated in tandem with oral dosing; peak concentrations were noted at 6.5 hours.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The terminal half-life of methylphenidate was similar for the three formulations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The dose-normalized methylphenidate Cmax for OROS (methylphenidate HCl) was significantly lower than for IR and SR methylphenidate.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The bioavailability of methylphenidate and PPA from OROS (methylphenidate HCl) relative to the IR and SR formulations was complete.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Mean methylphenidate AUC and terminal half-life were similar after single (32.9 ng.h/mL and 3.9 hours) and multiple doses (35.2 ng.h/mL and 3.9 hours) of OROS (methylphenidate HCl).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The authors investigated the impact of the CYP2D6 genotype on steady-state concentrations of nortriptyline (NT) and its metabolites, trans-10-hydroxynortriptyline (EHNT) and cis-10-hydroxynortriptyline in a Japanese population of psychiatric patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Forty-one patients (20 men and 21 women) were orally administered nortriptyline hydrochloride.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The allele frequencies of the CYP2D6*5 and CYP2D6*10 were 4.9% and 34.1%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Significant differences in NT concentrations corrected for dose and weight were observed between the subjects with no mutated alleles and those with one mutated allele (mean +/- SD for no mutated alleles vs. one mutated allele: 70.3 +/- 25.4 vs. 98.4 +/- 36.6 ng/mL x mg(-1) x kg(-1); t = 2.54, dcf = 33, p < 0.05) and between the subjects with no mutated alleles and two mutated alleles (no mutated alleles vs. two mutated alleles: 70.3 +/- 25.4 vs. 147 +/- 31.1 ng/mL x mg(-1) x kg(-1); t = 5.87, df = 19, p < 0.0001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Also, a significant difference in the NT/EHNT ratio, which is representative of the hydroxylation ratio of NT, was observed between the subjects with no mutated alleles and those with two mutated alleles (no mutated alleles vs. two mutated alleles: 0.82 +/- 0.30 vs. 2.71 +/- 0.84; t = 7.86, df = 19, p < 0.0001).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Also, a significant difference in the NT/EHNT ratio, which is representative of the hydroxylation ratio of NT, was observed between the subjects with no mutated alleles and those with two mutated alleles (no mutated alleles vs. two mutated alleles: 0.82 +/- 0.30 vs. 2.71 +/- 0.84; t = 7.86, df = 19, p < 0.0001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Multiple regression analysis showed that the number of mutated alleles of CYP2D6, which was the only significant factor, accounted for 41% and 48% of the variability in log(NT corrected for dose and weight) and log(NT/EHNT), respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacologic profile of perphenazine's metabolites.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The authors hypothesized that this atypical side effect profile is due to perphenazine's principal metabolite, n-dealkylperphenazine (DAPZ), which is usually present in vivo at concentrations 1.5 to 2 times that of the parent drug.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Perphenazine, DAPZ, and 7-hydroxyperphenazine affinities were examined in vitro by competition-binding analysis to isolated human receptors expressed in transfected cell lines.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Perphenazine and metabolite effects were examined in vivo in 54 older patients who were treated with perphenazine, at a target dose of 0.1 mg/kg, for 10 to 17 days.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Drug concentrations were determined by high-performance liquid chromatography with electrochemical detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In in vitro binding studies, DAPZ demonstrated a higher affinity for serotonin-2A receptors than for dopamine-2 receptors to an extent comparable to that of some atypical neuroleptic agents.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, perphenazine and 7-hydroxyperphenazine demonstrated a higher affinity for dopamine-2 receptors than for serotonin-2A receptors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean +/- SD concentrations in the 54 subjects were the following: perphenazine, 1.5 +/- 1.4 ng/mL; DAPZ, 2.0 +/-1.6 ng/mL; and 7-hydroxyperphenazine, 0.8 +/- 1.9 ng/mL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean +/- SD quotient for the DAPZ/perphenazine concentration was 1.7 +/- 1.1 and for the 7-hydroxyperphenazine/perphenazine was 0.54 +/-1.6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EPS onset was not correlated with the perphenazine concentration, the metabolite concentrations, the DAPZ/perphenazine quotient, or the 7-hydroxyperphenazine/perphenazine quotient.

$$$$
>  <CLASS>
Parent

>  <TARGET>
EPS onset was not correlated with the perphenazine concentration, the metabolite concentrations, the DAPZ/perphenazine quotient, or the 7-hydroxyperphenazine/perphenazine quotient.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Despite a moderately atypical receptor-binding profile, DAPZ does not seem to moderate perphenazine effects in vivo in older patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This outcome likely reflects the low potency of DAPZ for dopamine-2 and serotonin-2A receptors relative to the potency of perphenazine for these receptors.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Further exploration of atypical properties of DAPZ should include de novo administration of this metabolite in animal models.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Psychopathology was monitored with the Brief Psychiatric Rating Scale (BPRS), and extrapyramidal adverse effects were assessed with the Extrapyramidal Symptom Rating Scale (EPS).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Significantly linear relationships were found between haloperidol dose (D) and pyridinium metabolite serum concentrations, as well as between C(H) and the pyridinium metabolite serum concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
C(HP+) (range, 0.2-4.9 ng/mL) and C(RHP+) (range, 0.03-6.23 ng/mL) were low compared with C(H) and C(RH), being as mean values approximately 7% and 14% of C(H) and C(RH), respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Additionally, the values of C(RHP+) and the slope of the correlation of C(H) with the C(RHP+)/C(HP+) ratio were considerably lower than in a previous report of long-term treatment with haloperidol.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is explained by the shorter time of treatment of the present study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Carbamazepine comedication was found to not influence relative pyridinium metabolite serum concentrations C(HP+)/D and C(RHP+)/D.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Carbamazepine comedication was found to not influence relative pyridinium metabolite serum concentrations C(HP+)/D and C(RHP+)/D.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, the aromatization ratios of haloperidol (C(HP+)/C(H)) and reduced haloperidol (C(RHP+)/C(RH)) were increased by concomitant carbamazepine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As the main result, no relationships between the pyridinium metabolite serum concentrations and clinical variables (BPRS change, EPS, dose of biperiden) were detected.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
As the main result, no relationships between the pyridinium metabolite serum concentrations and clinical variables (BPRS change, EPS, dose of biperiden) were detected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For instance, the aromatization ratios C(HP+)/C(H) and C(RHP+)/C(RH) did not predict clinical improvement or extrapyramidal adverse effects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therefore, no confirmation of the "pyridinium hypothesis," which suggests haloperidol pyridinium metabolites to be the origin of adverse effects and decreased therapeutic effect, can be derived from this study.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Therefore, no confirmation of the "pyridinium hypothesis," which suggests haloperidol pyridinium metabolites to be the origin of adverse effects and decreased therapeutic effect, can be derived from this study.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
However, the authors emphasize that pyridinium metabolites cannot be excluded as the origin of decreased therapeutic effect in long-term treatment and of adverse effects not investigated in the present study, such as tardive dyskinesia.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Finally, it is concluded that the serum concentration of the parent drug remains the main variable of interest in the therapeutic drug monitoring of haloperidol during short-term treatment.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Sensitive and selective determination of tetracaine and its metabolite in human samples by gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A sensitive and reliable method was developed for the determination of tetracaine and its metabolite, p-butylaminobenzoic acid, in human samples.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Tetracaine and the metabolite, effectively extracted using a liquid-liquid extraction procedure from 0.5 g of sample, were analyzed by gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Tetracaine was analyzed without derivatization, and the metabolite was analyzed after tert-butylolimethylsilyl derivatization.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Tetracaine was analyzed without derivatization, and the metabolite was analyzed after tert-butylolimethylsilyl derivatization.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Dibucaine and p-dimethylaminobenzoic acid were used as internal standards for tetracaine and the metabolite, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Dibucaine and p-dimethylaminobenzoic acid were used as internal standards for tetracaine and the metabolite, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The calibration curve for each compound was linear in the concentration range from 10 to 1,000 ng/0.5 g, and the lower limits of detection were 10 ng/g for tetracaine and 0.6 ng/g for the metabolite in whole blood and tissues.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The accuracy and precision of the method were evaluated in whole blood and brain at the concentrations of 50 ng/0.5 g and 500 ng/0.5 g for tetracaine and 10 ng/0.5 g and 100 ng/0.5 g for the metabolite.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The coefficients of variation ranged from 0.8 to 3.0% for tetracaine and 2.4 to 9.8% for the metabolite.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We used this method to determine tetracaine and its metabolite in human whole blood and tissues of an autopsied patient who died during spinal anesthesia induced by tetracaine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simultaneous plasma level analysis of clomipramine, N-desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A simple reversed-phase liquid chromatographic method enabling the simultaneous analysis in plasma of the tricyclic antidepressant clomipramine, its demethylated metabolite, and the selective serotonin reuptake inhibitor fluvoxamine, was developed.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A simple reversed-phase liquid chromatographic method enabling the simultaneous analysis in plasma of the tricyclic antidepressant clomipramine, its demethylated metabolite, and the selective serotonin reuptake inhibitor fluvoxamine, was developed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The drugs and dibenzepine, the internal standard, were extracted from 1 mL plasma through an automated solid-phase procedure, eluted in a total chromatographic time of approximately 14 min and detected by means of an ultraviolet spectrophotometer preset at 254 nm.

$$$$
>  <CLASS>
NONE

>  <TARGET>
An assay sensitivity of 10 microg/L was observed for all analytes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Recoveries for these drugs and their metabolites ranged between 65% and 98% and their coefficient of variation (within-day and day-to-day) between 1.9% and 2.9%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In spiked plasma, within-day and day-to-day imprecision data were less than 5%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The simultaneous determination of clomipramine, N-desmethylclomipramine, and fluvoxamine with adequate sensitivity and accuracy may be useful for the monitoring of drug treatment in depression and obsessive-compulsive disorder, where combinations of such drugs are employed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Studies on the metabolism and toxicological detection of the amphetamine-like anorectic fenproporex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Studies on the metabolism and toxicological detection of the amphetamine-like anorectic fenproporex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Studies on the metabolism and the toxicological analysis of fenproporex (R,S-3-[(1-phenyl-2-propyl)-amino]-propionitrile, FP) using GC-MS and fluorescence polarization immunoassay are described.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The metabolites were identified in urine samples of volunteers by GC-MS after cleavage of conjugates, extraction and acetylation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Besides unchanged FP, fourteen metabolites, including amphetamine, could be identified.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Two partially overlapping metabolic pathways could be postulated: ring degradation by one- and two-fold aromatic hydroxylation followed by methylation and side chain degradation by N-dealkylation to amphetamine (AM).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A minor pathway leads via beta-hydroxylation of AM to norephedrine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For GC-MS detection, the systematic toxicological analysis procedure including acid hydrolysis, extraction at pH 8-9 and acetylation was suitable (detection limits 50 ng/ml for FP and 100 ng/ml for AM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Excretion studies showed, that only AM but neither FP nor its specific metabolites were detectable 30-60 h after ingestion of 20 mg of FP.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Excretion studies showed, that only AM but neither FP nor its specific metabolites were detectable 30-60 h after ingestion of 20 mg of FP.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Therefore, misinterpretation can occur.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The Abbott TDx FPIA amphetamine/methamphetamine II gave positive results up to 58 h. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
All the positive immunoassay results could be confirmed by the described GC-MS procedure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The soy isoflavones, daidzein and genistein, and the lignans, matairesinol and secoisolariciresinol, are phytoestrogens metabolized extensively by the intestinal microflora.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The soy isoflavones, daidzein and genistein, and the lignans, matairesinol and secoisolariciresinol, are phytoestrogens metabolized extensively by the intestinal microflora.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Considerable important evidence is already available that shows extensive interindividual variation in isoflavone metabolism, and we have investigated the extent of this variation in a crossover study of a soy-containing food low or high in isoflavones (each treatment period lasted for 17 days, and the 2 treatment periods were separated by a 25-day washout period) in 24 healthy subjects [19 women and 5 men, mean age 30 yr, range 19-40, mean body mass index 22.5 +/- 3.5 (SD) kg/m2].

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was a 16-fold variation in total isoflavonoid excretion in urine after the high-isoflavone treatment period.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The variation in urinary equol excretion was greatest (664-fold), and subjects fell into two groups: poor equol excretors and good equol excretors (36%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A significant negative correlation was found between the proportion of energy from fat in the habitual diet and urinary equol excretion (r = -0.55; p = 0.012).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Good equol excretors consumed less fat as percentage of energy than poor excretors (26 +/- 2.3% compared with 35 +/- 1.6%, p < 0.01) and more carbohydrate as percentage of energy than poor excretors (55 +/- 2.9% compared with 47 +/- 1.7%, p < 0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Interindividual variation in the urinary excretion of O-desmethyl-angolensin (O-DMA) was also apparent (76-fold after the high-isoflavone treatment period), but there was no relationship between equol excretion and O-DMA excretion.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Enterolactone was the major lignan metabolite in urine and plasma but showed less interindividual variation than equol and O-DMA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Enterolactone was the major lignan metabolite in urine and plasma but showed less interindividual variation than equol and O-DMA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is suggested that the dietary fat intake decreases the capacity of gut microbial flora to synthesize equol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The human cytochrome P450 (CYP) isozymes catalyzing the oxidative metabolism of the widely abused amphetamine derivatives MDMA (N-methyl-3,4-methylenedioxyamphetamine, "Ecstasy"), MDE (N-ethyl-3, 4-methylenedioxyamphetamine, "Eve"), and MDA (3, 4-methylenedioxyamphetamine) were identified.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Using a simplified non-extractive reversed-phase HPLC assay with fluorescence detection, biphasic Michaelis-Menten kinetics were obtained for formation of all three dihydroxyamphetamines in liver microsomes from a CYP2D6 extensive metabolizer subject.

$$$$
>  <CLASS>
Parent and any other metabolite

>  <TARGET>
Using a simplified non-extractive reversed-phase HPLC assay with fluorescence detection, biphasic Michaelis-Menten kinetics were obtained for formation of all three dihydroxyamphetamines in liver microsomes from a CYP2D6 extensive metabolizer subject.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In contrast, no low K(m) component was detectable in microsomes from a poor metabolizer subject.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Additional specific probes for CYP2D6 further confirmed this isozyme as the exclusive low K(m) component for demethylenation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
P450-selective inhibitors applied to CYP2D6-inhibited microsomes and activity measurements in a series of recombinant P450s suggested CYP1A2 as the major high K(m) component with contributions by CYP2B6 and CYP3A4.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Moreover, the relative CYP1A2 content of a panel of 12 human livers was weakly but significantly correlated to the high K(m) demethylenase activity (Spearman rank correlation coefficient [r(s)] = 0.58; P < 0.05).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Microsomal maximal velocities for N-dealkylation were at least 7-fold lower than for demethylenation and were characterized by apparently monophasic kinetics.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The most important isozyme for this reaction appeared to be CYP2B6, the microsomal content of which was found to be strongly correlated to N-deethylation of MDE (r(s) = 0.90; P < 0.001).

$$$$
>  <CLASS>
Parent

>  <TARGET>
We conclude that, in addition to CP2D6 as the sole high-affinity demethylenase, several other P450 isozymes have the capacity to contribute to microsomal oxidative metabolism of methylenedioxyamphetamines.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This may be of particular importance in individuals genetically lacking functional CYP2D6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Busulphan and cyclophosphamide (Bu/CP) are widely used in preparative regimens for bone marrow transplantation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Many studies have shown a wide variation in busulphan pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Moreover, higher rates of liver toxicity were reported in Bu/CP protocols than in a total body irradiation (TBI)-containing regimen.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In the present paper we investigated the effect of the time interval between the last dose of busulphan and the first dose of cyclophosphamide on the pharmacokinetics of CP and its cytotoxic metabolite 4-hydroperoxycyclophosphamide (4-OHCP).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the present paper we investigated the effect of the time interval between the last dose of busulphan and the first dose of cyclophosphamide on the pharmacokinetics of CP and its cytotoxic metabolite 4-hydroperoxycyclophosphamide (4-OHCP).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Thirty-six patients undergoing bone marrow transplantation (BMT) were included in the study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We also investigated the occurrence of veno-occlusive disease, mucositis and graft-versus-host disease.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Ten patients conditioned with CP followed by TBI served as a control group (TBI).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Twenty-six patients were conditioned with Bu/CP.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The patients received Bu (1 mg/kg x 4 for 4 days), followed by CP (60 mg/kg for 2 days) administered as a 1-h infusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Patients received their CP therapy either 7-15 h (group A, n = 12) or 24-50 h (group B, n = 14) after the last dose of Bu.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
None of the patients were given phenytoin or any other drug known to enhance CP metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
None of the patients were given phenytoin or any other drug known to enhance CP metabolism.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The administration of CP less than 24 h after the last dose of Bu resulted in: (1) a significantly (P = 0.003) lower clearance for cyclophosphamide was observed in group A (0.036 l/h/kg) compared to 0.055 and 0.055 l/h/kg, in the B and TBI groups, respectively; (2) significantly (P = 0.002) longer elimination half-life in group A (10.93 h) than in groups B and TBI (6.87 and 7.52 h, respectively); (3) significantly (P < 0.001) lower exposure to the cytotoxic metabolite (4-OHCP), expressed as the ratio AUC4-OHCP/AUCCP, in group A (0.0053) than that obtained in group B (0.013) and group TBI (0.012); (4) the patients in group A had a significantly (P < 0.05) higher incidence of VOD (seven of 12) than the other groups, B and TBI (2/14 and 1/10, respectively); and (5) mucositis was significantly higher in group A patients (8/12), being seen in only one patient in group B and none in the TBI group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The present study has shown that the interval between busulphan and cyclophosphamide administration can negatively affect the pharmacokinetics of cyclophosphamide and its cytotoxic metabolite.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The present study has shown that the interval between busulphan and cyclophosphamide administration can negatively affect the pharmacokinetics of cyclophosphamide and its cytotoxic metabolite.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We conclude that the timing of CP administration must be considered in order to improve drug efficacy and reduce conditioning-related toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times daily for 6 weeks.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Tolcapone withdrawal caused a transient elevation in COMT activity by 64% in patients receiving 100 mg three times daily and by 128% in those receiving 200 mg three times daily at approximately 1-2 weeks after discontinuation of drug.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Thereafter, COMT activity was declining but did not reach baseline values by the 12-week study endpoint.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, this had no effect on plasma levodopa and 3-O-methyldopa (3-OMD) concentrations or on levodopa requirements.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
During treatment, tolcapone increased "on" time and decreased "off" time; after discontinuation of study medication and levodopa dose adjustment, on and off times were similar to baseline.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Withdrawal was generally well tolerated; no patients withdrew from the trial during the posttreatment period, and no serious adverse events were observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In conclusion, the transient increase in erythrocyte COMT activity observed after discontinuation oftolcapone is not associated with changes in peripheral levodopa metabolism and therefore has no significant clinical consequences in terms of levodopa requirements, clinical symptoms, or adverse events.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In conclusion, the transient increase in erythrocyte COMT activity observed after discontinuation oftolcapone is not associated with changes in peripheral levodopa metabolism and therefore has no significant clinical consequences in terms of levodopa requirements, clinical symptoms, or adverse events.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Halothane undergoes both oxidative and reductive metabolism by cytochrome P450 (CYP), respectively causing rare immune-mediated hepatic necrosis and common, mild subclinical hepatic toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Halothane also causes lipid peroxidation in rodents in vitro and in vivo, but in vivo effects in humans are unknown.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In vitro investigations have identified a role for human CYPs 2E1 and 2A6 in oxidation and CYPs 2A6 and 3A4 in reduction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mechanism-based CYP2E1 inhibitor disulfiram diminished human halothane oxidation in vivo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mechanism-based CYP2E1 inhibitor disulfiram diminished human halothane oxidation in vivo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This investigation tested the hypotheses that halothane causes lipid peroxidation in humans in vivo, and that CYP2A6 or CYP3A4 inhibition can diminish halothane metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Patients (n = 9 each group) received single doses of the mechanism-based inhibitors troleandomycin (CYP3A4), methoxsalen (CYP2A6) or nothing (controls) before a standard halothane anaesthetic.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Reductive halothane metabolites chlorotrifluoroethane and chlorodifluoroethylene in exhaled breath, fluoride in urine, and oxidative metabolites trifluoroacetic acid and bromide in urine were measured for 48 h postoperatively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Reductive halothane metabolites chlorotrifluoroethane and chlorodifluoroethylene in exhaled breath, fluoride in urine, and oxidative metabolites trifluoroacetic acid and bromide in urine were measured for 48 h postoperatively.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Lipid peroxidation was assessed by plasma F2-isoprostane concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The halothane dose was similar in all groups.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methoxsalen decreased 0- to 8-h trifluoroacetic acid (23 +/- 20 micromol vs 116 +/- 78 micromol) and bromide (17 +/- 11 micromol vs 53 +/- 49 micromol) excretion (P < 0.05), but not thereafter.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma F2-isoprostanes in controls were increased from 8.5 +/- 4.5 pg/ml to 12.5 +/- 5.0 pg/ml postoperatively (P < 0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Neither methoxsalen nor troleandomycin diminished reductive halothane metabolite or F2-isoprostane concentrations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Neither methoxsalen nor troleandomycin diminished reductive halothane metabolite or F2-isoprostane concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results provide the first evidence for halothane-dependent lipid peroxidation in humans.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methoxsalen effects on halothane oxidation confirm in vitro results and suggest limited CYP2A6 participation in vivo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Methoxsalen effects on halothane oxidation confirm in vitro results and suggest limited CYP2A6 participation in vivo.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP2A6-mediated, like CYP2E1-mediated human halothane oxidation, can be inhibited in vivo by mechanism-based CYP inhibitors.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In contrast, clinical halothane reduction and lipid peroxidation were not amenable to suppression by CYP inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Acylation of protein lysines by trichloroethylene oxide.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Stable lysine adducts were formed in proteins following reaction with trichloroethylene (TCE) oxide, the major reactive compound generated by the metabolism of TCE.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Stable lysine adducts were formed in proteins following reaction with trichloroethylene (TCE) oxide, the major reactive compound generated by the metabolism of TCE.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The order of formation of these adducts is N(6)-formyllysine > N(6)-(dichloroacetyl)lysine >> N(6)-glyoxyllysine, with the ratio being influenced by the particular protein.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Protein lysine adducts were also analyzed following the enzymatic oxidation of TCE with several different cytochrome P450 (P450) enzyme systems.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Protein lysine adducts were also analyzed following the enzymatic oxidation of TCE with several different cytochrome P450 (P450) enzyme systems.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The ratio of formyl/dichloroacetyl lysine adducts was influenced by the enzyme system that was used.

$$$$
>  <CLASS>
 Metabolite

>  <TARGET>
The ratio of formyl/dichloroacetyl lysine adducts was influenced by the enzyme system that was used.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Chloral and TCE oxide formation was more extensive with rat liver microsomes isolated from phenobarbital-treated rats than with rat microsomes in which P450 2E1 was induced by treatment with isoniazid or in human P450 2E1 systems.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Chloral and TCE oxide formation was more extensive with rat liver microsomes isolated from phenobarbital-treated rats than with rat microsomes in which P450 2E1 was induced by treatment with isoniazid or in human P450 2E1 systems.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Glutathione (GSH) and GSH transferase had inhibitory effects on the reaction of TCE oxide with albumin, with formylation being atteunated much more than the formation of dichloroacetyllysine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Glutathione (GSH) and GSH transferase had inhibitory effects on the reaction of TCE oxide with albumin, with formylation being atteunated much more than the formation of dichloroacetyllysine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
GSH is likely to react with the reactive acyl chloride intermediates formed from TCE oxide hydrolysis, instead of direct reaction with TCE oxide, as judged by the lack of an effect of GSH on the rate of decomposition of TCE oxide.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
GSH is likely to react with the reactive acyl chloride intermediates formed from TCE oxide hydrolysis, instead of direct reaction with TCE oxide, as judged by the lack of an effect of GSH on the rate of decomposition of TCE oxide.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Studies with the model enzymes aldolase and glucose-6-phosphate dehydrogenase, both known to have sensitive lysine groups, indicate that TCE oxide has effects similar to known acylating agents that form the same adducts; concentrations of TCE oxide (or the model acylating agents) in the low-millimolar range were needed for inhibition.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The characterization of TCE-derived protein adducts can be used as a basis for consideration of the exposure and risk of TCE to humans.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Human P450 2E1 was less likely to oxidize TCE to form TCE oxide and protein lysine adducts than rat P450 2B1, and the difference is rationalized in terms of the influence of the protein on chloride migration in an enzyme reaction intermediate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human P450 2E1 was less likely to oxidize TCE to form TCE oxide and protein lysine adducts than rat P450 2B1, and the difference is rationalized in terms of the influence of the protein on chloride migration in an enzyme reaction intermediate.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Irinotecan (CPT-11) is an anticancer agent widely employed in the treatment of colorectal carcinoma.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A simple, rapid and sensitive high-performance liquid chromatographic method for the simultaneous determination of CPT-11 and its metabolite SN-38 in plasma, and their preliminary clinical pharmacokinetics are described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both deproteinisation of plasma specimens (100 microl) and addition of the internal standard, camptothecin (CPT), are achieved by incorporating to samples 100 microl of a solution of CPT (1 microg/ml) in acetonitrile-1 mM orthophosphoric acid (90:10); 200 microl of this acidified acetonitrile solution, drug-free, is also added to accomplish complete deproteinisation: this procedure reduces sample preparation time to a minimum.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After deproteinisation, samples are treated with potassium dihydrogenphosphate (0.1 M) and injected into a Nucleosil C18 (5 microm, 250 x 4.0 mm) column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Mobile phase consists of potassium dihydrogenphosphate (0.1 M)-acetonitrile (67:33), at a flow-rate of 1 ml/min.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CPT-11, SN-38 and CPT are detected by fluorescence with excitation wavelength set at 228 nm and emission wavelengths of CPT-11, SN-38 and CPT fixed, respectively, at 450, 543 and 433 nm.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limits of quantitation for CPT-11 and SN-38 are 1.0 and 0.5 ng/ml, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This method shows good precision: the within day relative standard deviation (RSD) for CPT-11 (1-10000 ng/ml) is 5.17% (range 2.15-8.27%) and for SN-38 (0.5-400 ng/ml) is 4.33% (1.32-7.78%); the between-day RSDs for CPT-11 and SN-38, in the previously described ranges, are 6.82% (5.03-10.8%) and 4.94% (2.09-9.30%), respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Using this assay, plasma pharmacokinetics of CPT-11, SN-38 and its glucuronidated form, SN-38G, have been determined in one patient receiving 200 mg/m2 of CPT-11 as a 90 min intravenous infusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using this assay, plasma pharmacokinetics of CPT-11, SN-38 and its glucuronidated form, SN-38G, have been determined in one patient receiving 200 mg/m2 of CPT-11 as a 90 min intravenous infusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The peak plasma concentration of CPT-11 at the end of the infusion is 3800 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Plasma decay is biphasic with a terminal half-life of 11.6 h. The volume of distribution at steady state (Vss) is 203 l/m2, and the total body clearance (Cl) is 14.8 l/h x m2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The maximum concentrations of SN-38 and SN-38G reach 28.9 and 151 ng/ml, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Enantioselective analysis of (R)- and (S)-atenolol in urine samples by a high-performance liquid chromatography column-switching setup.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An HPLC column-switching method for the enantioselective determination of (R,S)-atenolol in human urine was developed and validated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Diluted urine samples were injected onto a LiChrospher ADS restricted access column and atenolol was separated from most of the matrix components using 0.01 M Tris buffer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The atenolol peak was sharpened by a step gradient of 30% acetonitrile and the atenolol-containing fraction was switched onto an enantioselective column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Separation of the atenolol enantiomers was carried out on a Chirobiotic T (Teicoplanin) column using acetonitrile-methanol-acetic acid-triethylamine (55:45:0.3:0.2, v/v/v/v) as eluent.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Detection of the effluent was performed by fluorescence measurement.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Several experiments were carried out to suppress the high blank reading, which was efficiently achieved using Tris buffer in the first dimension.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the enantioselective analysis of (R)- and (S)-atenolol in plasma under the same conditions the sample capacity of the ADS column is considerably lower.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A reliable multi-dimensional column chromatographic method employing amperometric detection using a carbon fibre microelectrode procedure was used for monitoring the plasma profiles and to evaluate the pharmacokinetics and bioavailability of levodopa (L-dopa) and carbidopa (C-dopa), after ingestion of oral formulations containing these drugs.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The peak currents obtained for the different analytes were directly proportional to the analyte over the concentration range 0.02-4 micrograms ml-1.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Recovery studies ranged from 93.83 to 89.76%, with a relative standard deviation of less than 7%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The study was carried out in two separate weeks on five healthy non-patient fasted male/female volunteers in the age range 20-37 years and weighing between 60 kg and 78 kg.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetic profile of two controlled-release products containing both L-dopa and C-dopa (Sinemet CR3 and CR4) was compared on the one hand and Sinemet conventional tablets on the other.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The pharmacokinetic parameters, peak concentration (Cmax), the time taken to obtain this level (Tmax), elimination half-time T1/2, elimination rate constant (Kel), plasma level ratio, fluctuation index (FI) and the area under the time-concentration curve (AUC0-8), were investigated for each individual formulation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A comparison of the uptake of L-dopa from the conventional formulation showed that L-dopa entered the plasma and achieved peak levels higher than that of the controlled release formulations.

$$$$
>  <CLASS>
NONE

>  <TARGET>
However, it showed a much higher fluctuation index and the plasma concentrations were more stable with the controlled release formulations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The data also indicated a very low accumulation of both levodopa and carbidopa following repeated administration of the drugs, which was consistent with their relatively short half-lives (less than 2 h).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In contrast, the half-life for the metabolite 3-orthomethyl dopa (3-OMD) is in the order of 13 h. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As a result, there was an extensive accumulation of 3-OMD and its levels were significantly higher than those of levodopa or carbidopa upon repeated administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine recoveries of the three analytes over one 8 h dosing interval showed that the majority of the excreted levodopa and carbidopa was recovered during the first 4 h, and there is proportionally greater excretion of the carbidopa dose than the levodopa dose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Previously unknown metabolites from the two macrolide immunosuppressants rapamycin (sirolimus) and SDZ RAD [40-O-(2-hydroxyethyl)rapamycin] obtained after in vitro incubation with human liver microsomes have been purified.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Previously unknown metabolites from the two macrolide immunosuppressants rapamycin (sirolimus) and SDZ RAD [40-O-(2-hydroxyethyl)rapamycin] obtained after in vitro incubation with human liver microsomes have been purified.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Structure elucidation was performed by nanoelectrospray ionization tandem mass spectrometry applying low energy collision activated dissociation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This ionization method is, as shown here, a powerful tool to determine metabolic pathways by analysis of even low abundance products.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Product ion spectra of the isolated metabolites indicate a new kind of biotransformation reaction for rapamycin and SDZ RAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The proposed metabolic pathway starts with an ester hydrolysis which leads to a ring-opened structure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A dehydration on C33-C34 and a supplementary hydrogenation at C33-C34 result in a structure similar to the ring-opened isomer with an single bond at C33-C34.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of styrene by human liver and lung.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In mice, styrene is pneumotoxic, and there is some evidence of tumorigenicity.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
This toxicity is thought to be related to its bioactivation to styrene oxide in lung.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To determine if human tissues have this capacity, the metabolism of styrene to styrene oxide was measured in human liver and lung microsomal preparations.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Hepatic microsomes metabolized styrene to styrene oxide, but lung microsomes had essentially no activity.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
However, microsomes from both tissues metabolized benzene to phenol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The data suggest that human lung has low styrene metabolizing activity and may be much less of a target organ than in mouse.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Fozivudine tidoxil (FZD) is a thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity demonstrated in vitro and in pilot phase I studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To assess its safety, efficacy and pharmacokinetics, we conducted a multicenter, randomized, double-blind, placebo-controlled trial of FZD monotherapy in 72 HIV-infected patients who had not previously received antiretroviral therapy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In each dosage group (200 mg daily, 400 mg daily, 200 mg twice daily, 800 mg daily, 400 mg twice daily, and 600 mg twice daily), 12 patients were randomized to receive in a 10:2 ratio either FZD or a placebo for 4 weeks.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Overall, FZD was well tolerated in all dosage groups; only 1 patient discontinued the drug, because of a moderate rise in aminotransaminase activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
HIV viral load fell in all the patients who were receiving FZD, except in the 200 mg daily group.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The largest decrease (-0.67 log10) was observed in the 600 mg twice daily group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The plasma half-life was significantly longer (approximately 3.8 hours) than that of the parent drug ZDV.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Exposure to ZDV, as reflected by the area under the time-concentration curve, was much lower after FZD than after ZDV administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
FZD thus appears to be as effective as and potentially better tolerated than ZDV during short-term administration and has the advantage of once daily intake.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of a genetic polymorphism of inducibility of cytochrome P450 (CYP) 1A2 on the steady state plasma concentrations (Css) of haloperidol and reduced haloperidol was studied to clarify if these Css are dependent on the CYP1A2 activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The subjects were 101 Japanese schizophrenic inpatients receiving oral haloperidol 12 mg/d.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The Css of haloperidol and reduced haloperidol were measured in duplicate by high performance liquid chromatographic method, and were corrected to the mean body weight.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A point mutation from guanine (wild-type) to adenine (mutated-type) at position -2964 in the 5'-flanking region of CYP1A2 gene was identified by polymerase chain reaction (PCR)-fragment length polymorphism method.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on the present results, i.e., significant effects of CYP2D6 genotypes on the Css of haloperidol and reduced haloperidol, analyses were separately performed in two groups, i.e., patients with 0 mutated allele of the CYP2D6 (41 cases) and those with 1 or 2 mutated alleles (60 cases).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Subjects in each CYP2D6 genotype group consisted of 4 subgroups according to smoking habit and the presence of the mutated allele of the CYP1A2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Neither the Css of haloperidol nor that of reduced haloperidol significantly differed among the 4 subgroups in either CYP2D6 genotype group.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The present study thus suggests that the CYP1A2 activity does not play an important role in controlling the Css of haloperidol or reduced haloperidol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Salbutamol administration in athletes is permitted only by inhalation, for the management of asthma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors discuss different criteria for suspecting oral use of salbutamol, taking into account the data obtained by application of two conventional screening procedures for doping control: gas chromatography/mass spectrometry (GC/MS) and enzyme-linked immunosorbent assay (ELISA).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine samples obtained after administration of oral and inhaled salbutamol to asthmatic and nonasthmatic swimmers were analyzed using both analytical approaches.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As expected, concentrations obtained by the ELISA test (detection of total salbutamol) were higher than those obtained using the GC/MS procedure (detection of nonsulfated salbutamol).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After oral administration, the ELISA test detected significantly higher salbutamol concentrations than those detected after inhalation, reflecting the greater doses administered orally.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine samples with total salbutamol greater than 1400 ng/mL were obtained after oral doses, but no sample reached this value after inhaled doses.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Higher concentrations of nonsulfated salbutamol have also been detected after oral intake, although there is an overlap between the distributions of concentrations after oral and inhaled doses.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A cut-off concentration of 500 ng/mL can be used for nonsulfated salbutamol to select suspicious samples, giving 11.8% false negative results and 4.3% false positive results.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An additional criterion evaluated was the androsterone-salbutamol peak height ratio, which was lower after oral doses because of the higher concentrations of salbutamol in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This ratio was lower than 2 for all the samples collected after oral administration, although 6.8% false positive samples resulted because of low concentrations of androsterone in female urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Several possibilities for detecting suspicious samples from athletes who have taken prohibited oral salbutamol are available with conventional screening procedures in doping control.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Inhibition selectivity of grapefruit juice components on human cytochromes P450.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Five compounds including furanocoumarin monomers (bergamottin, 6', 7'-dihydroxybergamottin (DHB)), furanocoumarin dimers (4-6-hydroxy-71-(1-hydroxy-1-methyl)ethyl-4-methyl-6-(7-oxo-7H- furo3,2-g1benzopyran-4-yl)-4-hexenyl]oxy]-3,7-dimethyl- 2-octenyl]oxy]-7H-furo[3,2-g]1benzopyran-7-one (GF-I-1) and 4-6-hydroxy-74-methyl-1-(1-methylethenyl)-6-(7-oxo-7H-furo3, 2-g1benzopyran-4-yl)-4-hexenylxy-3, 7-dimethyl-2-octenylxy-7H-furo3,2-g1benzopyran-7-one (GF-I-4)), and a sesquiterpene nootkatone have been isolated from grapefruit juice and screened for their inhibitory effects toward human cytochrome P450 (P450) forms using selective substrate probes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Addition of ethyl acetate extract of grapefruit juice into an incubation mixture resulted in decreased activities of CYP3A4, CYP1A2, CYP2C9, and CYP2D6.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All four furanocoumarins clearly inhibited CYP3A4-catalyzed nifedipine oxidation in concentration- and time-dependent manners, suggesting that these compounds are mechanism-based inhibitors of CYP3A4.

$$$$
>  <CLASS>
Parent

>  <TARGET>
All four furanocoumarins clearly inhibited CYP3A4-catalyzed nifedipine oxidation in concentration- and time-dependent manners, suggesting that these compounds are mechanism-based inhibitors of CYP3A4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Of the furanocoumarins investigated, furanocoumarin dimers, GF-I-1 and GF-I-4, were the most potent inhibitors of CYP3A4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibitor concentration required for half-maximal rate of inactivation (K(I)) values for bergamottin, DHB, GF-I-1, and GF-I-4 were calculated, respectively, as 40.00, 5.

$$$$
>  <CLASS>
NONE

>  <TARGET>
56, 0.31, and 0.13 microM, whereas similar values were observed on their inactivation rate constant at infinite concentration of inhibitor (k(inact), 0.05-0.08 min(-1)).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Apparent selectivity toward CYP3A4 does occur with the furanocoumarin dimers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, bergamottin showed rather stronger inhibitory effect on CYP1A2, CYP2C9, CYP2C19, and CYP2D6 than on CYP3A4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
DHB inhibited CYP3A4 and CYP1A2 activities at nearly equivalent potencies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among P450 forms investigated, CYP2E1 was the least sensitive to the inhibitory effect of furanocoumarin components.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A sesquiterpene nootkatone has no significant effect on P450 activities investigated except for CYP2A6 and CYP2C19 (K(i) = 0.8 and 0.5 microM, respectively).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Low-flow desflurane and sevoflurane anesthesia minimally affect hepatic integrity and function in elderly patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Hepatic blood flow is reduced in a dose-related manner by all inhaled anesthetics now in use.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We assessed hepatic function in elderly patients anesthetized with desflurane or sevoflurane.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We measured the cytosolic liver enzyme alpha glutathione S-transferase (alpha GST), the formation of the lidocaine metabolite monoethylglycinexylidide (MEGX), and gastric mucosal tonometry-derived variables as sensitive markers of hepatic function and splanchnic perfusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thirty patients, 70 to 90 yr old, were allocated randomly to receive desflurane or sevoflurane anesthesia.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Anesthetic exposure ranged from 2.1-4.5 minimum alveolar concentration hours.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No significant changes in standard liver enzyme markers were seen throughout the study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In both anesthetic groups, tonometric measurements showed a significant decrease from baseline in regional PCO(2), regional to arterial difference in PCO(2), and intramucosal pH at 90 min after skin incision.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
alpha GST concentrations increased significantly in both groups (desflurane: median peak concentrations 5.8 microg/L [25th, 75th percentile 5.3 microg/L, 7.2 microg/L]; sevoflurane: 7.0 microg/L [5.8 microg/L, 7.3 microg/L]) without showing differences between both anesthetic groups.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A return to baseline values in tonometric values and alpha GST levels was seen 24 h postoperatively.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
MEGX formation did not change significantly after surgery.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Median MEGX concentrations postoperatively were 70.0 ng/mL (56.2 ng/mL, 102.0 ng/mL) and 70.0 ng/mL (60.0 ng/mL, 94.2 ng/mL) in the desflurane and sevoflurane groups, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We conclude that, overall, liver function in elderly patients is well preserved during desflurane and sevoflurane anesthesia.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Increased serum levels of alpha GST and changes of gastric tonometry-derived variables imply a reduction in splanchnic perfusion, leading to a temporary impairment of hepatocyte oxygenation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We measured the lidocaine metabolite monoethylglycinexylidide, the cytosolic liver enzyme, alpha glutathione S-transferase, and gastric mucosal tonometry-derived variables to evaluate the effects of desflurane and sevoflurane on hepatic function in elderly patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We measured the lidocaine metabolite monoethylglycinexylidide, the cytosolic liver enzyme, alpha glutathione S-transferase, and gastric mucosal tonometry-derived variables to evaluate the effects of desflurane and sevoflurane on hepatic function in elderly patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Liver function was well preserved, whereas increased alpha glutathione S-transferase levels and changes in tonometry-derived variables indicated a reduction in splanchnic blood flow and a temporary impairment of hepatocyte oxygenation for both anesthetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ethyl glucuronide in human hair.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ethyl glucuronide (EtG) is considered to be a promising candidate marker of alcohol consumption, but exhibits a short window of detection in blood or urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Keratinized tissues are known to retain foreign substances and to provide a greater retrospective window of detection than body fluids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therefore, post-mortem hair, skin swabs, and stratum corneum samples were collected from four subjects with a reported history of alcohol misuse and from seven subjects with a report of regular, socially accepted drinking behaviour, and were investigated for EtG.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Additionally, certain specimens were collected from three children, who had not yet consumed any alcoholic beverages.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
EtG was detectable in most of the hair and stratum corneum samples as well as in perspiration stains from alcohol-consuming subjects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results indicated that EtG might be formed locally in very small and highly variable amounts.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The most important finding was that EtG cannot be expected to be generally detectable in keratinized tissues or perspiration stains from alcohol-drinking subjects, whereas a positive result is always associated with recent alcohol consumption.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This in vitro study used human liver microsomes to evaluate the inhibitory activity of zafirlukast versus six human cytochrome P450 (CYP) isoforms.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zafirlukast (0-250 microM) was co-incubated with fixed concentrations of index substrates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zafirlukast inhibited the hydroxylation of tolbutamide (CYP2C9; mean IC(50)=7.0 microM), triazolam (CYP3A; IC(50)=20.9 microM) and S-mephenytoin (CYP2C19; IC(50)=32.7 microM), and was a less potent inhibitor of phenacetin O-deethylation (CYP1A2; IC(50)=56 microM) and dextromethorphan O-demethylation (CYP2D6; IC(50)=116 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Zafirlukast inhibited the hydroxylation of tolbutamide (CYP2C9; mean IC(50)=7.0 microM), triazolam (CYP3A; IC(50)=20.9 microM) and S-mephenytoin (CYP2C19; IC(50)=32.7 microM), and was a less potent inhibitor of phenacetin O-deethylation (CYP1A2; IC(50)=56 microM) and dextromethorphan O-demethylation (CYP2D6; IC(50)=116 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zafirlukast produced negligible inhibition of CYP2E1.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Zafirlukast deserves further clinical study as an inhibitor of other CYP2C9 substrates such as nonsteroidal anti-inflammatory agents, tolbutamide, phenytoin and mestranol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Zafirlukast deserves further clinical study as an inhibitor of other CYP2C9 substrates such as nonsteroidal anti-inflammatory agents, tolbutamide, phenytoin and mestranol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clinically important inhibition by zafirlukast of other CYP isoforms is not established.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
HLM or REC was preincubated with erythromycin in the presence of NADPH and then triazolam was added.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
alpha- and 4-hydroxy (OH) triazolam were quantified after a 3 min incubation and the kinetic parameters for enzyme inactivation (k(inact) and K('app)) were obtained.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Drug-drug interaction in vivo was predicted based on a physiologically-based pharmacokinetic (PBPK) model, using triazolam and erythromycin pharmacokinetic parameters obtained from the literature and kinetic parameters for the enzyme inactivation obtained in the in vitro studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Whichever enzyme was used, triazolam metabolism was not inhibited without preincubation, even if the erythromycin concentration was increased.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Whichever enzyme was used, triazolam metabolism was not inhibited without preincubation, even if the erythromycin concentration was increased.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The degree of inhibition depended on preincubation time and erythromycin concentration.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The values obtained for k(inact) and K('app) were 0.062 min(-1) and 15.9 microM (alpha-OH, HLM), 0.055 min(-1) and 17.4 microM (4-OH, HLM), 0.173 min(-1) and 19.1 microM (alpha-OH, REC), and 0.097 min(-1) and 18.9 microM (4-OH, REC).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on the kinetic parameters obtained using HLM and REC, the AUCpo of triazolam was predicted to increase 2.0- and 2.6-fold, respectively, following oral administration of erythromycin (333 mg t.i.d. for 3 days), which agreed well with the reported data.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vivo interaction between triazolam and erythromycin was successfully predicted from in vitro data based on a PBPK model involving a mechanism-based inhibition of CYP3A4.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Determination of enantiomeric amphetamines as metabolites of illicit amphetamines and selegiline in urine by capillary electrophoresis using modified beta-cyclodextrin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The determination of enantiomeric amphetamine and methamphetamine in urine samples is important in order to distinguish use of the prescription drug selegiline (metabolized to R(-)-A and R(-)-MA) from the illicit use of S(+)-A and S(+)-MA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The determination of enantiomeric amphetamine and methamphetamine in urine samples is important in order to distinguish use of the prescription drug selegiline (metabolized to R(-)-A and R(-)-MA) from the illicit use of S(+)-A and S(+)-MA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the analysis of enantiomeric amphetamine (A) and methamphetamine (MA) in biological samples, the optimization of analytical condition was performed by capillary electrophoresis using chiral selectors including beta-cyclodextrin, carboxymethyl-beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We have examined the factors to obtain the best chiral resolutions, separation efficiency and sensitivity, and wide concentration linearity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Optimum resolutions were achieved using 100 mM phosphate buffer, pH 2.5, containing 10 mM of carboxymethyl-beta-cyclodextrin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This method was applied for the quantitative determination of enantiomeric amphetamine and methamphetamine in urine samples obtained from patients taking illicit amphetamines or from rats and patients taking selegiline.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Acceptable quantitative results in terms of resolution, precision, sensitivity and linearity were obtained from the real urine samples containing wide-ranging concentrations of A and MA by using two concentrations of internal standards, alpha(+)- (1 microg/ml) and beta-phenylethylamine (50 microg/ml).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To use pharmacostatistical models to evaluate the overall exposure of patients with Parkinson's disease to levodopa in the presence and absence of tolcapone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Four hundred twelve patients with Parkinson's disease with fluctuating and nonfluctuating responses to levodopa participated in three multicentered, parallel, double-blind, placebo-controlled dose-finding studies and received either placebo or tolcapone in addition to levodopa-decarboxylase inhibitor therapy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sparse blood samples were obtained from 393 patients for levodopa and 3-O-methyldopa assay, and the data were analyzed with use of the NONMEM program.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The fraction of levodopa metabolized to 3-O-methyldopa was substantially reduced by the co-administration of tolcapone (by 65%, 74%, and 84% with tolcapone doses of 50, 200, and 400 mg, respectively, in fluctuators, and by 50% and 90% with doses of 200 and 400 mg, respectively, in nonfluctuators).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The fraction of levodopa metabolized to 3-O-methyldopa was substantially reduced by the co-administration of tolcapone (by 65%, 74%, and 84% with tolcapone doses of 50, 200, and 400 mg, respectively, in fluctuators, and by 50% and 90% with doses of 200 and 400 mg, respectively, in nonfluctuators).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This led to an overall reduction in levodopa clearance (CL) of approximately 15% to 25% in fluctuators and 20% to 30% in nonfluctuators.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Because this was partly compensated for by a reduction in levodopa dose in these studies, the total daily exposure of patients to levodopa was only slightly increased (11% to 16%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The peak-trough fluctuations of plasma levodopa (Cmax-Cmin) were reduced in both populations in a dose-dependent fashion.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Tolcapone effectively inhibited the formation of 3-O-methyldopa and resulted in a decrease in levodopa CL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Tolcapone effectively inhibited the formation of 3-O-methyldopa and resulted in a decrease in levodopa CL.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The consequent increase in levodopa bioavailability was mostly offset by reductions in levodopa dose.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It is possible that decreased fluctuations in plasma levodopa concentrations rather than increased levodopa exposure may explain the clinical benefits obtained with tolcapone.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In vitro metabolism of acitretin by human liver microsomes: evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro metabolism of acitretin by human liver microsomes: evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The aromatic retinoid acitretin is the primary active metabolite of etretinate, and in this study we investigated the ethyl esterification of acitretin to etretinate using [(14)C]acitretin and human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aromatic retinoid acitretin is the primary active metabolite of etretinate, and in this study we investigated the ethyl esterification of acitretin to etretinate using [(14)C]acitretin and human liver microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Samples were analysed by TLC, HPLC, and LC-MS.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Essential requirements for the transesterification reaction were identified and included viable microsomal protein, ATP, CoASH, and ethanol.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Human liver microsomes catalysed formation of acitretinoyl-CoA at the rate of 0.08 +/- 0.02 nmol/min/mg (mean +/- SD, N = 10).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Acitretinoyl-CoA was pivotal for the transesterification to etretinate and in the presence of methanol, ethanol, n-propanol, n-butanol, and hexanol, the corresponding esters, namely methyl-, ethyl (etretinate)-, propyl-, butyl-, and hexyl-acitretinate, were formed.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Acitretinoyl-CoA was pivotal for the transesterification to etretinate and in the presence of methanol, ethanol, n-propanol, n-butanol, and hexanol, the corresponding esters, namely methyl-, ethyl (etretinate)-, propyl-, butyl-, and hexyl-acitretinate, were formed.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
On average, 1.7% of the acitretin present in the incubation was converted to etretinate in the presence of ethanol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On average, 1.7% of the acitretin present in the incubation was converted to etretinate in the presence of ethanol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the absence of ethanol, transesterification did not proceed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibition of the ester hydrolysis of etretinate by bis-p-nitrophenylphosphate (BNPP, 1 mM) prevented futile cycling of etretinate via acitretinoyl-CoA.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Inhibition of the ester hydrolysis of etretinate by bis-p-nitrophenylphosphate (BNPP, 1 mM) prevented futile cycling of etretinate via acitretinoyl-CoA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An additional finding was that acitretin (15-30 microM) activated significantly human liver microsomal long-chain fatty acid-CoA ligase (E.C.6.2.1.3, LCL), resulting in enhanced formation of palmitoyl-CoA.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
An additional finding was that acitretin (15-30 microM) activated significantly human liver microsomal long-chain fatty acid-CoA ligase (E.C.6.2.1.3, LCL), resulting in enhanced formation of palmitoyl-CoA.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
This study demonstrated that in the presence of ethanol the ethyl esterification of acitretin to etretinate proceeds via formation of acitretinoyl-CoA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study demonstrated that in the presence of ethanol the ethyl esterification of acitretin to etretinate proceeds via formation of acitretinoyl-CoA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Predicting clearance of acitretin in vivo via this unique metabolic pathway will be a challenge, as the intracellular concentration of ethanol could never be predicted with any degree of accuracy in humans.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cilostazol (OPC-13013) undergoes extensive hepatic metabolism.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The hydroxylation of the quinone moiety of cilostazol to OPC-13326 was the predominant route in all the liver preparations studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The hydroxylation of the quinone moiety of cilostazol to OPC-13326 was the predominant route in all the liver preparations studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The hydroxylation of the hexane moiety to OPC-13217 was the second most predominant route in vitro.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The hydroxylation of the hexane moiety to OPC-13217 was the second most predominant route in vitro.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ketoconazole (1 microM) was the most potent inhibitor of both quinone and hexane hydroxylation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both the CYP2D6 inhibitor quinidine (0.1 microM) and the CYP2C19 inhibitor omeprazole (10 microM) failed to consistently inhibit metabolism of cilostazol via either of these two predominant routes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Both the CYP2D6 inhibitor quinidine (0.1 microM) and the CYP2C19 inhibitor omeprazole (10 microM) failed to consistently inhibit metabolism of cilostazol via either of these two predominant routes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Data obtained from a bank of pre-characterized human liver microsomes demonstrated a stronger correlation (r2=0.68, P < 0.01) between metabolism of cilostazol to OPC-13326 and metabolism of felodipine, a CYP3A probe, that with probes for any other isoform.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Data obtained from a bank of pre-characterized human liver microsomes demonstrated a stronger correlation (r2=0.68, P < 0.01) between metabolism of cilostazol to OPC-13326 and metabolism of felodipine, a CYP3A probe, that with probes for any other isoform.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cimetidine demonstrated concentration-dependent competitive inhibition of the metabolism of cilostazol by both routes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cimetidine demonstrated concentration-dependent competitive inhibition of the metabolism of cilostazol by both routes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Kinetic data demonstrated a Km value of 101 microM for cilostazol, suggesting a relatively low affinity of cilostazol for CYP3A.

$$$$
>  <CLASS>
Parent

>  <TARGET>
While recombinant CYP1A2, CYP2D6 and CYP2C19 were also able to catalyze formation of specific cilostazol metabolites, they did not appear to contribute significantly to cilostazol metabolism in whole human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We describe a normal-phase HPLC method for the stereospecific determination of R- and S-acenocoumarol and R- and S-phenprocoumon with S-warfarin as internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The compounds were separated using a Whelk-O1 chiral stationary phase, detected by UV at 310 nm and quantified in the internal standard mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Linearity was verified for acenocoumarol in the range of 15-2000 microg/l and for phenprocoumon from 15 to 2200 microg/l, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection limits were 5 microg/l for all compounds.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The recovery was >84% for R- and S-acenocoumarol and >74% for R- and S-phenprocoumon.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The imprecision (C.V.) (50-1800 microg/l) for R- and S-acenocoumarol was <4.7% within-day and <7.8% between-day.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For R- and S-phenprocoumon the respective values were <5.6% and <5.9%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Silibinin, the main constituent of silymarin, a flavonoid drug from silybum marianum used in liver disease, was tested for inhibition of human cytochrome P-450 enzymes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolic activities were determined in liver microsomes from two donors using selective substrates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With each substrate, incubations were carried out with and without silibinin (concentrations 3.7-300 microM) at 37 degrees in 0.1 M KH2PO4 buffer containing up to 3% DMSO.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Metabolite concentrations were determined by HPLC or direct spectroscopy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
First, silibinin IC50 values were determined for each substrate at respective K(M) concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Silibinin had little effect (IC50>200 microM) on the metabolism of erythromycin (CYP3A4), chlorzoxazone (CYP2E1), S(+)-mephenytoin (CYP2C19), caffeine (CYP1A2) or coumarin (CYP2A6).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Silibinin had little effect (IC50>200 microM) on the metabolism of erythromycin (CYP3A4), chlorzoxazone (CYP2E1), S(+)-mephenytoin (CYP2C19), caffeine (CYP1A2) or coumarin (CYP2A6).

$$$$
>  <CLASS>
Parent

>  <TARGET>
A moderate effect was observed for high affinity dextromethorphan metabolism (CYP2D6) in one of the microsomes samples tested only (IC50=173 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Clear inhibition was found for denitronifedipine oxidation (CYP3A4; IC50=29 microM and 46 microM) and S(-)-warfarin 7-hydroxylation (CYP2C9; IC50=43 microM and 45 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When additional substrate concentrations were tested to assess enzyme kinetics, silibinin was a potent competitive inhibitor of dextromethorphan metabolism at the low affinity site, which is not CYP2D6 (Ki.c=2.3 microM and 2.4 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
When additional substrate concentrations were tested to assess enzyme kinetics, silibinin was a potent competitive inhibitor of dextromethorphan metabolism at the low affinity site, which is not CYP2D6 (Ki.c=2.3 microM and 2.4 microM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Inhibition was competitive for S(-)-warfarin 7-hydroxylation (Ki,c=18 microM and 19 microM) and mainly non-competitive for denitronifedipine oxidation (Ki,n=9 microM and 12 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With therapeutic silibinin peak plasma concentrations of 0.6 microM and biliary concentrations up to 200 microM, metabolic interactions with xenobiotics metabolised by CYP3A4 or CYP2C9 cannot be excluded.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Paraoxonase (PON1) is tightly associated with high-density lipoprotein particles and is believed to contribute to the prevention of atherosclerosis by metabolizing oxidized lipids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PON1 also hydrolyses the bioactive oxon forms of organophosphorus pesticides such as parathion, diazinon and chlorpyrifos.

$$$$
>  <CLASS>
Parent

>  <TARGET>
PON1 also hydrolyses the bioactive oxon forms of organophosphorus pesticides such as parathion, diazinon and chlorpyrifos.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Two common polymorphisms have been identified in the coding sequence of human PON1: L55M and R192Q.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Several previous studies have found that the presence of the PON1R192 allele raises the risk of cardiovascular disease while others found no correlation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The studies, however, have focused on the genotype of PON1 and not the expression level of the protein.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We found that the PON1 expression level in plasma, as determined by the rates of paraoxon and diazoxon hydrolysis, varies widely among individuals and within a genotype.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Previous studies found that individuals having Met at PON155 have lower levels of both PON1 mRNA and activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In this study, we determined the plasma activity levels of PON1 and examined the relationships between PON155 genotype and PON1 level.

$$$$
>  <CLASS>
NONE

>  <TARGET>
As with PON1192, we found considerable overlap in activity among the PON155 genotypes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Of the 317 individuals whose PON1 status was determined in this study, 48.9% were PON1Q192 homozygotes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Analysis of the PON1QQ192 population showed that while the average PON1 activity (diazoxon hydrolysis) was 12266 U/L for PON1LL55 and 7777 U/L for PON1MM55, a given PONMM55 individual could have more than twice the activity of a PON1LL55 individual.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PON1 status, which includes PON1 level as well as PON1192 genotype, may be a better predictor for cardiovascular disease or organophosphate susceptibility than PON1 genotype alone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes).

$$$$
>  <CLASS>
NONE

>  <TARGET>
A new member of the CYP3A gene family has been cloned from the teleost fish medaka (Oryzias latipes) by reverse-transcriptase polymerase chain reaction (RT-PCR).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Degenerate primers homologous to highly conserved regions of known CYP3A sequences were used for initial RT-PCRs.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Individual PCR products were cloned, sequenced, and identified as those belonging to the cytochrome P450 superfamily based on amino acid sequence similarity and the presence of the highly conserved heme-binding region.

$$$$
>  <CLASS>
NONE

>  <TARGET>
PCR products were subsequently used as probes to screen a complementary DNA library.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A full-length cDNA clone was identified containing a 1758-base-pair (bp) insert with an open reading frame encoding a single peptide of 500 amino acids.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Comparisons of the deduced amino acid sequence to other known cytochrome P450 sequences indicate that this gene product is most similar to the CYP3A gene family and has been designated as CYP3A38 by the cytochrome P450 nomenclature committee.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Northern blot analysis identified two abundant CYP3A related transcripts in liver of both male and female adults and demonstrated quantitative differences in abundance according to gender.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similarly, Western blot analysis demonstrated the presence of two abundant cytochrome P450 related proteins in liver of both male and female adults.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These results suggests that O. latipes contains multiple forms of CYP3A.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Heterologous expression of CYP3A38 cDNA in HEK 293 cells produced a single protein that was reactive with anti-scup P450A (CYP3A) polyclonal antibody.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Microsomes of HEK 293 cells expressing recombinant CYP3A38 protein actively catalyzed the hydroxylation of testosterone.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
An assay for the simultaneous quantitative determination of thioTEPA, TEPA and the recently identified metabolite N,N'-diethylene-N"-2-chloroethylphosphoramide (monochloroTEPA) in human urine has been developed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
MonochloroTEPA was synthesized by incubation of TEPA with sodium chloride at pH 8.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, with this assay monochloroTEPA is quantified as TEPA equivalents.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Analysis of the three analytes in urine was performed using gas chromatography with selective nitrogen-phosphorous detection after extraction with a mixture of 1-propanol and chloroform from urine samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Diphenylamine was used as internal standard.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Recoveries ranged between 70 and 100% and both accuracy and precision were less than 15%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Linearity was accomplished in the range of 25-2500 ng/ml for monochloroTEPA and 25-5000 ng/ml for thioTEPA and TEPA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
MonochloroTEPA proved to be stable in urine for at least 4 weeks at -80 degrees C. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
ThioTEPA, TEPA and monochloroTEPA cummulative urinary excretion from two patients treated with thioTEPA are presented demonstrating the applicability of the assay for clinical samples and that the excreted amount of monochloroTEPA exceeded that of thioTEPA on day 2 to 5 of urine collection.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Glucuronidation of phenols (1-naphthol, 4-methylumbelliferone) and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen, naproxen and carprofen was investigated in human colon carcinoma Caco-2 cell clones.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Glucuronidation of these substances was highly effective in microsomes of the clones PD-7 and TC-7, but much lower in the PF-11 clone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The activity increased up to a maximum after 21 days of culture.

$$$$
>  <CLASS>
Parent

>  <TARGET>
RT-PCR experiments indicated that the PD-7 and TC-7 clones expressed the UDP-glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A3 and UGT2B7, which could account for the glucuronidation of phenols and carboxylic acids observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Beta-naphthoflavone stimulated by 2-fold the enzyme activity toward 1-naphthol in PD-7 and TC-7 clones, but not in PF-11 cells.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Beta-naphthoflavone stimulated by 2-fold the enzyme activity toward 1-naphthol in PD-7 and TC-7 clones, but not in PF-11 cells.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This increase was parallel to that of the UGT1A6 mRNA level.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Glucuronidation of ketoprofen was also sensitive to the inducing effect of beta-naphthoflavone.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Glucuronidation of ketoprofen was also sensitive to the inducing effect of beta-naphthoflavone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Actinomycin D and cycloheximide did not affect the induction of UGT1A6 by beta-naphthoflavone, but suppressed that of ketoprofen UGT.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The UGT1A3 mRNA content was enhanced by beta-naphthoflavone; by contrast, that of UGT2B7 was insensitive to the inducer.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In conclusion, several UGT isoforms of both families 1 and 2, which glucuronidate phenols and carboxylic NSAIDs, have been identified in Caco-2 cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
They are differently sensitive to beta-naphthoflavone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Lack of interaction between citalopram and the CYP3A4 substrate triazolam.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Lack of interaction between citalopram and the CYP3A4 substrate triazolam.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To determine the effect of the selective serotonin reuptake inhibitor citalopram on plasma levels of triazolam, and to determine the effect of a single dose of triazolam on steady-state levels of citalopram and its major metabolites.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To determine the effect of the selective serotonin reuptake inhibitor citalopram on plasma levels of triazolam, and to determine the effect of a single dose of triazolam on steady-state levels of citalopram and its major metabolites.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Open-label, multidose study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Clinical Studies, Ltd., Fort Lauderdale, Florida.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Eighteen healthy male and female volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Subjects received triazolam 0.25 mg alone and another 0.25-mg dose after 4 weeks of citalopram 20 mg/day for 1 week, followed by 3 weeks of citalopram 40 mg/day.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetic parameters were determined after single-dose administration of triazolam alone, after administration of citalopram alone at steady state, and after coadministration of the drugs.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The pharmacokinetics of triazolam and its metabolite alpha-hydroxytriazolam were unchanged by citalopram coadministration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of triazolam and its metabolite alpha-hydroxytriazolam were unchanged by citalopram coadministration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Triazolam appeared to be absorbed slightly more quickly during coadministration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Citalopram kinetics were unaffected by coadministration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No pharmacokinetic interaction between the drugs was observed, suggesting that triazolam and other cytochrome P450 3A4 substrates can be coadministered safely with citalopram.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on preclinical data demonstrating synergy between camptothecin analogues and taxanes, we determined the maximum tolerated dose (MTD) of irinotecan that could be given in combination with a fixed dose of paclitaxel of 75 mg/m2, when both drugs were delivered on a weekly schedule.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of this combination were explored to determine whether the sequence of administration affected the elimination of irinotecan.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For the first cycle patients with advanced cancer were treated with irinotecan given as a 90-min infusion followed immediately by paclitaxel given at a dose of 75 mg/m2 over 1 h. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
The sequence of drug administration was reversed in subsequent cycles for most patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Chemotherapy was given weekly for 4 weeks, followed by a 2-week rest.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In selected patients, plasma concentrations of irinotecan were determined by high-performance liquid chromatography during the first 24 h of cycle 1 and after the first dose of cycle 2 to determine whether the order of drug administration affected the elimination of irinotecan, or the toxicologic effects of the chemotherapy.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A total of 53 cycles were delivered to 21 patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Reversible neutropenia was dose-limiting.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Suppression of the other blood cell elements was modest.

$$$$
>  <CLASS>
NONE

>  <TARGET>
There was one partial response in a man with a previously treated cholangiocarcinoma that lasted 26 weeks.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Prolonged stabilization of disease (6 months or more) was observed in five of the patients (24%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
At the recommended dose of irinotecan (50 mg/m2), transfusions of red cells and platelets were not required.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The sequence of drug administration produced no significant differences in the pharmacokinetic parameters of irinotecan or SN-38, which were similar to the values reported when irinotecan is administered alone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The most prominent nonhematologic toxicities were mild diarrhea and fatigue.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The recommended dose of irinotecan on this schedule is 50 mg/m2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The sequence of drug administration affects neither the elimination of irinotecan nor the chemotherapy-related toxicity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This combination is well tolerated and causes minimal clinical side effects.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The aims were to refine experimental conditions (using 76 human hepatocyte preparations) in terms of the selection of enzyme inducers and their optimal concentration, the treatment duration with inducers and the choice of specific cytochrome P450 isoform(s) probes to optimize the use of primary hepatocytes for predicting the potential induction by new chemical entities of cytochrome P450 isoforms in vivo in man.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In the absence of any inducer, basal cytochrome P450 isoform(s)-mediated activities decreased to 20% of their initial activity (end of the seeding period) by 72-96 h. In contrast, UGT-dependent enzyme activities remained at a constant level (+/- 20%) up to the fifth day of culture.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Beta-naphthoflavone, at an optimal concentration of 50 microM and after a 3-day treatment, specifically and potently induced 7-ethoxyresorufin (10.4 +/- 10.4-fold, n = 74) and phenacetin (6.6 +/- 6.4-fold, n = 60) O-deethylation processes, markers for CYP1A1 and CYP1A2 isoforms respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Beta-naphthoflavone, at an optimal concentration of 50 microM and after a 3-day treatment, specifically and potently induced 7-ethoxyresorufin (10.4 +/- 10.4-fold, n = 74) and phenacetin (6.6 +/- 6.4-fold, n = 60) O-deethylation processes, markers for CYP1A1 and CYP1A2 isoforms respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Only a 2-fold increase was noted following treatment with 2 mM phenobarbitone, whereas dexamethasone and rifampicin had no effect at all.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A 3-day treatment of human hepatocytes with 50 microM dexamethasone was associated with a major induction of both coumarin 7-hydroxylation (9.4 +/- 11.4-fold, n = 49) and nifedipine dehydrogenation (4.7 +/- 3.8-fold, n = 61), markers for CYP2A6 and CYP3A4 respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A 3-day treatment of human hepatocytes with 50 microM dexamethasone was associated with a major induction of both coumarin 7-hydroxylation (9.4 +/- 11.4-fold, n = 49) and nifedipine dehydrogenation (4.7 +/- 3.8-fold, n = 61), markers for CYP2A6 and CYP3A4 respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Phenobarbitone, however, exhibited a broad but moderate inducing effect on 7-ethoxyresorufin (2.2 +/- 1.5-fold, n = 55) and phenacetin (1.7 +/- 0.9-fold, n = 54) O-deethylation, coumarin 7-hydroxylation (3.9 +/- 9.2-fold, n = 50) and nifedipine dehydrogenation (2.1 +/- 2.0-fold, n = 47).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Phenobarbitone, however, exhibited a broad but moderate inducing effect on 7-ethoxyresorufin (2.2 +/- 1.5-fold, n = 55) and phenacetin (1.7 +/- 0.9-fold, n = 54) O-deethylation, coumarin 7-hydroxylation (3.9 +/- 9.2-fold, n = 50) and nifedipine dehydrogenation (2.1 +/- 2.0-fold, n = 47).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Km obtained for the different cytochrome P450 isoform substrates in untreated hepatocytes were in the same range of magnitude that those determined on human hepatic microsomal fractions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Enzyme induction processes were characterized by a large increase in apparent Vmax whereas apparent Km were not affected.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These studies demonstrate that human hepatocytes in primary culture can respond specifically and quantitatively to model inducers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This in vitro system offers a useful approach to study the regulation of human hepatic biotransformation activities and should facilitate the demand for a reproducible method for addressing cytochrome P450 induction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A gas chromatographic-mass spectrometric (GC-MS) screening procedure was developed for detection of selective serotonin reuptake inhibitors (SSRIs) in urine as part of a systematic toxicological analysis procedure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After acid hydrolysis of one aliquot of urine, another aliquot was added.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mixture was then liquid-liquid extracted at pH 8-9, acetylated, and GC separated.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Using mass chromatography with the ions m/z 58, 72, 86, 173, 176, 234, 238, and 290, the possible presence of SSRIs and/or their metabolites could be indicated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The identity of positive signals in such mass chromatograms was confirmed by comparison of the peaks underlying full mass spectra with the reference spectra recorded during this study.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The overall recoveries of citalopram, sertraline, and paroxetine ranged between 60 and 80%, and those of fluoxetine and fluvoxamine, which were destroyed during acid hydrolysis, were between 40 and 45%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The coefficients of variation were less than 10-20%, and the limit of detection was at least 100 ng/mL (signal-to-noise ratio = 3).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This method allowed the detection of therapeutic concentrations of citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline in human urine samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Carbidopa (CD), a competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Carbidopa (CD), a competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using a stable isotope-labeled form of LD, the authors examined in 9 PD patients the effects of variable CD absorption on peripheral and central LD metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Using a stable isotope-labeled form of LD, the authors examined in 9 PD patients the effects of variable CD absorption on peripheral and central LD metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Subjects were administered orally 50 mg of CD followed in 1 hour by a slow bolus intravenous infusion of 150 mg stable isotope-labeled LD (ring 1',2',3',4',5',6'-13C).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Eight patients underwent a lumbar puncture 6 hours following the infusion.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood and cerebrospinal fluid (CSF) samples were analyzed for labeled and unlabeled metabolites using a combination of high-performance liquid chromatography and mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
When patients were divided into "slow" and "rapid" CD absorption groups, significantly greater peripheral LD decarboxylation (as measured by area under the curve [AUC]-labeled serum HVA) was noted in the poor absorbers (p = 0.05, Mann-Whitney U test).

$$$$
>  <CLASS>
Parent

>  <TARGET>
When patients were divided into "slow" and "rapid" CD absorption groups, significantly greater peripheral LD decarboxylation (as measured by area under the curve [AUC]-labeled serum HVA) was noted in the poor absorbers (p = 0.05, Mann-Whitney U test).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Elimination half-lives for serum LD did not differ between groups, suggesting a further capacity for decarboxylation inhibition in the "rapid" absorbers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A significant correlation between AUC serum CD and percent-labeled HVA in CSF was found for all patients (R = 0.786, p = 0.02).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rapid as compared to "slow" CD absorbers had significantly more percent-labeled CSF HVA (60 vs. 49, p = 0.02, Mann-Whitney U test), indicating greater central-labeled DA production in the better CD absorbers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The data suggest that peripheral aromatic l-amino acid decarboxylase activity is not saturated at CD doses used in current practice.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors believe that future studies to better examine a dose dependence of CD on peripheral LD decarboxylation and LD brain uptake are warranted.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The authors believe that future studies to better examine a dose dependence of CD on peripheral LD decarboxylation and LD brain uptake are warranted.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The pharmacokinetics of S-(-)- and R-(+)-ofloxacin, enantiomers of the fluoroquinolone ofloxacin, were characterized after prophylactic administration in 15 patients undergoing elective biliary surgery.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of S-(-)- and R-(+)-ofloxacin, enantiomers of the fluoroquinolone ofloxacin, were characterized after prophylactic administration in 15 patients undergoing elective biliary surgery.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A single dose of ofloxacin 400 mg given intravenously as an infusion was administered 1 hour before surgery.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma levels of S-(-)- and R-(+)-ofloxacin showed very small differences between both enantiomers, although the ratio of S-(-)- to R-(+)-enantiomer concentration in plasma showed significant differences (p < 0.05) at 4 and 12 hours.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Adequate S-(-)-ofloxacin (levofloxacin, the active enantiomer) plasma levels (> or = minimum inhibitory concentration [MIC90] for Escherichia coli) were found throughout the procedure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
For pharmacokinetic parameters, the authors found small but statistically significant differences (p < 0.05) in the area under the concentration-time curve, AUC0-infinity (22.30 +/- 2.72 mg h/L for S-(-)-ofloxacin vs. 20.50 +/- 2.06 mg h/L for R-(+)-ofloxacin), and in the clearance (0.15 +/- 0.04 L/h/Kg for S-(-)-ofloxacin vs. 0.16 +/- 0.04 L/h/Kg for R-(+)-ofloxacin).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To test the penetration of ofloxacin enantiomers into tissues, the authors measured levels in subcutaneous cell tissue and gall-bladder cell tissue.

$$$$
>  <CLASS>
NONE

>  <TARGET>
They did not observe statistical differences between the two isomers, which means that distribution is not an estereoselective process.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Enantiomer levels in these two tissues decreased rapidly, but the highest concentrations were reached during the 4 first hours (i.e., when the surgical procedure was being performed).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In conclusion, with the prophylactic treatment used, levofloxacin plasma and tissue levels are high enough to prevent surgical infections.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Despite its potent biologic effect on human sebocytes, 13-cis retinoic acid exhibits low binding affinity for cellular retinoic acid binding proteins and nuclear retinoid receptors.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Hence, 13-cis retinoic acid may represent a pro-drug possibly acting through all-trans isomerization.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this study, marked isomerization of 13-cis retinoic acid has been confirmed in cultured SZ95 sebocytes showing 2- to 15-fold higher levels of all-trans retinoic acid at 12-72 h, as measured by high performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, only low amounts of all-trans retinoic acid were converted intracellularly to its 13-cis isoform.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
9-cis retinoic acid was not detected after either 13-cis retinoic acid or all-trans retinoic acid treatment.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The rapid isomerization of 13-cis retinoic acid to high levels of all-trans retinoic acid was a sebocyte-specific event, as no significant isomerization of 13-cis retinoic acid to all-trans retinoic acid occurred in HaCaT keratinocytes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
De novo mRNA expression of cytochrome P450 1A1, a major xenobiotic metabolizing enzyme, in SZ95 sebocytes was induced by all-trans retinoic acid, but not by 13-cis retinoic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition, mRNA levels of cellular retinoic acid-binding protein II, which is supposed to regulate the concentration of intracellular all-trans retinoic acid, rapidly increased under all-trans retinoic acid treatment (30 min-6 h), whereas the 13-cis retinoic acid effect was markedly weaker and delayed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both 13-cis retinoic acid and all-trans retinoic acid suppressed mRNA expression of cytochrome P450 1A2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In parallel experiments, 13-cis retinoic acid significantly reduced SZ95 sebocyte proliferation at 10-7 M, show- ing 30-40% inhibition after 9 d. 

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All-trans retinoic acid and 9-cis retinoic acid exhibited similar anti-proliferative effects.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
AGN 193109, a pan-antagonist of the retinoic acid receptors, antagonized the anti-proliferative activity of all retinoic acid isomers tested in a concentration-dependent manner with complete abolishment at ratios of 1:10 13-cis retinoic acid and 1:1 all-trans retinoic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
AGN 193109, a pan-antagonist of the retinoic acid receptors, antagonized the anti-proliferative activity of all retinoic acid isomers tested in a concentration-dependent manner with complete abolishment at ratios of 1:10 13-cis retinoic acid and 1:1 all-trans retinoic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Coincubation of SZ95 sebocytes with 13-cis retinoic acid and AGN 193109 did not alter the intracellular concentration of 13-cis retinoic acid and its isomerization profile.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, the retinoid X receptor antagonist CD 3507 did not affect the inhibition of SZ95 sebocyte proliferation induced by retinoic acids.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Our findings indicate: (i) a selective 13-cis retinoic acid isomerization to all-trans retinoic acid in the intracellular compartment of SZ95 sebocytes; (ii) a reduced all-trans retinoic acid inactivation process after 13-cis retinoic acid treatment as compared with treatment with all-trans retinoic acid; and (iii) a retinoic acid receptor-mediated inhibition of SZ95 sebocyte proliferation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These data explain the sebocyte-specific activity of 13-cis retinoic acid and support a pro-drug/drug relation between 13-cis retinoic acid and all-trans retinoic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Biotransformation of triazolam to its alpha-hydroxy and 4-hydroxy metabolites by human liver microsomes in vitro was used as an index of human cytochrome P450 3A (CYP3A) activity.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The reaction was strongly inhibited by co-incubation with the viral protease inhibitors ritonavir (IC50 = 0.14 microM) and amprenavir (IC50 = 2.5 2.9 microM), and by the azole derivative ketoconazole (IC50 = 0.07 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The reaction was strongly inhibited by co-incubation with the viral protease inhibitors ritonavir (IC50 = 0.14 microM) and amprenavir (IC50 = 2.5 2.9 microM), and by the azole derivative ketoconazole (IC50 = 0.07 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pre-incubation of microsomes with ritonavir or amprenavir increased inhibitory potency (IC50 reduced to 0.07 microM and 1.4 microM, respectively).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This was not the case with ketoconazole.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, ritonavir and amprenavir are highly potent mechanism-based inhibitors of human CYP3A isoforms.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A comparison of activity in red blood cell samples of 199 blood donors.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To compare 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) as substrates for the methylation reaction catalysed by the enzyme thiopurine S-methyltransferase (TPMT).

$$$$
>  <CLASS>
Parent

>  <TARGET>
TPMT activity in haemolysed red blood cells of healthy blood donors was determined twice, using the same experimental setting and equal molar concentrations of 6-TG and 6-MP as substrates.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
After extraction, the reaction products 6-methyl-TG and 6-methyl-MP were quantified using specific high-performance liquid chromatography procedures.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The medians of the TPMT activities from 199 blood donors were 54.4 nmol 6-MTG g(-1)Hb h(-1) when measured with 6-TG as the substrate and 35.8 nmol 6-MMP g(-1) Hb h(-1) when measured with 6-MP.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The medians of the TPMT activities from 199 blood donors were 54.4 nmol 6-MTG g(-1)Hb h(-1) when measured with 6-TG as the substrate and 35.8 nmol 6-MMP g(-1) Hb h(-1) when measured with 6-MP.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The correlation coefficient for the 199 pairs of values was 0.8695.

$$$$
>  <CLASS>
Parent

>  <TARGET>
On average, TPMT activity was 34% lower with 6-MP as substrate than with 6-TG as substrate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
N-Acetylbenzidine-DNA adduct formation by phorbol 12-myristate-stimulated human polymorphonuclear neutrophils.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
N-Acetylbenzidine-DNA adduct formation by phorbol 12-myristate-stimulated human polymorphonuclear neutrophils.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
N'-(3'-Monophosphodeoxyguanosin-8-yl)-N-acetylbenzidine (dGp-ABZ) is the major adduct in exfoliated urothelial cells and in peripheral white blood cells of workers exposed to benzidine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
N'-(3'-Monophosphodeoxyguanosin-8-yl)-N-acetylbenzidine (dGp-ABZ) is the major adduct in exfoliated urothelial cells and in peripheral white blood cells of workers exposed to benzidine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
This study was designed to assess the metabolic pathways leading to dGp-ABZ formation in human peripheral white blood cells.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
[(3)H]-N-Acetylbenzidine (ABZ) transformation was assessed using myeloperoxidase (MPO), hypochlorous acid (HOCl), and human peripheral white blood cells in the absence and presence of DNA or dGp.

$$$$
>  <CLASS>
Parent

>  <TARGET>
[(3)H]-N-Acetylbenzidine (ABZ) transformation was assessed using myeloperoxidase (MPO), hypochlorous acid (HOCl), and human peripheral white blood cells in the absence and presence of DNA or dGp.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
MPO metabolism required H(2)O(2), but not NaCl.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
While transformation by HOCl was completely inhibited by 10 mM taurine, the level of metabolism of ABZ by MPO was only reduced 56%.

$$$$
>  <CLASS>
Parent

>  <TARGET>
While transformation by HOCl was completely inhibited by 10 mM taurine, the level of metabolism of ABZ by MPO was only reduced 56%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Transformation by either MPO or HOCl was inhibited by 100 mM DMPO, 1 mM glutathione, and 1 mM ascorbic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Glutathione formed a new product with MPO, but not with HOCl.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Previously identified oxidation products of ABZ, N'-hydroxy-N-acetylbenzidine or 4'-nitro-4-acetylaminobiphenyl, were not detected.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With DNA or dGp present, a new product was observed that corresponded to synthetic dGp-ABZ in its HPLC elution profile, in nuclease P(1) hydrolysis to dG-ABZ, and in (32)P-postlabeling analysis.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
With DNA or dGp present, a new product was observed that corresponded to synthetic dGp-ABZ in its HPLC elution profile, in nuclease P(1) hydrolysis to dG-ABZ, and in (32)P-postlabeling analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The HOCl-derived adduct was identified by electrospray ionization mass spectrometry, with collision-activated dissociation, as dGp-ABZ.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Metabolism of [(3)H]ABZ by peripheral blood cells was stimulated about 3-fold with 30 ng/mL beta-phorbol 12-myristate 13-acetate (PMA).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of [(3)H]ABZ by peripheral blood cells was stimulated about 3-fold with 30 ng/mL beta-phorbol 12-myristate 13-acetate (PMA).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using (32)P-postlabeling, dGp-ABZ was detected only in the presence of PMA and its level was increased more than 300-fold if either 0.7 mg/mL DNA or dGp was present.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Indomethacin (0.1 mM) did not alter adduct formation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
With dGp, dGp-ABZ formation could be detected with as little as 0.12 x 10(6) neutrophils.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
With dGp, dGp-ABZ formation could be detected with as little as 0.12 x 10(6) neutrophils.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using specific chromatographic and enzymatic techniques, neutrophil-derived dGp-ABZ was identical to the synthetic standard.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Thus, these results are consistent with human polymorphonuclear neutrophils forming dGp-ABZ by a peroxidatic mechanism involving MPO.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Effects of 2-(substituted-sulfanyl)-3,5-dihydro-imidazole-4-one and 2-(substituted-sulfanyl)-1H-imidazole-4,5-dione derivatives on serum HDL-cholesterol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Effects of 2-(substituted-sulfanyl)-3,5-dihydro-imidazole-4-one and 2-(substituted-sulfanyl)-1H-imidazole-4,5-dione derivatives on serum HDL-cholesterol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A series of 2-substituted sulfanyl-3,5-dihydro-imidazole-4-ones and 2-substituted sulfanyl-1H-imidazole-4,5-diones was prepared and shown to increase high density lipoprotein cholesterol over other lipid fractions.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A series of 2-substituted sulfanyl-3,5-dihydro-imidazole-4-ones and 2-substituted sulfanyl-1H-imidazole-4,5-diones was prepared and shown to increase high density lipoprotein cholesterol over other lipid fractions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Compound 1f showed efficacy in additional animal models.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The major metabolite of 1f was isolated and its synthesis is reported.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The effects of the metabolite on the lipid profile in rats were investigated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin, a sharp decrease in 4-hydroxycyclophosphamide concentration was observed immediately after the start of the thioTEPA infusion.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin, a sharp decrease in 4-hydroxycyclophosphamide concentration was observed immediately after the start of the thioTEPA infusion.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A drug-drug interaction was suspected.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This putative interaction was investigated in this study.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Possible sequence dependency, due to inhibition of the formation of 4-hydroxycyclophosphamide by thioTEPA, was investigated by altering the sequence of infusion in three patients (four courses) receiving high-dose chemotherapy with cyclophosphamide (1,000 or 1,500 mg/m2 per day), thioTEPA (80 or 120 mg/m2 per day) and carboplatin (265 or 400 mg/m2 per day) in short infusions for four consecutive days.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Possible sequence dependency, due to inhibition of the formation of 4-hydroxycyclophosphamide by thioTEPA, was investigated by altering the sequence of infusion in three patients (four courses) receiving high-dose chemotherapy with cyclophosphamide (1,000 or 1,500 mg/m2 per day), thioTEPA (80 or 120 mg/m2 per day) and carboplatin (265 or 400 mg/m2 per day) in short infusions for four consecutive days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were established.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Possible inhibition of the metabolism of cyclophosphamide and thioTEPA was investigated in human microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A striking sequence dependency of the pharmacokinetics of 4-hydroxycyclophosphamide was observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Administration of thioTEPA 1 h prior to cyclophosphamide resulted in decreased Cmax (-62%) and AUC (-26%) values of 4-hydroxycyclophosphamide compared to those of thioTEPA administered 1 h after cyclophosphamide.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In human microsomes an inhibition of the conversion of cyclophosphamide to 4-hydroxycyclophosphamide by thioTEPA was observed at clinically relevant concentrations with an IC50 of 23 microM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In human microsomes an inhibition of the conversion of cyclophosphamide to 4-hydroxycyclophosphamide by thioTEPA was observed at clinically relevant concentrations with an IC50 of 23 microM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
No inhibition of the formation of TEPA by cyclophosphamide was observed.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
No inhibition of the formation of TEPA by cyclophosphamide was observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
ThioTEPA strongly inhibits the bioactivation of cyclophosphamide and this may decrease both efficacy and toxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
ThioTEPA strongly inhibits the bioactivation of cyclophosphamide and this may decrease both efficacy and toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Our results seriously question the practice of the simultaneous continuous infusion of cyclophosphamide and thioTEPA and suggest that the sequencing and scheduling of these two agents in high-dose chemotherapy regimens may be of critical importance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In vitro studies have shown that the formation of 3-hydroxyquinidine from quinidine is catalyzed almost exclusively by CYP3A4.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In vivo this result has been supported in various interaction studies, and the use of this reaction as an in vivo biomarker reaction of CYP3A4 activity has been suggested.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
We studied the possible correlation of the formation clearance of 3-hydroxyquinidine with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Descriptive analyses of the outcome of various biomarker reactions were performed.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Forty-two healthy, young male volunteers participated in an open study consisting of two identical test periods separated by a 12- to 14-week washout period.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In each period biomarker reactions of CYP1A2 (caffeine), CYP2C9 (tolbutamide), CYP2C19 (mephenytoin), CYP2D6 (sparteine), CYP3A4 (urinary excretion of 6beta-hydroxycortisol), as well as the pharmacokinetics of quinidine after a 200-mg single oral dose of quinidine sulfate were studied.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In each period biomarker reactions of CYP1A2 (caffeine), CYP2C9 (tolbutamide), CYP2C19 (mephenytoin), CYP2D6 (sparteine), CYP3A4 (urinary excretion of 6beta-hydroxycortisol), as well as the pharmacokinetics of quinidine after a 200-mg single oral dose of quinidine sulfate were studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In each period biomarker reactions of CYP1A2 (caffeine), CYP2C9 (tolbutamide), CYP2C19 (mephenytoin), CYP2D6 (sparteine), CYP3A4 (urinary excretion of 6beta-hydroxycortisol), as well as the pharmacokinetics of quinidine after a 200-mg single oral dose of quinidine sulfate were studied.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
As measured by the formation clearance of 3-hydroxyquinidine, the intraindividual coefficient of variation for CYP3A4 activity was 18%, whereas the interindividual activity varied fourfold.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The formation clearance of 3-hydroxyquinidine did not correlate with the outcome of indexes for activities of CYP1A2, CYP2C9, CYP2C19, or CYP2D6 or the urinary excretion of 6beta-hydroxycortisol.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The formation clearance of 3-hydroxyquinidine did not correlate with the outcome of indexes for activities of CYP1A2, CYP2C9, CYP2C19, or CYP2D6 or the urinary excretion of 6beta-hydroxycortisol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The formation clearance of 3-hydroxyquinidine correlated well to point values of 3-hydroxyquinidine to quinidine ratios in plasma and urine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The formation clearance of 3-hydroxyquinidine correlated well to point values of 3-hydroxyquinidine to quinidine ratios in plasma and urine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The formation clearance of 3-hydroxyquinidine after a single oral dose of 200 mg quinidine sulfate may represent a useful index of CYP3A4 activity in vivo.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A fast method using liquid-liquid extraction and HPLC/tandem-mass spectrometry (LC/MS/MS) was developed for the simultaneous detection of 11-Nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid beta-glucuronide (THC-COOH-glucuronide) and 11-Nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in urine samples.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This highly specific method, which combines chromatographic separation and MS/MS analysis, can be used for the confirmation of positive immunoassay results even without hydrolysis of the sample or derivatisation of extracts.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Liquid-liquid extraction was optimised: with ethylacetate/diethylether (1:1, v/v) THC-COOH-glucuronide and THC-COOH could be extracted in one step.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Molecular ions of the glucuronide (MH(+), m/z 521) and THC-COOH (MH(+), m/z 345) were generated using a PE/SCIEX turboionspray source in positive ionisation mode; specific fragmentation was performed in the collision cell of an API 365 triple-quadrupole mass spectrometer and yielded major fragments at m/z 345 (for THC-COOH-glucuronide) and m/z 327 as well as m/z 299 for both cannabinoids.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Chromatographic separation was performed using a reversed-phase C8 column and gradient elution with 0.1% formic acid/1 mM ammonium formate and acetonitrile/0.1% formic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Retention times were 22.2 min for the glucuronide and 26.8 min for THC-COOH.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After enzymatic hydrolysis of urine samples with beta-glucuronidase/arylsulfatase (37 degrees C, 5 h), THC-COOH-glucuronide was no longer detectable by LC/MS/MS in urine samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, the THC-COOH concentration was increased.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
For quantitation of THC-COOH, THC-COOH-D(3) was added to the urine samples as internal standard prior to analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
From the difference of THC-COOH in the native urine and urine after enzymatic hydrolysis, molar concentration ratios of THC-COOH-glucuronide/THC-COOH in urine samples of cannabis users were determined and found to be between 1.3 and 4.5.

$$$$
>  <CLASS>
Parent

>  <TARGET>
From the difference of THC-COOH in the native urine and urine after enzymatic hydrolysis, molar concentration ratios of THC-COOH-glucuronide/THC-COOH in urine samples of cannabis users were determined and found to be between 1.3 and 4.5.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human term placental lipoxygenase-mediated N-demethylation of phenothiazines and insecticides in the presence of linoleic acid.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Human term placental lipoxygenase-mediated N-demethylation of phenothiazines and insecticides in the presence of linoleic acid.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study investigated the hypothesis that human term placental lipoxygenase (HTPLO) and soybean lipoxygenase (SLO) are capable of mediating N-demethylation of selected phenothiazines and insecticides in the presence of linoleic acid (LA).

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study investigated the hypothesis that human term placental lipoxygenase (HTPLO) and soybean lipoxygenase (SLO) are capable of mediating N-demethylation of selected phenothiazines and insecticides in the presence of linoleic acid (LA).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition to being LA dependent, the N-demethylation reaction mediated by HTPLO and SLO was limited by incubation time, pH of the medium, concentration of the enzyme and the substrate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Using Nash reagent to monitor formaldehyde production, the specific activity for LA-dependent N-demethylation of chlorpromazine, a model phenothiazine, was determined to be 1.7+/-0.3 nmoles/min/mg HTPLO.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Using Nash reagent to monitor formaldehyde production, the specific activity for LA-dependent N-demethylation of chlorpromazine, a model phenothiazine, was determined to be 1.7+/-0.3 nmoles/min/mg HTPLO.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Besides chlorpromazine, N-demethylation of promazine, promethazine and trimeprazine was also observed.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The insecticide, aminocarb, displayed a specific activity of 2.2+/-0.3 nmoles/min/mg HTPLO for N-demethylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Other insecticides, namely chlordimeform, dicrotophos and zectran, were oxidized in a similar manner.

$$$$
>  <CLASS>
Parent

>  <TARGET>
As compared with HTPLO, the rates of N-demethylation of phenothiazines and insecticides mediated by SLO were higher.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Classical inhibitors of lipoxygenase, as well as antioxidants and free radical scavengers, caused a dose-dependent reduction in the production of formaldehyde from chlorpromazine and aminocarb by HTPLO.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results clearly demonstrate the ability of polyunsaturated free fatty acids to support N-demethylation of xenobiotics via the lipoxygenase pathway.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography-mass spectrometry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
We report here the development and validation of an LC-MS method for quantitation of loperamide (LOP) and its N-demethyl metabolite (DMLOP) in human plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
O-Acetyl-loperamide (A-LOP) was synthesized by us for use as an internal standard in the assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After addition of the internal standard, the compounds of interest were extracted with methyl tert.-butylether and separated by HPLC on a C18 reversed-phase column using an acetonitrile-water gradient containing 20 mM ammonium acetate.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The three compounds were well separated by HPLC and no interfering peaks were detected at the usual concentrations found in plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Analytes were quantitated using positive electrospray ionization in a triple quadrupole mass spectrometer operating in the MS-MS mode.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Selected reaction monitoring was used to quantify LOP (m/z 477-266), DMLOP (m/z 463-->252) and A-LOP (m/z 519-->266) on ions formed by loss of the 4-(p-chlorophenyl)-4-hydroxy-piperidyl group upon low energy collision-induced dissociation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Calibration curves, which were linear over the range 1.04 to 41.7 pmol/ml (LOP) and 1.55 to 41.9 pmol/ml (DMLOP), were run contemporaneously with each batch of samples, along with low (4.2 pmol/ml), medium (16.7 pmol/ml) and high (33.4 pmol/ml) quality control samples.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The lower limit of quantitation (LLQ) of LOP and DMLOP was about 0.25 pmol/ml in plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The extraction efficiency of LOP and DMLOP from human plasma was 72.3+/-1.50% (range: 70.7-73.7%) and 79.4+/-12.8% (64.9-88.8%), respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The intra- and inter-assay variability of LOP and DMLOP ranged from 2.1 to 14.5% for the low, medium and high quality control samples.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The method has been used successfully to study loperamide pharmacokinetics in adult humans.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Because of the ubiquity of phthalates and their potential role in increasing risk for cancer and reproductive dysfunction, the need for human exposure assessment studies is urgent.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In response to this need, we developed a high-throughput, robust, sensitive, accurate, and precise assay for simultaneous measurement of trace levels of eight phthalate metabolites in human urine by HPLC-MS/MS.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human urine samples were processed using enzymatic deconjugation of the glucuronides followed by solid-phase extraction.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The eluate was concentrated, and the phthalate metabolites were chromatographically resolved by reversed-phase HPLC, detected by APCI-tandem mass spectrometry, and quantified by isotope dilution.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This selective analytical method permits rapid detection (7.7 min total run time) of eight urinary metabolites of the most commonly used phthalates with detection limits in the low nanagram per milliliter range.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Assay precision was improved by incorporating 13C4-labeled internal standards for each of the eight analytes, as well as a conjugated internal standard to monitor deconjugation efficiency.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This selective, sensitive, and rapid method will help elucidate potential associations (if any) between human exposure to phthalates and adverse health effects.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The role of specific cytochrome P450 isoforms in catalysing the oxidative biotransformation of the organophosphorothioate pesticides parathion, chlorpyrifos and diazinon into structures that inhibit cholinesterase has been investigated in human liver microsomes using chemical inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pesticides were incubated with human liver microsomes and production of the anticholinergic oxon metabolite was investigated by the inhibition of human serum cholinesterase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quinidine and ketoconazole at 10 micromol/l inhibited oxidative biotransformation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Compared to control incubations (no inhibitor) where cholinesterase activity was inhibited to between 1 and 4% of control levels, incorporation of the CYP2D6 inhibitor quinidine into the microsomal incubation resulted in cholinesterase activity of 50% for parathion, 38% for diazinon and 30% for chlorpyrifos.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Compared to control incubations (no inhibitor) where cholinesterase activity was inhibited to between 1 and 4% of control levels, incorporation of the CYP2D6 inhibitor quinidine into the microsomal incubation resulted in cholinesterase activity of 50% for parathion, 38% for diazinon and 30% for chlorpyrifos.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Addition of the CYP3A4 inhibitor ketoconazole to microsomal incubations resulted in 66% cholinesterase activity with diazinon, 20% with parathion and 5% with chlorpyrifos.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Addition of the CYP3A4 inhibitor ketoconazole to microsomal incubations resulted in 66% cholinesterase activity with diazinon, 20% with parathion and 5% with chlorpyrifos.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The unexpected finding that CYP2D6, as well as CYP3A4, catalysed oxidative biotransformation was confirmed for chlorpyrifos and parathion using microsomes prepared from a human lymphoblastoid cell line expressing CYP2D6.

$$$$
>  <CLASS>
Parent

>  <TARGET>
While parathion has been investigated only as a model compound, chlorpyrifos and diazinon are both very important, widely used pesticides and CYP2D6 appears to be an important enzyme in their bioactivation pathway.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP2D6 is polymorphic and hence may influence individual susceptibility to exposure to chlorpyrifos and diazinon as well as other structurally similar pesticides.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Irinotecan (CPT-11) is a topoisomerase I inhibitor commonly used in the treatment of colorectal tumors.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
It is a prodrug, converted to an active metabolite, SN-38, by carboxylesterases (CEs).

$$$$
>  <CLASS>
NONE

>  <TARGET>
CEs are ubiquitary enzymes that react with numerous substrates.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A specific CPT-11 converting enzyme was isolated from rat serum, with different kinetic properties than other CEs.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We determined kinetic properties of specific CPT-11 CE activity (CPT-CE) in human normal liver and colon tumors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Km were very similar (3.4 microM in liver and 3.8 microM in colon tumors), but Vmax was higher in liver (2.7 pmol/min/mg protein) than in colon tumor (1.7 pmol/min/mg protein).

$$$$
>  <CLASS>
Parent

>  <TARGET>
CPT-CE and total CE (using p-nitro-phenylacetate as substrate) were weakly correlated in colon tumors.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The large interpatient variability observed in liver CPT-CE activity could play a potential role in the pharmacokinetic variability observed with irinotecan.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary methanol and formic acid as indicators of occupational exposure to methyl formate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To evaluate the validity of methanol (MeOH) and formic acid (FA) in urine as biological indicators of methyl formate (MF) exposure in experimental and field situations.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The subjects were 28 foundrymen and two groups of volunteers (20 control and 20 exposed).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Exposure assessment of the workers was performed by personal air and biological monitoring.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methyl formate vapour collected on charcoal tube was analysed by gas chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The concentration of MF in the exposure chamber (volunteer-study) was monitored by two independent methods [flame ionisation detection (FID) and Fourier transformation infra-red detection (FTIR)].

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Urinary metabolites (MeOH and FA) were analysed separately by headspace gas chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The volunteers exposed to 100 ppm MF vapour at rest for 8 h excreted 3.62 +/- 1.13 mg MeOH/l (mean +/- SD) at the end of the exposure.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This was statistically different (P < 0.001) from pre-exposure MeOH excretion (2.15 +/- 0.80 mg/1), or from that of controls (1.69 +/- 0.48 mg/l).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The urinary FA excretion was 32.2 +/- 11.3 mg/g creatinine after the exposure, which was statistically different (P < 0.001) from pre-exposure excretion (18.0 +/- 9.3 mg/g creatinine) or that of controls (13.8 +/- 7.9 mg/g creatinine).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In foundrymen, the urinary FA excretion after the 8 h workshift exposure to a time weighted average (TWA) concentration of 2 to 156 ppm MF showed a dose-dependent increase best modelled by a polynomial function.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The highest urinary FA concentration was 129 mg/g creatinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pre-shift urinary FA of the foundrymen (18.3 +/- 5.6 mg/g creatinine) did not differ from that of controls (13.8 +/- 7.9 mg/g creatinine).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The urinary MeOH excretion of the foundrymen after the shift, varied from < 1 to 15.4 mg/l, while the correlation with the preceding MF exposure was poor.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The foundrymen excreted more (P = 0.01) FA (2.12 +/- 3.56 mg/g creatinine) after the workshift than experimentally, once-exposed volunteers (0.32 +/- 0.11 mg/g creatinine) at a similar inhaled MF level of 1 ppm).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In spite of its high background level in non-exposed subjects, urinary FA seems to be a useful biomarker of methyl formate exposure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The question remains as to what is the reason for the differences in chronic and acute exposure respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Urinary metabolites of halothane in man.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The urinary metabolites of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) were investigated in five individuals given trace doses (25 muCi), and in three individuals given large doses (1 mCi) of radioactively labeled 14C-halothane.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The latter were donor subjects for heart transplant operations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Separation of the nonvolatile urinary metabolites of halothane was accomplished by chemical extraction, electrophoresis, ion-exchange and high-pressure liquid chromatography, and gas chromatography.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Identification of the individual metabolites was by nuclear magnetic resonance and mass spectrometry.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Three major metabolites were identified: trifluoroacetic acid, N-trifluoroacetyl-2-aminoethanol, and N-acetyl-S-(2-bromo-2-chloro-1,1-difluoroethyl)-L-cysteine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Smaller unidentified radioactive peaks were also found.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The presence of both ethanolamide and cysteine conjugates of halothane is of concern.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The presence of both ethanolamide and cysteine conjugates of halothane is of concern.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These urinary products imply the presence of reactive intermediates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The conjugation of such intermediates to proteins and phospholipids may give rise to the high-molecular-weight covalently bound metabolites demonstrated to be present in the liver following halothane anesthesia.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The conjugation of such intermediates to proteins and phospholipids may give rise to the high-molecular-weight covalently bound metabolites demonstrated to be present in the liver following halothane anesthesia.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Elucidation of the structures of the urinary metabolites provides information important to an understanding of halothane metabolism and its potential hepatotoxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Elucidation of the structures of the urinary metabolites provides information important to an understanding of halothane metabolism and its potential hepatotoxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It has recently been suggested that when adjusting doses of cyclosporine (CsA), determining its concentration in blood samples taken 2 h postdose (C(2)) is more clinically beneficial than using the predose concentration (C(0)).

$$$$
>  <CLASS>
Parent

>  <TARGET>
We determined C(0) and C(2) concentrations of CsA and their metabolites in samples taken from nine kidney and seven liver transplant patients.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Similarly, the so-called metabolic ratios (MR)-metabolites to CsA parent ratios-were calculated to characterise the most suitable moment of blood sampling for obtaining a greater analytical specificity with monoclonal immunoassays.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The determination of CsA and CsA + metabolites was made using the enzyme multiplied immunotechnique and the polyclonal fluorescence polarization immunoassay Abbott TDx, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The poor correlation between C(0) and C(2) of CsA (n = 82, r = 0.387, p < 0.001) is greatly inferior to that obtained between C(0) and C(2) of metabolites (n = 82, r = 0.912, p < 0.001).

$$$$
>  <CLASS>
NONE

>  <TARGET>
A highly significant difference (p < 0.001) was found between MR(0) values (mean 2.87 +/- 0.12, median 2.48) and MR(2) values (mean 1.73 +/- 0.09, median 1.46), although there is a good correlation between them (r = 0.878, p < 0.001).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The extent of the positive bias (deviation) of CsA immunoassays compared with the high-performance liquid chromatography results is related to the MR values.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
As the MR(2) values are significantly lower than the corresponding MR(0), in practice a greater analytical specificity would be obtained with the different monoclonal immunoassays in the determination of the 2 h postdose CsA concentration than in that of trough concentration.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cyclosporine is used in the prevention of allograft rejection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Owing to its narrow therapeutic index, regular monitoring of the whole blood levels of cyclosporine is required.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We observed that immunoassays measured significantly higher cyclosporine levels than did high-performance liquid chromatography (HPLC) over time after transplantation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
As cyclosporine metabolites cross-react even with immunoassays, this observation might be due to alterations of the cyclosporine metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We analyzed cyclosporine metabolite concentrations in the early and in the late posttransplantation periods in 127 patients after kidney, bone marrow, heart-lung, and liver transplantation by HPLC and determined whole blood levels of cyclosporine by 4 immunoassays (enzyme-multiplied immunoassay [EMIT], cloned enzyme donor immunoassay [CEDIA], AxSYM [Abbott Laboratories, Chicago, IL], and TDx [Abbott Laboratories]).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Despite reduced dose, we found significantly higher cyclosporine concentrations measured by the EMIT, AxSYM, and TDx assays in various patient groups.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These results are due to the increased metabolite/cyclosporine ratio in the late posttransplantation period.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In particular, the metabolites AM1 and AM19 increased significantly over time in bone marrow transplant recipients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Therefore, cyclosporine levels measured by immunoassays should be interpreted with caution.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Perazine (PER) is a phenothiazine antipsychotic drug frequently used in Germany that undergoes extensive metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Perazine (PER) is a phenothiazine antipsychotic drug frequently used in Germany that undergoes extensive metabolism.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To anticipate metabolic drug interactions and to explore the relevance of polymorphisms of metabolic enzymes, perazine-N-demethylation and perazine-N-oxidation were investigated in vitro using human liver microsomes and cDNA expressed enzymes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP3A4 and CYP2C9 were identified as the major enzymes mediating PER-N-demethylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
At 10 microM PER, a concentration consistent with anticipated in vivo liver concentrations, CYP3A4 and CYP2C9 contributed 50% and 35%, respectively, to PER-N-demethylation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
With increasing PER concentrations, contribution of CYP2C9 decreased and CYP3A4 became more important.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In human liver microsomes, PER-N-demethylation was inhibited by ketoconazole (>40%) and sulfaphenazole (16%).

$$$$
>  <CLASS>
Parent

>  <TARGET>
In human liver microsomes, PER-N-demethylation was inhibited by ketoconazole (>40%) and sulfaphenazole (16%).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Allelic variants of recombinant CYP2C9 showed differences in PER-N-demethylase activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The wild type allele CYP2C9*1 was the most active variant.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Maximal activities of CYP2C9*2 and CYP2C9*3 were 88% and 18%, respectively, compared to the wild type activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Perazine-N-oxidation was mainly mediated by FMO3.

$$$$
>  <CLASS>
Parent

>  <TARGET>
In the absence of NADPH, heat treatment of microsomes abolished PER-N-oxidase activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Methimazole inhibited PER-N-oxidation, while CYP specific inhibitors had no inhibitory effect.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Methimazole inhibited PER-N-oxidation, while CYP specific inhibitors had no inhibitory effect.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Perazine is a potent inhibitor of dextromethorphan-O-demethylase, S-mephenytoin-hydroxylase, alprazolam-4-hydroxylase, phenacetin-O-deethylase and tolbutamide-hydroxylase activity in human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Perazine is a potent inhibitor of dextromethorphan-O-demethylase, S-mephenytoin-hydroxylase, alprazolam-4-hydroxylase, phenacetin-O-deethylase and tolbutamide-hydroxylase activity in human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Alterations in the activity of CYP3A4, CYP2C9 and FMO3 through genetic polymorphisms, enzyme induction or inhibition bear the potential to cause clinically significant changes in perazine clearance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PER may alter the clearance of coadministered compounds metabolized by CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cyclophosphamide given in association with corticosteroids has markedly improved the prognosis of systemic vasculitis.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Little information has been reported on cyclophosphamide pharmacokinetics in these diseases and data evaluating its metabolite, 4-hydroxycyclophosphamide/aldophosphamide, pharmacokinetics and concentrations are lacking.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cyclophosphamide was administered as a 1-h intravenous infusion every 3 weeks for six cycles to ten vasculitis patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serum cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide concentrations were assayed on the first cycle of the treatment by reversed-phase high-pressure liquid chromatography with ultraviolet detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean (+/- SD) 4-hydroxycyclophosphamide/aldophosphamide and cyclophosphamide areas under the serum concentration-time curves were, respectively, 1.86 +/- 1.12 and 154.1 +/- 62.7 mg/L x h with a ratio of 1.30 +/- 0.76%.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The mean maximum serum 4-hydroxycyclophosphamide/aldophosphamide was reached 2.3 h after cyclophosphamide administration.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean (+/- SD) cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide half-lives were, respectively, 5.5 +/- 3.1 and 7.6 +/- 2.3 h. 

$$$$
>  <CLASS>
NONE

>  <TARGET>
The results are consistent with those obtained for cancer patients, in spite of a wide interpatient variability of concentrations and pharmacokinetic parameters.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Distinct Effect of Benzalkonium Chloride on the Esterase and Aryl Acylamidase Activities of Butyrylcholinesterase.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) from vertebrates, other than their predominant acylcholine hydrolase (esterase) activity, display a genuine aryl acylamidase activity (AAA) capable of hydrolyzing the synthetic substrate o-nitroacetanilide to o-nitroaniline.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This AAA activity is strongly inhibited by classical cholinesterase (ChE) inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the present study, benzalkonium chloride (BAC), a cationic detergent widely used as a preservative in pharmaceutical preparations, has been shown to distinctly modulate the esterase and AAA activities of BChEs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The detergent BAC was able to inhibit the esterase activity of human serum and horse serum BChEs and AChEs from electric eel and human erythrocyte.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The remarkable property of BAC was its ability to profoundly activate the AAA activity of human serum and horse serum BChEs but not the AAA activity of AChEs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus BAC seem to preferentially activate the AAA activity of BChEs alone.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Results of the study using the ChE active site-specific inhibitor diisopropyl phosphorofluoridate indicated that BAC binds to the active site of ChEs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, studies using a structural homolog of BAC indicated that the alkyl group of BAC is essential not only for its interaction with ChEs but also for its distinct effect on the esterase and AAA activities of BChEs.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This is the first report of a compound that inhibits the esterase activity, while simultaneously activating the AAA activity, of BChEs.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Saliva and sweat have been presented as two alternative matrices for the establishment of drug abuse.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The noninvasive collection of a saliva or sweat sample, which is relatively easy to perform and can be achieved under close supervision, is one of the most important benefits in a driving-under-the-influence situation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Moreover, the presence of certain analytes in saliva is a better indication of recent use than when the drug is detected in urine, so there is a higher probability that the subject is experiencing pharmacological effects at the time of sampling.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We developed an original procedure using gas chromatography-mass spectrometry to test for delta9-tetrahydrocannabinol (THC), the psychoactive ingredient of cannabis, in oral fluid and forehead wipes, collected with Sarstedt Salivettes and cosmetic pads, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood, urine, oral fluid, and forehead wipes were simultaneously collected from 198 injured drivers admitted to an Emergency Hospital in Strasbourg, France.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Of the 22 subjects positive for 11-nor-9-carboxy-THC (THCCOOH) in urine, 14 and 16 were positive for THC in oral fluid (1 to 103 ng/Salivette) and forehead wipe (4 to 152 ng/pad), respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
11-Hydroxy-THC and THCCOOH were not detected in these body fluids.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Two main limitations of saliva and sweat are apparent: the amount of matrix collected is smaller when compared to urine, and the levels of drugs are higher in urine than in saliva and sweat.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A current limitation in the use of these specimens for roadside testing is the absence of a suitable immunoassay that detects the parent compound in sufficiently low concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Loxapine intoxication: case report and literature review.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Loxapine is a dibenzoxazepine tricyclic compound used to treat schizophrenia in the United States since 1976.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Metabolism includes demethylation to its primary metabolite, amoxapine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There are few documented reports of the disposition of loxapine in deaths due to overdose.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This report discusses the overdose suicide of a 69-year-old white female found dead in her home by her husband.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A prescription for loxapine (50-mg capsules) was found near the body.

$$$$
>  <CLASS>
NONE

>  <TARGET>
An autopsy was performed and heart blood, bile, vitreous humor, and gastric contents were submitted for toxicological analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The blood specimen was subjected to comprehensive testing that included volatile analysis by headspace gas chromatography (GC); acidic/neutral and basic drug screening by GC; benzodiazepine screening by high-performance liquid chromatography; opiate screening by modified immunoassay; and acetaminophen, salicylate, and ethchlorvynol screening by colorimetry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Loxapine and amoxapine were detected in the basic drug screen.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No other drugs were detected in the case specimens.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The respective concentrations of loxapine and amoxapine in each specimen were as follows: heart blood, 9.5 and 0.6 mg/L; bile, 28.8 and 4.7 mg/L; gastric, 278 mg/L and negative; and vitreous, 1.5 mg/L and negative.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A review of the literature showed that the heart blood concentration of loxapine measured in this case was the highest reported to date.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on the autopsy findings, patient history, and toxicology results, the cause of death was determined to be acute intoxication of loxapine and the manner, suicide.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A simple and selective assay for the determination of the alkylating cyclophosphamide metabolite phosphoramide mustard (PM) in plasma was developed and validated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
PM was determined after derivatisation by high-performance liquid chromatography (HPLC) with ultraviolet detection at 276 nm.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sample pre-treatment consisted of derivatisation of PM with diethyldithiocarbamate (DDTC) at 70 degrees C for 10 min, followed by extraction with acetonitrile in the presence of 0.7 M sodium chloride.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Phase separation occurred due to the high salt content of the aqueous phase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The HPLC system consisted of a C8 column with acetonitrile-0.025 M potassium phosphate buffer, pH 8.0, (32:68, v/v) as the mobile phase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The entire sample handling procedure, from collection at the clinical ward until analysis in the laboratory, was optimised and validated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Calibration curves were linear from 50 to 10,000 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The lower limit of quantification and the limit of detection (using a signal-to-noise ratio of 3) were 50 and 40 ng/ml, respectively, using 500 microl of plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Within-day and between-day precisions were below 11% over the entire concentration range and the accuracies were between 100 and 106%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PM was found to be stable at -30 degrees C for at least 10 weeks both in plasma and as a DDTC-derivative in a dry sample.

$$$$
>  <CLASS>
Parent

>  <TARGET>
PM was found to be stable at -30 degrees C for at least 10 weeks both in plasma and as a DDTC-derivative in a dry sample.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A pharmacokinetic pilot study in two patients receiving 1,000 mg/m2 CP in a 1-h infusion demonstrated the applicability of the assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of terbutaline enantiomers in human plasma by coupled achiral-chiral high performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Achiral-chiral column switching HPLC assay was developed to allow the separation and quantification of the enantiomers of terbutaline in human plasma by means of fluorescence detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Plasma samples were prepared by solid-phase extraction with sep-pak silica, followed by HPLC assay.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The enantiomers of terbutaline and the internal standard were separated from the biological matrix on a silica column, and the two enantiomers were resolved and quantified on a Sumichiral OA-4900 column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The two columns were connected by a switching valve equipped with silica trap column.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The trap column was used to concentrate the terbutaline in the eluent from the achiral column before back flushing onto the chiral phase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For each enantiomers, the assay was linear between 2.5-125 ng/ml (r=0.9999) and detection limit was 1.0 ng/ml.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The aim of the study was to investigate the pharmacokinetics and metabolism of the new immunosuppressant SDZ RAD during concomitant therapy with cyclosporin in stable renal transplant patients.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The aim of the study was to investigate the pharmacokinetics and metabolism of the new immunosuppressant SDZ RAD during concomitant therapy with cyclosporin in stable renal transplant patients.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, we studied the influence of SDZ RAD on the pharmacokinetics of cyclosporin at steady state levels.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Furthermore, we studied the influence of SDZ RAD on the pharmacokinetics of cyclosporin at steady state levels.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
SDZ RAD was administered orally in different doses (0.25-15 mg day-1) to seven patients, who were on standard cyclosporin-based immunosuppression.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The blood concentrations of both drugs including their main groups of metabolites were measured simultaneously by LC/electrospray-mass spectrometry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
On both study days Cmax, and tmax of cyclosporin were not significantly different.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The metabolite pattern of cyclosporin did not change.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h. 

$$$$
>  <CLASS>
Parent and its metabolite;

>  <TARGET>
The metabolites of SDZ RAD found in blood were hydroxy-SDZ RAD, dihydroxy-SDZ RAD, demethyl-SDZ RAD, and a ring-opened form of SDZ RAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A single dose of SDZ RAD did not influence significantly the pharmacokinetics of cyclosporin.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The most important metabolite of SDZ RAD was the hydroxy-SDZ RAD, its AUC(0,24 h) being nearly half that of the parent compound SDZ RAD.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Probing the binding pocket of the active site of aromatase with 6-ether or 6-ester substituted androst-4-ene-3,17-diones and their diene and triene analogs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A series of 6-ester- (3 and 4) and 6-ether- (7 and 8) substituted androst-4-ene-3,17-diones (androstenediones) and their 1,4-diene analogs (5 and 6, and 9 and 10) as well as C6-substituted 4,6-diene and 1,4,6-triene steroids 11 and 12 were synthesized as aromatase inhibitors to gain insight into the structure-activity relationship between various substituents and inhibitory activity.

$$$$
>  <CLASS>
NONE

>  <TARGET>
All of the inhibitors synthesized blocked aromatase in a competitive manner.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The inhibitory activities of all of the steroids, except for the 6beta-benzoates 4g and 6h and the 6beta-acetate 6a, were fairly effective to very powerful (K(i): 7.0-320 nM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The 6alpha-n-hexanoyloxy- and 6alpha-benzyloxyandrostenediones (3e and 7e) were the most potent inhibitors (K(i): 7.0 nM each).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the series of 4-ene and 1,4-diene steroids, the 6alpha-substituted steroids had higher affinity for the enzyme than the corresponding 6beta-isomers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In the 1,4-diene steroid series, 6beta-substituted steroids 6a, e, g, and 10a, b, e caused a time-dependent inactivation of aromatase, whereas their 6alpha-isomers 5 and 9 essentially did not.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The ether-substituted 1,4,6-trienes 12 inactivated the enzyme in a time-dependent manner; in contrast, their 4,6-diene analogs 11 did not.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The substrate androstenedione blocked the inactivation, but no significant effect of L-cysteine was observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Based on molecular modeling with the PM3 method, along with the present inhibition and inactivation results, it is thought that both the steric effects of the 6-substituents as well as the electronic effects of the C-6 oxygen functions play a critical role in the binding of inhibitors to the active site of aromatase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Air and biological monitoring of solvent exposure during graffiti removal.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The principal aim of the study was to estimate the level of exposure to organic solvents of graffiti removers, and to identify the chemicals used in different cleaning agents.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A secondary objective was to inform about the toxicity of various products and to optimise working procedures.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Exposure to organic solvents was determined by active air sampling and biological monitoring among 38 graffiti removers during an 8-h work shift in the Stockholm underground system.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The air samples and biological samples were analysed by gas chromatography.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Exposure to organic solvents was also assessed by a questionnaire and interviews.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Solvents identified were N-methylpyrrolidone (NMP), dipropylene glycol monomethyl ether (DPGME), propylene glycol monomethyl ether (PGME), diethylene glycol monoethyl ether (DEGEE), toluene, xylene, pseudocumene, hemimellitine, mesitylene, ethylbenzene, limonene, nonane, decane, undecane, hexandecane and gamma-butyrolactone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The 8-h average exposures [time-weighted average (TWA)] were below 20% of the Swedish permissible exposure limit value (PEL) for all solvents identified.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In poorly ventilated spaces, e.g .in elevators etc., the short-term exposures exceeded occasionally the Swedish short-term exposure limit values (STEL).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The blood and urine concentrations of NMP and its metabolites were low.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Glycol ethers and their metabolites (2-methoxypropionic acid (MPA), ethoxy acetic acid (EAA), butoxy acetic acid (BAA), and 2-(2-methoxyethoxy) acetic acid (MEAA)) were found in low concentrations in urine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
There were significant correlation between the concentrations of NMP in air and levels of NMP and its metabolites in blood and urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The use of personal protective equipment, i.e. gloves and respirators, was generally high.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Many different cleaning agents were used.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The average exposure to solvents was low, but some working tasks included relatively high short-term exposure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
To prevent adverse health effects, it is important to inform workers about the health risks and to restrict the use of the most toxic chemicals.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Furthermore, it is important to develop good working procedures and to encourage the use of personal protection equipment.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The objective of this study was to determine the concentrations of enoxacin and its oxo-metabolite in human prostatic tissue after multiple oral doses (400 mg bd) in 13 patients.

$$$$
>  <CLASS>
Parent

>  <TARGET>
On the first day of treatment, elimination half-lives were 6.8 h for enoxacin and 7.1 h for its metabolite; they were increased on day 4 (10.3 and 13.2 h, respectively).

$$$$
>  <CLASS>
Parent

>  <TARGET>
The ratios of drug concentration in prostatic tissue and plasma averaged 2.2 for enoxacin and 1.4 for its metabolite.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In conclusion, concentrations of enoxacin achieved within the prostatic tissue were higher than plasma concentrations suggesting that there was an active transport mechanism.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We investigated the role of phase II (conjugation) and phase III (efflux) detoxification of the anticancer drugs melphalan (MLP) and chlorambucil (CHB).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Although both drugs are substrates of Alpha-class glutathione S-transferases (GST) and the monoglutathionyl conjugates formed in these enzymatic reactions are transported by MRP1, we found that GSTA1-1 and MRP1 acted in synergy to confer resistance to CHB but not to MLP (Morrow, C. S., Smitherman, P. K., Diah, S. K., Schneider, E., and Townsend, A. J. (1998) J. Biol. Chem. 273, 20114-20120).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Although both drugs are substrates of Alpha-class glutathione S-transferases (GST) and the monoglutathionyl conjugates formed in these enzymatic reactions are transported by MRP1, we found that GSTA1-1 and MRP1 acted in synergy to confer resistance to CHB but not to MLP (Morrow, C. S., Smitherman, P. K., Diah, S. K., Schneider, E., and Townsend, A. J. (1998) J. Biol. Chem. 273, 20114-20120).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
To explain this selectivity of MRP1/GST-mediated resistance, we report results of side-by-side experiments comparing the kinetics of MLP- versus CHB-glutathione conjugate: formation, product inhibition of GSTA1-1 catalysis, and transport by MRP1.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The monoglutathionyl conjugate of CHB, CHB-SG, is a very strong competitive inhibitor of GSTA1-1 (K(i) 0.14 microM) that is >30-fold more potent than that of the corresponding conjugate of MLP, MLP-SG (K(i) 4.7 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The monoglutathionyl conjugate of CHB, CHB-SG, is a very strong competitive inhibitor of GSTA1-1 (K(i) 0.14 microM) that is >30-fold more potent than that of the corresponding conjugate of MLP, MLP-SG (K(i) 4.7 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The efficiency of GSTA1-1-mediated monoglutathionyl conjugate formation is more than 4-fold higher for CHB than MLP.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The efficiency of GSTA1-1-mediated monoglutathionyl conjugate formation is more than 4-fold higher for CHB than MLP.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Lastly, both CHB-SG and MLP-SG are efficiently transported by MRP1 with similar V(max) although the K(m) for CHB-SG (0.37 microm) is significantly lower than for MLP-SG (1.1 microM).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
These results indicate that MRP1 is required for GSTA1-1-mediated resistance to CHB in order to relieve potent product inhibition of the enzyme by intracellular CHB-SG formed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The kinetic properties of MRP1 are well suited to eliminate CHB-SG at pharmacologically relevant concentrations.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
For MLP detoxification, where product inhibition of GSTA1-1 is less important, GSTA1-1 does not confer resistance because of the relatively poorer catalytic efficiency of MLP-SG formation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Similar analyses can be useful for predicting the pharmacological and toxicological consequences of MRP and GST expression on cellular sensitivity to various other electrophilic xenobiotics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The effect of diflunisal on the elimination of triamterene in human volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A major metabolic pathway for triamterene (a potassium sparing diuretic) is aromatic hydroxylation followed by sulphate conjugation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
A major metabolic pathway for triamterene (a potassium sparing diuretic) is aromatic hydroxylation followed by sulphate conjugation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Diflunisal (a salicylate anti-inflammatory agent) also undergoes sulphate conjugation of its phenolic group as a major pathway.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Diflunisal (a salicylate anti-inflammatory agent) also undergoes sulphate conjugation of its phenolic group as a major pathway.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We investigated the possible effect of diflunisal on the elimination of triamterene (competition for phenolic sulphonation) in six healthy volunteers by studying the disposition of single doses of triamterene (100 mg) taken alone and in the presence of steady-state levels of diflunisal.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We investigated the possible effect of diflunisal on the elimination of triamterene (competition for phenolic sulphonation) in six healthy volunteers by studying the disposition of single doses of triamterene (100 mg) taken alone and in the presence of steady-state levels of diflunisal.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Diflunisal coadministration (500 mg b.i.d.) had no effect on the pharmacokinetics of triamterene itself.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, plasma AUC of p-hydroxytriamterene sulphate was greater (4.6 times), and its renal clearance lower (0.24 times), in the presence of diflunisal.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was no change in the formation clearance or protein binding of p-hydroxytriamterene sulphate in the presence of diflunisal.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The data point to competition for renal excretory pathways rather than sulphonation capacity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This interaction could have clinical relevance since p-hydroxytriamterene sulphate is pharmacologically active.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Blood concentrations of tetracaine and its metabolite following spinal anesthesia.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Blood concentrations of tetracaine and its metabolite, p-butylaminobenzoic acid, were measured after spinal anesthesia with tetracaine which had been administered to patients under going orthopedic surgery.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Tetracaine, an ester anesthetic, was given to 10 patients, the dose was 8-14mg, and blood samples were collected 1, 2 and 6h after the injection of tetracaine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
We used gas chromatography/mass spectrometry for purposes of analysis.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Tetracaine was not detected in any blood sample, but the metabolite was detected in each sample with the mean concentrations of 126.5, 97.9 and 43.3ng/ml at 1, 2 and 6h, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This data will be useful in determination of the cause of death after spinal anesthesia with tetracaine.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Conjugation position of quercetin glucuronides and effect on biological activity.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Quercetin glycosides are common dietary antioxidants.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In general, however, potential biological effects of the circulating plasma metabolites (e.g., glucuronide conjugates) have not been measured.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
We have determined the rate of glucuronidation of quercetin at each position on the polyphenol ring by human liver cell-free extracts containing UDP-glucuronosyltransferases.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We have determined the rate of glucuronidation of quercetin at each position on the polyphenol ring by human liver cell-free extracts containing UDP-glucuronosyltransferases.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The apparent affinity of UDP-glucuronosyltransferase followed the order 4'- > 3'- > 7- > 3, although the apparent maximum rate of formation was for the 7-position.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The 5-position did not appear to be a site for conjugation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After isolation of individual glucuronides, the inhibition of xanthine oxidase and lipoxygenase were assessed.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
The K(i) for the inhibition of xanthine oxidase by quercetin glucuronides followed the order 4'- > 3'- > 7- > 3-, with quercetin-4'-glucuronide a particularly potent inhibitor (K(i) = 0.

$$$$
>  <CLASS>
NONE

>  <TARGET>
25 microM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The glucuronides, with the exception of quercetin-3-glucuronide, were also inhibitors of lipoxygenase.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Quercetin glucuronides are metabolites of quercetin in humans, and these compounds can retain some biological activity depending on conjugation position at expected plasma concentrations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Because metabolites play a major role in the clinical response to clomipramine, the objective of the current study was to develop a population model and evaluate its performance to describe the pharmacokinetic profiles of clomipramine (C) and its active metabolites desmethylclomipramine (DC), 8-hydroxy-clomipramine (OHC) and 8-hydroxy-desmethylclomipramine (OHDC).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A first sample of 14 patients served for development of a 2-molecule C and DC model, which was shown to provide reasonable estimates of AUC-based clearances, as well as precise estimation of interindividual variability.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simulated data, generated to mimic a semi-rich sampling design and chronic treatment with clomipramine, indicated that clearance estimation was feasible under routine treatment conditions.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A second sample of 30 patients, recruited prospectively and followed for a median 4-week period, was used to extend the 2-molecule model to a 4-molecule model.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Goodness-of-fit assessment revealed that model-predicted concentrations were reasonably close to observed concentrations for a majority of patients.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Interindividual variability was 50% to 60% for hydroxylation and desmethylation clearances, and residual variability was 30%.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The proposed model incorporates much of what is known about the metabolism of clomipramine and may valuably integrate the influence of genetic and environmental factors on each metabolic pathway.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A high-performance liquid chromatographic assay has been developed for the simultaneous quantitation of flurbiprofen and its major metabolite, 4'-hydroxyflurbiprofen, in urine and plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
No extraction procedure was necessary for analysis of these compounds, which reduced time involved in sample preparation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The analytes were separated on a Brownlee Spheri-5 C18 column with a mobile phase of acetonitrile-20 mM dibasic potassium phosphate pH 3 buffer (40:60, v/v).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Fluorescence detection was utilized with an excitation wavelength of 260 nm and an emission wavelength of 320 nm, providing excellent sensitivity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The limit of quantitation for 4'-hydroxyflurbiprofen and flurbiprofen was 0.25 microg/ml in urine and 0.05 microg/ml and 0.25 microg/ml, respectively, in plasma.

$$$$
>  <CLASS>
NONE

>  <TARGET>
All components were eluted within 16 min.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Intra-day, inter-day, freeze-thaw, and in process stability were tested for both compounds and the coefficient of variation was less than 14% in all cases.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
This method provides a sensitive and specific assay for the detection of flurbiprofen and 4'-hydoxyflurbiprofen in urine and plasma and is suitable for use in in vivo studies evaluating the regulation of CYP2C9 activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A novel fast HPLC method was developed for the determination of cyclosporine A (CyA) and its two metabolites M17 (AM1) and M21 (AM4N) in blood.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Whole blood was precipitated with zinc sulphate, extracted with diethyl ether, evaporated, dissolved in aqueous methanol and partitioned twice with n-hexane.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Chromatography was carried out using a microbore RP-column under isocratic elution with acetonitrile-methanol-water (200:80:140, v/v/v) at 70 degrees C and a detector set at 205 nm.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Linearity for all three compounds was tested in the range of 1-1000 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Recovery was 97-109%, and a coefficient of variation was 1.6-8.8% depending on the particular compound and its concentration.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The method was used for a group of renal transplant patients having an inadequate response to CyA therapy in order to evaluate the possible role of CyA and its metabolites on the occurrence of hypertension and other toxicological events.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The effects of repeated treatment cycles and different doses on intraindividual variation in oral bioavailability of chlorambucil and its first, active, and more toxic metabolite, phenylacetic acid mustard, were studied.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Chlorambucil and phenylacetic acid mustard concentrations were measured with HPLC on Day 1 and on Day 4 in 15 timed blood samples from 11 chronic lymphocytic leukaemia patients receiving chlorambucil therapy cycles.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Bioavailability was evaluated also after the first chlorambucil doses of six consecutive treatment cycles repeated every 4 weeks with increasing chlorambucil doses starting with 0.8 mg/kg/4 days, and increased by 0.1 mg/kg/4 days cycle.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Area under the concentration-time-curve (AUC) from t=0 to infinite was in average 3.2 hr* microg/ml for the first cycle, and decreased by 17% in four days (P<0.05).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The mean distribution half-life of chlorambucil was 0.49 hr and the terminal elimination half-life 2.45 hr.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The bioavailability of chlorambucil decreased further when 4-day treatment cycles were repeated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For the fifth cycle, dose-corrected AUC for the first 2 hr was 33% smaller than that for the first cycle (P for trend <0.01).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Data suggest accelerated metabolism and elimination of chlorambucil and phenylacetic acid mustard, but reduced oral bioavailability of chlorambucil cannot be excluded.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, except for AUC, none of the pharmacokinetic parameters of chlorambucil changed significantly during the first 4-day treatment period.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The maximal plasma concentration and AUC of phenylacetic acid mustard did not change significantly during repeated treatment cycles.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
According to this trial a dose adjustment of chlorambucil is not necessary during a short-term course, but may be necessary when treatment cycles are repeated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
An average increase in the chlorambucil dose of 10% per cycle maintains similar plasma concentration of chlorambucil.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We studied the biotransformation of haloperidol, bromperidol and their reduced forms by human liver microsomes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nifedipine oxidation (CYP3A) activity correlated significantly with N-dealkylation rates of haloperidol and bromperidol and oxidation rates of their reduced forms, while neither ethoxyresorufin O-deethylation (CYP1A2) activity nor dextromethorphan O-deethylation (CYP2D6) activity did.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In chemical and immunoinhibition studies, only troleandomycin and anti-CYP3A4 serum inhibited both formation rates of 4-fluorobenzoylpropionic acid, a metabolite of haloperidol and bromperidol, and back oxidation rates.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In chemical and immunoinhibition studies, only troleandomycin and anti-CYP3A4 serum inhibited both formation rates of 4-fluorobenzoylpropionic acid, a metabolite of haloperidol and bromperidol, and back oxidation rates.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Among 10 recombinant isoforms examined, only CYP3A4 showed catalytic activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The Vmax and Km values of N-dealkylation of bromperidol and reoxidation of reduced bromperidol were similar to those of haloperidol and reduced haloperidol, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The present study indicates that CYP3A plays a major role in N-dealkylation of and oxidation back to bromperidol as well as haloperidol and suggests that modification of in vivo CYP3A activity by inhibition or induction may affect the pharmacokinetics and therapeutic effects of haloperidol and bromperidol.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The compounds WHI-05 (5-bromo-6-methoxy-5, 6-dihydro-3'-azidothymidine-5'-[p-methoxyphenyl] methoxyalaninyl phosphate) and WHI-07 (5-bromo-6-methoxy-5, 6-dihydro-3'-azidothymidine-5'-[p-bromophenyl] methoxyalaninyl phosphate) are aryl phosphate derivatives of zidovudine (ZDV) with dual-function anti-human immunodeficiency virus and contraceptive activity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The compounds WHI-05 (5-bromo-6-methoxy-5, 6-dihydro-3'-azidothymidine-5'-[p-methoxyphenyl] methoxyalaninyl phosphate) and WHI-07 (5-bromo-6-methoxy-5, 6-dihydro-3'-azidothymidine-5'-[p-bromophenyl] methoxyalaninyl phosphate) are aryl phosphate derivatives of zidovudine (ZDV) with dual-function anti-human immunodeficiency virus and contraceptive activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These drugs were rationally designed to bypass the thymidine kinase (TK) dependency of ZDV activation as well as to achieve spermicidal activity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
We investigated the TK activity and intracellular metabolism of WHI-05 and WHI-07 in normal human vaginal and cervical epithelial cells as well as sperm.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The time- and concentration-dependent intracellular formation of ZDV metabolites following addition of WHI-05 and WHI-07 to normal human vaginal, ectocervical, and endocervical epithelial cells as well as motile sperm was studied by analytical HPLC.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Thymidine kinase activity in these cells was determined by the flow cytometric method based on intracellular phosphorylation of the fluorescent nucleoside, 5-amino-2-deoxyuridine-dansyl chloride and by the ability of cell-free extracts to convert [(3)H]thymidine to thymidine monophosphate in comparison to NALM-6, a pre-B leukemia cell line.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Thymidine kinase activity in these cells was determined by the flow cytometric method based on intracellular phosphorylation of the fluorescent nucleoside, 5-amino-2-deoxyuridine-dansyl chloride and by the ability of cell-free extracts to convert [(3)H]thymidine to thymidine monophosphate in comparison to NALM-6, a pre-B leukemia cell line.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thymidine kinase activity in these cells was determined by the flow cytometric method based on intracellular phosphorylation of the fluorescent nucleoside, 5-amino-2-deoxyuridine-dansyl chloride and by the ability of cell-free extracts to convert [(3)H]thymidine to thymidine monophosphate in comparison to NALM-6, a pre-B leukemia cell line.

$$$$
>  <CLASS>
NONE

>  <TARGET>
TK activity of genital tract epithelial cells and sperm was found to be relatively low or lacking.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Addition of WHI-05 and WHI-07 to vaginal and cervical epithelial cells resulted in their concentration- and time-dependent conversion to alaninyl ZDV monophosphate (Ala-ZDV-MP) and 5'-ZDV monophosphate as the major metabolites.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Studies using motile human sperm also demonstrated the conversion of WHI-05 and WHI-07 to Ala-ZDV-MP.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
These results demonstrate that human female genital tract epithelial cells and sperm efficiently convert WHI-05 and WHI-07 to bioactive ZDV metabolites despite their TK deficiency.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved.

$$$$
>  <CLASS>
Parent

>  <TARGET>
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction.

$$$$
>  <CLASS>
Parent

>  <TARGET>
CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
HLM-mediated N-dealkylation of perphenazine accounted for 57% of the total amount of substrate consumed during incubation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The present in vitro study suggests that CYP isoforms 1A2, 3A4, 2C19 and 2CD6 are primarily involved in the N-dealkylation of perphenazine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The relatively modest role of CYP2D6 is at variance with in vivo studies, which indicate a greater contribution of this isoform.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Alternative metabolic pathways, corresponding to 43% of the HLM-mediated metabolism of the drug, may depend more strongly on CYP2D6.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quercetin is a flavonoid with a wide range of biological activities.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It mainly occurs in plants as glycosides, such as rutin (quercetin rutinoside) in tea.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Quercetin and rutin are used in many countries as vasoprotectants and are ingredients of numerous multivitamin preparations and herbal remedies.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The primary objective was to characterise and compare the absorption and the pharmacokinetics of quercetin from quercetin aglycone and rutin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A secondary objective was to investigate which forms of quercetin are present in plasma.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this double blind, diet-controlled, two-period cross-over study, 16 healthy volunteers received three different doses of quercetin and rutin orally.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The doses corresponded to 8 mg, 20 mg and 50 mg quercetin aglycone.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Blood samples were obtained between 0 h and 32 h post-dose.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The overall kinetic behaviour of quercetin differed remarkably after ingestion of quercetin aglycone or rutin.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mean area under the plasma concentration-time curve from 0 h to 32 h [AUC(0-32)] and maximum plasma concentration (Cmax) values of the two treatments were similar.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, time to reach Cmax (tmax) was significantly shorter after the quercetin aglycone treatment than after the rutin treatment (1.9, 2.7 and 4.8 versus 6.5, 7.4 and 7.5 h, for doses 1, 2 and 3, respectively).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Also, the absorption of quercetin from quercetin aglycone was predictable and inter-individual variation was small.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In contrast, after ingestion of rutin, inter-individual variations in AUC(0-32) and Cmax values were considerable and seemed to be associated with gender and use of oral contraceptives.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Quercetin and rutin were found in plasma as glucuronides and/or sulfates of quercetin and as unconjugated quercetin aglycone, but no rutin was detected.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In clinical trials, studying the effects of quercetin from rutin, bioavailability must be taken into consideration and plasma quercetin concentrations monitored.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Whether our results apply to other glycosidic drugs as well, especially other rutosides, should be investigated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).

$$$$
>  <CLASS>
NONE

>  <TARGET>
Twenty-four healthy male subjects were randomized to one of two cohorts.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rifabutin did not significantly affect amprenavir's pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir decreased the results of the ERMBT by 83%.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir plus rifampin was well tolerated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and carboplatin (265-400 mg x m(-2) x day(-1)) for 4 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and carboplatin (265-400 mg x m(-2) x day(-1)) for 4 days.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
ThioTEPA and TEPA kinetic data were processed with a two-compartment model using the nonlinear mixed effect modelling program NONMEM.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Interindividual variability (IIV), interoccasion variability (IOV) and residual variability in the pharmacokinetics were estimated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The influence of patient characteristics on the pharmacokinetics was also determined.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A total number of 40 patients receiving 65 courses of chemotherapy was included.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Clearance of thioTEPA (CL) was 34 l x h(-1) with an IIV and IOV of 18 and 11%, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The volume of distribution of thioTEPA was 47 l (IIV = 7.5%; IOV = 19%).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The fraction of thioTEPA converted to TEPA divided by the volume of distribution of TEPA was 0.030 l-1 (IIV = 39%; IOV = 32%) and the elimination rate constant of TEPA was 0.64 h(-1) (IIV = 27%; IOV = 32%).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CL of thioTEPA was correlated with alkaline phosphatase and serum albumin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The volume of distribution of thioTEPA and the elimination rate constant of TEPA were correlated with total protein levels and body weight, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A model for the description of the pharmacokinetics of thioTEPA and TEPA was developed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Factors involved in the interpatient variability of thioTEPA and TEPA pharmacokinetics were identified.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Since, IOV of both thioTEPA and TEPA was equal to or smaller than IIV, therapeutic drug monitoring based on data of previous courses may be meaningful using this population model.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Metabolism of ochratoxin A: absence of formation of genotoxic derivatives by human and rat enzymes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ochratoxin A (OTA) is a potent renal carcinogen in male rats, although its mode of carcinogenicity is not known.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The metabolism and covalent binding of OTA to DNA were investigated in vitro with cytochromes P450, glutathione S-transferases, prostaglandin H-synthase, and horseradish peroxidase.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Incubation of OTA with rat or human liver microsomes fortified with NADPH resulted in formation of 4-(R)-hydroxyochratoxin A at low rates [10-25 pmol min(-1) (mg of protein)(-1)].

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Incubation of OTA with rat or human liver microsomes fortified with NADPH resulted in formation of 4-(R)-hydroxyochratoxin A at low rates [10-25 pmol min(-1) (mg of protein)(-1)].

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was no evidence of OTA metabolism and glutathione conjugate formation with rat, mouse, or human kidney microsomes or postmitochondrial supernatants (S-9) [<5 pmol min(-1) (mg of protein)(-1)].

$$$$
>  <CLASS>
Parent

>  <TARGET>
There was no evidence of OTA metabolism and glutathione conjugate formation with rat, mouse, or human kidney microsomes or postmitochondrial supernatants (S-9) [<5 pmol min(-1) (mg of protein)(-1)].

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Recombinant human cytochromes P450 (P450) 1A1 and 3A4 formed 4-(R)-hydroxyochratoxin A at low rates [0.08 and 0.06 pmol min(-1) (pmol of P450)(-1), respectively]; no oxidation products of OTA were detected with recombinant human P450 1A2 or 2E1 or rat P450 1A2 or 2C11 [<0.02 pmol min(-1) (pmol of P450)(-1)].

$$$$
>  <CLASS>
Parent

>  <TARGET>
Prostaglandin H-synthase produced small amounts of an apolar product [33 pmol min(-1) (mg of protein)(-1)], and OTA products were not formed with horseradish peroxidase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was no evidence of DNA adduct formation when [(3)H]OTA was incubated with these enzyme systems in the presence of calf thymus DNA (<20 adducts/10(9) DNA bases); however, these enzymes catalyzed DNA adduct formation with the genotoxins aflatoxin B(1), 2-amino-3-methylimidazo[4,5-f]quinoline, benzo[a]pyrene, and pentachlorophenol.

$$$$
>  <CLASS>
Parent

>  <TARGET>
There was no evidence of DNA adduct formation when [(3)H]OTA was incubated with these enzyme systems in the presence of calf thymus DNA (<20 adducts/10(9) DNA bases); however, these enzymes catalyzed DNA adduct formation with the genotoxins aflatoxin B(1), 2-amino-3-methylimidazo[4,5-f]quinoline, benzo[a]pyrene, and pentachlorophenol.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
There was also no detectable [(3)H]OTA bound in vivo to kidney DNA of male Fischer-344 rats treated orally with [(3)H]OTA (1 mg/kg, 100 mCi/mmol, 24 h exposure, <2.7 adducts/10(9) DNA bases), based upon liquid scintillation counting.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
However, (32)P-postlabeling experiments did show evidence of DNA lesions with total adduct levels ranging from 31 to 71 adducts/10(9) DNA bases, while adducts in untreated rat kidney ranged from 6 to 24 adducts/10(9) DNA bases.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These results do not support the premise that OTA or metabolically activated species covalently bind to DNA and suggest that the (32)P-postlabeled lesions are due to products derived from OTA-mediated cytotoxicity.

$$$$
>  <CLASS>
Parent

>  <TARGET>
These results do not support the premise that OTA or metabolically activated species covalently bind to DNA and suggest that the (32)P-postlabeled lesions are due to products derived from OTA-mediated cytotoxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Pharmacokinetics of orally administered camptothecins.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Phase I trials of oral camptothecins, including camptothecin (CPT) and irinotecan (CPT-11), have reported substantial interpatient variability in systemic exposure, which could result in suboptimal antitumor activity in some patients or enhanced risk for toxicity in others.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This investigation evaluates the contribution of intestinal absorption and first-pass metabolism in the disposition of oral CPT and CPT-11, respectively.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This investigation evaluates the contribution of intestinal absorption and first-pass metabolism in the disposition of oral CPT and CPT-11, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Cumulatively, this data was indicative of carrier-mediated intestinal transport.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In addition, a reduction of transport in the presence of sodium azide plus deoxyglucose suggested ATP dependence.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Thus, variable expression and availability of intestinal transporters could contribute to the observed wide variability in the exposure to oral CPT.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
CPT-11 is hydrolyzed by the ubiquitous enzyme carboxyl esterase to active SN-38, and first-pass metabolism of oral CPT-11 would include both intestinal and hepatic hydrolysis.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Incubation of CPT-11 with S9 fractions of human liver and intestinal tissues resulted in variable rates of formation of SN-38.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Interestingly, there was a decrease in SN-38 formation by tumor tissue compared to matched normal liver and colon tissues.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Therefore variable first-pass metabolism could contribute to the substantial differences in the systemic exposures to CPT-11 and SN-38 in patients receiving oral CPT-11.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Ethylbenzene is an important constituent of widely used solvent mixtures in industry.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The objective of the present study was to provide information about biological monitoring of occupational exposure to ethylbenzene, and to review the biological limit values corresponding to the threshold limit value of ethylbenzene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A total of 20 male workers who had been exposed to a mixture of ethylbenzene and xylene, through painting and solvent mixing with commercial xylene in a metal industry, were recruited into this study.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Environmental and biological monitoring were performed during an entire week.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The urinary metabolites monitored were mandelic acid for ethylbenzene and methylhippuric acid for xylene.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Correlations were analyzed between urinary metabolites and environmental exposure for ethylbenzene and xylene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The interaction effects of a binary exposure to ethylbenzene and xylene were also investigated using a physiologically based pharmacokinetic (PBPK) model.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The average environmental concentration of organic solvents was 12.77 ppm for xylene, and 3.42 ppm for ethylbenzene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A significant correlation (R2 = 0.503) was found between environmental xylene and urinary methylhippuric acid.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Urinary level of methylhippuric acid corresponding to 100 ppm of xylene was 1.96 g/g creatinine in the worker study, whereas it was calculated as 1.55 g/g creatinine by the PBPK model.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary level of methylhippuric acid corresponding to 100 ppm of xylene was 1.96 g/g creatinine in the worker study, whereas it was calculated as 1.55 g/g creatinine by the PBPK model.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Urinary level of mandelic acid corresponding to 100 ppm of ethylbenzene was found to be 0.7 g/g creatinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urinary level of mandelic acid corresponding to 100 ppm of ethylbenzene was found to be 0.7 g/g creatinine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PBPK results showed that the metabolism of ethylbenzene was highly depressed by co-exposure to high concentrations of xylene leading to a non-linear behavior.

$$$$
>  <CLASS>
Parent

>  <TARGET>
PBPK results showed that the metabolism of ethylbenzene was highly depressed by co-exposure to high concentrations of xylene leading to a non-linear behavior.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
At low exposures, both methylhippuric acid and mandelic acid can be used as indicators of commercial xylene exposures.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
However at higher concentrations mandelic acid cannot be recommended as a biological indicator due to the saturation of mandelic acid produced by the co-exposure to xylene.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simultaneous determination of cefotaxime and desacetylcefotaxime in human plasma and cerebrospinal fluid by high-performance liquid chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A simple and sensitive HPLC method for the simultaneous determination of cefotaxime (I) and desacetylcefotaxime (II) in human plasma and cerebrospinal fluid (CSF) is described.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The assay involves deproteinisation and subsequent separation on a reversed-phase HPLC column, with ultraviolet detection at 262 nm.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Retention times were 6.8 and 2.2 min for cefotaxime and desacetylcefotaxime, respectively.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Average recoveries for the analytes were 78% (I) and 88% (II) from both matrices.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Linear responses were observed over a wide range (0.58-940 microg/ml for (I) in plasma, 0.80-55.8 microg/ml for (I) in CSF, 0.54-148 microg/ml for (II) in plasma and 0.50-36.0 microg/ml for (II) in CSF).

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A HPLC-UV determination of clobazam and N-desmethylclobazam in human serum and urine is presented.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
After simple liquid-liquid extraction with dichloromethane the compounds and an internal standard diazepam were separated on a Supelcosil LC-8-DB column at ambient temperature under isocratic conditions using the mobile phase: CH3CN-water-0.5 M KH2PO4-H3PO4 (440:540:20:0.4, v/v and 360:580:60:0.4, v/v for serum and urine, respectively).

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection was performed at 228 nm with limits of quantification of 2 ng/ml for serum and 1 ng/ml for urine.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Relative standard deviations for intra- and inter-assay precision were found below 8% for both compounds for all the tested concentrations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The described procedure may be easily adapted for several 1,4-benzodiazepines.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The role of metabolites in bioequivalency assessment.

$$$$
>  <CLASS>
NONE

>  <TARGET>
III.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Highly variable drugs with linear kinetics and first-pass effect.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Simulated pharmacokinetic (PK) studies were done to determine the effect of intrinsic clearance (CL(INT)) on the probability of meeting bioequivalence criteria for extent (AUC) and rate (Cmax) of drug absorption when the absorption rate and fraction absorbed (F) were formulated either to be equivalent or to differ by 25%.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Simulated PK studies were done using a linear first-pass model with CL(INT) values ranging from 15 L/HR to 900 L/HR.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Test/Reference absorption rate constants (Ka) and fraction absorbed (Fa) ratios of 1.0 or 1.25 were used for all simulations.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The impact of the value of CL(INT) and its intrasubject variation upon the probability of concluding bioequivalence at the two different Ka and F ratios was studied.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Additionally, the effect of fraction metabolized i.v., (Fm) on the probabilities of concluding equivalence was studied at values of 0.25 and 0.75.

$$$$
>  <CLASS>
NONE

>  <TARGET>
When CL(INT) values were raised above those for liver blood flow, the frequency of trials in which bioequivalence was correctly declared decreased when parent AUC was used as a bioequivalence criterion.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Only when CL(INT) exceeded liver blood flow did the metabolite become important in assessing extent of absorption.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The Cmax for the parent drug provided the most accurate assessment of bioequivalence.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The Cmax for the metabolite was insensitive to changes related to rate of input, and when CL(INT) exceeded liver blood flow, evaluation of the metabolite Cmax data may lead to a conclusion of bioequivalence for products that were not.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes.

$$$$
>  <CLASS>
NONE

>  <TARGET>
A gas chromatography-mass spectrometry (GC-MS) procedure for the detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine is presented.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The metabolites were first identified in rat liver microsome preparations by GC-MS after isolation and derivatization.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Using these GC-MS data, a GC-MS screening was developed for urine as part of the authors' modified systematic toxicologic analysis procedure.

$$$$
>  <CLASS>
NONE

>  <TARGET>
After acid hydrolysis of a 2.5-mL aliquot of urine, a further aliquot was added.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The mixture was then liquid-liquid extracted at pH 8-9, acetylated, and GC separated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Using mass chromatography with the ions m/z 58, 100, 120, 182, 195, 235, 261, 276, 284. and 293, the presence of new antidepressants, neuroleptics, hypnotics, and their metabolites could be indicated.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Positive peaks could be identified by library search using the reference mass spectra recorded during the microsome studies.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The intake of therapeutic doses of the following drugs could be monitored in urine: dosulepin, mirtazapine, moclobemide, nefazodone, trazodone, venlafaxine, and zolpidem.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Olanzapine and zotepine were detectable in human urine only under steady-state conditions, and low-dose zopiclone was detectable only in overdose.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The detection limit was less than 100 ng/mL (signal-to-noise ratio = 3) for the parent drugs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Morphine or oxycodone in cancer pain?

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Oxycodone is an opioid analgesic that closely resembles morphine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Oxymorphone, the active metabolite of oxycodone, is formed in a reaction catalyzed by CYP2D6, which is under polymorphic genetic control.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The role of oxymorphone in the analgesic effect of oxycodone is not yet clear.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In this study, controlled-release (CR) oxycodone and morphine were examined in cancer pain.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
CR oxycodone and morphine were administered to 45 adult patients with stable pain for 3-6 days after open-label titration in a randomized, double-blind, cross-over trial.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Twenty patients were evaluable.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both opioids provided adequate analgesia.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Liver dysfunction affected selectively either oxycodone or morphine metabolism.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Three patients with markedly aberrant plasma opioid concentrations are presented.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Significant individual variation in morphine and oxycodone metabolism may account for abnormal responses during treatment of chronic cancer pain.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The capacity of three clinically available nonnucleoside reverse transcriptase inhibitors (NNRTIs) to inhibit the activity of human cytochromes P450 (CYPs) was studied in vitro using human liver microsomes.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O-deethylation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O-deethylation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nevirapine did not inhibit hydroxylation of tolbutamide (CYP2C9) or S-mephenytoin (CYP2C19), but these CYP isoforms were importantly inhibited by delavirdine and efavirenz.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Nevirapine did not inhibit hydroxylation of tolbutamide (CYP2C9) or S-mephenytoin (CYP2C19), but these CYP isoforms were importantly inhibited by delavirdine and efavirenz.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This indicates the likelihood of significantly impaired clearance of CYP2C substrate drugs (such as phenytoin, tolbutamide, and warfarin) upon initial exposure to these two NNRTIs.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The in vitro microsomal model provides relevant predictive data on probable drug interactions with NNRTIs when the mechanism is inhibition of CYP-mediated drug biotransformation.

$$$$
>  <CLASS>
NONE

>  <TARGET>
However, the model does not incorporate interactions attributable to enzyme induction.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Modified method for determination of hippuric acid and methylhippuric acid in urine by gas chromatography.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A modified method for the simultaneous determination of hippuric acid (HA) and o-, m- and p-methylhippuric acids (o-, m- and p-MHAs) in urine is described.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These metabolites were extracted, derivatized into their methyl ester derivatives and analyzed using a gas chromatograph equipped with flame ionization detector and a DB-1 capillary column.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The derivatives of HA, o-, m- and p-MHAs were well separated within 11 min.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The accuracy and precision in the present method were sufficient for quantitative analysis, and the results obtained by the GC method were highly correlated with those by the HPLC method (NIOSH 8301).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Determination of terbutaline enantiomers in human urine by coupled achiral-chiral high-performance liquid chromatography with fluorescence detection.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A coupled achiral-chiral high-performance liquid chromatographic system with fluorescence detection at excitation/emission wavelengths of 276/306 nm has been developed for the determination of the enantiomers of terbutaline, (S)-(+)-terbutaline and (R)-(-)-terbutaline in urine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Urine samples were prepared by solid-phase extraction with Sep-pak silica, followed by HPLC.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The terbutaline was preseparated from the interfering components in urine on Phenomenex silica column and the terbutaline enantiomers and betaxolol were resolved and determined on a Sumichiral OA-4900 chiral stationary phase.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The terbutaline was preseparated from the interfering components in urine on Phenomenex silica column and the terbutaline enantiomers and betaxolol were resolved and determined on a Sumichiral OA-4900 chiral stationary phase.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The two columns were connected by a switching valve equipped with silica precolumn.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The precolumn was used to concentrate the terbutaline in the eluent from the achiral column before back flushing onto the chiral phase.

$$$$
>  <CLASS>
NONE

>  <TARGET>
For each enantiomer the assay was linear between 1 and 250 ng/ml (R2=0.9999) and the detection limit was 0.3 ng/ml.

$$$$
>  <CLASS>
NONE

>  <TARGET>
The intra-day variation was between 4.6 and 11.6% in relation to the measured concentration and the inter-day variation was 4.3-11.0%.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
It has been applied to the determination of (S)-(+)-terbutaline and (R)-(-)-terbutaline in urine from a healthy volunteer dosed with racemic terbutaline sulfate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
It has been applied to the determination of (S)-(+)-terbutaline and (R)-(-)-terbutaline in urine from a healthy volunteer dosed with racemic terbutaline sulfate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Determination of monobromobimane derivatives of phenylmercapturic and benzylmercapturic acids in urine by high-performance liquid chromatography and fluorimetry.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Determination of monobromobimane derivatives of phenylmercapturic and benzylmercapturic acids in urine by high-performance liquid chromatography and fluorimetry.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
A method was developed for the determination in human urine of S-phenylmercapturic (PMA) and S-benzylmercapturic (BMA) acids, metabolites respectively of benzene and toluene.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
PMA and BMA were determined, after alkaline hydrolysis, to give respectively thiophenol and benzylmercaptan, and coupling of the thiol-containing compounds with monobromobimane (MB), by reversed-phase HPLC on a diphenyl-silica bonded cartridge (100 x 4.6 mm I.D., 5 microm particle size) with fluorimetric detection.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
PMA and BMA were determined, after alkaline hydrolysis, to give respectively thiophenol and benzylmercaptan, and coupling of the thiol-containing compounds with monobromobimane (MB), by reversed-phase HPLC on a diphenyl-silica bonded cartridge (100 x 4.6 mm I.D., 5 microm particle size) with fluorimetric detection.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Wavelengths for excitation and emission were 375 and 480 nm, respectively.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The recovery of PMA and BMA from spiked urines was >90% in the 10-500 microg/l range; the quantification limits were respectively 1 and 0.5 microg/l; day-to-day precision at 42 microg/l was C.V. <7%.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The suitability of the proposed procedure for the biological monitoring of exposure to low-level airborne concentrations of benzene and toluene, was evaluated by analyzing the urinary excretion of PMA and BMA in subjects exposed to different sources of aromatic hydrocarbons, namely occupationally-unexposed referents (non-smokers, n=15; moderate smokers, n=8; mean number of cigarettes smoked per-day=17 cig/day) and non-smoker workers occupationally exposed to toluene in maintenance operations of rotogravure machines (non-smokers, n=17).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The suitability of the proposed procedure for the biological monitoring of exposure to low-level airborne concentrations of benzene and toluene, was evaluated by analyzing the urinary excretion of PMA and BMA in subjects exposed to different sources of aromatic hydrocarbons, namely occupationally-unexposed referents (non-smokers, n=15; moderate smokers, n=8; mean number of cigarettes smoked per-day=17 cig/day) and non-smoker workers occupationally exposed to toluene in maintenance operations of rotogravure machines (non-smokers, n=17).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among referents, non-smokers showed values of PMA ranging from <1 to 4.6 microg/l and BMA from 1.0 to 10.4 microg/l; in smokers, PMA values ranging from 1.2 to 6.7 microg/l and BMA from 9.3 to 39.9 microg/l, were observed.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In occupationally exposed non-smoker subjects, BMA median excretion value (23.6 microg/l) was higher than in non-smoker referents (3.5 microg/l) (P<0.001) and individual BMA values (y, microg/l) were associated and increased with airborne toluene concentration (x, mg/m3) according to the equation y=6.5+0.65x (r=0.69, P<0.01, n=17).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The proposed analytical method appears to be a sensitive and specific tool for biological monitoring of low-level exposure to benzene and toluene mixtures in occupational and environmental toxicology laboratory.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Metabolism of the beta-oxidized intermediates of N-nitrosodi-n-propylamine: N-nitroso-beta-hydroxypropylpropylamine and N-nitroso-beta-oxopropylpropylamine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The rat liver carcinogen N-nitrosodi-n-propylamine (NDPA) is metabolized to a propylating and methylating species in vivo.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Metabolism to a methylating species is believed to require an initial hydroxylation by cytochrome P450s (P450s) to N-nitroso-beta-hydroxypropylpropylamine (NHPPA), which is oxidized to N-nitroso-beta-oxopropylpropylamine (NOPPA), followed by a P450-mediated depropylation to beta-oxopropyldiazotate, which non-enzymatically breaks down to the methylating agent.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Purified rat liver P450 2B1 and rabbit liver 2E1 in the reconstituted system and liver microsomes from phenobarbital (PB) and pyridine (Pyr) treated rats readily metabolized NOPPA to a methylating species as determined by the in vitro formation of 7-methylguanine (m7Gua) in DNA.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Purified rat liver P450 2B1 and rabbit liver 2E1 in the reconstituted system and liver microsomes from phenobarbital (PB) and pyridine (Pyr) treated rats readily metabolized NOPPA to a methylating species as determined by the in vitro formation of 7-methylguanine (m7Gua) in DNA.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Purified rat liver P450 2B1 and rabbit liver 2E1 in the reconstituted system and liver microsomes from phenobarbital (PB) and pyridine (Pyr) treated rats readily metabolized NOPPA to a methylating species as determined by the in vitro formation of 7-methylguanine (m7Gua) in DNA.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Exposure of cells derived from the human liver epithelium transfected with human 2E1 (T5-2E1) to NOPPA resulted in the formation of m7Gua DNA adducts and a dose dependent toxicity.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Exposure of cells derived from the human liver epithelium transfected with human 2E1 (T5-2E1) to NOPPA resulted in the formation of m7Gua DNA adducts and a dose dependent toxicity.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In vitro incubation of NHPPA with microsomes from PB, Pyr and non-treated (NT) rats and a human microsomal sample also resulted in m7Gua formation.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In vitro incubation of NHPPA with microsomes from PB, Pyr and non-treated (NT) rats and a human microsomal sample also resulted in m7Gua formation.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
P450s 2B1 and 2E1 oxidized NHPPA to NOPPA, forming 16.5 +/- 3.1 and 20.0 +/- 4.4 pmol NOPPA/pmol P450 in 1 h, respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Rat liver cytosol, in the presence of NAD+, oxidized NHPPA to NOPPA at a rate of 13.7 +/- 3.0 pmol/min/mg protein while microsomes from NT rats catalyzed this reaction at 95.6 +/- 16.5 pmol/min/mg protein.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Rat liver cytosol, in the presence of NAD+, oxidized NHPPA to NOPPA at a rate of 13.7 +/- 3.0 pmol/min/mg protein while microsomes from NT rats catalyzed this reaction at 95.6 +/- 16.5 pmol/min/mg protein.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Cells derived from hamster lung tissue (V79 control) and T5-neo cells oxidized NHPPA to NOPPA.

$$$$
>  <CLASS>
NONE

>  <TARGET>
This oxidation was about 15 fold higher in T5-2E1 or V79 cells transfected with human 2E1 or rat 2B1, respectively.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
The results are consistent with the putative sequential oxidation pathway and suggest that, at the concentrations tested, oxidation of NHPPA to NOPPA may be predominantly mediated by cytochrome P450s.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In addition, it appears that rabbit, rat and human P450 2E1 can catalyze both oxidations.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Reactive nitrogen oxygen species metabolize N-acetylbenzidine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Reactive nitrogen oxygen species metabolize N-acetylbenzidine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
A close association has been reported for certain types of cancers influenced by aromatic amines and infection/inflammation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Reactive nitric oxygen species (RNOS), components of the inflammatory response, are bactericidal and tumoricidal, and contribute to the deleterious effects attributed to inflammation on normal tissues.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
This study assessed the possible transformation of the aromatic amine N-acetylbenzidine (ABZ) by RNOS.

$$$$
>  <CLASS>
Parent

>  <TARGET>
This study assessed the possible transformation of the aromatic amine N-acetylbenzidine (ABZ) by RNOS.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
RNOS were generated by various conditions to react with ABZ, and samples were evaluated by HPLC.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Conditions which generate nitrogen dioxide radical (NO(2)(-) + myeloperoxidase + H(2)O(2), ONOO(-), and NO(2)(-) + HOCl) produced primarily a single new product termed 3'-nitro-ABZ.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Conditions which generate nitrogen dioxide radical (NO(2)(-) + myeloperoxidase + H(2)O(2), ONOO(-), and NO(2)(-) + HOCl) produced primarily a single new product termed 3'-nitro-ABZ.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The myeloperoxidase-catalyzed reaction with 0.3 mM NO(2)(-) was completely inhibited by 1 mM cyanide, and not effected by 100 mM chloride with or without 1 mM taurine.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In contrast, conditions which generate N(2)O(3), such as spermine NONOate, did not produce 3'-nitro-ABZ, but rather two compounds termed 4'-OH-AABP and AABP.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In contrast, conditions which generate N(2)O(3), such as spermine NONOate, did not produce 3'-nitro-ABZ, but rather two compounds termed 4'-OH-AABP and AABP.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
(1)H NMR and mass spectrometry identified 3'-nitro-ABZ as 3'-nitro-N-acetylbenzidine, 4'-OH-AABP as 4'-OH-4-acetylaminobiphenyl, and AABP as 4-acetylaminobiphenyl.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Human polymorphonuclear neutrophils incubated with [(3)H]ABZ and stimulated with beta-phorbol 12-myristate 13-acetate produced 3'-nitro-ABZ in the presence of NO(2)(-) (0.1-1 mM).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Human polymorphonuclear neutrophils incubated with [(3)H]ABZ and stimulated with beta-phorbol 12-myristate 13-acetate produced 3'-nitro-ABZ in the presence of NO(2)(-) (0.1-1 mM).

$$$$
>  <CLASS>
Parent

>  <TARGET>
Neutrophil 3'-nitro-ABZ formation was verified by mass spectrometry and was consistent with myeloperoxidase oxidation of NO(2)(-).

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Neutrophil 3'-nitro-ABZ formation was verified by mass spectrometry and was consistent with myeloperoxidase oxidation of NO(2)(-).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The results demonstrate that ABZ forms unique products in the presence of nitrosating and nitrating RNOS, which could influence the carcinogenic process and serve as biomarkers for these reactive species.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The results demonstrate that ABZ forms unique products in the presence of nitrosating and nitrating RNOS, which could influence the carcinogenic process and serve as biomarkers for these reactive species.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The disposition and metabolic fate of [4-14C]coumarin in a 70% aqueous ethanol solution was studied in male Lister Hooded rats after occluded dermal application and in three male volunteers after an exposure designed to simulate that which may be encountered when using an alcohol-based perfumed product.

$$$$
>  <CLASS>
NONE

>  <TARGET>
In both cases, the 6-h exposure was 0.02 mg/cm(2) (rats 0.023 mg/kg and humans 0.77 mg/kg).

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In both, coumarin was quickly absorbed, distributed and excreted in urine and feces, although fecal excretion of coumarin in humans was only 1% of the applied dose as opposed to 21% in rats.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Total absorption was 72% of the applied dose with rats and 60% with humans.

$$$$
>  <CLASS>
NONE

>  <TARGET>
Peak plasma radioactivity in both was at 1 h. 

$$$$
>  <CLASS>
Parent

>  <TARGET>
The mean plasma half-life of coumarin and metabolites was approximately 1.7 h for humans and 5 h for rats.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
In humans, coumarin was primarily metabolized to and excreted in urine as 7-hydroxycoumarin glucuronide and 7-hydroxycoumarin sulfate.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Small amounts of unconjugated 7-hydroxycoumarin and o-hydroxyphenylacetic acid (o-HPAA) were also excreted.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
In rats, about twenty metabolites were present, but only o-HPAA was identified.

$$$$
>  <CLASS>
NONE

>  <TARGET>
These studies show the rat is a very poor model for humans and toxicity in the rat cannot be extrapolated to humans.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Melatonin, the predominant product of the pineal gland, is involved in the maintenance of diurnal rhythms.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Nocturnal blood concentrations of melatonin have been shown to be enhanced by fluvoxamine, but not by other serotonin reuptake inhibitors.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Melatonin was found to be almost exclusively metabolized by CYP1A2 to 6-hydroxymelatonin and N-acetylserotonin with a minimal contribution of CYP2C19.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Both reactions were potently inhibited by fluvoxamine, with a Ki of 0.02 microM for the formation of 6-hydroxymelatonin and 0.05 microM for the formation of N-acetylserotonin.

$$$$
>  <CLASS>
Metabolite

>  <TARGET>
Both reactions were potently inhibited by fluvoxamine, with a Ki of 0.02 microM for the formation of 6-hydroxymelatonin and 0.05 microM for the formation of N-acetylserotonin.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Other than fluvoxamine, fluoxetine, paroxetine, citalopram, imipramine, and desipramine were also tested at 2 and 20 microM.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Among the other antidepressants, only paroxetine was able to affect the metabolism of melatonin at supratherapeutic concentrations of 20 microM, which did not reach by far the magnitude of the inhibitory potency of fluvoxamine.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Among the other antidepressants, only paroxetine was able to affect the metabolism of melatonin at supratherapeutic concentrations of 20 microM, which did not reach by far the magnitude of the inhibitory potency of fluvoxamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The authors concluded that fluvoxamine is a potent inhibitor of melatonin degradation.

$$$$
>  <CLASS>
Parent

>  <TARGET>
The authors concluded that fluvoxamine is a potent inhibitor of melatonin degradation.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Because this inhibitory action is also found in vivo, fluvoxamine might be used as an enhancer of melatonin, which might offer new therapeutic possibilities of fluvoxamine.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
BN 80915, a lead compound of the homocamptothecin (hCPT) family, has entered clinical trials.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
BN 80915 is a difluoro-hCPT where the six-membered alpha-hydroxylactone ring of camptothecin (CPT) is replaced by a seven-membered beta-hydroxylactone ring.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
BN 80915 is a difluoro-hCPT where the six-membered alpha-hydroxylactone ring of camptothecin (CPT) is replaced by a seven-membered beta-hydroxylactone ring.

$$$$
>  <CLASS>
Parent and its metabolite

>  <TARGET>
Preclinical data reported here show that in spite of the modification to the crucial E-ring of CPTs, BN 80915 retains topoisomerase I poisoning activity as shown in living HT29 cells as well as in cell-free assays, where BN 80915 always performs better than SN-38 or TPT.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Preclinical data reported here show that in spite of the modification to the crucial E-ring of CPTs, BN 80915 retains topoisomerase I poisoning activity as shown in living HT29 cells as well as in cell-free assays, where BN 80915 always performs better than SN-38 or TPT.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
In antiproliferative assays BN 80915 is also very potent as evidenced by IC50s values consistently lower than those of SN38 in sensitive cell lines as well as in their related multidrug-resistant lines overexpressing P-glycoprotein or multidrug resistance-associated protein.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Furthermore, in human plasma, in contrast to CPT analogs, the hydrolysis of BN 80915 is slow, leading to improved plasma stability, and irreversible, thus avoiding toxicity related to the accumulation of active principle during excretion in the urinary tract.

$$$$
>  <CLASS>
Parent

>  <TARGET>
Furthermore, in human plasma, in contrast to CPT analogs, the hydrolysis of BN 80915 is slow, leading to improved plasma stability, and irreversible, thus avoiding toxicity related to the accumulation of active principle during excretion in the urinary tract.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
These findings may account for the good in vivo efficacy observed in PC3 xenograft experiments where BN 80915 administered orally at very low doses doubled the tumor growth delay in comparison to CPT-11 administered i.p.

$$$$
>  <CLASS>
Chemical

>  <TARGET>
Altogether, these results strongly support further development of BN 80915.

$$$$
